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Summary  
Age-related macular degeneration (AMD) is the leading cause of visual impairment in 
the developed world (Wong et al., 2014). The exact causes of AMD are unclear but 
hypoxia has been implicated (Stefánsson et al., 2011). If hypoxia has a role in the 
pathogenesis of AMD treatments that mitigate the effect of retinal hypoxia may slow 
disease progression.  
This thesis aimed to establish the impact of light therapy, as delivered using a light 
emitting mask, on the progression of AMD. A phase I/IIa randomised controlled trial 
was implemented in which 60 participants with early and intermediate AMD were 
allocated to the intervention or the untreated control group in a 1:1 ratio and monitored 
over 12 months. The ability of secondary outcome measures (including: rate of cone 
dark adaptation, 14Hz flicker threshold and chromatic thresholds) to identify the likely 
risk of progression from early and intermediate AMD to advanced AMD was also 
assessed in a cross-sectional study evaluating the relationship between each 
baseline outcome measure and the severity of fundus changes.   
Sixty participants were recruited of which 47 (20 intervention, 27 control) completed 
the 12 month follow-up period. No significant difference was found in the change of 
any parameter between groups apart from the time constant of cone-photoreceptor 
recovery (cone τ), which was increased to a greater extent in the treated group. An 
additional 40 participants were recruited to the cross-sectional study (n=100). 
Measurement of cone τ was identified as the best independent predictor of increased 
AMD severity based on the AREDS Simplified Severity Scale (Ferris et al., 2005).    
Although a greater proportion of controls (48%) than mask wearers (38%) showed 
disease progression over the duration of the trial this difference did not reach 
statistical significance. 
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Chapter 1.  Introduction 
Age-related macular degeneration (AMD) is the leading cause of visual impairment in 
the UK and affects millions of people on a global scale. Currently there are no 
treatments for early AMD, intermediate AMD or geographic atrophy. The causes of 
AMD are not yet fully understood but hypoxia may play a role. Hypoxia has been 
found to be most acute at night when the retina is most metabolically active. By 
exposing the eye to very dim light at night the level of hypoxia is reduced. In practice, 
this can be achieved through low-level night-time light therapy provided by a light 
emitting mask. The overall objective of the work described in this PhD was to 
implement a clinical trial which aims to primarily assess the impact of low-level night-
time light therapy on the progression of early and intermediate AMD, and retreatment 
rates for neovascular AMD (nAMD). The performance of a range of biomarkers for 
AMD and the safety and comfort of the light mask were also evaluated. This 
introductory chapter begins by providing an overview of the structure of a normal 
retina and retinal physiology in photopic and scotopic conditions. This is followed by 
a description of the risk factors, pathophysiology, classification, treatment and 
investigation of AMD. The latter part of the chapter provides an overview of visual 
psychophysics, focusing on the psychophysical investigative techniques of particular 
importance to the clinical trial. This chapter concludes with an outline of the specific 
aims of this PhD.      
1.1. Normal retinal structure  
In order to understand AMD pathogenesis and the value of potential therapeutics it is 
useful for the reader to have an understanding of the structure and function of a 
normal retina. With this in mind this section aims to provide an introduction to the 
retina and its component layers. Travelling from the outer to the inner retina, emphasis 
will be placed in this section on the layers that are of particular importance to AMD 
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pathogenesis. The retina is a light-sensitive layer of tissue that covers around 65% of 
the eye’s interior surface (Oyster, 2006). It is situated between the choroid and the 
vitreous humour and extends from the optic nerve to the ora serrata (Figure 1.1) 
(Oyster, 2006). The retina acts as the primary stage of the visual processing pathway. 
Structurally it consists of nine individual layers including three layers of neuronal cell 
bodies interconnected by synapses (Figure 1.2) (Kolb, 2013).  
When light focused by the cornea and lens strikes the photosensitive cells of the retina 
a cascade of chemical and electrical events is triggered. These events are collectively 
known as phototransduction and lead to the conversion of the incident light energy 
into an electrical signal. The signal is processed by the various neurons that reside 
within the retina and is transported via the optic nerve to the brain, where it is 
interpreted as an image (Forrester et al., 2016). 
 
The direct appearance of the retina is displayed in Figure 1.1. When observed in this 
manner the optic nerve is referred to as the optic disc and can be seen as the pale 
circular area from which the major blood vessels of the retina radiate. The macula is 
an area of the retina located around 3.5mm temporally to the edge of the optic disc. 
It sits 1mm inferiorly to the centre of the optic disc and spans a diameter of 5-6mm 
Figure 1.1. Diagram of a sagittal section of a human eye (left panel) and a healthy retinal 
appearance (right panel). The macular regions are circled and accompanied by typical 
measurements of diameter (Kolb, 2013; copyright permission from 
http://webvision.med.utah.edu/). 
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(Oyster, 2006). At the centre of the macula lies the fovea, an area specialised to 
provide high resolution visual acuity. The maximum resolving power of the eye is 
found at the centre of the fovea, known as the foveola, where the retinal thickness is 
at its minimum (Polyak, 1949). Surrounding the fovea is the parafoveal region which 
contains a large accumulation of retinal bipolar and ganglion cells. Outside of this lies 
the perifoveal region which ultimately merges with the peripheral retina.  
   
 Blood supply to the retina  
The retina is extremely metabolically active and has one of the highest oxygen 
consumptions (per weight) of any tissue within the human body (Wong-Riley, 2010). 
It is served by a dual blood supply and maintains a blood-retinal barrier. The barrier 
is primarily upheld by the structural formation of the retina and is designed to promote 
the optimum environment for neural transmission.     
The inner retinal layers are nourished via the central retinal artery which arises from 
the ophthalmic artery and enters the eye through the optic disc (Hayreh, 1962). Upon 
its emergence into the globe, the 100μm diameter central retinal artery divides into 
Figure 1.2. A diagrammatic representation of the retinal layers and neuronal cell bodies 
merged with a light micrograph (Wright et al., 2010; copyright permission from Elsevier 
[2018] licence 4274211239188) of the central retina (Kolb, 2013; copyright permission from 
http://webvision.med.utah.edu/). 
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superior and inferior branches which, in turn, separate into nasal and temporal arteries 
within the nerve fibre layer (Hayreh, 1962). Each subdivision of the artery is tasked 
with servicing a specific section of retinal tissue and is usually found in conjunction 
with similar subdivisions of the central retinal vein.  
The temporal vessels make their way into the peripheral retina via an arching route 
around the macular region. This results in a 500μm diameter vessel-free area around 
the fovea (Oyster, 2006). In comparison, the nasal vessels run a more direct course 
to the ora serrata. Continued branching and bifurcation of the retinal vessels gives 
rise to the formation of a web-like capillary network within the nerve fibre or ganglion 
cell layer (known as the superficial network) and within the inner nuclear layer (known 
as the deep network) (Iwasaki and Inomata, 1986).   
The retinal capillaries are characterised by their small luminal diameter (3.5 to 6μm), 
low flow rate and high oxygen exchange with surrounding tissue (Wang et al., 2011). 
Their structure is composed of a single layer of unfenestrated endothelium 
surrounded by a thick basal lamina (Ishikawa, 1963; Bernstein and Hollenberg, 1965). 
Pericytes overlie the basal lamina and are thought to facilitate the flow of blood due 
to their contractile nature (Chakravarthy and Gardiner, 1999). The vessels of this 
system do not anastomose with any other vascular structures and are therefore 
termed ‘end vessels’. This characteristic leaves the retina open to ischaemic assault 
in the event of an artery occlusion. The risk of complete inner retinal ischaemia in the 
case of central retinal artery occlusion is combated in 20-35% of the population by the 
cilioretinal artery which arises from the choroid (Justice and Lehmann, 1976). 
Nutrition to the outer retinal layers is supplied by the choroidal circulation which, in 
turn, feeds off the short posterior ciliary arteries. In contrast to the retinal circulation, 
which is mainly influenced by local factors, the choroidal blood supply is controlled by 
sympathetic innervation and is not autoregulated (Delaey and Van De Voorde, 2000). 
The vascular structure of the choroid is generally divided into 3 layers. Moving from 
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the outermost to the innermost these are known as Haller’s layer, Sattler’s layer and 
the choriocapillaris. Vessel diameter is found to be largest within Haller’s layer and 
gradually decreases towards the choriocapillaris (Hayreh, 1975). As the arteries 
decrease in size, the muscularis layer and internal elastic laminae are lost. The vessel 
walls become fenestrated, and therefore permeable, within the choriocapillaris layer. 
The choriocapillaris vessels are arranged into a network of individual lobules. Each 
lobule functions as an independent unit and, in a similar fashion to the retinal artery, 
derived vasculature does not anastomose (Hayreh, 1975). The greatest density of 
choriocapillary vasculature lies below the macula due to the high metabolic activity 
and avascular nature of this area. 
 All retinal layers that lie posteriorly to the outer plexiform layer are found to be 
avascular and rely heavily on the choroidal circulation for nourishment. The avascular 
macula region is also entirely dependent on the underlying choroidal blood supply 
(Nickla and Wallman, 2010). Before reaching their intended destination within the 
outer retina, metabolites are required to diffuse from the choriocapillary network and 
to pass through Bruch’s membrane. This contributes to the choroidal circulation 
having a low rate of oxygen exchange in comparison to its high rate of flow (Nickla 
and Wallman, 2010).  
 The effect of luminance on retinal oxygen demand  
In vivo oxygen (O2) profiling of the macaque retina shows that, under light adapted 
conditions, retinal oxygen tension (PO2) falls steeply between the choriocapillaris and 
photoreceptors (Wangsa-Wirawan and Linsenmeier, 2003). This is due to the high 
metabolic activity and oxygen demand of the photoreceptor inner segments. A more 
gradual reduction is then observed through the rest of the outer retina as shown in 
Figure 1.3 (Wangsa-Wirawan and Linsenmeier, 2003). The direction of this monotonic 
PO2 gradient indicates that the choroid alone is responsible for photoreceptor 
oxygenation when light adapted (Ahmed et al., 1993).  
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When dark adapted, Figure 1.3 shows that the PO2 level in the outer retina is 
considerably lower and approaches 0mmHg at the proximal side of the photoreceptor 
inner segments. Birol et al. (2007) found a decrease in PO2 level from 48mmHg to 
3.8mmHg when travelling from the choroid to the photoreceptor inner segment of the 
dark adapted macaque retina. Due to the O2 gradient reversal seen at an inner 
segment level, retinal circulation has been found to be involved, alongside the choroid, 
with photoreceptor oxygenation when dark adapted (Ahmed et al., 1993).   
The increased oxygen demand displayed by the photoreceptors under scotopic 
conditions is attributable to the high metabolic demand of the ‘dark current’ in the 
approximately 92 million rods (Hagins et al., 1989; Sivaprasad and Arden, 2016). 
Oxygen profiles within this environment suggest that there is little O2 reserve at the 
photoreceptor level. Increasing the volume of O2 inhaled has been found to 
dramatically increase PO2, in particular for the outer retina as the choroidal circulation 
does not autoregulate (Wangsa-Wirawan and Linsenmeier, 2003). The introduction 
of light under previously dark adapted conditions has also been found to reduce the 
O2 consumption of the photoreceptors in the parafovea and fovea by 16-36% (Ahmed 
et al., 1993).   
Figure 1.3. Intra retinal oxygen profile during light and dark adaptation. Note the near zero 
oxygen tension at 80% retinal depth observed in the dark (Linsenmeier and Zhang. 2017; 
copyright permission from Elsevier [2018] licence 4274230457173). 
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 Bruch’s membrane 
Bruch’s membrane is a thin modified connective tissue layer situated between the 
retinal pigment epithelium (RPE) and the choriocapillaris. The accepted model of 
Bruch’s membrane structure involves 5 layers. This consists of the RPE basal lamina, 
an inner collagenous layer, a middle elastic layer, an outer collagenous layer and the 
basal lamina of the choriocapillary endothelium (Guymer et al., 1999). Histologically, 
Bruch’s membrane appears as an acellular glassy layer of elastin and collagen rich 
tissue. Its structure aids to physically strengthen the RPE whilst also acting as a 
molecular sieve in order to regulate the exchange of biomolecules, nutrients, oxygen 
and metabolic waste between the retina and choroidal circulation (Booij et al., 2010). 
Bruch’s membrane has been found to thicken with age. Ramrattan et al. (1994) 
documented a 2.7μm increase in thickness over ten decades. Other age-related 
changes include the accumulation of hydrophobic lipid-rich material within the inner 
collagenous zone and increased calcification of the elastic fibres (Huang et al., 2007; 
Booij et al., 2010). These changes have the potential to disturb normal function by 
acting as a diffusion barrier against metabolic exchange (Bird, 1992; Booij et al., 
2010).     
 The retinal pigment epithelium 
The RPE is the outermost retinal layer and is situated exteriorly to the neural layers 
of the retina. Located between the choroid and the photoreceptor outer segments, it 
exists as a monolayer of between 3 and 4 million regularly arranged hexagonal cells 
(Panda-Jonas et al., 1996). The cells are structured into a cuboidal formation which 
is densely packed and columnar in the central retina, but becomes shorter and flatter 
with increasing retinal eccentricity (Boulton and Dayhaw-Barker, 2001). Infoldings 
anchor the basal aspect of the RPE to Bruch’s membrane whilst the apical surface 
extends microvilli towards the inter-photoreceptor matrix (IPM). The microvilli interact 
with the tips of the photoreceptor outer segments extending from the outer retinal 
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surface (Bonilha et al., 2006). The RPE cells are interconnected via gap junctions, 
which allow the controlled transfer of metabolites between neighbours, and tight 
junctions (zonulae occludens) which ensure a strong adhesion between cells 
(Hudspeth and Yee, 1973). Each cell contains melanin pigment which can vary in 
density between retinal areas, leading to a mottled fundus appearance. The melanin 
content of RPE cells also varies between individuals, leading to inter-individual 
variations in fundus appearance. The cell cytoplasm houses the smooth and rough 
endoplasmic reticulum, Golgi apparatus, mitochondria and lysosomes responsible for 
upholding the many functions of the RPE.  Despite not being directly associated with 
the neural events of vision the RPE has been found to possess many physical, optical, 
metabolic and transport functions which play a critical role in the visual process (Bok, 
1993; Strauss, 2005). These include:  
1. Phagocytosis of shed photoreceptor outer segment discs.  
2. Absorption of stray light and the prevention of light scatter within the eye. 
3. Acting as a blood-retinal barrier between the choroid and neural retina. 
4. Regeneration of visual pigment all-trans-retinal into its 11-cis configuration 
during the visual cycle. 
5. Secretion of growth factors required for healthy choroidal maintenance. 
6. Active exchange of nutrients with the choroid. 
7. Facilitation of metabolite transport from the bloodstream to the 
photoreceptors.  
 
The regular RPE array is often replaced by a more heterogeneous mixture of shapes 
and sizes through natural age-related changes. This is due to numerous changes 
including loss of melanin granules, thickening of Bruch’s membrane, microvilli atrophy 
and basal infolding disorganisation (Bonilha, 2008). RPE function is also susceptible 
to disruption by the pigment granule lipofuscin which accumulates with age. 
Lipofuscin is composed of the lipid-containing residues of photoreceptor 
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phagocyctosis and has been found to correlate with RPE dysfunction, leading to 
apoptosis (Dorey et al., 1989; Holz et al., 1999; Suter et al., 2000).  
 The photoreceptor layer 
There are two types of specialised neurons found within the retina, known as rod and 
cone photoreceptors. Both are capable of performing phototransduction by converting 
light energy into a neuronal impulse in order to generate information useful to the 
visual system (Hecht et al., 1942). Rods provide maximum sensitivity in scotopic 
conditions, although at the expense of temporal sensitivity and visual acuity. Cones 
operate under photopic conditions, and are responsible for high acuity vision and 
temporal resolution (Fu, 2010). Human colour vision is based on the three subtypes 
of cone photoreceptor, each of which is characterised by its response characteristics 
to different wavelengths of light (i.e. its spectral sensitivity curves). There are no 
subtypes of rods therefore the rod system is monochromatic (Lee, 2008).  
There are approximately 92 million rods and 4.6 million cones found within the human 
retina, which vary in density with eccentricity (Curcio et al., 1990). The peripheral 
retina is dominated by rods which reach a density of 160,000 to 190,000 cells/mm2 at 
20-30° eccentricity (Ahnelt, 1998). The fovea exclusively houses cones, where they 
can be found at their greatest density of 200 000 cells/mm2 (Curcio et al., 1990). Cone 
density decreases sharply with increasing retinal eccentricity as seen in Figure 1.4.  
The major elements of a photoreceptor are shown in Figure 1.5. The photopigment, 
responsible for the capture and conversion of light energy, is located within the outer 
segment which is adjacent to the RPE. This is joined by a narrow connecting cilium 
to the inner segment which is filled with mitochondria in order to fuel metabolic activity 
(Hoang et al., 2002). An axon extends from the inner segment through the external 
limiting membrane and outer nuclear layer into the outer plexiform layer where it forms 
a synaptic terminal (Mustafi et al., 2009). Cones are associated with a complex 
network of postsynaptic cells, whereas the circuitry associated with rods is minimal. 
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Even though rods outnumber cones by approximately 20-fold, most mammalian 
retinas have 8-10 cone-driven neurons for every cell associated with the rod pathway 
(Masland, 2001).  
A typical rod appears small in cell body but long and slender in inner and outer 
segment. Their shape is maximised for high density packing in order to enhance the 
capture of photons. Contained within their outer segments are the photopigment 
molecules embedded in a stack of around 600-1000 membranous discs (Sharma and 
Ehinger, 2003). Rod-based discs, unlike their cone counterparts, are free of 
attachment from the surrounding cell membrane and each is separated from the 
others. The discs of both rods and cones are produced at the base of the outer 
segment and are displaced to the tip by underlying newly formed discs (Young, 1971). 
Once at their final destination, the disc is encapsulated by the RPE microvilli, shed 
and phagocytosed (Young and Bok, 1969; Anderson et al., 1978). Cone outer 
segments are characteristically conical in shape measuring around 6μm at the base 
and 1.5μm at the tip. However, at the fovea their appearance is likened to rods due 
to the high density of the cones present (Borwein and Borwein, 1980). The discs 
contained within cones have a longer lifespan than their rod counterparts which take 
around 10 days to relocate from the base to the tip of the outer segment (Young, 
1971).  
The visual pigment found within the membranous discs consists of a variable protein 
component (opsin) and a bound chromophore which has been identified in humans 
as a vitamin A derivative (11-cis retinal). The photopigment found within rods has a 
peak spectral sensitivity of around 500nm and is known as rhodopsin (Wald and 
Brown, 1958). The visual pigment of cones is collectively termed iodopsin and exists 
in 3 forms (cyanolabe, chlorolabe and erythrolabe) corresponding to the peak 
wavelength absorption of each cone subtype (Lucas et al., 2013).  
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Figure 1.4. A graph displaying retinal rod and cone densities across the horizontal meridian 
(Kolb et al., 2013; copyright permission from http://webvision.med.utah.edu/). 
 
 
1.2. Light and dark retinal physiology  
Changes in light level elicit changes in visual function via the alteration of physiological 
processing at a retinal level. Therefore, retinal physiology can be found to differ under 
photopic and scotopic conditions. In the presence of light visual perception is initiated 
by activation of the visual pigment, this process is known as visual phototransduction. 
Adjustments to increases of light level are called light adaptation whereas 
adjustments to decreases are called dark adaptation. This section provides detail on 
Figure 1.5. Schematic diagram of rod and cone photoreceptor structure (Wright et al., 2010; 
copyright permission from Elsevier [2018] licence 4274211239188). 
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the photochemical changes that occur within the retina in both light and dark 
conditions.    
 Visual phototransduction cascade 
Visual phototransduction is a process by which light is converted into electrical signals 
at a photoreceptor level. Once generated the electrical signals are transmitted through 
the visual pathway and ultimately processed into a visual interpretation of 
surroundings. The process of generating a visual signal in this manner is complex and 
consists of numerous stages. The following text provides a brief summary of the 
phototransduction pathway however for a more detailed description of the mechanism 
and its components the reader is directed to the excellent review articles by Lamb and 
Pugh (2004) and Yau and Hardie (2009).      
 The visual phototranduction pathway is initiated when a photon is absorbed 
by visual pigment. 
 The captured light energy causes the retinal found within the visual pigment 
to undergo a process known as photoisomerisation. 
 Photoisomeration causes a structural change within the pigment as it alters 
from an 11-cis retinal to an all-trans retinal configuration. 
 Opsin is unable to bind to all-trans retinal and is forced to undergo a 
conformational change into metarhodopsin II. At this stage the pigment is 
deemed to be ‘bleached’. 
 Metarhodopsin II is unstable causing the pigment to split. This yields opsin and 
all-trans retinal.  
 The free opsin activates a regulatory protein identified as transducin. This 
event causes transducin already bound to guanosine diphosphate (GDF) to 
dissociate and bind to guanosine triphosphate (GTP) instead. 
 Once bound with GTP, the alpha subunit of transducin dissociates from its 
beta and gamma subunits. 
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 The alpha subunit-GTP complex activates phosphodiesterase (PDE).     
 PDE breaks down cyclic guanosine monophosphate (cGMP).  
 The decrease in cGMP causes photoreceptor Na+ channels to close (Ebrey 
and Koutalos, 2001). 
 The closure of photoreceptor cation channels results in a reduction in the 
current of ions between the photoreceptor and its surrounding extracellular 
matrix. The photoreceptor is deemed to be ‘hyperpolarised’ at this stage. 
 Hyperpolarisation of the photoreceptor results in a reduction of 
neurotransmitter release which in turn leads to the generation of a 
physiological nerve signal. 
 Once generated the electrical signal is propagated down the visual pathway.  
 
This aforementioned process relies upon the presence of light. When the photon 
source is removed the events of phototransduction cease. The deactivation of the 
phototransduction cascade begins when transducin is driven to hydrolyse its bound 
GTP into guanosine diphosphate (GDP). This in turn halts the action of PDE. 
Following this, upregulation of guanylate cyclase obtained from calcium within the 
photoreceptor causes the transformation of GTP into cGMP. This leads to the 
replenishment of cGMP levels and the reopening of Na+ channels. 
 Recycling of visual pigment 
Visual pigment is recycled following phototransduction. In addition to the summary 
provided below, the mechanism via which bleached pigment is regenerated can be 
seen in Figure 1.6. For greater detail the reader is directed to the review articles by 
Lamb and Pugh (2004) and Yau and Hardie (2009).   
 Phosphorylation of metarhodopsin II initiates visual pigment recycling. 
 Once phosphorylated metarhodopsin II loses its affinity for transducin. 
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 Following this, the deactivation of metarhodopsin II is completed when it is 
bound by arrestin.  
 Simultaneous phototransduction cessation at this point causes the release of 
the neurotransmitter glutamate to be resumed.  
 All-trans retinal is then found to be reduced into all-trans retinol by an enzyme 
driven reaction (Wang and Kefalov, 2011).  
 The all-trans retinol is transferred into the RPE where it is transformed into all-
trans retinyl via the addition of an ester bond.  
 RPE derived enzymes are then instrumental in the isomerisation of all-trans 
retinyl into 11-cis retinol.  
 The 11-cis retinol is stored or converted into 11-cis retinal and diffused back 
into the photoreceptor. 
 Once back in the outer segment the regeneration of visual pigment is 
completed via the recombination of 11-cis retinal and opsin.  
 
Due to repeated recycling, retinol is susceptible to degradation over time and cannot 
be replaced by direct human synthesis. Levels required for phototransduction can be 
maintained via the sufficient intake of Vitamin A in the diet (Blomhoff and Blomhoff, 
2006). 
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 Alternative method of visual pigment regeneration  
Evidence based on a number of animal models has implicated Müller cell activity in 
the regeneration of cone photopigment (Das et al., 1992; Mata et al., 2002; Wang and 
Kefalov, 2011). The RPE derived protein RPE65 has been identified as an integral 
part of all-trans retinyl to 11-cis retinal conversion during the regeneration of rhodopsin 
(Redmond et al., 1998). However evidence suggests there is a secondary or 
substitute mechanism which results in retinoid production within a RPE65 deficient 
environment (Wang and Kefalov, 2011). Müller cells have been suggested as the 
alternative source due to their cellular content of 11-cis-retinyl-ester synthase and all-
trans-retinol isomerase. It is proposed that these enzymes allow the conversion of all-
trans retinol into 11-cis retinol which is later procured and utilised by cone 
photoreceptors (Mata et al., 2002). Rod photoreceptors are unable to facilitate 
photopigment regeneration via this method due to their lack of the enzyme 11-cis-
retinol dehydrogenase. Therefore, this pathway is specific to the regeneration of cone 
visual pigment.   
Figure 1.6. The process via which 11-cis retinal is recycled following usage within the 
phototransduction cascade. Rhodopsin is denoted as RHO (Wright et al., 2010; copyright 
permission from Elsevier [2018] licence 4274211239188). 
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 The dark current 
Under scotopic conditions, cation channels located in the outer segment are kept 
open. The channels are controlled by cyclic guanosine monophosphate (cGMP) 
which is present at a high level under scotopic conditions (Miller, 1985). Sodium ions 
(Na+), which passively enter the cell through these channels, travel into the inner 
segment via the connecting cilium and are actively pumped out of the photoreceptor 
via a sodium/potassium ion pump (Na+/K+) (Arshavsky et al., 2002). This process 
reduces the membrane potential of the photoreceptor and in combination with the 
steady inflow of Na+ into the outer segment keeps the cell depolarised at around minus 
40mV. The flow of Na+ through the photoreceptor is known as the dark current. These 
conditions favour the release of the neurotransmitter glutamate which in turn transfers 
the neuronal signal onto synapsing bipolar cells. Off-centre bipolar cells are 
hyperpolarised by glutamate release at the synapse whilst on-centre bipolar cells are 
hyperpolarised in response to the downregulation of glutamate release. The 
photoreceptor Na+/K+ pump is driven by ATP, and generates a high metabolic demand 
in conditions of darkness. 
Assessment of the effect of light intensity on the toad (Hamer et al., 2005) and 
salamander (Koutalos et al. 1995; Hamer et al., 2005) rod circulating current has 
suggested that progressively increasing the intensity of a background adapting light 
causes a progressive decrease in the rod circulating current. Complete cessation of 
the dark current occurs at a light intensity which varies between species (see Figure 
1.7). An intensity of approximately 46 and 30 scotopic trolands (Td) is needed to 
reduce the rod circulating current by half in salamander (Nikonov et al., 2000) and 
mice (Lyubarsky et al., 1999), respectively. In comparison, a higher intensity is 
necessary to illicit the same reduction of rod circulating current in humans. Based on 
the assessment of one subject, Pepperberg et al. (1997) found that exposure to a 
luminance of 100 scotopic Td was required to reduce the rod current by 50%. Thomas 
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and Lamb (1999) used an electrophysiological technique to determine the attenuation 
of the maximal response of rod photoreceptors achieved at different background 
levels in 8 subjects. Their data suggested that a steady-state background intensity of 
70 scotopic Td resulted in a 50% reduction in the human rod circulating current.        
 
 
 
 
 
 
1.3. Age-related macular degeneration 
Age-related macular degeneration is a condition that typically manifests over the age 
of 55 (Klein et al., 2006) and affects the macular region of the retina. With progression 
over time it can lead to severe central vision loss in those affected. At present AMD 
is recognised as the principal cause of blindness in developed countries and is 
responsible for 8.7% of blindness worldwide (World Health Organisation, 2009). AMD 
can be classified into the following four subtypes (Ferris et al., 2013); early and 
intermediate AMD, which aren’t associated with marked visual loss, and two forms of 
late AMD, geographic atrophy (GA) which causes a slow progressive visual loss, and 
nAMD which causes rapid loss of central vision if untreated.   
Figure 1.7. This unified model of light adaptation and its effects on circulating current in rods 
has been adapted from Hamer et al. (2005). It features data collected by both Hamer et al. 
(2005) and Koutalos et al. (1995). The figure plots steady-state circulating current as a function 
of background light adaptation. The data points show Koutalos et al.’s (1995) control 
(triangles) and suppressed dark adaption (circles) data. The solid curves form the basis of 
Hamer et al.’s (2005) predictions of suppression as based on their unified model. The data 
from Koutalos et al. (2005) has been shifted along the horizontal axis to compensate for 
differences in sensitivity between the salamander and the more sensitive toad model used by 
Hamer et al. (2005; copyright permission from Cambridge University Press [2018] licence 
4274230980679).  
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Studies show that AMD has a high prevalence and correlation with visual impairment 
in North America (Chou et al., 2013), Asia (Kawasaki et al., 2010) and the United 
Kingdom (UK) where it is recognised as the primary source of sight impairment 
registration (Bunce et al., 2010; 2015). The AMD subtype that leads to slightly more 
than half of registrations of sight impairment in the UK is GA, this is due to the 
widespread adoption of intravitreal treatment for nAMD (Bunce et al., 2015). The 
actual prevalence however is thought to be even higher than registration figures 
suggest due to the exclusion of those who choose not to be registered with a visual 
impairment. Around 600,000 people in the UK are estimated to have advanced AMD, 
a figure that is expected to rise to around 750,000 by 2020 (Minassian et al., 2011). 
When combined with those who exhibit only early signs the total number of UK 
residents with AMD is estimated to be over 1.5 million (Owen et al., 2012).    
Future projection suggests that due to population ageing, AMD cases within the UK 
are likely to increase by a third between 2012 and 2020 (Owen et al., 2012). This 
prevalence renders AMD a significant and growing socio-economic burden due to the 
cost of detection, treatment and provision of social care (Owen et al., 2012). With the 
potential to cause devastating effects on an individual’s lifestyle AMD has also been 
linked to loss of independence and depression (Brody et al., 2001; Casten and 
Rovner, 2013; Jivraj et al., 2013; Zheng et al., 2017), loss of ability to carry out daily 
tasks (Scilley et al., 2002; Gopinath et al., 2017; Ugurlu et al., 2017), increased risk 
of falling (see reviews by Dhital et al., 2010 and Moenter et al., 2014), and reduced 
quality of life (Hassell et al., 2006; Coleman et al., 2010). On a global scale, based on 
the analysis of 39 population-based studies, it is expected that 196 million people will 
exhibit some form of AMD by 2020. This figure is predicted to rise to 288 million by 
2040 (Wong et al., 2014).   
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 Risk factors for AMD 
There are many risk factors associated with the development and progression of 
AMD. Age is widely accepted as the greatest unpreventable risk factor for advanced 
AMD development (AREDS, 2000; Klein et al., 2006; Buch et al., 2005; Wang et al., 
2007; Srinivasan et al., 2017) however other key risk factors have been identified and 
are documented in the following summary. In addition to those mentioned, refractive 
error (Wang et al., 1998; Wong et al., 2002; Tao and Jonas, 2010), cataract surgery 
(Wang et al., 2003a; Klein et al., 2002a), gender (AREDS, 2000; 2005; Owen et al., 
2012; Grassmann et al., 2015), iris colour (Frank, 2000; Klein et al., 2014a; Schick et 
al., 2016), exposure to sunlight (Mitchell et al., 1998; Schick et al., 2016; AREDS, 
2000; 2005; Fletcher et al., 2008), alcohol consumption (Adams et al., 2012) and 
diet/nutrition (Seddon et al., 2001; Smith et al., 2000; San Giovanni et al., 2009; 
AREDS, 2001a; AREDS2, 2013; see Section 1.3.2.1) have also been associated with 
AMD risk. For additional information the reader is directed to the excellent reviews by 
Chakravarthy et al. (2010) and Lambert et al., (2016).   
 Genetics 
It has been estimated that between 46 and 71% of AMD risk is attributable to genetic 
variation and that first degree relatives of those with late AMD are at a substantially 
elevated risk of developing the condition themselves (Seddon et al., 2005; Klaver et 
al., 1998; Priya et al., 2012). Based on a study of 506 twin pairs, Hammond et al. 
(2002) found the phenotype of large soft drusen (>125µm) and the presence of ≥20 
hard drusen were the most hereditable components of AMD. Genetic susceptibility 
was also confirmed via the finding of a higher concordance of AMD in monozygotic 
twins when compared to dizygotic twins. The risk of developing advanced AMD has 
been found to be increased nearly 4-fold for those with a family history of AMD, 
particularly in cases of nAMD (Smith and Mitchell, 1998). The presence of an 
immediate family member with AMD amplifies this risk, which has been estimated as 
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a 28 times and 12 times increase in risk for those with an affected parent or sibling, 
respectively (Shahid et al., 2012).   
To date, approximately 40 genes have been identified that may be associated with 
the development of AMD (Lambert et al., 2016). It is likely that more genes will be 
identified in the future given the continued exploration of the seven previously 
unidentified loci associated with AMD highlighted by the AMD consortium in 2013 
(AMD Gene Consortium, 2013).   
The genes currently identified as being involved in AMD pathogenesis can be broadly 
classified into 5 groups depending on their biological pathway: the complement 
system, cholesterol metabolism, extracellular matrix remodeling, oxidative stress and 
retinal-specific function (Haddad et al., 2006). Genetic variants within each of these 
functional groups have been found to be particularly associated with the prevalence 
of AMD. It is estimated that nearly 50% of the risk of developing AMD can be attributed 
to gene mutations within the complement system (Klein et al., 2013; Shen et al., 
2015). In particular, complement factor H (CFH), complement factor B, complement 
factor D, and complement components C2, C3, and C5 have been identified as 
relevant genes contributing to AMD risk (Maller et al., 2006; Gold et al., 2006; Yates 
et al., 2007; Jakobsdottir et al., 2008; Wu et al., 2013). From the remaining groups 
mutations in the hepatic lipase (LIPC), hemicentin-1 (HMCN1), apolipoprotein E 
(ApoE), ABC-binding cassette A1 (ABCA1), tissue inhibitor of matrix 
metalloproteinase-r (TIMP-3), cholesterol ester transfer protein (CETP) and the age-
related maculopathy susceptibility 2 (ARMS2) gene have all been implicated with risk 
of AMD (Allikmets et al., 1997; Schultz et al., 2003; Yang et al., 2006; Yu et al., 2011; 
Baird et al., 2006; Chakravarthy et al., 2013a; Fritsche et al., 2015; Wang et al., 2015; 
Neale et al., 2010; Levy et al., 2015; Paun et al., 2015). For further information on 
each genetic variant the reader is referred to the review articles by Leveziel et al. 
(2011) and Lambert et al. (2016).     
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 Race 
Multiple studies have demonstrated that those of a white racial origin have a 
consistently higher incidence of AMD when compared to people of other ethnic 
backgrounds (Bressler et al., 2008; AREDS, 2005; Eye Disease Prevalence Research 
Group, 2004; Rein et al., 2009; Klein et al., 2011). In particular, a higher prevalence 
of both nAMD and GA has been found in white people when compared to black people 
(Klein et al., 2006; 2011; Bressler et al., 2008). It has also been identified that whilst 
black, Asian and Hispanic people manifest early AMD with almost the same 
prevalence as white people, they are subsequently less likely to progress to the end-
stage of the disease (Friedman et al., 1999; Chang et al., 2008; Varma et al., 2010; 
Vanderbeek et al., 2011). The reason for the difference in AMD prevalence between 
these racial groups is not fully understood. It was originally speculated that, due to its 
ability to scavenge free radicals, melanin plays a protective role against disease 
progression in those where it is found in increased concentrations (Jampol and 
Tielsch, 1992). This is supported by the prevalence of AMD in different racial groups, 
which  suggests that the degree of ocular pigmentation could be a significant 
protective factor, with white Caucasians showing the highest rates (5.4%), followed 
by Chinese (4.6%), Hispanics (4.2%) and those of black racial origin (2.4%) (Klein et 
al., 2006; Priya et al., 2012). Advances in genetic research have also identified various 
genotypes which increase an individual’s vulnerability to AMD (see Section 1.3.1.1). 
Each genetic variant presents with varying frequency within different racial groups 
and therefore has the potential to influence AMD incidence and progression (Klein, 
2011).     
 General Health  
An association has been found between AMD and cardiovascular disease on 
numerous occasions (Tan et al., 2008a; Hogg et al., 2008, Wu et al., 2014). The 
strength of association has been found to be maximal when referring to advanced 
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AMD, where those with cardiovascular disease may be twice as likely to develop late 
stage manifestations of the disease (Chakravarthy et al., 2010). Conversely evidence 
has also been reported which shows that the presence of cardiovascular disease does 
not increase the risk of advanced AMD (DelCourt et al., 2001).    
The presence of AMD has also been found to be positively associated with systemic 
hypertension (Hyman et al., 2000; AREDS, 2000; Churchill et al., 2006; Klein et al., 
2003; Tan et al., 2008a; Duan et al., 2007). In comparison to normotensive individuals, 
a study by Klein et al. (2003) found that patients with both treated and uncontrolled 
blood pressure have a three-fold increase in the development of nAMD. The findings 
of the aforementioned studies included in this section indicate that AMD, 
atherosclerosis and cardiovascular disease may have similar pathogenic pathways. 
Other associations between general health and AMD have been identified, such as 
reduced blood triglyceride levels, increased body mass index and elevated fibrinogen 
levels. However, more investigation is required in order to solidify current, 
unsubstantial evidence regarding these factors (Seddon et al., 2003; AREDS, 2005; 
Hogg et al., 2008; Ngai et al., 2011).    
 Smoking 
Cigarette smoking is the strongest environmental risk factor for nAMD (Pons and 
Marin-Castano, 2011). Cigarette smokers have consistently been identified as being 
2-3 times more likely to develop AMD when compared to those who have never 
smoked (Thornton et al., 2005; Evans et al., 2005). They are also at risk of developing 
AMD on average 10 years earlier than non-smokers (Mitchell et al., 2002). Cigarette 
smoking has been found to increase the risk of both early AMD (Klein et al., 2002b) 
and end-stage AMD, with the strongest correlation to the development of nAMD 
(Vingerling et al., 1995; AREDS, 2005; Thornton et al., 2005; Woo et al., 2015). 
Furthermore, evidence suggests that smoking has a dose-dependent relationship with 
AMD risk, which increases with the number of pack years smoked (Seddon et al., 
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1996; Chang et al., 2008). The cessation of smoking has also been found to lead to 
a subsequent reduction in AMD risk especially in those who have previously smoked 
fewer than 20 cigarettes per day (Christen et al., 1996; Khan et al., 2006). This finding 
is however not definitive as some studies have significant findings to suggest that 
former smokers are still at an increased risk (Smith et al., 2001; Thornton et al., 2005). 
The mechanism underlying the association between smoking and AMD remains 
unclear. Theories proposed include smoking induced vascular changes (Solberg et 
al., 1998), similar to those seen in atherosclerosis, complement pathway activation 
(Kew et al., 1985) and the reduction of antioxidants as induced by the multitude of 
chemicals found in tobacco smoke (Bernhard and Wang, 2007; Connell et al., 2009). 
 AMD pathogenesis 
The precise mechanism behind AMD development and progression is unknown, 
Current evidence suggests that its pathogenesis is a multi-factorial process in which 
oxidative stress, age-related changes to Bruch’s membrane, lipofuscin formation, 
chronic inflammation, hypoxia and choroidal vascular changes have all been 
implicated. Visual loss resulting from AMD pathogenesis ultimately arises via the 
dysfunction of photoreceptors secondary to an atrophic or neovascular event. This 
section gives a brief overview of the three most widely accepted mechanisms of AMD 
pathogenesis. For greater detail on the aforementioned factors and how they are 
implicated in AMD pathogenesis the reader is directed to the review papers by Ambati 
et al. (2003), Stefánsson et al. (2011) and Luthert (2011). 
 Oxidative stress 
Oxidative stress is a mechanism of cellular damage resulting from the byproducts of 
oxygen metabolism during aerobic respiration. Energy required by the human body is 
primarily obtained through the oxidation of dietary carbohydrates, proteins and lipids. 
This is achieved through a series of reactions known as the tricarboxylic acid cycle. 
Products created via this method are transported to mitochondria where a process of 
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high oxygen consumption, known as oxidative phosphorylation, occurs (Beatty et al., 
2000). This culminates in the creation of usable units of energy in the form of 
adenosine triphosphate (ATP). As well as generating intended ATP, this pathway has 
also been found to result in the formation of reactive oxygen intermediates (ROIs). 
ROIs are molecules found to be in an unstable or reactive state. They are formed as 
byproducts from active sites of enzymes, for example ATP synthase used in oxidative 
phosphorylation (Beatty et al., 2000). Stimuli including ageing, irradiation, 
inflammation and cigarette smoking have all been linked to the production of ROIs, 
such as free radicals, hydrogen peroxide and singlet oxygen (Beatty et al., 2000; Cui 
et al., 2012). Reactions between ROIs and other cellular molecules are often 
unfavourable as they can lead to direct apoptosis, inhibition of function or the 
formation of more harmful ROIs. It is for this reason that cumulative damage arising 
from reactions involving ROIs was originally proposed as a mechanism for ageing and 
age-related disorders (Harman, 1956).  
The retina is particularly susceptible to the generation of ROIs. This is due to a number 
of factors including: 
 Its high oxygen consumption. 
 Its exposure to a high level of natural irradiation through visible light. 
 The readily oxidised structure of its photoreceptor outer segments, due to high 
levels of polyunsaturated fatty acids. 
 Excess ROI generation by neighbouring RPE phagocytosis. 
 The presence of photosensitising agents such as lipofuscin, which promote 
further oxidation (see Beatty et al. 2000 for review). 
 
In humans the activity of ROIs is suppressed by antioxidants, such as vitamin C, 
glutathione and carotenoids. The primary antioxidants found at the macula are the 
macular carotenoids, lutein and zeaxanthin. With increasing age, the changes that 
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manifest at the macula can be attributed to the ever growing imbalance between rising 
numbers of ROIs in comparison to antioxidants that naturally reside within the area. 
As a long-term result of unregulated ROI activity it is hypothesised that clinical 
features of AMD such as photoreceptor death and vascular endothelial growth factor 
(VEGF) upregulation are in some part resultant from the mechanism of oxidative 
stress (Beatty et al., 2000).  
Numerous studies such have investigated the link between oxidative stress and AMD 
progression (Seddon et al., 2006; San Giovanni et al., 2007; Tan et al., 2008b; 
AREDS, 2001a; AREDS2, 2013; Weikel et al., 2012). Oxidative protein modifications 
have been identified as a component of drusen (Crabb et al., 2002; Hollyfield et al., 
2003) and slower rates of disease progression have been found in those who take 
oral supplements high in antioxidant (AREDS, 2001a; AREDS2, 2013; Chew et al., 
2014). The Age-Related Eye Disease Study (AREDS) demonstrated the efficacy of 
zinc-antioxidant supplements for preventing or delaying progression of early AMD to 
late AMD in those who are at high risk (AREDS, 2001a; AREDS2, 2013). The study 
showed that antioxidant supplementation reduced the 5-year risk of progression to 
advanced AMD by 25% for those with intermediate AMD or unilateral nAMD at 
baseline (AREDS, 2001a). This is supported by other studies that have reported a 
reduced risk of long-term incident AMD for those with a high dietary intake of lutein 
and zeaxanthin (Tan et al., 2008b) and naturally high levels of systemic carotenoids 
(Zhou et al., 2011). The reverse is also true, in that those who smoke or have a 
naturally high predisposition to ROI formation have been found to be at an increased 
risk of AMD development (Khandhadia and Lotery, 2010). 
 Chronic inflammation and immune response  
Inflammatory involvement in AMD pathogenesis was hypothesised following evidence 
from numerous studies documenting the presence of immunological proteins within 
drusen (Hageman et al., 2001; Johnson et al., 2001; Anderson et al., 2002). It was 
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suggested by Roth et al. (2004) that drusen and other debris generated as a result of 
ageing and AMD release a pro-inflammatory signal which, in turn, initiates part of the 
innate immune system known as the complement cascade. This hypothesis has since 
been substantiated via the finding of other raised inflammatory markers involved with 
blood clotting and pathogenic defence in those with AMD (Shankar et al., 2007; 
Chakravarthy et al., 2010).  
As introduced in Section 1.3.1.1, associations have also been found between genetic 
polymorphisms in genes which govern complement pathway activity, and increased 
risk of AMD. These polymorphisms have the potential to lead to altered cellular 
responses to assault or injury and unregulated complement activation (Donoso et al., 
2005). Mutation of the CFH gene has been found to display an association with all 
stages of AMD (Despriet et al., 2006; Li et al., 2006; Sparrow et al., 2012). The 
Tyr402His polymorphism associated with CFH has been found to affect its binding 
properties and thus impair function (Donoso et al., 2010). Based on the results of 
three separate investigations assessing the relationship between CFH polymorphism 
and AMD development, Haddad et al. (2006) concluded that close to a half of all AMD 
cases in adults may be attributable to the CFH gene. In accordance with this, those 
who carry two copies of the polymorphism may have over a 10 fold increased risk of 
developing AMD compared to those who do not display the mutation (Despriet et al., 
2006).  
 Outer retinal hypoxia  
Changes have been found to occur to the choroidal vasculature and circulation in 
early AMD that may result in outer retinal hypoxia (Feigl, 2009). This has the potential 
to cause the formation of a choroidal neovascular membrane (CNVM) or direct cell 
apoptosis leading to GA, via the upregulation of hypoxia inducible factor (HIF) 
(Arjamaa et al., 2009). In addition to decreases in choroidal flow and volume, hypoxia 
in AMD may be exacerbated by such factors as increased scleral rigidity, Bruch’s 
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membrane thickening and vitreoretinal adhesion, all of which reduce the diffusion of 
oxygen across the outer retina (Stefánsson et al., 2011). The reader is referred to 
Chapter 2 where the implication of hypoxia in the pathogenesis of AMD is discussed 
in detail.   
 Clinical features of AMD 
Visual loss as a result of AMD is associated with the advanced forms of the disease 
as opposed to early manifestation. The clinical features that represent the 2 end-stage 
subtypes of AMD differ, however manifestations of early and intermediate AMD can 
appear in combination. This section provides an overview of clinical features 
encountered in AMD. 
 Drusen 
Drusen represent an accumulation of extra-cellular material that is deposited between 
the RPE and the inner collagenous layer of Bruch’s membrane, or between the RPE 
and its basement membrane. Identified morphologic phenotypes of drusen include 
hard, soft, calcified, reticular, large colloid, cuticular and basal laminar subgroups. The 
particular category that drusen are assigned to depends on their size, shape, colour, 
elevation, location within the retinal layers and definition. Drusen within each category 
also differ in component structure and may contain a combination of hydrophilic (e.g. 
CFH), hydrophobic (e.g. esterified cholesterol) and amphiphilic (e.g. Apolipoprotein 
B) factors (Anderson et al., 2002; Li et al., 2007; Curcio et al., 2010). Drusen < 63μm 
in diameter are referred to as small drusen or drupelets, drusen between 63μm and 
up to 125μm in diameter are classified as medium drusen, whilst those over 125μm 
in diameter are large drusen (Ferris et al., 2013).  
Hard drusen consist of hyaline material and appear as small hemispherical yellow or 
white discrete deposits with well-defined borders (Figure 1.8). The formation of hard 
drusen is generally regarded as being part of the normal ageing process although the 
impact of their presence has been linked to mechanical disruption of the RPE and 
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photoreceptors (Al-Hussaini et al., 2009; Johnson et al., 2003). The presence of 
multiple hard drusen is a risk factor for AMD onset (Klein et al., 2002b; 2015). In 
contrast, the presence of soft drusen is diagnostic for early AMD. Soft drusen are 
larger than hard drusen (often exceeding 125μm in diameter), and their boundary may 
be distinct or indistinct. Appearing as yellow or grey in colour, they can arise 
independently or stem from pre-existing hard drusen (Sarks et al., 1994). The 
appearance of soft drusen is indicative of underlying diffuse changes to Bruch’s 
membrane (basal laminar and linear deposits) (Sarks et al., 1994).  Upon 
enlargement, several soft drusen may coalesce into a confluent form. The presence 
of soft drusen in large numbers has been associated with a significant risk of AMD 
progression (Wang et al., 2003b; Klein et al., 2008a). Once visible, drusen may persist 
as a clinical feature or regress over time via calcification and macrophage removal 
(Querques et al., 2014). Regression can be accompanied by the appearance of RPE 
pigmentary change and choriocapillary atrophy, or may precede the onset of choroidal 
neovascular growth (Yehoshua et al., 2011). 
Reticular pseudodrusen (RPD), also known as subretinal drusenoid deposits, appear 
as yellowish interlacing networks of drusen which are deposited internal to the RPE 
(Mimoun et al., 1990; Hogg, 2014). RPD have similar constituents to soft drusen and 
are most commonly found in conjunction with other AMD features such as drusen, 
pigmentary changes, or late AMD (Zweifel et al., 2010; Sarks et al., 2011). Multiple 
longitudinal studies have revealed RPD as a strong predictor for progression to both 
nAMD (Ueda-Arakawa et al., 2013; Sarks et al., 2011; Cohen et al., 2007; Lee et al., 
2012; Sawa et al., 2014; McBain et al., 2011; Klein et al., 2008b; Smith et al., 2006) 
and GA (Smith et al., 2006; Joachim et al., 2014; Finger et al., 2014; GAP Study 
Group, 2011). Despite this, the prevalence and specific role of RPD in AMD 
pathogenesis is unclear. Several of the studies reporting a relationship between RPD 
and nAMD also reported an association between RPD and retinal angiomatous 
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proliferation compared with other subtypes of nAMD (Ueda-Arakawa et al., 2013; 
Cohen et al., 2007; Sawa et al., 2014; McBain et al., 2011). As RPD are best 
visualised using infrared imaging or spectral domain optical coherence tomography, 
future analysis of epidemiological data using multimodal imaging will enable a more 
accurate determination of the population prevalence and risk factors associated with 
its development. Furthermore, the localisation of RPD internal to the RPE suggests 
that AMD may be a 2-component disease comprising of both subretinal and choroidal 
changes, however further research is needed to clarify whether choroidal changes 
associated with AMD pathogenesis are secondary to changes internal to the RPE 
(Sivaprasad et al., 2016).      
 Pigmentary abnormalities  
The effect of AMD progression upon RPE melanin concentration results in clinically 
evident pigmentary changes as seen in Figure 1.8. Focal hyperpigmentation results 
from increased melanin, cell proliferation or migration of pigment epithelial cells within 
the RPE. The areas of pigment clumping appear darker than the surrounding healthy 
RPE tissue and can be found to overlie both soft and hard drusen (Bressler et al., 
1994). The presence of focal hyperpigmentation has been reported as a risk factor for 
the development of neovascular AMD (Klein et al., 2002b). Focal hypopigmentary 
changes are also characteristic of AMD and manifest due to RPE degeneration (Klein 
et al., 2008a). The loss of melanin granules with age is a normal occurrence, however, 
the loss through AMD as a result of RPE atrophy or thinning leads to visible areas of 
mottled RPE appearance (Bonilha, 2008). 
 Geographic atrophy  
Geographic atrophy is considered to be the end stage of dry AMD. It is defined by a 
well demarcated round or oval area of hypopigmentation in which choroidal vessels 
are more visible than in the surrounding retinal tissue (Figure 1.8). It is characterised 
by RPE and photoreceptor degeneration which results in a dense scotoma 
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corresponding to the area of atrophy. The development of GA is gradual. During 
progression initial paracentral loss is typically accompanied by foveal sparing until late 
in the disease process (Sunness et al., 2007; Holz et al., 2014). Over time GA has 
the potential to significantly impair visual function and can result in difficulty when 
performing tasks such as reading, watching television and recognising faces 
(Sunness et al., 1997). As a result, those with bilateral GA may require low vision aids 
and the provision of social services in order to maintain their independence (Klein et 
al., 1995).  
 
 
Figure 1.8. The fundus appearance of (A) hard drusen, (B) soft drusen, (C) reticular 
pseudodrusen, (D) neovascular AMD, (E) pigmentary changes at the macula and (F) 
geographic atrophy. 
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 Choroidal neovascularisation  
Choroidal neovascularisation is a feature of neovascular AMD, and occurs as a result 
of an imbalance between anti- and pro-angiogenic growth factors responsible for 
choroidal maintenance in healthy eyes. In advanced AMD the up-regulation of VEGF 
outweighs its anti-angiogenic counterpart, pigment epithelial derived factor (PEDF), 
resulting in the new vessel growth (Schlingemann, 2004). These new vessels grow 
from the choroid, through Bruch’s membrane and into the subretinal space. Their 
arrival at the RPE results in either cessation of their growth, or barrier penetration to 
form a CNVM between the RPE and sensory retina (Grossniklaus and Gass, 1998). 
Due to their fragility, the new vessels are prone to leakage and rupturing. At a retinal 
level this process may be visible via the appearance of haemorrhaging (sub or 
intraretinal), intraretinal or subretinal fluid, hard exudates or a pigment epithelial 
detachment (Figure 1.8). At this stage blurred vision or metamorphopsia may be 
experienced (Fine et al., 1986). Classically the symptom of straight lines appearing 
bent or kinked is reported. Diagnosis and classification is generally based on optical 
coherence tomography and fluorescein angiography. Based on the location of the 
CNVM the two main designations of nAMD are classic (the CNVM penetrates the 
RPE) and occult (the CNVM is sub-RPE). In contrast, prior to CNVM formation 
angiomatous proliferation originating from the retina has also been reported in a 
second subtype of nAMD known as retinal angiomatous proliferation (RAP). The 
retinal vessels evident in RAP extend posteriorly into the subretinal space and may 
eventually communicate with choroidal neovascularisation (Yannuzzi et al., 2001; 
Freund et al., 2008).  
Visual loss through a CNVM occurs at a rapid rate when compared to the timescale 
of GA development, therefore early detection and treatment is imperative. If left 
untreated the retinal haemorrhaging will eventually lead to the formation of a disciform 
scar which defines the end stage of neovascular AMD (Green and Enger, 1993; 
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Green, 1999). The resultant macular scarring is accompanied by a scotoma and a 
reduction in BCVA which in turn has been shown to have a major impact on quality-
of-life (Brody et al., 2001; Brown et al., 2001). In a clinical trial of those with unilateral 
nAMD of varying impact on BCVA (n=136) Berdeaux et al. (2004) found that vision-
related quality-of-life in those with nAMD was found to be the sum of two independent 
factors: worst eye BCVA and best eye BCVA. Suggesting that, the preservation of 
minimal VA in the worst eye of those with nAMD would help maintain vision-related 
quality-of-life. The most affected quality-of-life aspects reported by those with nAMD 
were driving, close vision activities (for example cooking, sewing, using hand tools), 
mental health and dependency (Berdeaux et al., 2004).        
 Pigment epithelial detachment (PED) 
Pigment epithelial detachments occur when the basal lamina of the RPE is physically 
displaced from the inner collagenous layer of Bruch’s membrane. Serous, 
fibrovascular and drusenoid PED subtypes are associated with AMD and can be 
identified via angiographic methods (Zayit-Soudry et al., 2007). Clinically, a serous 
PED is visible as a well demarcated, dome-like elevation of the retina. A serous PED 
manifests due to the accumulation of fluid between the RPE and Bruch’s membrane 
which may be as a result of leakage from a CNVM (around 80% of cases), or may be 
due to impaired movement of fluid from the RPE to the choroid due to increased 
hydrophobicity of Bruch’s membrane. PEDs are seen in up to 62% of eyes with 
advanced AMD (Coscas et al., 2007) and around half of those with newly diagnosed 
PEDs will experience significant visual loss (>3 ETDRS chart lines) one year from 
diagnosis (Pauleikhoff et al., 2002).  
 AMD grading scales  
In order to enhance the comparability of results between research studies, the 
Wisconsin Age-Related Maculopathy Grading Scale was devised (Klein et al., 1991). 
Since its creation, the scale has been used as a basis for grading in a number of 
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longitudinal AMD studies, including the Beaver Dam, Rotterdam and Blue Mountains 
studies (Klein et al., 1992; Vingerling et al., 1995; Mitchell et al., 1995). Although the 
grading fundamentals were retained, each study tailored the scale slightly based on 
individual requirements. This process ultimately lead to further refinement of the scale 
and the collaborative creation of the International AMD Classification and Grading 
System (Bird et al., 1995).   
More recently, widely used grading scales include the Age-Related Eye Disease 
Study System (AREDS, 2001b), the Three Continent AMD Consortium Age-Related 
Macular Degeneration Severity Scale (Klein et al., 2014b), and the Clinical 
Classification of AMD system (Ferris et al., 2013). Due to its large cohort size, 
longitudinal design and multi-centre approach the AREDS scale was designed to 
emphasise repeatability between graders (AREDS, 2001b). Following the completion 
of the study it was redesigned using the 5 year longitudinal data into a scale that 
reflected the risk of conversion to advanced AMD (Davis et al., 2005). This scale 
utilises the identification of key disease features, such as drusen characteristics and 
pigmentary abnormalities, from colour stereoscopic fundus photographs.  
In order to aid ease of grading during clinical examination and reduce demanding 
photographic procedures, the original AREDS 9-step scoring structure has also been 
further simplified into a 5-step system called the AREDS Simplified Severity Scale 
(Ferris et al., 2005). This scale is based on a scoring system that grades each eye 
independently, then sums the score across both eyes to determine the final grade. 
The severity grade determined is based on the assignment of risk factors for 
approximate 5-year risk of developing advanced AMD in at least 1 eye (Table 1.1).  
When summed across eyes the risk factors form a 5-step scale (steps 0-4) for which 
the 5-year risk of advanced AMD developing in at least 1 eye increases as follows: 0 
factors, 0.4%; 1 factor, 3%; 2 factors, 12%; 3 factors, 26%; and 4 factors, 47% (Ferris 
et al., 2005). In accordance with the scale those with late AMD in one eye are graded 
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≥2 depending on the clinical signs within their fellow eye (Table 1.1). The AREDS 
Simplified Severity Scale has been used throughout this thesis to supplement analysis 
of the predictive capacity to AMD progression of the visual function tests used.   
Disease 
stage 
Risk 
category 
Clinical signs 
Late AMD 
conversion 
Normal 0 Small drusen in one eye/both eyes or intermediate drusen in 
one eye AND no pigmentary abnormalities 
0.4% 
Normal 1 Intermediate drusen in one eye/both eyes or large drusen in 
one eye AND no pigmentary abnormalities OR small drusen in 
one eye/both eyes or intermediate drusen in one eye AND 
pigmentary abnormalities in one eye 
3% 
Early 
AMD 
2 Large drusen in both eyes AND no pigmentary abnormalities 
OR intermediate drusen in one eye/both eyes or large drusen 
in one eye AND pigmentary abnormalities in one eye OR small 
drusen in one eye/both eyes or intermediate drusen in one eye 
AND pigmentary abnormalities in both eyes OR GA or nAMD in 
one eye and small drusen in the fellow eye AND no pigmentary 
abnormalities 
12% 
Early 
AMD 
3 Large drusen in both eyes AND pigmentary abnormalities in 
one eye OR intermediate drusen in one eye/both eyes or large 
drusen in one eye AND pigmentary abnormalities in both eyes 
OR GA or nAMD in one eye and large drusen or pigmentary 
abnormalities in the fellow eye 
26% 
Late 
AMD 
4 Large drusen AND pigmentary abnormalities in both eyes OR 
GA or nAMD in one eye and large drusen and pigmentary 
abnormalities in the fellow eye 
47% 
 
Since its introduction the performance of the AREDS Simplified Severity Scale has 
been validated by Liew et al. (2016). Briefly, this validation study involved re-grading 
baseline, 5- and 10-year fundus photographs of those enrolled into the Blue 
Mountains Eye Study (n=2134) with the AREDS Simplified Severity Scale. Following 
this the 5- and 10-year risk of advanced AMD progression rate for each severity grade 
was re-calculated and compared with that of the original AREDS cohort. The results 
showed a high-degree of concordance between predicted (using the AREDS 
Simplified Severity Scale) and expected (using Blue Mountains Eye Study data) 5- 
and 10-year incident late AMD rates. It was suggested that this supports the 
robustness of the AREDS Simplified Severity Scale, which has been applied widely 
across different study types (Liew et al., 2016).  
Table 1.1. The AREDS simplified grading scale documenting the pathological attributes for 
which risk factors are assigned to each eye. The risk factors are summed to give a grading of 0-
4 which reflects the percentage risk of developing late AMD over 5 years (Ferris et al., 2005).  
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 Prevention and treatment 
At present, most treatments target the neovascular form of AMD. The first medical 
treatment to show promising results against the continued progression of nAMD was 
a technique known as focal laser photocoagulation. When performing this procedure 
a laser is used to directly seal the site of leakage. This technique is no longer in 
frequent use, however, due to its negative impact on healthy retina and high rate of 
CNV recurrence (Virgili and Bini, 2007). Verteporfin photodynamic therapy (PDT) has 
also been widely used to treat nAMD and has been found to successfully stop or 
reverse vision loss over a short-term period of around 1 year. Its effectiveness is 
however variable and very dependent on the type and location of the presenting 
macular lesion (Bressler and Bressler, 2000). Currently, the use of focal laser 
photocoagulation and PDT has been superseded by that of Anti-VEGF drugs as 
discussed in this section. In contrast, there are no effective treatments available for 
early AMD, intermediate AMD or GA. With regards to these conditions early patient 
management involves lifestyle and nutritional advice. Such preventative measures 
are, however, only aimed at reducing the risk of disease progression as opposed to 
reversing its effects (AREDS, 2001a; AREDS2, 2013). Following the onset of GA, the 
provision of low vision aids is often necessary in order to utilise any remaining central 
vision. Depending on their need, patients with untreatable visual impairment 
attributable to AMD may also be referred to their GP, social services, or voluntary 
sector organisations for further practical or emotional help. In addition to the 
treatments documented in this chapter further investigation into AMD treatment is 
currently being directed towards, Angiopoietin antagonists (ClinicalTrials.gov 
identifier: NCT02713204), VEGF C/D inhibitors (ClinicalTrials.gov identifier: 
NCT02543229), designed Ankyrin repeat proteins (Souied et al., 2014), topical eye 
drop treatment (ClinicalTrials.gov identifier: NCT02727881) and stem-cell therapy 
(Fields et al., 2016).  
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 Anti-VEGF drugs  
At present, anti-VEGF drugs are widely used as the first choice of treatment against 
the effects of nAMD. When compared to other treatments such as Verteporfin PDT, 
anti-VEGF therapy has been found to be more effective at preventing vision loss, and 
is the first treatment which is actually able to restore vision (Brown et al., 2006; 2009). 
The treatment itself addresses the imbalance between anti-angiogenic and pro-
angiogenic growth factors, which is seen during CNVM formation. A number of anti-
VEGF drugs are in existence, including ranibizumab (Lucentis; Novartis), pegaptanib 
(Macugen; OSI Pharmaceuticals), bevacizumab (Avastin; Genentech/Roche) and, 
more recently, aflibercept (Eylea; Bayer). National Institute for Health and Clinical 
Excellence (NICE) guidelines currently only approve the use of ranibizumab (NICE 
TA 155, 2008), and alfibercept (NICE TA 294, 2013) for the treatment of nAMD.  
Ranibizumab is a monoclonal antibody fragment which binds to and inhibits the action 
of VEGF-A. It has been deemed appropriate for the treatment of all major types of 
CNVM and is administered via direct intravitreal injection (Mitchell et al., 2010). When 
investigating the effectiveness of ranibizumab two pivotal phase II trials known as 
MARINA and ANCHOR (MARINA, 2006; Brown et al., 2009) demonstrated best-
corrected visual acuity (BCVA) outcomes far superior to any previously published 
study in the treatment of nAMD. Bevacizumab is a humanised monoclonal antibody 
originally developed for use with metastatic colon cancer. It is molecularly larger than 
ranibizumab however is still able to penetrate ocular tissue in order to inhibit VEGF 
activity (CATT Research Group, 2011; Chakravarthy et al., 2013b). Although a review 
of clinical research studies since 2008 has identified ranibizumab as the most effective 
treatment for nAMD (Lanzetta et al., 2013), clinical outcomes such as logMAR visual 
acuity and foveal thickness have been found to show minimal variation between 
ranibizumab and bevacizumab over a 1, 2 and 5 year treatment period (Martin et al., 
2011; 2012; CATT Research Group, 2016). Despite its financially lower unit cost when 
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compared to ranibizumab, bevacizumab has been associated with a slightly elevated 
rate of serious systemic adverse events and therefore is still not licensed for National 
Health Service (NHS) usage within the UK (Martin et al., 2012; Lanzetta et al., 2013). 
When considering the long-term outcomes for the treatment of nAMD the initial 
increase in BCVA often exhibited following the initiation of ranibizumab or 
bevacizumab anti-VEGF treatment has not been found to be sustained over a 5-year 
period (CATT Research Group, 2016). The Comparison of AMD Treatment Trials 
(CATT) (CATT Research Group, 2016) showed that after 5 years the mean BCVA of 
647 participants was 3 letters worse than at baseline (when anti-VEGF therapy was 
initiated) and 10 letters worse than after 2 years of anti-VEGF therapy. Despite this 
the average visual acuity reported after 5 years of anti-VEGF treatment remained far 
superior to previous visual acuity outcomes using PDT (CATT Research Group, 
2016).    
Aflibercept differs to the other VEGF inhibitors in that it is not an antibody or antibody 
fragment. It is a recombinant fusion protein composed of human VEGF binding 
portions fused to a portion of human IgG1 immunoglobulin (Khan et al., 2014). Due to 
its ability to bind to all isoforms of VEGF-A and VEGF-B, aflibercept is able to 
penetrate further into the retina and bind with greater affinity than existing treatments 
(Khan et al., 2014). A number of clinical trials have demonstrated that aflibercept has 
the same efficacy as ranibizumab but requires fewer subsequent intravitreal injections 
(Dixon et al., 2009; CATT Research Group, 2011; Heier et al., 2012; Trichonas and 
Kaiser, 2013; Schmidt-Erfurth et al., 2014). Furthermore, retrospective analysis of 88 
patients with previously untreated nAMD showed good long-term outcomes in a 
clinical setting can be achieved by using aflibercept (Eleftheriadou et al., 2017). 
Anatomical improvement (Hatz and Prünte, 2017; Lim et al., 2017) and improved 
visual-related quality of life (Zhu et al., 2017) has also been attributed to aflibercept 
use in those who have previously shown a limited response to ranibizumab. A recent 
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phase II study has also shown promising results regarding the efficacy of a VEGF 
inhibitor known as brolucizumab (Dugel et al., 2017). This single-chain antibody 
fragment of smaller molecular weight than both ranibizumab and bevacizumab has 
been shown to demonstrate non-inferiority to aflibercept when both were administered 
on an 8-weekly treatment regimen (Dugel et al., 2017). Two phase III studies are 
currently underway to further investigate the efficacy of brolucizumab when compared 
to aflibercept (HAWK, 2014; HARRIER, 2015).  
Although the advent of VEGF inhibitors has revolutionised the management of nAMD, 
there is some debate regarding the most effective regimen to mitigate the treatment 
burden for those with nAMD without compromising BCVA outcomes (Park et al., 
2012). Initially, in accordance with the MARINA and ANCHOR studies a fixed monthly 
treatment regimen was considered. These studies did however report a biphasic 
treatment effect after the initial 3-month loading phase which raised the possibility 
that, after the loading phase, maintenance of VA may be achieved with less frequent 
injections. This was investigated in the CATT research trials (CATT Research Group, 
2011; Rosenfeld 2011) which included 4 treatment arms comparing ranibizumab or 
bevacizumab administered on variable (pro re nata [PRN]) or fixed monthly schedules 
over 12 months. The results showed no difference between the 12 month change in 
BCVA for those treated with ranibizumab as necessary following monthly evaluation 
(PRN) when compared to those on a monthly fixed regimen. Quarterly ranibizumab 
administration following an initial 3-month loading dose has also been investigated 
but was shown to be inferior to monthly treatment when using change in BCVA as a 
primary outcome measure (Schmidt-Erfurth et al., 2011; Regillo et al., 2008; Abraham 
et al., 2010).  
Presently in clinical practice intravitreous VEGF inhibitors are commonly administered 
in accordance with one of two approaches, both of which implement a ‘loading’ phase 
followed by a maintenance phase. The maintenance phase is modelled on a 
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traditional PRN (Spaide 2007) or a treat and extend (Brown and Regillo, 2007; Chiang 
and Regillo, 2011) regimen. Traditional PRN involves regular (often monthly) follow-
up and treatment as necessary (Lalwani et al., 2009; Boyer et al., 2009; Tano and 
Ohji, 2010; Dadgostar et al., 2009; Gupta et al., 2010). In contrast to this, the treat 
and extend approach involves regular and frequent treatment until the macular is dry, 
followed by a gradual extension of the treatment interval and corresponding follow-up 
visit. To date, a number of ranibizumab comparator studies of treat-and-extend versus 
PRN have shown an improvement in both visual and anatomical outcomes using a 
treat-and-extend approach over a period of 6 months to 36 months (Oubraham et al., 
2011; Calvo et al., 2014; Hatz and Prünte, 2016; 2017; Giannakaki-Zimmermann et 
al., 2016; Kvannli and Krohn, 2017). Using data from 11 treat-and-extend studies a 
general algorithm has been devised to facilitate optimal application of treat-and-
extend regimens in clinical practice (Freund et al., 2015). The algorithm suggests the 
extension of treatment intervals by up to 2 weeks at a time (reaching a maximum 
extension period of 12 weeks) for those with continued absence or stabilisation of 
intraretinal fluid following initial dosage.  
 Nutrition 
Even though there is currently no effective treatment for early or intermediate AMD, 
lifestyle advice such as the cessation of smoking (Smith et al., 2001; AREDS, 2005) 
and the adoption of an active lifestyle (Knudtson et al., 2006; Williams, 2009) can be 
advised as preventative strategies against disease progression. In addition, current 
evidence also suggests that dietary advice and the recommendation of nutritional 
supplementation may also be effective.    
The importance of dietary intake relates to the susceptibility of the retina to oxidative 
damage, which has been suggested as a contributing factor to AMD pathogenesis 
(Beatty et al., 2000). Therefore, in order to prevent AMD progression, the dietary 
intake of elements such as vitamins and carotenoids has been proposed as being 
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advantageous due to their antioxidant properties (Weikel et al., 2012). The AREDS 
research group undertook a randomised placebo controlled trial of 3640 participants 
with AMD severity ranging from early to unilateral advanced, to investigate the effect 
of high dose antioxidants on disease progression. They documented a 25% reduction 
in the risk of progression to advanced AMD in those who took an anti-oxidant vitamin, 
zinc and copper formulation (500mg vitamin C, 400IU vitamin E, 15mg beta-carotene, 
80mg zinc and 2mg copper) over a 5 year period for those with extensive intermediate 
drusen, large drusen, or non-central GA in 1 or both eyes, or advanced AMD in 1 eye 
at baseline (AREDS, 2001a).  
Other dietary supplements that have shown promise with regards to the inhibition of 
AMD progression include xanthophylls and omega-3 fatty acids, neither of which can 
be synthesised by humans. Lutein and zeaxanthin are obtained through the dietary 
intake of a variety of fruit and vegetables. They are found at their highest 
concentration at the macula and are thought to play a protective role via the inhibition 
of light induced damage (Snodderly, 1995; Landrum and Bone, 2001). Long chain 
omega-3 fatty polyunsaturated fatty acid Docosahexaenoic acid (DHA) is primarily 
found within photoreceptor outer segments. Mainly obtained through sources such as 
fish and plant oils, the regular intake of DHA has shown promising results in reducing 
the risk of AMD onset and progression (Seddon et al., 2006; San Giovanni et al., 
2007; Tan et al., 2009). Despite this, a subsequent follow-up to the AREDS study 
(AREDS2, 2013) investigating the potential benefit of adding omega-3 fatty acids, 
lutein and zeaxanthin to combinations based on the original AREDS formula reported 
less encouraging findings. The results indicated that there was no benefit to adding 
omega-3 fatty acids to the supplement, whilst the xanthophyll additions were only 
beneficial in those who had very low dietary levels of lutein and zeaxanthin at baseline 
(AREDS2, 2013).  
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 Clinical investigation of AMD 
A range of tests is available for the evaluation of AMD, each of which can be utilised 
to focus on various traits and manifestations of disease progression. Traditionally, in 
order to diagnose the presence of AMD, measurement of visual acuity, central visual 
field assessment (for example, using the Amsler Chart), fundus photography and 
fluorescein angiography have been employed. Advancements in retinal imaging, for 
example, ultra-high resolution optical coherence tomography and fundus 
autofluorescence, have increased the sensitivity of detection of AMD (Holz et al., 
2007; Padnick-Silver et al., 2012). In recent years, it has become apparent that 
various other tests of visual function, such dark adaptation (Dimitrov et al., 2008; 
2011; Gaffney et al., 2011; Jackson et al., 2014a; 2014b; Owsley et al., 2001; 2007; 
2016; 2017), microperimetry (Cassels et al., 2017; Acton et al., 2012) and photostress 
recovery time (Wu et al., 1990; Midena et al., 1997; Bartlett et al., 2004) are more 
sensitive than VA in detecting early functional loss in AMD. The investigative 
techniques of particular importance to this study are hereby documented. For 
additional information on other techniques available the reader is directed to the 
review papers by Neelam et al. (2009) and Nivison-Smith et al. (2014). 
 Optical coherence tomography (OCT) 
Optical coherence tomography (OCT) is a non-invasive, cross-sectional imaging 
technique which utilises the principle of interferometry in order to generate 3-D 
representations of the retina (Drexler et al., 1999). OCT images consist of individual 
data points representing the superimposition of two light waves. These data points 
exist as a-scans and comprise a series of reflectivity measurements at varying depths 
within the retina. The combination of a number of a-scans produces a cross sectional 
image of the retina known as a b-scan, as seen in Figure 1.9 (Huang et al., 1991). 
The introduction of spectral domain OCT (SD-OCT), optical coherence tomography 
angiography (OCTA), swept-source OCT (SS-OCT) and adaptive optics OCT (AO-
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OCT) has provided the opportunity to study outer retinal structures and clinical 
characteristics of interest in AMD in greater resolution. For example AO-OCT can be 
used to visualise photoreceptor wellbeing via the assessment of photopigment disc 
renewal in the outer segment (Zhang et al., 2005; Zawadzki et al., 2005; Jonnal et al., 
2016). An application of SD-OCT is the visualisation of drusen in fine detail. In addition 
to this, when coupled with segmentation algorithms, the high definition b-scans 
provided by SD-OCT can be used to extract quantitative information describing the 3-
dimensional geometry of the RPE. Quantification of the deformations of the RPE 
provides an indication of the volume of underlying drusen. Drusen volume evaluation 
using the OCT has been shown to be highly reproducible (Gregori et al., 2011). 
The structural measurement of drusen volume has been identified as a potentially 
useful biomarker of AMD (Yehoshua et al., 2011; Abdelfattah et al., 2016; Schlanitz 
et al., 2017). In a study of 100 patients Yehoshua et al. (2011) assessed the potential 
utility of drusen volume evaluation as a clinical end point in trials designed to 
investigate AMD treatment. The drusen volume within areas of 3mm and 5mm 
circumference, centred on the fovea, were measured at 6, 12 and 24 monthly 
intervals. The results showed that drusen have an undulating pattern of growth over 
time. Quantitatively, the volume was found to increase in 48% of eyes and decrease 
in 40% of eyes assessed over 12 months. Eyes with markedly decreasing drusen 
volume were also found to be at an increased risk of subsequent exudative AMD or 
GA development (Figure 1.10). This finding correlates with other evidence which 
suggests drusen size as an important risk factor for the development of advanced 
AMD (Bressler et al., 1990; Pauleikhoff et al., 1990a; Klein et al., 2008a). It also 
supports the applicability of drusen volume analysis as a viable clinical tool when 
determining the likelihood of AMD progression.  
Numerous studies comparing measurements of drusen area taken manually from 
colour fundus photographs and via an automated SD-OCT algorithm have been 
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undertaken (Jain et al., 2010; Iwama et al., 2012; Yehoshua et al., 2013; Mokwa et 
al., 2013; Diniz et al., 2014). Despite the tendency of OCT based analysis to slightly 
underestimate drusen volume it has been documented as a reproducible and reliable 
method for use in studies including people with AMD (Yehoshua et al., 2013; Diniz et 
al., 2014).  
 
 Visual acuity 
Within both optometric practice, hospital based optometry and in clinical trials, visual 
acuity (VA) is regularly used as a measure of visual function. Despite this, evidence 
suggests that measurements of VA do not correlate well with the visual performance 
Figure 1.9. An SD-OCT horizontal b-scan displaying the outer retinal layers (A) and a large 
drusen underlying the macular region (B). 
Figure 1.10. An example of the Zeiss Cirrus OCT drusen volume analysis software used by 
Yehoshua et al. (2011). Images displayed were taken from a 76 year old woman who displayed 
a reduction in drusen volume, prior to GA development. Images A-E show baseline 
measurements in comparison to F-J which document the changes seen 12 months later. The 
images represent a B-scan (A,F), horizontal B-scan (B,G), RPE segmentation map (C,H), 
hybrid OCT fundus image/drusen thickness map (D,I) and fundus autofluorescence (E,J). 
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of everyday tasks in people with AMD (Hogg and Chakravarthy, 2005). Also, 
depending on the stage of progression and retinal pathology, VA amongst those with 
advanced AMD can be variable and changes are often masked by the 1-2 line test-
retest variability of the Early Treatment Diabetic Retinopathy Study (ETDRS) chart 
(Arditi and Cagenello, 1993; Lovie-Kitchin and Brown, 2000). VA during earlier stages 
of disease progression is often found to exhibit minor or even no reduction, therefore 
the use of VA alone would not be sufficient to detect AMD until relatively late in 
disease progression (Klein et al., 1995). 
 Colour vision 
Histopathological evidence suggests that cone photoreceptors are disrupted as a 
result of AMD at a functional and neuronal level (Curcio et al., 1996; Jackson et al., 
2002; Shelley et al., 2009). Taking this into account, changes in visual performance 
relating to cone function, such as colour contrast sensitivity, can be measured in order 
to derive information on disease status and progression.     
Using the Nagel Anomaloscope, Eisner et al. (1991) found that individuals with 
abnormal colour vision (denoted by a reduction in the effect of stimulus size on the 
red-green Rayleigh colour matching range, or rejection of all colour matches) had a 
high-risk fundus appearance for the development of nAMD. Further investigation by 
the same group resulted in the identification of red/green Rayleigh colour matching, 
when used alongside dark adaptation, as an effective predictive biomarker for nAMD 
development (Eisner et al., 1992). In a subsequent 2 year longitudinal study, Holz et 
al. (1995) measured tritan and protan colour contrast sensitivity using a bespoke 
computer graphics technique. The results indicated that measurement of blue colour 
contrast sensitivity at a foveal level may serve to monitor the progression of AMD prior 
to GA or exudative changes. These results were seconded by the finding that tritan 
thresholds are elevated in the presence of drusen (Frennesson et al., 1996; Arden 
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and Wolf, 2004) and continue to elevate in relation to the severity of AMD 
manifestation (Arden and Wolf, 2004).    
The Colour Assessment and Diagnosis (CAD) test is currently used by the Civil 
Aviation Authority (CAA) as gold standard when testing colour contrast sensitivity. As 
seen in Figure 1.11, by employing dynamic luminance contrast noise to mask the 
detection of any residual luminance contrast cues, the test isolates red-green (RG) 
and yellow-blue (YB) thresholds along 16 directions of the International Commission 
on Illumination (CIE) chromaticity diagram (CAA, 2009). This allows the severity of 
colour vision loss to be quantified when compared to the pre-determined limits of 250 
normal trichromats (Barbur et al., 2006). When implementing the CAD test on 18 
participants with varying stages of AMD, O’Neill-Biba et al. (2010) found acquired loss 
of YB and, to a lesser degree, RG chromatic sensitivity. The exhibited threshold 
increase was found to be larger for YB chromatic sensitivity across all grades of AMD 
and exhibited a positive correlation to disease severity.  
 
Figure 1.11. Coloured stimuli (overlying contrast luminance noise) as presented during the 
CAD test (left panel), and result plot generated following chromatic sensitivity measurement 
using the CAD test (right panel). A range of colours is shown in the left panel however during 
threshold testing a single colour is presented at any one time. During threshold testing the 
participant is asked to identify the direction of movement of the coloured square across the 
field of dynamic luminance contrast noise (Barbur et al., 2006). The range of chromatic 
threshold variation expected in normal colour vision falls within the grey shaded area of the 
CAD result plot shown in the right panel. Upon completion of the test measured thresholds are 
plotted as small red, green, yellow and blue circles upon the result plot. A subject’s colour 
vision is considered normal if both RG and YB chromatic thresholds lie within the shaded area 
(CAA, 2009). 
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 Temporal flicker sensitivity 
Temporal sensitivity describes the ability of the eye to resolve and therefore respond 
to a flickering stimulus. The human eye is able to resolve flickering stimuli of up to 60-
80Hz (Brown and Lovie-Kitchin, 1987). The ability of an individual to resolve a 
flickering stimulus can be clinically measured by increasing the temporal frequency 
whilst maintaining a constant background luminance until flickering can just be 
detected. Evidence suggests that in comparison to static stimuli, a flickering target 
increases the metabolic demand of the retina due to higher cortical processing rate 
via magno- and parvocellular neural pathways (Polak et al., 2002; Phipps et al., 2004). 
Haemodynamic studies have identified increases in retinal artery diameter and blood 
flow in response to flickering stimuli (Michelson et al., 2002; Polak et al., 2002) with 
peak vascular changes localised to the mid-perifoveal region. This, unsurprisingly, 
coincides with the location of the maximum ganglion cell and nerve fibre density (Kiryu 
et al., 1995). It is suspected that AMD-related pathological damage to both the outer 
retina and choriocapillaris results in compromised outer retinal metabolism and the 
inability to meet the increased flicker-induced metabolic demands (Neelam et al., 
2009). Ultimately, this leads to a reduction in temporal sensitivity to a greater extent 
than expected through normal ageing (Kim and Mayer, 1994). 
A series of studies conducted by Mayer et al. reviewed the effectiveness of foveal 
flicker sensitivity as a predictive measure for the development of nAMD in the fellow 
eye of those with a monocular manifestation (Mayer et al 1990; 1992a; 1992b; 1994). 
It was initially identified that a flickering stimulus of 10 or 14Hz was needed to correctly 
identify eyes at risk of nAMD development when compared to age-matched controls. 
This was with 78% accuracy on the basis of foveal flicker sensitivity alone (Mayer et 
al., 1992b). Subsequent investigations led to the conclusion that those at risk of nAMD 
development were found to have maximally reduced flicker sensitivity to mid-temporal 
frequencies (10-40Hz), leading to the designation of a 14Hz stimulus as optimal 
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(Mayer et al., 1992a). Participants who went on to develop nAMD were also found to 
have significantly lower sensitivities up to 9 months before the appearance of 
exudative retinal changes (Mayer et al., 1992b).  
These findings are substantiated by Luu et al. (2012) who, following analysis of data 
from a 2-year longitudinal study also documented a reduced flicker sensitivity in eyes 
that went on to develop late AMD. In addition, based on severity grading, the reduction 
in foveal flicker sensitivity has been found to show significant concordance with 
related fundus changes typical of AMD progression (Mayer et al., 1994; Dimitrov et 
al., 2012; Luu et al., 2013). In a study of 293 participants with AMD Dimitrov et al. 
(2012) reported that 14Hz flicker threshold declined progressively along the 
continuum of AMD severity. Therefore, it was suggested that flicker threshold 
assessment had the potential to monitor disease progression and detect possible 
stabilisation or reversal of AMD pathogenesis with new treatments (Dimitrov et al., 
2012).  
The clinical value of temporal sensitivity testing was assessed in a study by Dimitrov 
et al. (2011) of 221 participants with varying AMD status. When evaluated against 
other steady state and dynamic tests, 14Hz foveal flicker sensitivity returned a modest 
diagnostic capacity of 34% of abnormal cases correctly identified. Despite this, when 
combined with scoring based on reproducibility and clinical applicability the test was 
ranked above dark adaptation and photostress recovery as a potential clinical tool for 
monitoring AMD progression within a research and clinical environment.      
 Dark adaptation 
Due to its physiology, the visual system is generally able to adapt swiftly to changes 
in ambient illumination over a vast range of light intensity. This trait, however, is not 
upheld following extended retinal exposure to an intense adapting light source. The 
accumulation of a high concentration of ‘bleached’ or deactivated visual pigment leads 
to a slow, biphasic recovery of visual sensitivity which is known as dark adaptation 
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(DA) (Lamb and Pugh, 2004). Following exposure to the adapting light source, the 
threshold intensity needed to detect a visual stimulus over time can be plotted as a 
dark adaptation curve (Figure 1.12). When viewing the curve, the initial rapid reduction 
of visual threshold is mediated by the cone photoreceptors and is followed by the cone 
plateau. The subsequent slower threshold reduction is rod governed and is preceded 
by the rod-cone-break (RCB), which indicates a time-dependent shift in the dominant 
photoreceptor system. The appearance of the curve is dependent on multiple factors 
such as the percentage of photopigment bleached and stimulus specifics, such as 
size or retinal eccentricity (Hecht et al., 1935; 1937, Thomas and Lamb, 1999; Lamb 
and Pugh, 2004; Dimitrov et al., 2008, Gaffney et al., 2011; 2013).  
 
The recovery of visual sensitivity in the dark is dependent on the regeneration of visual 
pigment via the retinoid cycle (Rushton and Campbell, 1954; Lamb and Pugh, 2004). 
This cycle is reliant on the integrity of the RPE and photoreceptors, and is supported 
by the choroidal circulation, via Bruch’s membrane. Therefore pathology, such as 
AMD, that disrupts the outer retina and associated structures has been found to cause 
Figure 1.12. Dark adaptation functions in response to stimulus size for a typical healthy control 
(a) and in early AMD (b). For each stimulus size the raw data is shown with a best fitting model. 
To aid visualisation, the 12° data is correctly placed with regards to the y-axis however all 
other data have been displaced upwards. The 7 degree data has been displaced upwards by 
0.3 log units from the 12 degree data, the 2 degree data has been displaced upwards by 0.3 
log units from the 7 degree data and the 0.5 degree data has been displaced upwards by 0.3 
log units from the 2 degree data (Gaffney et al., 2011; copyright permission from Wolters 
Kluwer Health [2018] licence 4274220230945). 
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prolonged dark adaptation in rods and cones (Eisner et al., 1991; Midena et al., 1997; 
Phipps et al., 2003; Dimitrov et al., 2008; 2011; Gaffney et al., 2011; Jackson et al., 
2014a; Owsley et al., 2001; 2007; 2016; 2017). Rod-mediated parameters of dark 
adaptation, such as time to RCB and rod recovery rate, have been consistently found 
to be delayed in early AMD (Owsley et al., 2001; 2016; Dimitrov et al., 2008; Jackson 
and Edwards, 2008). Rod-mediated dark adaptation has also been found to be 
delayed over a 2 year period in those with intermediate AMD (Owsley et al., 2017).  
Accurate measurement of the threshold changes that occur during the rapid initial 
stages of cone dark adaptation has been found to be a difficult process. Consequently 
initial evidence, recorded at 12° retinal eccentricity by Owsley et al. (2001), 
documented disturbances in rod mediated dark adaptation only in early AMD. Since 
this, studies by Dimitrov et al. (2008, 2011) and Gaffney et al. (2011, 2013), utilising 
larger visual stimuli and longer bleach durations, have provided compelling evidence 
that cone recovery dynamics in dark adaptation are also significantly impaired in AMD 
and can be used as a powerful diagnostic tool. This correlates with the histological 
findings of cone synapse irregularity, alongside loss of rods, in early AMD (Pow and 
Sullivan, 2007; Shelley et al., 2009). It may also reflect the underlying diffuse 
pathology of the RPE, Bruch’s membrane and choroidal circulation in AMD, which will 
affect regeneration of both rod and cone photopigments.  
When compared to a battery of other dynamic and steady state threshold tests by 
Dimitrov et al. (2011), the recovery parameters of dark adaptation were found to have 
excellent diagnostic capacity. Assessment using receiver operating characteristic 
(ROC) area under curve (AUC) analysis showed rod and cone recovery yielded 0.93 
± 0.016 and 0.86 ± 0.023 respectively using a 2° stimulus at 3.5° eccentricity in the 
inferior field. Quantitatively, the dark adaptation parameters of rod and cone rate of 
recovery were found to detect 86% and 62% of abnormal cases, respectively, when 
compared to 14Hz flicker threshold (34%), cone photostress recovery time (64%) and 
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blue colour contrast threshold (41%) (Dimitrov et al., 2011). Despite the potential 
displayed as an effective diagnostic tool for early AMD, dark adaptation has not 
generally been considered as a clinically viable technique. However, issues such as 
test duration and patient friendliness are currently being addressed. Promising results 
suggest accurate measurement of photoreceptor recovery parameters are possible 
within a 10 minute time frame (Gaffney et al., 2011; Jackson et al., 2014b) and that 
dark adaptation may be used as a suitable functional end point when evaluating 
treatments for early (Jackson et al., 2014b; Owsley et al., 2016) and intermediate 
AMD (Owsley et al., 2017). Recent longitudinal analysis of those graded 1 (normal) 
on the Age-Related Eye Disease Study System (AREDS, 2001b) showed that those 
with delayed rod-mediated DA at baseline were twice as likely to have AMD after 3 
years when compared to those with normal DA (Owsley et al., 2016). This finding 
further supports the usefulness of this visual functional measure as a biomarker for 
early AMD.     
 Functional biomarkers for AMD 
Biological markers (biomarkers) can serve many unique purposes, including 
confirmation of diagnosis, monitoring treatment effects or disease progression, and 
prediction of clinical outcomes (Biomarkers Definitions Working Group, 2001). The 
theoretical advantage of using validated biomarker outcomes in definitive trials 
includes smaller, faster and less expensive studies (Holloway and Dick, 2002). For 
this reason, structural and functional biomarkers are often adopted in research as 
primary endpoints for clinical trials (Law and Miles, 2013; Moyer and Barrett, 2009; 
Lesko and Atkinson, 2001). A high level of stringency is required when a biomarker 
response is substituted for a clinical outcome. The scientific program for evaluating 
biomarkers must be planned as early as possible with a blueprint to bring the 
biomarker into clinical trials and establish the link between the biomarker and clinical 
outcome (Fleming and DeMets, 1996). Evaluation of a biomarker can be based on an 
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exploratory process of determining how many of the characteristics of an ideal 
biomarker are met relative to the context of its use. Characteristics of biomarkers that 
underpin their utility include: clinical relevance, sensitivity, specificity, reliability and 
practicality (Lesko and Atkinson, 2001). There are multiple pathways to validate a 
biomarker for an intended use. Validation data itself often rises from the totality of 
evidence provided by preclinical animal studies and longitudinal analysis including 
clinical studies in healthy volunteers and late-phase efficacy/safety trials in patients 
with a targeted disease (Lesko and Atkinson, 2001; Fleming and DeMets, 1996).  
Visual loss in AMD occurs due to the dysfunction and death of photoreceptors (rods 
and cones) secondary to the death or dysfunction of RPE cells, or a neovascular event 
(Ambati and Fowler, 2012). Therefore, psychophysical tests of vision, which depend 
on the functional status of the photoreceptors, RPE and associated structures, may 
detect subtle alterations in the macula before morphological fundus changes become 
visibly apparent. They also have the potential to not only identify those with early AMD 
but to also act as prognostic biomarkers for disease progression.  
A number of visual function tests have been investigated in order to determine a 
potential biomarker for AMD. Three promising candidates (chromatic sensitivity, dark 
adaptation and flicker sensitivity) have been used throughout this thesis. As briefly 
mentioned in Sections 1.3.6.3 (colour vision), 1.3.6.4 (flicker sensitivity) and 1.3.6.5 
(dark adaptation) each of these visual function tests has a body of evidence to support 
their relationship with disease severity and as such their usefulness as a biomarker 
for AMD progression. Whilst these visual function tests have been identified as 
functional biomarker candidates, further validation of their capability as surrogate 
biomarkers, as achieved through longitudinal evaluation, is still necessary. 
Early AMD develops very slowly over time (Davis et al., 2005) and, therefore, it is not 
practicable to use end stage disease as an outcome measure in phase I/II trials of 
new interventions. Hence, the use of validated functional biomarkers is imperative for 
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the development of modern treatment strategies for early AMD. This necessitates the 
identification of biomarkers that may be used as surrogate outcome measures in 
clinical trials such as that presented in this thesis. For greater detail on AMD 
biomarkers and biomarker validation the reader is directed to the review articles by 
Lambert et al. (2016) and Lesko and Atkinson (2001).   
1.4. Visual psychophysics  
Psychophysics is the scientific study of the relation between stimulus and sensation 
(Gescheider, 1997). Its relevance to this study is paramount as many of the data 
collection techniques used are based on psychophysical methods. These methods 
rely upon the concept of threshold testing and are introduced in this section. 
 Classical psychophysical methods 
Visual psychophysics commonly relies upon the presentation and detection of a 
stimulus. The stimulus can be manipulated in order to investigate various visual 
perception thresholds however in all cases it must exceed a critical strength, known 
as a sensory threshold, before a subject can be aware of its presence (Graham, 
1965). There are two kinds of thresholds: absolute and difference. The lowest level of 
stimulus energy for which detection is achievable is known as the ‘absolute threshold’ 
(Gescheider, 1997). When discriminating between stimuli, the ‘difference threshold’ 
is the magnitude of the smallest detectable difference (also known as a ‘just 
noticeable difference’) between two stimuli (Gescheider, 1997). 
There are three documented classical psychophysical methods of threshold testing:  
1. The method of adjustment. 
2. The method of limits. 
3. The method of constant stimuli. 
 
In order to determine a threshold using the method of adjustment or the method of 
limits an observer is asked to respond to a series of ascending (stimulus going from 
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non-seen to seen) and descending (stimulus going from seen to non-seen) steps. The 
threshold is ultimately obtained from the averaged value of responses (Kalloniatis and 
Luu, 2013). Even though threshold determination is similar the methods differ in that 
during the method of adjustment the observer is given the responsibility of controlling 
the stimulus level. The method of constant stimuli does not employ a sequential series 
of presentations. Instead, the stimulus is presented multiple times at each intensity, 
in a random order to the observer (Norton et al., 2002). The responses are then used 
to create a psychometric function which plots the probability of a correct response at 
a range of stimulus intensities in order to determine the threshold (Figure 1.13) 
(Kalloniatis and Luu, 2013).  
During visual psychophysics, detection of a stimulus is often confirmed via a 
subjective response. However, the variability in response patterns found between 
participants can lead to the determination of inaccurate threshold levels (Gescheider, 
1997). In order to counteract this effect stimuli are often presented repeatedly at each 
intensity and threshold levels are determined in probabilistic terms via a psychometric 
function.  
The repetitive and time consuming nature of performing consecutive trials also leads 
to habituation and anticipation errors. Particularly when performing the method of 
limits habituation errors occur when a subject becomes accustomed to reporting that 
they perceive a stimulus. As a result they may continue reporting the same way even 
beyond threshold (Norton et al., 2002). Alternately when performing the method of 
adjustment a subject may anticipate that a stimulus is about to become detectable or 
undetectable and make a premature judgement. These errors can be minimised by 
preventing a sequential series or presentation as with the method of constant stimuli 
(Gescheider, 1997).  
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 Adaptive psychophysical methods 
Adaptive psychophysical methods are widely regarded as more efficient than classical 
methods. This is because in adaptive methods stimuli presented are based on the 
observer’s previous responses. This maximises the presentation of stimuli around the 
threshold value of the parameter of interest and minimises the time spent collecting 
data at points on the psychometric function that provide little information (Kalloniatis 
and Luu, 2013). Adaptive methods are classified into staircase and maximum-
likelihood procedures, a summary of both has been provided here.  
 Staircase procedure 
The staircase procedure can be considered as a modification of the method of limits 
(Cornsweet, 1962). A staircase procedure will usually begin with an easily detectable, 
high intensity stimulus. The stimulus intensity is then decreased in the initial series 
until the observer is no longer able to detect it, at which point, the presentations are 
reversed and the stimulus intensity is increased until the observer once again 
indicates their perception of the stimulus, which marks the completion of the second 
series. With each passing series the stimuli presented start progressively closer to 
the threshold value. To determine the final threshold an average of the reversal values 
Figure 1.13. A psychometric function. Threshold is often taken as the stimulus intensity at 
which detection occurs for 50% of the presentations (Kalloniatis and Luu, 2013; copyright 
permission from http://webvision.med.utah.edu/). 
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is taken. Before a staircase procedure can be implemented there must be clarity on 
such factors as the step-size of the stimulus testing level and the termination 
procedure.      
It is common when performing a staircase procedure to use an ‘n up, 1 down’ 
paradigm. For example, if the observer makes a correct response ‘n’ times in a row 
then the testing level is reduced by 1 step-size. If the observer does not identify the 
stimulus correctly then the testing level is increased by ‘n’ step-sizes. A 1 up, 3 down 
paradigm was utilised to collect dark adaptation data throughout this trial.  
 Maximum likelihood procedures 
During a maximum likelihood procedure the testing level presented is based on a 
statistical estimation of threshold derived from all of the observers’ previous 
responses. After each trial, a new threshold estimate is calculated in order to 
determine the new stimulus level to be presented. The number of trials is pre-
determined and should be enough to allow a final threshold level to be reached. 
Statistically this technique relies upon the assumption that the underlying 
psychometric function of the parameter in question has a specific form, for example 
Gaussian (cumulative normal distribution), logistic or Weibull (Gescheider, 1997). 
Before being able to perform a maximum-likelihood procedure prior knowledge of the 
distribution of threshold for a given stimulus must be known. This is often obtained 
through pilot studies or published data. From this data a probability distribution 
function (PDF) can be constructed which, in turn, allows the stimulus threshold that is 
most likely to correspond to the observer’s threshold to be determined. The PDF is 
modified according to the observer’s response to each stimulus presentation. This 
allows each subsequent presentation to be ever closer to the observer’s actual 
threshold until the stimulus intensity becomes stable. It is at this point that the final 
threshold is recorded.  Procedures that utilise this method of threshold determination 
include ZEST (zippy estimate of sequential testing) and QUEST (quick estimate by 
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sequential testing). Although fundamentally similar these 2 methods differ in that the 
mean of the PDF is used to estimate stimulus intensity when performing ZEST (King-
Smith et al., 1994), whereas the mode of the PDF is used when performing QUEST 
(Watson and Pelli 1983).    
Throughout the course of this PhD temporal sensitivity data were measured using a 
QUEST Bayesian adaptive procedure. The QUEST psychometric method was 
developed by Watson and Pelli (1983) and relies upon the following assumptions:  
 The psychometric function has the same shape under all conditions, when 
expressed as a function of log intensity.  
 The subject’s threshold does not vary from trial to trial.  
 Individual trials are statistically independent. 
 
QUEST relies upon Bayes' Theorum which can be used to combine the results of an 
experiment (in the form of the likelihood function) with pre-existing knowledge 
regarding the threshold parameter (in the form of a prior-probability distribution) to 
derive the probability distribution across possible values of the threshold parameter 
(Kingdom and Prins 2009). The use of prior knowledge regarding the threshold 
intensity when performing QUEST initially prevents excessive step-sizes into 
threshold intensities of little interest. As data collection proceeds however the prior 
knowledge plays a smaller and smaller role relative to the contribution of the data 
collected (Figure 1.14).  
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 Forced-choice procedure 
The forced-choice psychophysical method is based on the theory of signal detection 
(TSD). During this procedure the observer is forced to choose from alternative 
choices, one of which contains the stimulus. The exact procedure employed can be 
described by the number of alternative choices made available e.g. a procedure in 
which the observer chooses from 2 options is described as a 2-alternative forced 
choice procedure (2AFC). As the number of options available to the observer 
increases, the probability of a correct response due to chance alone declines 
(Gescheider, 1997). With every trial the stimulus alternatives are shown and the 
observer is required to select one stimuli as a response. The assumption can be made 
that in absence of response bias the observer chooses the option that contains the 
largest sensory stimulus (Gescheider, 1997). This results in the procedure being 
criterion-free. In order to determine the final threshold a psychometric function is often 
constructed. Figure 1.15 shows the psychometric function used for the colour 
assessment and diagnosis test used in this trial (4AFC procedure).  
After any presentation the observer has at least a 25% chance of guessing correctly. 
This leads to a percentage of correct responses in which the observer did not in fact 
Figure 1.14. An example of data collected using the QUEST procedure. The circles represent 
successive stimuli (trials) presented to the observer. After each trial a new threshold estimate 
is calculated based upon previous responses. The final threshold level, after 40 trials, is 
represented by the solid blue line. The dashed lines display the standard deviation above and 
below the final threshold. 
58 
 
detect the stimulus. The psychometric function allows the final threshold to be 
adjusted for chance in order to eliminate the effect of guessing. This is done by plotting 
the percentage of correct responses against the stimulus intensity and by selecting a 
value for percentage correctly identified to be designated as the threshold.  
 
Figure 1.15. A psychometric function constructed from responses to a 4AFC procedure. In this 
example the final threshold value for this stimulus is recorded at the point where 66% of 
presentations were correctly identified. 
 
1.5. PhD objectives 
The overarching objectives of this PhD were: 
1. To implement a longitudinal clinical trial (the ALight trial) in order to evaluate 
the impact of light therapy on the progression of early and intermediate AMD.  
2. To carry out a simultaneous cross-sectional study alongside the longitudinal 
evaluation, in order to evaluate the trial outcome measures as biomarkers for 
AMD severity. 
 Pilot study aims  
A further aim of this thesis was to perform 2 pilot studies to optimise and evaluate the 
psychophysical tests of visual function prior to recruitment for the ALight trial or cross 
sectional study. The specific aims of the pilot studies were: 
1. To check the test sequence and time of the data collection techniques. 
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2. To verify that a new handheld photopigment bleach source could be used 
reliably in a dark adaptation experiment.  
3. To optimise parameters of dark adaptation, flicker threshold and chromatic 
threshold measurement for use in the ALight clinical trial and cross-
sectional study.  
 Cross-sectional study aims  
A simultaneous cross-sectional study was conducted alongside the ALight clinical 
trial. The primary aim of this study was to evaluate the ability of dark adaptation, 14Hz 
flicker threshold, YB chromatic threshold and RG chromatic threshold tests to identify 
the likely risk of an increase in graded AMD severity (Chapter 4). The study also had 
two secondary aims:  
1. To explore the relationship between the functional and structural outcome 
measures.  
2. To determine the relationship between disease severity and the observed 
functional and structural deficits.  
 Longitudinal clinical trial (the ALight trial) aims 
The primary aim of the ALight trial was to collect preliminary phase I/IIa proof of 
concept randomised controlled trial data from people with early or intermediate AMD 
in one eye and advanced nAMD in the fellow eye, in order to assess the effect of low-
level night-time light therapy, compared with no intervention, on disease progression 
in the eye with early/intermediate AMD (Chapter 6).  
An additional primary outcome measure was to assess the safety and tolerance of a 
CE marked device to deliver the light therapy (Noctura 500 light mask) within the 
cohort of participants with AMD (Chapter 5).   
The secondary aims of the ALight trial (assessed in Chapters 5 and 6) were as follows: 
1. To establish the effect of low-level night-time light therapy when compared to 
controls on:  
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i. The change in drusen volume over 12 months (measured using OCT 
software). 
ii. The number of ranibizumab injections required on the fellow eye over 
12 months. 
iii. The change in visual function using the CAD test, BCVA and 14Hz 
flicker threshold. 
iv. The change in self-reported quality of life (EuroQol-5D [EQ-5D]) 
(EuroQol Group, 1990) and visual function (VFQ-48 [Stelmack et al., 
2004a; 2004b]).  
2. To establish the acceptability of low-level night-time light therapy in those with 
AMD by monthly qualitative interviews. 
3. To determine the effect of the light therapy on sleep patterns for those using 
the light mask intervention.  
4. To evaluate the ability of all clinical tests to act as prognostic biomarkers for 
AMD progression.  
5. To evaluate the ability of all clinical tests to act as predictive biomarkers for 
the effectiveness of low-level night-time light therapy in AMD.  
6. To compare the sensitivity of all clinical tests to disease progression over 12 
months.  
1.6. Conclusion  
Throughout the course of this chapter it has been stated that the causes of AMD are 
not yet fully understood but hypoxia may play a role. The ALight trial itself aims to 
reduce the level of hypoxia at night by exposing the eye to a dim light. In order to 
further evaluate the role of hypoxia in the pathogenesis of AMD a systematic review 
of literature is presented in the next chapter.  
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Chapter 2. Evaluating the role of hypoxia in the pathogenesis of 
AMD: a literature review  
 
2.1. Introduction 
The aetiology of AMD is multifactoral. There is evidence to suggest that hypoxia, 
oxidative stress, inflammation, mitochondrial disease and genetics are involved 
(Feigl, 2009; Stefansson et al., 2011; Ding et al., 2009; Coleman et al., 2008; 2013; 
Haines et al., 2005; Jarrett et al., 2008; Lin et al., 2011). The degree to which each 
factor contributes to AMD pathogenesis is unknown. Whilst all of these mechanisms 
may have a role in AMD this review examines the literature on hypoxia because any 
beneficial effects of low-level light therapy are likely to stem from increased tissue 
oxygenation.   
Having one of the highest metabolic demands of any bodily tissue, the retina is 
particularly susceptible to the effect of hypoxia (Wangsa-Wirawan and Linsenmeier, 
2003; Beatty et al., 2000). Hypoxia is defined as a decrease in available oxygen 
reaching the tissues of the body. The fact that humans thrive under varying 
environmental conditions, including at high altitude, dictates that it is possible for 
human beings to adapt to live under conditions of reduced oxygen tension (Moore et 
al., 1998; West, 2004). However, when human tissue oxygenation drops below 3-5% 
it is considered to be in a hypoxic state (Semenza, 2012) and as such may encourage 
damage at a cellular level.   
As introduced in Section  1.1.2, using microelectrodes to measure the in vivo O2 profile 
of the macaque retina shows that when the retina is dark adapted, the PO2 level in 
the outer retina is low and approaches 0mmHg at the proximal side of the 
photoreceptor inner segments (Wangsa-Wirawan and Linsemeier, 2003). The 
increased oxygen demand displayed by the photoreceptors under scotopic conditions 
is attributable to the high metabolic demand of the ‘dark current’ in the approximately 
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92 million rods (Hagins et al., 1989; Arden et al., 2011). Oxygen profiles within this 
environment suggest that there is little O2 reserve at the photoreceptor level. 
Therefore anatomical changes observed in AMD, such as increased thickening of 
Bruchs membrane (Chen et al., 1992; Schlingemann, 2004; Booij et al., 2010) and 
choroidal haemodynamic dysfunction (Pauleikhoff et al., 1999; Stefánsson et al., 
2011), have the potential to impede the flow of oxygen to the outer retina and disrupt 
the fragile balance between metabolic demand and oxygenation still further, 
especially under dark adapted conditions. The physiological knife-edge of retinal 
oxygenation is exemplified, functionally, by the finding that dark adaptation in normals 
is incomplete at modestly reduced air pressures (McFarland and Evans, 1939), and 
by the adverse effects of hypoxia on colour vision (Karakucuk et al., 2004; Connolly 
et al., 2008; Vingrys and Garner, 1989), dark adaptation (Connolly and Hosking., 
2006; Karakucuk et al., 2004; Vingrys and Garner, 1987; Brinchmann-Hansen and 
Myhre, 1989), mesopic sensitivity (Connolly and Hosking, 2009), and the 
electroretinogram (ERG) (Feigl et al., 2007; Tinjust et al., 2002; Feigl et al., 2008; 
Pavlidis et al., 2005; Schatz et al., 2014). 
A number of hypotheses have been put forward regarding the relationship between 
hypoxia and the numerous metabolic and physical changes that manifest during AMD. 
These include that: 
 Thickening of Bruch’s membrane leads to hypoxia due to the increased 
distance over which oxygen must travel to diffuse from the choriocapillaris to 
the RPE complex (Chen et al., 1992; Schlingemann, 2004).  
 Mechanical changes to the choroidal vasculature as a result of scleral rigidity 
and vitreoretinal adhesion lead to an increased vascular resistance within the 
short posterior ciliary arteries resulting in hypoxia (Friedman et al., 1995; 
Stefánsson et al., 2011).  
63 
 
 Reduced perfusion of the choroid leads to hypoxia, activation of molecular 
sensors and CNVM formation (Grundwald et al., 2005; Metelitsina et al., 2008; 
Mendrinos and Pournaras, 2009).  
 Chronic inflammation leads to an increased retinal metabolic demand and 
exacerbates hypoxia (Arjamma et al., 2009).  
 Interactions between hypoxia, oxidative stress and autophagy lead to 
impairment of RPE function (Blasiak et al., 2014).     
However, it is still unclear if hypoxia is an initiating factor in AMD pathogenesis or a 
secondary product of the condition’s development. To address this, the primary 
objective of this systematic review is to evaluate the literature regarding the role of 
hypoxia in the pathogenesis of AMD. A further aim is to identify any gaps in the current 
evidence base.  
2.2. Literature review methods 
The following eligibility criteria were used to determine which studies were included 
and which were excluded:  
1. Studies had to specify AMD as a pathology considered and could investigate 
any form or stage of AMD.  
2. Studies had to specify hypoxia or ischaemia in relation to the pathogenesis of 
AMD.   
3. Studies could be of any design and could include human and/or animal 
models.  
4. Studies had to be reported in the English language. 
5. Studies had to be reported as full text articles. Conference abstracts were 
excluded. 
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 Literature searching methods 
In June 2017 a comprehensive literature search was undertaken of the following 
databases; Web of science (1900-June 2017), Embase (1947-June 2017), Ovid 
Medline (1946- June 2017).  
The search terms were defined by AMD synonyms and the area of interest as 
displayed in Table 2.1. The use of an asterisk denotes that all variants of the word 
were searched for, i.e. hypoxia and hypoxic.   
Table 2.1. Search terms used in order to find appropriate studies for inclusion within the review. 
 
 
 
 
 
 
 
The reference lists of all included studies were hand searched along with selected 
relevant reviews (Feigl, 2009; Stefánsson et al., 2011; Arjamaa et al., 2009) to ensure 
that no applicable studies were overlooked. Once search results had been compiled, 
all titles and abstracts were read to evaluate the eligibility of each study for inclusion 
in the review. Relevant references identified from each of the databases were 
amalgamated and duplicate papers were removed. Full manuscripts were obtained 
and read for all studies that appeared to satisfy the inclusion criteria on first evaluation. 
Any studies which failed to meet the eligibility criteria on reading the full manuscript 
were excluded at this stage. The relevant data for each study were summarised in a 
data extraction table. This formed the basis of the table of included studies (see 
Appendix I).  
   
Age-related macular degeneration   
OR   
Age-related maculopathy  Hypox* 
OR  OR 
Senile macular degeneration AND Ischaem* 
OR  OR 
ARMD  Ischem* 
OR   
AMD   
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Studies of any design were included in the review. No formal evaluation of the quality 
of included studies was carried out as the nature of the research question meant that 
a wide range of evidence was included, including basic science and animal studies, 
as well as studies including human participants. However, the text highlights the 
largest and/or most robust studies. Any particular issues with study design are also 
highlighted in the text. Furthermore, in the table of included studies, the study design 
is described and the identified limitations in each study are stated. No meta-analysis 
was carried out because of the diverse outcome measures incorporated by studies 
included in the review. Studies included in the review have been categorised into 
those that present ‘direct evidence’ and those that present ‘indirect evidence’ relating 
to the role of hypoxia in AMD pathogenesis.    
2.3. Results 
The results of the database search are summarised in Figure 2.1. After reading the 
titles and abstracts of 1527 articles identified by the literature searching strategy 53 
appeared to meet the inclusion/exclusion criteria. All of these were confirmed as being 
relevant to the eligibility criteria after evaluating the full text, however only 52 were 
included as 2 studies reported the same data in 2 separate articles. Figure 2.2 shows 
the design of the 52 studies included within the review. The majority of studies were 
case-control to allow comparisons between those with AMD and healthy controls. All 
retrospective studies were based on haemodynamics as measured by fluorescein and 
indocyanine green angiography. All in vitro models used human or animal cells.   
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Figure 2.1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow diagram of the study identification pathway (Moher et al., 2009). 
 
Figure 2.2. Breakdown of study design of studies included within the review. 
 
 Direct evidence of hypoxia in AMD 
There is limited direct evidence of the role of hypoxia in the pathogenesis of AMD. 
The evidence which is available relates to the presence of HIF in the retina of 
individuals with AMD (Kvanta et al., 1996; Lopez et al., 1996; Sheridan et al., 2009; 
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Inoue et al., 2007). HIF is a transcription factor that responds to decreases in available 
oxygen in the cellular environment, or hypoxia. An additional 12 studies (6 animal 
models, 6 in vitro models) demonstrated evidence suggesting changes associated 
with AMD pathogenesis such as the upregulation of VEGF (Young et al., 2005; Lima 
Silva et al., 2007; Aiello et al., 1995; Iwase et al., 2013; Nishijima et al., 2007; Kurihara 
et al., 2016; Nakajima et al., 2013; Fuchshofer et al., 2009; Mousa et al., 1999; 
Coassin et al., 2010; Fooroghian et al., 2007; Liu et al., 2000). No studies found 
provided direct evidence against hypoxia as a factor in the pathogenesis of AMD. The 
following paragraphs describe the studies in more detail.    
 Relationship between hypoxia, HIF and VEGF in the    
retina 
Hypoxia inducible factor has been identified as the master transcription factor 
responsible for mediating cellular activity in response to reduced oxygen. The 
dysregulation and overexpression of HIF-1 has been heavily implicated in the area of 
cancer biology, particularly in relation to angiogenesis (see review articles by Shi and 
Fang, 2004 and Wykoff et al., 2001). As HIF upregulation is a known indicator of 
hypoxia it is also of interest when discussing AMD pathophysiology. HIF isoforms 
(HIF-1α, HIF-2α and HIF-3α) are constantly produced under normoxic conditions but 
are short lived due to the natural process of hydroxylation via prolyl hydroxylase 
domain (PHD) proteins (Caprara and Grimm, 2012). When not under hypoxic strain, 
HIF-1α is tagged for degradation by the von Hippel-Lindau (VHL) protein and 
functionally obstructed by Factor-Inhibiting HIF (FIH) (Ohh et al., 2000; Mahon et al., 
2001). When oxygen demand outweighs its availability the effectiveness of PHD, VHL 
and FIH are reduced, resulting in the accumulation of HIF-1α. The HIF-1α is 
translocated into the nucleus where it binds to HIF-1β and a co-activating protein 
(CBP/p300) at the hypoxia response element (HRE) (Caprara and Grimm, 2012). 
Following this, transcriptional activation of target genes can be initiated (Figure 2.3). 
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Within the retina the achievement of HIF stabilisation may also be dependent on the 
chaperone properties of heat shock protein 90 (HSP90) which, when blocked, results 
in reduced HIF-1α levels (Wu et al., 2007).  
 
Figure 2.3. Schematic illustrating the activity of HIF-1α (HIFA) under normoxic and hypoxic conditions. 
Under normoxia after being functionally obstructed by Factor Inhibiting HIF (FIH) and tagged by Prolyl-
4-hydroxylase (PHD) HIF-1α undergoes proteasomal degredation (Pro) and binds to the Von-Hippel 
Lindau (VHL). It then becomes polyubiquitylated (Ub) and targeted for proteosomal degradation. 
Under hypoxic conditions PHD activity is reduced, HIF-1α escapes hydroxylation and dimerises with HIF-
1β (HIFB) and co-activating protein p300/CBP. Transcription of target genes then occurs at the hypoxia 
response element (HRE) (Caprara and Grimm, 2012; copyright permission from Elsevier [2018] licence 
4274220739507). 
 
At a retinal level HIF has been identified in both in vitro (Nakajima et al., 2013) and in 
vivo (Iwase et al., 2013) models of induced hypoxia. HIF-1 is known to induce 
transcription of more than 60 genes of varying function including angiogiogenesis and 
erythropoiesis, both of which assist the oxygenation of hypoxic areas. The HIF 
mediated signal protein responsible for new vessel growth is referred to as VEGF. 
Increased VEGF levels have been found in the presence of upregulated HIF-1α (Liu 
et al., 2000; Fooroghian et al., 2007) and HIF-2α (Sheridan et al., 2009). In addition 
to the stimulation of angiogenesis, VEGF has been found to play an active role in the 
maintenance of choroidal vasculature and neuroprotection of the retina (Nishijima et 
al., 2007). Therefore, it can be found at a background level within the retina even 
under normoxic conditions.  
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A strong relationship has been found between the induction of hypoxia and the 
resultant up-regulation of VEGF. Coassin et al. (2010) documented an 84% VEGF 
rise within cultured human RPE cells under a hypoxic (1% O2) environment when 
compared to normoxia. This finding is consistent with that of Wu et al. (2007) who 
found a 3.4 fold rise in VEGF levels and Mousa et al. (1999) who documented a 
doubling of VEGF levels under similar hypoxic conditions. As VEGF increases in a 
time dependent manner the difference in levels of upregulation between each study 
is likely to be due to differences in time of RPE exposure to hypoxia (Mousa et al., 
1999). In vitro animal studies also provide evidence of hypoxia induced VEGF up-
regulation. Increased VEGF expression as a result of exposing cultured RPE cells to 
a hypoxic environment has been documented in rat (Young et al., 2005), mouse (Lima 
Silva et al., 2007; Kurihara et al., 2016) and bovine (Aiello et al., 1995) models. The 
relationship between HIF activity and VEGF production is further strengthened by the 
finding that the use of a HIF antagonist (doxorubicin) results in significantly reduced 
VEGF levels when compared to controls in mouse and rabbit models of stimulated 
choroidal neovascularisation (Iwase et al., 2013). Similarly, the use of a HIF 
antagonist results in longer VEGF restriction than the use of an anti-VEGF agent 
(Iwase et al., 2013).  
 Evidence of hypoxia mediated choroidal 
neovascularisation in AMD 
Direct evidence of HIF-mediated, VEGF-induced angiogenesis can be found in-situ 
when analysing the components of CNVMs after surgical removal from nAMD patients 
(Kvanta et al., 1996; Lopez et al., 1996; Sheridan et al., 2009). Sheridan et al. (2009) 
analysed 9 CNVMs obtained from nAMD patients and found HIF-1α in 56% and HIF-
2α in 89% of samples assessed. Both isoforms were most abundant in the outer retina 
which can be expected taking into account the location’s dependence on oxygenation 
from the choroid. HIF-1α was localised within the RPE of 55% of samples analysed, 
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suggesting RPE hypoxia at some stage during nAMD pathogenesis. Inoue et al. 
(2007) also found evidence of HIF in 5 of 6 surgically removed CNVMs analysed. 
Although no HIF presence was found directly at the RPE level, both isoforms were 
detected in neighbouring macrophage and endothelial cells. In addition to VEGF, HIF 
has been linked to the transcription of other proteins found within the CNVM, such as 
connective tissue growth factor (CTGF) and plasminogen activator inhibitor-1 (PAI-1). 
As HIF-1 is known to induce the transcription of over 60 genes its capability to induce 
the transcription of targeted cells that not only lead to angiogenesis but also augment 
extra-cellular membrane deposit accumulation is currently under investigation 
(Fuchshofer et al., 2009). 
2.4. Indirect evidence of hypoxia in AMD 
Thirty-six studies provided indirect evidence of the role of hypoxia in the pathogenesis 
of AMD. The evidence which is available relates to changes to ocular structures 
affiliated with AMD pathogenesis, such as the choroid, Bruch’s Membrane and RPE. 
The studies discussed in this section cover a wide range of study designs: 4 in vitro 
models, 1 longitudinal study, 1 case report, 1 histological analysis, 5 retrospective 
studies and 24 case control studies.   
 Choroidal blood flow volume and velocity  
Given the evidence that the outer retina is principally oxygenated by the choroidal 
circulation (Wangsa-Wirawan and Linsenmeier, 1989; Ahmed et al., 1993), in addition 
to the evidence that the oxygen supply to the inner segments of the photoreceptors is 
barely sufficient to meet the demands of the dark adapted retina (Wangsa-Wirawan 
and Linsenmeier, 1989), it is logical to hypothesise that a deficiency in the 
haemodynamic profile of the choroidal circulation may result in outer retinal hypoxia.  
Choroidal blood velocity in those with dry AMD was originally assessed using colour 
Doppler imaging by Ciulla et al. (1999). The peak systolic and end-diastolic blood 
velocity within the central retinal and posterior ciliary arteries of 25 patients with 
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drusen >63µm in diameter, RPE pigmentary changes or GA was compared to those 
without the disease. The flow velocity within the posterior ciliary arteries leading into 
the choroidal supply was found to be reduced in the presence of AMD. This finding 
was substantiated in another study via measurements of ocular surface temperature 
(OST) which is a method that provides an indirect assessment of blood perfusion 
below a structure (Sodi et al., 2014). When measured at three anterior ocular 
locations, the OST was lower in those with a range of AMD severities (n=142) than 
age-matched controls suggesting a potential underlying choroidal blood flow 
decrease beneath the sclera.    
The reduction in choroidal blood volume and flow has been found to be proportional 
to disease severity in both advanced AMD subtypes (Grundwald et al., 2005; 
Metelitsina et al., 2008; Boltz et al., 2010; Berenberg et al., 2012; Chen et al., 2001) 
and has been associated with a risk of vision loss through disease progression (Piguet 
et al., 1992). One study that measured blood flow in the major retinal arteries as 
opposed to the choroid reported no significant difference between blood velocity or 
flow in healthy controls and those with AMD (Sato et al., 2006). In contrast, the 
opposite finding was reported by all other LDF studies, which reported choroidal 
(Grundwald et al., 2005; Metelitsina et al., 2008; Boltz et al., 2010, Berenberg et al., 
2012) and ophthalmic artery (Üretmen et al., 2003) haemodynamic measurements.  
Following the eventual emergence of a CNVM an increase in blood flow is measurable 
due to the filling of new vasculature (Pournaras et al., 2006). However, this is a 
temporary event. Due to fibrotic scarring as a result of new vessel leakage, the level 
of foveal blood velocity and flow eventually drops to a below-average level (Remsch 
et al., 2000; Chen et al,. 2001; Mori et al,. 2001).  
Measurements of blood flow and volume indicate that hypoxia, if evident in AMD, may 
be a result of choroidal dysfunction (Grundwald et al., 2005). The finding of disturbed 
blood flow in both dry and nAMD subtypes further evidences this (Metelitsina et al., 
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2008). Despite this, it is not possible to determine if the haemodynamic changes 
evidenced in AMD are unequivocally the only source of hypoxia. Other possible 
sources such as the structural changes that occur during AMD must also be 
considered.  
 Structural changes to the choroid  
In addition to the evidence of changes in blood flow, the haemodynamic measurement 
of vascular resistance is also of interest when looking at the role of hypoxia in AMD 
pathogenesis. This measurement refers to the resistance that must be overcome to 
push blood through the circulatory system. Increased vascular resistance of the major 
temporal retinal arteries (as measured by resistivity index) has been documented in 
those with AMD (Sato et al., 2006). Similar results were found relating to the resistivity 
of the retrobulbar vessels as calculated from measurements of pulsatility and diastolic 
velocity (Friedman et al., 1995; Dimitrova et al., 2002). These results suggest that 
those with AMD have a more generalised circulatory abnormality proximal to the eye 
such as a stiffer, less compliant vasculature when compared to healthy age-matched 
normals. Such a haemodynamic change may be a result of sclerotic vessels trapped 
between an unyielding sclera one side and a stiff Bruch’s membrane on the other. 
This in turn would cause a reduction of blood flow, the generation of a hypoxic 
environment and the presentation of drusen and other AMD clinical manifestations as 
demonstrated in Figure 2.4 (Friedman et al., 1989; Mullins et al., 2000; Pallikaris et 
al., 2006). 
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Figure 2.4. Proposed pathogenesis of AMD based on increased vessel rigidity. Retinal 
hypoxia caused by lipoidal infiltration with age or vascular disease disrupts RPE function 
leading to the propagation of Bruch’s membrane thickening and RPE detachment or 
formation of a choroidal neovascular membrane (CNVM) (Friedman et al., 1989). 
 
Histological analysis shows narrowed choriocapillary lumen found in those with early 
and established AMD when compared to controls (Kornzweig, 1977). Of the 31 AMD 
eyes reviewed by Kornzweig (1977), focal capillary atrophy was found in 59% and 
attributed to loss of cellular content and nuclei damage. Changes in choriocapillary 
density have also been found and are dependent on the stage of AMD, with early 
stages showing an increase (Spraul et al., 1996) and end-stages showing a reduction 
in density (Ramrattan et al., 1994; McLeod et al., 2009). This relationship is 
furthermore connected to RPE function. Regions of 100% RPE loss in people with 
geographic atrophy were found to be associated with a 51% mean decrease in 
vascular density, with the remaining 49% of functional vessels displaying lumen 
restriction (McLeod et al., 2002; 2009). Anatomically the use of high resolution 
ultrasound has identified Sattler’s layer of the choroid as the site most susceptible to 
ischaemic damage in those with dry AMD.  It has been postulated that damage to 
Sattler’s layer at a cellular level is caused by vascular endothelial dysfunction or 
parasympathetic neuronal deterioration, however more research is required in order 
to substantiate this conclusion (Coleman et al., 2013).  
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 Changes to choroidal blood flow perfusion  
The use of videoangiograms has allowed proposed velocity and flow reduction of the 
choroidal vasculature to be visualised in relation to perfusion of blood throughout the 
macula. Anatomically, the choroidal blood supply originates from the posterior ciliary 
arteries and ultimately branches into segmented structures, each of which supplies 
one proportion of retinal tissue. Obstruction of a retrobulbar artery results in a periodic 
delay and incomplete filling of various areas of the choroid. Changes relating to AMD 
have shown preferential involvement of the perifoveal choroid (Ciulla et al., 2002). 
The locations most at risk of ischaemic insult are referred to as watershed zones, and 
represent the boundaries between regions supplied by different branches of the 
posterior ciliary arteries (Figure 2.5) (Hayreh and Baines, 1972).  
 
Figure 2.5. Schematic illustrations of different choroidal watershed zone (WZ) patterns and 
their relationships to neovascularisation in nAMD. Red lines denote the pattern of the WZ and 
dark grey areas represent neovascularisation. (A) Vertical pattern coursing through the optic 
nerve head (ONH) in a normal subject. (B) Stellate pattern WZ. (C) Vertical pattern coursing 
through the ONH and extending to the fovea. (D) Vertical pattern coursing through the ONH 
without foveal extension. (E) Vertical pattern coursing through the fovea. (F) Angled pattern of 
a WZ coursing through and adjacent to the ONH (Mendrinos and Pournaras. 2009; copyright 
permission from John Wiley and Sons [2018] licence 4274231455116).   
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Topographic analysis of the watershed zones shows that the boundaries between 
them often meet around the foveal region. As a result, the macula is deemed to be an 
area predisposed to chronic ischaemia (Mendrinos and Pournaras, 2009; Ross et al., 
1998). The risk of ischaemia is compounded by the finding of delayed filling of the 
choroidal vessels in the presence of AMD (Melrose et al., 1987; Prünte and Niesel, 
1988; Pauleikhoff et al., 1990b; Giovannini et al., 1994; Zhao et al., 1995). Such a 
delay results in poor perfusion of the macular tissue causing new vessel growth to be 
localised within the watershed zone boundaries in 70% of those with nAMD 
(Giovannini et al., 1994). Other pathological changes seen in AMD, such as the 
emergence of reticular pseudo-drusen and the formation of a CNVM, have also been 
associated with perfusion abnormality (Alten et al., 2013; 2016; Hartnett et al., 1996). 
In addition to neovascularisation, poor perfusion has been associated with localised 
areas of RPE atrophy and confluent drusen (Pauleikhoff et al., 1999). The degree of 
perfusion disruption is also proportional to the graded severity of drusen (Remulla et 
al., 1995; Staurenghi et al., 1992).  
Figure 2.6 shows a potential mechanism of ischaemia-based AMD pathogenesis 
featuring impaired perfusion as a major contributing factor (Feigl, 2009). Reduced 
ocular blood flow is hypothesised to lead to impaired diffusion of factors necessary for 
the health of the choroidal circulation, which in turn exacerbates the existing choroidal 
perfusion abnormality. The resulting ischaemia is suggested to cause impaired RPE 
function leading to features such as increased deposition at the level of Bruch’s 
membrane and the emergence of a CNVM (Feigl, 2009; Ciulla et al., 1999).  
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Figure 2.6. Proposed pathogenesis of AMD based on impaired perfusion leading to hypoxia. 
Adapted from the ischaemia hypothesis proposed by Feigl (2009). The initial cause of 
reduced ocular blood flow is not yet fully understood but has been proposed as increased 
resistance of choroidal vessels with age (Friedman et al., 1989).   
 
 Bruch’s membrane and RPE dysfunction  
Lipoid infiltration of Bruch’s membrane is well documented in the process of normal 
ageing and is proposed to be exaggerated in the pathogenesis of AMD (Friedman, 
1989). Such infiltration of Bruch’s membrane is evidenced by thickening, 
degeneration of collagen, basal laminar deposition, drusen and calcification (Bird, 
1992; Pauleikhoff et al., 1990a; Booij et al., 2010). The net result of such changes is 
an increase in distance between the retinal cells and choriocapillaris, via which 
aqueous based metabolites must diffuse (Schlingemann, 2004). This causes a lower 
oxygen tension at an outer retinal level in accordance with Fick’s laws of diffusion, i.e. 
the rate of diffusion across a membrane is inversely proportional to the thickness of 
the membrane (Figure 2.7).  
In addition, the transfer of metabolites across the RPE-Bruch’s-membrane complex 
is further obstructed by a reduction in the hydraulic conductivity of Bruch’s due to 
compositional change and the diffusion barrier caused by deposition of abnormal 
material (Chen et al., 1992; Booij et al., 2010). The spectrum of lipids infiltrating 
Bruch’s membrane suggests that they originate, in part, from the phospholipids 
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derived from outer segment turnover. Their accumulation represents RPE inefficiency 
to remove retinal waste product (Booij et al., 2010).  
 
Figure 2.7. Examples of cat oxygen profiles collected at various retinal depths when breathing 
air. Increased distance between the choroid and retina can be seen to lower the oxygen 
tension at the outer retinal border as exhibited in the difference between (A) attached and (B) 
detached retina (IR: inner retina, OR: outer retina and FL: fluid layer under the retina) (Wang 
and Linsenmeier, 2007; copyright permission from ARVO).   
 
Such RPE dysfunction and the resultant changes to the structure of Bruch’s 
membrane are thought to contribute to choriocapillary degradation seen histologically 
in those with AMD. This degradation is attributed to a reduced level of RPE derived 
factors integral to vascular integrity reaching the choroid (McLeod et al., 2009; Spraul 
et al., 1996). The factors which have been shown to be affected include Basic 
fibroblast growth factor (bFGF), VEGF and endothelin-1 (McLeod et al., 2009). It is 
logical to suggest that a combination of increased RPE cell death and increased 
Bruch’s membrane thickening as exhibited in AMD may both contribute to reduced 
RPE derived factors. This theory is supported by the finding of an increased venous 
oxygen saturation in end-stage AMD suggesting less oxygen extraction as a result of 
retinal cell death (Geirsdottir et al., 2014) and a reduction in large choroidal vein 
density in eyes with increased basil laminar deposit within the outer retina (Spraul et 
al., 1996; 1999). The resultant reduced level of blood flow within this region further 
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propagates the accumulation of cellular debris as a vicious circle develops between 
haemodynamic disruption, RPE dysfunction and the deposition of metabolic waste.  
In addition to the impact on the choroid of RPE dysfunction, current evidence suggests 
that hypoxia-induced RPE metabolic stress results in a two-fold direct impact on RPE 
behaviour (Kurihara et al., 2016). Firstly, hypoxia alters RPE cellular activity resulting 
in changes in the rate of VEGF and metabolite secretion. Secondly, as opposed to 
oxidising glucose, the RPE cells commit to glycolysis upregulation in an attempt to 
gain energy at a faster rate. This allows the RPE cells to combat metabolic stress 
however doubles their glucose intake. As the RPE is the main supplier of glucose to 
the neurosensory retina this impacts photoreceptor function and survival (Kurihara et 
al., 2016).   
 Mitochondrial damage  
The mitochondria are a vital intracellular organelle for retinal cell function and survival. 
Mitochondria are found at high densities within cells that are metabolically active, such 
as the RPE, where they perform roles including provision of chemical energy, 
regulation of programmed cell death and control of cellular metabolism. Mitochondrial 
dysfunction has been associated with theories of ageing (Druzhyna et al., 2008; 
Golden and Melov, 2001; Moosmann and Behl, 2008; Mandavilli et al., 2002; 
Weissman et al., 2007). Chronic dysfunction has also been associated with age-
related macular degeneration (Blasiak and Szaflik, 2011; Jarrett et al., 2008; 2010; 
Lin et al., 2011; Karunadharma et al., 2010; Nordgaard et al., 2008). When studying 
the direct effect of hypoxia on mitochondrial structure, histological analysis shows that 
90 minutes of acute ischaemia is enough to cause mitochondrial damage within both 
RPE and photopigment disc cells (Johnson and Foulds, 1978). Mitochondria 
exhibiting deoxyribonucleic acid (DNA) damage as a result of acute hypoxia also 
demonstrate reduced levels of ATP production which, in turn, is associated with RPE 
apoptosis (Bellot et al., 2001).  
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The precise mechanism by which hypoxia and mitochondrial dysfunction are 
associated is unclear. The oxidative stress hypothesis states that AMD pathogenesis 
occurs as a result of mitochondrial DNA damage incurred through the action of ROIs, 
the production of which has been shown to increase in acute ischaemia/reperfusion 
(Beatty et al., 2000). Although AMD is not an acute ischaemic condition, evidence 
suggests it involves a chronic vascular insufficiency such that similar mechanisms 
may apply (Feigl, 2009). A link between ROIs and HIF stabilisation has also been 
established during hypoxia and thus elevated ROI levels may act as a precursor to 
the activation of HIF transcription factors (Cash et al., 2007). 
2.5. Discussion 
The finding of HIF in the outer retina of those with AMD provides an indication that 
hypoxia is evident at some stage during pathogenesis (Kvanta et al., 1996; Lopez et 
al., 1996; Sheridan et al., 2009; Inoue et al., 2007). At present there is however a lack 
of further direct evidence to clarify whether hypoxia is a causative factor in the 
pathogenesis of AMD, or at what stage in the disease process it manifests. 
Measurements of perfusion pressure, oxygen tension and blood flow rate indicate that 
hypoxia, if evident, is likely a result of diminished choroidal blood circulation 
(Grundwald et al., 2005; Metelitsina et al., 2008). The consequence of such an 
impairment is poor perfusion, particularly throughout the macular region, which is a 
fragile area with a large oxygen demand.  
The involvement of haemodynamic disruption as a source of hypoxia is further 
evidenced by: 
 The fragile oxygen balance of the inner retina, in which even for a healthy 
retina the oxygen demand is only just met under dark adapted conditions 
(Wangsa-Wirawan and Linsenmeier, 2003).    
 The positive correlation of reduced perfusion and AMD progression (Arjamaa 
et al., 2009).  
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 The finding of disturbed blood flow in both dry and nAMD subtypes (Metelitsina 
et al., 2008). 
Although haemodynamic changes appear to contribute to the generation of a hypoxic 
environment it cannot be determined if these changes are unequivocally the only 
source of hypoxia. Increased thickening of Bruch’s membrane, beyond that expected 
with normal ageing, causes a lower oxygen tension in the outer retina and may 
therefore provide another basis by which hypoxia could arise. In addition, lipid 
deposition and drusen formation cause further disruption to the transfer of metabolites 
between the choroid and the RPE which augments hypoxia long-term, for example by 
hindering the transport of RPE derived factors for maintaining the choroidal 
vasculature.  
This review, through a systematic evaluation of the literature regarding hypoxia in the 
pathogenesis of AMD, has identified limited direct evidence through the emergence 
of HIF that hypoxia features within the pathogenesis of nAMD. Indirect evidence also 
supports hypoxic involvement in early AMD and GA. Due to the complexity of the 
pathogenesis it is not possible to determine whether hypoxia, if present, contributes 
as an initiating factor towards or emerges as a consequence of AMD pathogenesis. 
Furthermore, a number of the pathological traits evident in AMD have been associated 
with RPE dysfunction of which the relationship to hypoxia is still not clear. Such 
deficiencies in the literature have highlighted the need for more longitudinal human 
studies to characterise whether choroidal changes precede clinical signs of disease 
onset. In addition it would be useful to further investigate cellular indicators of hypoxia, 
particularly in relation to RPE dysfunction, in order to improve current understanding 
of the role of hypoxia in AMD pathogenesis. 
It is also worth noting that all studies investigating HIF in relation to cultured human 
cells have focused on the RPE only. In accordance with the low oxygen tension when 
dark adapted (Wangsa-Wirawan and Linsenmeier, 2003) it is the inner retina as 
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opposed to the RPE that is of primary interest when investigating the effect of hypoxia 
on AMD pathogenesis. In order to further understand the role of hypoxia in AMD, 
deficiencies in the literature involving inner retinal HIF variation and level in response 
to light adaptation state need to be addressed. This would add to the rationale for 
studies which aim to manipulate the retinal oxygen level such as the ALight Clinical 
Trial for which the protocol is introduced in the next chapter.  
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Chapter 3.  General methods and protocol development  
Based on evidence to suggest that hypoxia plays a role in the pathogenesis of AMD 
the overarching objectives of this PhD were to evaluate the impact of light therapy on 
the progression of early and intermediate AMD, and to carry out a simultaneous cross-
sectional study alongside the longitudinal evaluation, in order to evaluate the trial 
outcome measures as biomarkers for AMD severity. 
This chapter begins with a section summarising the study design. The full trial protocol 
is not presented in this chapter, but is available in Appendix II, and has also been 
published (McKeague et al., 2014). The aims of the protocol development work 
described in the latter sections of this chapter were: (i) to optimise the original trial 
protocol in order to facilitate successful recruitment and data collection and (ii) to 
collect preliminary dark adaptation, flicker and chromatic threshold data from healthy 
control volunteers in order to assess the basic applicability of the techniques.  
3.1. Overview of original protocol 
The ALight trial was a Phase I/IIa proof-of-concept randomised controlled trial (RCT). 
To address the primary aim of the study (refer to Section 1.5 for a definitive list of trial 
objectives), 60 individuals with unilateral nAMD and early or intermediate AMD in the 
fellow eye were recruited from the Medical Retina unit of Bristol Eye Hospital (BEH). 
Participants were randomly allocated to receive either a light mask or no intervention 
(both groups continued to receive ranibizumab injections as required for the fellow 
eye). Safety was assessed through monitoring of progression rates to nAMD in the 
treated group, and through monitoring and reporting of adverse events (AE), serious 
adverse events (SAE) and adverse reactions (AR) relating to both eyes. This was 
done following a strictly defined protocol (McKeague et al., 2014). Figure 3.1 
illustrates the patient pathway through the trial by means of a study flow diagram. The 
following sections will summarise the key features of the trial protocol.  
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Figure 3.1. The participant pathway as displayed in flow diagram form (McKeague et al., 2014) 
The number of participants stated in each box represents the projected recruitment targets at 
the start of the trial. 
 
3.1.1. Primary outcome measures   
There were two co-primary outcome measures for the study - one a structural 
measure of disease progression based on retinal imaging, and one a measure of 
visual function: 
i. The proportion of participants who showed disease progression in the eye with 
early/intermediate AMD. Disease progression was defined as the onset of 
advanced AMD or a 12 month increase in drusen volume beyond test-retest 
95% confidence intervals. 
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ii. The change (baseline to 12 months) in the rate of cone dark adaptation 
(defined as the time constant of cone recovery [cone τ] after being exposed to 
a substantial photopigment bleach). 
The introduction of SD-OCT has provided the opportunity to study drusen in greater 
detail (see Section 1.3.6.1). It was found by Yehoshua et al. (2011) that irrespective 
of initial drusen volume, approximately 50% of those with AMD show a significant 
increase in drusen volume over 12 months, i.e. beyond test-retest 95% confidence 
intervals. This finding makes disease progression based on an increase in drusen 
volume a useful outcome measure within a limited timeframe. Although the overall 
pattern is growth, some large drusen can shrink abruptly just before the onset of 
advanced disease. Therefore, we also considered conversion to nAMD as being an 
indicator of disease progression in the analysis. Data from a trial on a similar group 
indicated that about 10% of people meeting the inclusion criteria would develop 
advanced AMD within 12 months (Maguire et al., 2013). Hence, 60% of participants 
were expected to show progression based on increased drusen volume or 
progression to late AMD. It was felt that a clinically relevant reduction in this proportion 
would be 50% (i.e. from 60% to 30%). The development of advanced AMD was 
determined on the basis of ophthalmologist diagnosis at the monthly follow-up 
appointments within the nAMD clinic. 
The rate of rod (Dimitrov et al., 2008; 2011; Owsley et al., 2001; 2007; 2016) and cone 
(Dimitrov et al., 2008; Gaffney et al., 2011; 2013; Jackson et al., 2014b) dark 
adaptation has been shown to be reduced in people with early AMD. Furthermore, 
longitudinal studies have shown that delayed cone adaptation is an indicator of 
increased risk of development of advanced AMD (Owsley et al., 2016; Sandberg et 
al., 1998). Therefore, the rate of retinal dark adaptation was chosen as a co-primary 
outcome measure as the functional measure which appears in the literature to be 
most sensitive to subtle changes in AMD status. The rate of cone, rather than rod, 
adaptation was chosen. This was done to allow a more rapid assessment of recovery 
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and based on evidence that cone adaptation is substantially delayed in people with 
AMD when a long duration bleach and large stimulus is used (Gaffney et al., 2011; 
2013). Based on dark adaptation, the time constant of cone recovery (cone τ) was 
specified as the outcome measure assessed. Cone τ denotes the time to regenerate 
~63% of cone photopigment, hence a larger cone τ denoted a slower recovery (i.e. 
greater impairment).  
3.1.2. Secondary outcome measures   
In addition to the primary outcome measures, a range of secondary outcome 
measures were also included to further evaluate the effectiveness of the intervention: 
i. The change in drusen volume over the 12 months. The quantitative evaluation 
of drusen morphology by SD-OCT is highly reproducible (Gregori et al., 2011) 
and a study of the natural history of change in drusen volume has shown that, 
over 12 months, drusen exhibit an undulating pattern of growth whereby 
increase in overall volume is more likely than shrinkage. Mean cube root 
drusen volume increases significantly (P=0.006) by 0.016mm (SD 0.059) over 
12 months (Yehoshua et al., 2011).  
ii. The number of ranibizumab retreatments required on the fellow eye over 12 
months. A review of medical records at the end of 12 months enabled us to 
quantify the impact of light therapy on the frequency of ranibizumab 
retreatment in eyes with active nAMD at baseline. Ranibizumab (as opposed 
to aflibercept) was chosen as a secondary outcome measure as at the time of 
study inception aflibercept was not widely used within Bristol Eye Hospital.   
iii. The change in visual function using the CAD test, BCVA and 14Hz flicker 
threshold.  
iv. The change in self-reported quality-of-life (EuroQol-5D [EQ-5D]) (EuroQol 
Group, 1990) and visual function (VFQ-48) (Stelmack et al., 2004a; 2004b).  
 
To obtain detailed information about the time-course of any therapeutic action drusen 
volume was assessed at baseline and then at monthly intervals (using OCT images 
obtained at the regular nAMD clinic follow up appointments).  
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3.1.3. Participant eligibility criteria 
All participants were aged between 55 and 88 years of age and had a BCVA in the 
test eye of logMAR score 0.3 (40 letters, Snellen 6/12) or better. A diagnosis of nAMD 
was made in one eye only. The fellow eye was classified as early or intermediate 
AMD, characterised by the presence of soft drusen and/or focal pigmentary changes, 
in the absence of signs of advanced AMD, e.g. retinal oedema, exudates, 
haemorrhage, GA (Ferris et al., 2013). In the original protocol those who had 
completed within the past month their initial 3 months of ranibizumab loading 
injections were deemed eligible. This was amended in January 2015 to also permit 
inclusion of those who were outside of their initial loading injections in the fellow eye 
– the rationale for this protocol amendment is discussed in Chapter 5. Participants 
also needed to be willing to adhere to the allocated treatment for the duration of the 
trial. Those recruited for the cross-sectional study were required to have grade 0 or 1 
AMD (according to the AREDS Simplified Severity Scale) (Ferris et al., 2005). Any 
potential participant was excluded if they had: 
 Ocular pathology other than macular disease, including: non-AMD related 
fundus changes, narrow anterior angles (≤grade 1 van Herrick), amblyopia, 
significant cataract (LOCS III graded, above grade 3 on any criterion), central 
corneal/media opacity, any posterior eye condition, glaucoma, history of 
prodromal symptoms of closed angle glaucoma. 
 Significant systemic disease known to affect visual function (e.g. diabetes, 
Parkinson’s disease, Alzheimer’s disease). 
 History of medication known to affect visual function (e.g. chloroquine, 
tamoxifen).  
 An insufficient level of English language comprehension to be able to carry 
out the questionnaires and monthly interviews with study personnel. 
 A history of falls, or a high risk of falling. 
87 
 
 A diagnosis of advanced AMD in both eyes. 
 Significant systemic disease that would compromise participation in a 1 year 
study (e.g. motor neurone disease). 
 Cognitive impairment as determined using an abridged Mini Mental State 
Examination (MMSE) (Schultz-Larsen et al., 2007). 
 An illness requiring an oxygen mask to be worn at night.  
 
3.1.4. Recruitment strategy 
The basic recruitment strategy outlined in the original protocol was as follows. 
Potential participants were either directly identified by an ophthalmologist when 
attending their appointment at the eye hospital or by the trial investigator based on 
medical records. Once identified they were provided with an information sheet and 
asked for their permission to be contacted by the study investigator. Potential 
participants were contacted by telephone or letter (as preferred) at least two days 
after their receipt of the information sheet, and invited to meet the study investigator 
at their next visit to the nAMD clinic to discuss the trial, provide consent if they chose 
to participate, and carry out some basic screening tests. Participants were informed 
after this screening visit whether they were eligible to take part in the study. 
Approximately two months after receiving the participant information sheet (PIS) 
eligible participants were invited to attend for the baseline data collection (preferably 
coinciding with a regular visit to the clinic), and were randomised to the treatment or 
control group (see the flow diagram in Figure 3.1).  
Participants with AMD severity grades of 0 and 1 according to the AREDS Simplified 
Severity Scale (Ferris et al., 2005) were recruited for the baseline cross-sectional 
analysis by local optometrists in Bristol and Cardiff, from Bristol Eye Hospital, from 
the list of research volunteers at the Cardiff University Eye Clinic and from staff and 
students of Cardiff University.   
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3.1.5. Withdrawal from trial: criteria and loss to follow-up  
Any participant was withdrawn from the trial if they wished to discontinue the study or 
exhibited a serious adverse event/unexpected change deemed to be related to the 
intervention or to impact on their suitability to continue with the trial. Upon initial 
presentation any issue relating to the comfort of the intervention was attended to via 
adjustment of the mask. As necessary the tightness of the mask was altered and the 
patient reinstructed on adjustment so that they could manipulate this parameter at 
home. In order to improve comfort around the ears an alternative choice of mask strap 
was available if appropriate. In the event of continued discomfort the participant was 
given the option of withdrawing from the trial.    
3.1.6. Registration 
Details of eligible consenting participants were recorded on case report form 1 (CRF1) 
by the study investigator at the screening visit. Additional data arising from the 
baseline data collection visit were recorded on Case Report Form 2 (CRF2). All CRFs 
(see Appendix VIII) were stored in a secure locked room and the data were inputted 
into a password protected database designed by the study investigator. Details of 
those who decline to take part or those who did not meet eligibility criteria were also 
recorded on CRF1 providing they gave consent to have their anonymised data used.  
3.2. Intervention 
Participants were given a light mask (Noctura 500: Polyphotonix, UK) that presents 
illumination to both eyes, overnight. Illumination provided by the mask is based on 
organic light-emitting diode (OLED) technology. By positioning a series of organic 
(carbon based) thin films between two conductors and applying an electrical current 
the mask eyepieces emit a dim green light. The peak output of the light mask is 505nm 
which falls outside the range of short wavelength visible light that has been associated 
with RPE photochemical damage (Ham et al., 1976; Taylor et al., 1992; Arnault et al., 
2013; Smick et al., 2013). Each OLED is powered by a 3V lithium cell battery. The 
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mask is depicted in Figure 3.2. It is activated when a touch sensor on the device is 
gently covered with a finger for 3 seconds. It deactivates if not worn continuously for 
the first 15 minutes, and after that, the light remains on for the remainder of the 8 hour 
treatment period. If the mask is removed or comes away from the face in this time 
data are still recorded to show that the mask is active but not being worn. In this trial, 
the masks were pre-programmed to function for a maximum of 8 hours within a time 
window, i.e. 8pm to 10am, to prevent misuse. Outside of these hours they did not 
illuminate if worn. Each mask was programmed using bespoke software (PPX Works) 
and hardware as developed by Polyphotonix, UK (Figure 3.3). 
 
Figure 3.2. Principle components of the OLED sleep mask. The top panel shows the light-
emitting ‘pod’ of peak output 502 nm. The bottom panel shows the cushioned fabric mask that 
houses the pod. 
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Treatment fidelity and acceptability were evaluated during a monthly interview with 
the study investigator, which coincided with the participant’s routine nAMD clinic 
appointment. Both treatment arms attended this brief, monthly appointment to 
quantify sleep quality using the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 
1989). Compliance data were obtained at the monthly visit from the treatment group 
i) through evaluation of a diary of mask usage, ii) objectively through data collected 
on a chip in the mask itself (based on a capacitive sensor which logs when the mask 
is in contact with the face). This provided precise data on the hours the mask was 
worn each night. As each mask was programmed with the unique participant 
identification code, compliance data stored on-chip were non-identifiable except via 
the password protected electronic database.  
 
Figure 3.3. A photograph of the hardware used to connect each mask to the PPX Works 
program. This system was used to program a mask before use, download compliance data at 
each monthly follow-up visit and record the return of a mask after 3 months wear. 
 
For several reasons, it was not appropriate in this study to use a sham treatment. 
Firstly, if any light, even that of a different colour or intensity to the treatment, was 
presented to the control group overnight, there was the possibility that it could have 
had a physiological effect. Secondly, if a mask that didn’t contain illuminated light-
emitting diodes (LEDs) was to be used as a sham, the participants would be aware 
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that they didn’t perceive light and so would be unmasked compared to the intervention 
group. Finally, a non-illuminated mask may have actually reduced the light levels 
entering the eye below the level that would normally be experienced in an urban 
environment, which may have impacted on the retinal physiology of the control group. 
The participants were not, therefore, masked as to whether they were in the 
intervention or control group.  
The study investigator who collected the outcome data also provided the masks and 
instructions on usage, hence was also not masked to the intervention group. However, 
the primary outcome measure, disease progression, was an objective measure 
carried out by automated computer software. This minimised the potential for 
experimenter bias. The ophthalmologists at BEH who were seeing the participants for 
their regular anti-VEGF injections were masked as to whether individuals were in the 
intervention or control arm of the study. This was designed to prevent any bias in their 
retreatment decisions (which could impact on the secondary outcome measure of this 
trial which related to ranibizumab retreatment rates).  
 Determining the optimum light level for the intervention 
The mask was set in this trial to provide a luminance of 75 photopic cd/m2 (± 10%). 
When adjusted for the spectral sensitivity of rod photoreceptors, this equated to 186 
scotopic cd/m2. To convert this value into units of retinal illuminance (Td) in the closed 
eye, the luminance is multiplied by pupil area and adjusted for eyelid transmission. 
Studies investigating light attenuation by the human eyelid have found transmission 
to range between 0.3%-2% for light in the region of 500-505nm (Moseley et al., 1988; 
Robinson et al., 1991; Ando and Kripke, 1996). Therefore, we may assume an 
average lid transmission of 1%. Hence, a luminance of around 0.75 photopic cd/m2 
would be reaching the retina during periods of mask use. Under these conditions, 
pupil diameter in people in the age group 60-85 years is on average 5mm (Winn et 
al., 1994). This would result in a retinal illuminance in the order of 36 scotopic Td. In 
92 
 
humans, Thomas and Lamb (1999) used an electrophysiological technique to 
determine the attenuation of the maximal response of rod photoreceptors achieved 
with different background light levels. According to their data, the illumination of the 
dark adapted retina by 36 scotopic Td would cause an approximate 40% reduction in 
rod circulating current (Thomas and Lamb, 1999), which would impact substantially 
on the oxygen requirements of the dark adapted eye. 
 Maintenance of the light level   
Each mask was replaced every 12 weeks at the participant’s routine nAMD clinic 
appointment so that the total duration of mask usage was 12 months. Frequent 
replacement of the mask was designed to ensure that peak output was maintained 
throughout the duration of the trial. The measured output of one OLED of one mask 
assessed over 12 weeks is shown in Figure 3.4, in order to illustrate the typical change 
over time. Whilst there was some reduction in luminance over the 12 week period of 
usage, the mask output remained within 10% of the target 75cd/m2. Mask condition 
was manually checked and function was verified on a monthly basis (via the collection 
of objective data documenting number of hours worn). As masks were programmed 
not to illuminate past 12 weeks of usage participants were given a new mask to use 
in advance of this date (up until when they were instructed to continue using their 
current mask). 
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Figure 3.4. Luminance output of one eye of a Noctura 500 OLED mask over 12 weeks as 
measured weekly. The output of the mask was maintained to within (± 10%) of the desired 
output of 75 photopic cd/m2. The mask was illuminated for 8hrs nightly during collection of 
output data. 
 
 Circadian rhythm 
A concern regarding the use of low-level night-time light therapy is the potential to 
cause a disturbance in sleep patterns via disruption of circadian rhythm. The term 
‘circadian rhythm’ is used to describe a set of physical, mental and behavioural 
changes including sleep that follow a roughly 24 hour cycle. Current evidence 
suggests that a subgroup of photosensitive retinal ganglion cells containing the 
photopigment melanopsin are responsible for mediating light-dark cycles, thus 
regulating the secretion of the tiredness-inducing hormone melatonin (Lyubarsky et 
al., 1999; Berson et al., 2002; Hattar et al., 2002). Melatonin release has been found 
to be directly inhibited by light exposure (Lewy et al., 1980; Boyce and Kennaway, 
1987) and a retinal luminance of 186 scotopic cd/m2 has the potential to suppress 
secretion by 50-60% (Brainard et al., 2001). Despite this, to date the use of light 
therapy in this manner has been found to be well tolerated over a 12 month period 
(Arden et al., 2010; 2011). A secondary aim of this trial was to further investigate the 
potential disruption to circadian rhythm by monitoring self-reported sleep quality. 
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 Ocular position during sleep 
Our nightly sleep consists of several sleep cycles of non-rapid eye movement (NREM) 
and rapid-eye movement (REM) sleep. The first sleep cycle typically lasts around 90 
minutes, with the succeeding cycles averaging around 100-120 minutes. Each cycle 
starts with NREM sleep which consists of 3 stages. An individual will typically proceed 
through stage 1, stage 2 and spend a period in stage 3 (Silber et al., 2007). The cycle 
is then reversed as the individual proceeds back down through stage 2. The return to 
stage 1 marks the end of NREM sleep. Following this REM sleep is entered. This is 
when most eye movement occurs during the sleep cycle. As the night progresses, the 
time spent in deep stage 3 sleep decreases and the time spent in REM sleep 
increases as seen in Figure 3.5.  
 
Figure 3.5. A hypnogram displaying a typical adult sleep pattern over 8hrs. 
The eye movement which occurs during sleep was not anticipated to be an issue in 
this trial with respect to the provision of the correct retinal illuminance for two reasons. 
Firstly, it was not intended for the intervention in this study to provide a point focus of 
luminance on the macular, but rather, a ‘wall of light’ large enough to encapsulate the 
pupil in all positions of gaze. Secondly, older adults such as those enrolled in the trial, 
only spend around 10% of their total sleep time in REM sleep (Institute of Medicine, 
2006). Therefore, trial participants are likely to only have spent around 30-60 minutes 
in REM sleep per night. Most of the time spent in this state will have dominated the 
latter half of the sleep period, especially the hours before waking. 
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3.3. Trial procedures   
This section provides an overview of the procedures employed in the clinical trial and 
cross-sectional study.  
 Informed consent and screening 
The study investigator was responsible for taking the informed consent of each 
participant at the beginning of the screening assessment. Following a full explanation 
of the study, they were invited to take part. Those who expressed interest in 
participating were then asked to sign the consent form. All investigators taking 
informed consent had received the appropriate training, i.e. “Good Clinical Practice” 
training provided by the National Institute for Social Care and Health Research. 
 Screening assessment 
The screening assessment for potential participants in the clinical trial took 
approximately 30-60 minutes. Following a discussion of the study, and the obtaining 
of informed consent, the study investigator questioned the participant regarding their 
ocular and medical history in order to ensure the eligibility criteria had been met 
(documented in Section 3.1.3).  
BCVA was measured for each eye with the participant’s habitual distance correction 
in place (following a brief refraction if necessary) using an ETDRS test chart (logMAR 
score and equivalent number of letters seen recorded). The letters displayed were 
altered for each eye to avoid repetition and memorisation. Prior to pupil dilation with 
1% Tropicamide the drainage angle was measured using Van Herick’s method. 
Following this the media clarity was assessed for each eye and the lens was graded 
according to the LOCS III grading scale (Chylack et al., 1993). An abridged version of 
the MMSE test was used to assess for cognitive impairment (Schultz-Larsen et al., 
2007). Those still deemed eligible for inclusion in the study also completed the 
following questionnaires through verbal interview with the investigator: visual function 
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(VFQ-48), health related quality-of-life (EQ-5D), Pittsburgh Sleep Quality Index 
(PSQI), smoking history (pack years), ocular vitamin supplementation and ethnic 
origin. Retinal photographs and OCT images were taken following pupil dilation and 
repeated if image quality was insufficient to allow evaluation. OCT and fundus 
photographs were assessed to check for eligibility. 
 Baseline assessment  
The baseline assessment for those with AMD took approximately 75 minutes. OCT 
images (5 Zeiss Cirrus SD-OCT 4000, 6x6mm macular cube scans centred on the 
fovea) and fundus photographs (Topcon 3D-OCT 2000 45º photographs centred on 
the fovea) obtained during the participant’s routine visit to the ranibizumab clinic were 
analysed to assess drusen volume and AMD grade, according to AREDS Simplified 
Severity Scale. If the images were of insufficient quality additional images were 
captured. Drusen volume analysis software was used to provide data regarding RPE 
elevation within 3mm2 and 5mm2 of the fovea (see Section 3.3.3.1 for further detail). 
Any changes in eligibility since screening were also addressed via ocular health 
examination. Repeated BCVA measurements (using a 4m ETDRS chart) were taken 
alongside auto-refraction (Topcon KR-7500) and data on current spectacle 
prescription. The following visual function tests were then completed: 
 Colour vision testing. Chromatic thresholds were measured for the eye with 
early AMD using the CAD test (O’Neill-Biba et al., 2010) (City Occupational 
Ltd). 
 Flicker thresholds. Contrast thresholds to a 14 Hz flickering stimulus were 
measured for the eye with early/intermediate AMD using the procedure 
outlined by Dimitrov et al. (2011).  
 Dark adaptometry. Cone τ was determined using a psychophysical procedure 
described in publications by Gaffney et al. (2011). This involved an initial 
training phase, of around 5 minutes, then the adapting light was presented 
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(bleaching approximately 92% of macular cone photopigment), and finally 
recovery of visual thresholds was monitored for 25 minutes after exposure to 
the adapting light. 
 
Details of the methods for collecting the visual function data are outlined in Section 
3.6.3.1 (dark adaptation) and Section 3.7.1.2 (flicker threshold and chromatic 
thresholds). 
 OCT acquisition and drusen volume measurement   
The Cirrus HD-OCT instrument was used to acquire 5 images for each participant 
from which the mean drusen volume measurement was recorded.  All images were 
macular cube scans (200 x 200mm3 A scans) covering a retinal area of 6 x 6mm2 (20° 
x 20° visual angle). The scans were performed by experienced operators of the Bristol 
Eye Hospital Retinal Imaging Unit who assessed the quality of the scan during its 
acquisition. Scan quality assessment was based on signal strength, a parameter 
provided by the manufacturer of each OCT instrument. Signal strength ranges from 1 
to 10, with lower scores indicating poorer quality. As with other studies that have used 
the same equipment to acquire drusen volume measurements in a cohort of those 
with AMD (Yehoshua et al., 2011; Abdelfattah et al., 2016), 5 scans were taken for 
the study eye and an image quality cut-off score of 7 or above was employed. 
Following image acquisition minor adjustments to head and participant positioning 
were made as necessary however there was no specific requirement to reset the 
instrument between scans. The Cirrus Advanced RPE Analysis Software (Version 
7.0.1) was used to measure drusen volumes and areas within the 3- and 5mm circles 
(centred on the fovea) of the Cirrus grid. The algorithm compares a virtual RPE map 
free-from deposits (RPE floor) to the actual RPE geometry to derive a drusen profile 
(Figure 3.6).  
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Figure 3.6. Example of quantitative measurements provided by the Cirrus automated 
algorithm. Drusen volume and area are measured within the 3- and 5mm concentric circles 
visible on the RPE elevation map. The sub-RPE slab denotes areas of atrophy and the RPE 
shows elevations in the RPE geometry when compared to a ‘virtual’ map.    
 
 Grading  
The fundus images were graded according to the AREDS Simplified Severity Scale 
(Ferris et al., 2005) by two independent graders both of which were familiar with the 
clinical presentation of AMD. Where disagreement occurred between the two graders, 
the results were adjudicated independently by one of the PhD supervisors (AB). In 
accordance with the AREDS Simplified Severity Scale (Ferris et al., 2005), the 
severity of AMD was based on scoring each eye independently then summing the 
number of risk factors across both eyes to determine the final severity grading. Risk 
factors were assigned for each of the following retinal features:  
 The presence of 1 of more large drusen (≥125µm; one risk point assigned per 
eye meeting this criterion).  
 Any pigment abnormality (one risk point assigned per eye meeting this 
criterion).  
 Bilateral intermediate drusen (≥63µm but <125µm) in the absence of large 
drusen (one risk point assigned if both eyes met this criterion).  
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Two risk factors were also assigned for any eye with advanced AMD. The summation 
of risk factors yielded a 5 step-scale (0-4). Hence, the 60 participants with unilateral 
nAMD had a severity grading of 2-4 and those included in the cross-sectional study 
without unilateral nAMD (n=40) had grades 0-1.  
 Enrolment  
Following successful completion of the visual function tests the participant was 
randomised to the intervention or control arm of the study (see Section 3.5.1 for a 
detailed description of the randomisation process). Those individuals who were 
assigned to the treatment group were at this stage given a light mask, and provided 
with written and oral instructions on its use. Before leaving, all participants were 
reprised of the key information provided in the participant information letter about 
follow-up appointments. The participants were given written copies to take home of 
the PSQI questionnaire which they were asked to complete the night before their next 
monthly follow-up visit.   
 Monthly assessment of medical records 
The investigator accessed the OCT images and medical records of all participants 
after they attended the nAMD clinic for each monthly follow up appointment. This was 
done in order to collect the measurement of drusen volume data on a monthly basis. 
The medical records also permitted monitoring of the conversion rate to advanced 
AMD in the control and intervention groups in the eye with early/intermediate AMD at 
baseline, and monitoring of ranibizumab retreatment rates in the eye with nAMD, for 
safety monitoring purposes. 
 Monthly follow-up appointment  
Participants in both intervention groups attended a short, monthly follow-up 
appointment following their routine nAMD clinic appointment, during which both 
groups returned their completed PSQI sleep quality questionnaire. In addition, the 
100 
 
participants enrolled in the treatment group were asked to bring their mask along to 
each monthly visit to allow: 
1. Objective compliance data (nightly hours of use) to be exported from the 
device onto a password protected computer.  
2. Functionality of the mask to be checked.  
3. Any broken or damaged masks to be replaced.  
4. A new fabric strap to be provided and fitted. 
5. A semi-structured interview to be carried out to determine the acceptability of 
the intervention.  
6. Retraining in mask use if the participant had experienced any problems. 
 Final visit  
This visit was the same as the baseline visit with the addition of a final semi-structured 
interview assessing compliance, an evaluation of the acceptability of the intervention 
and the oral completion of the self-report questionnaires (PSQI, VFQ-48, EQ-5D).  
 Data collection for the cross-sectional study  
The collection of cross-sectional data from age-matched participants with grade 0 and 
1 AMD severity in accordance with the AREDS Simplified Severity Scale (Ferris et al., 
2005) consisted of the following:  
 Informed consent was obtained following a discussion of the study.   
 Ocular and medical history obtained verbally and recorded on structured 
proforma. 
 BCVA was measured (logMAR score) for each eye at 4m. During 
measurement each eye was patched alternately and presented with a different 
EDTRS letter chart.  
 Slit lamp examination of the anterior and posterior eye was performed. In order 
to minimise any risk of inducing closed-angle glaucoma during pupil dilation, 
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the Van Herick technique was used to assess the irido-corneal angle adjacent 
to the temporal limbus for each eye. A grading was made for each eye 
between 4 and 0, (the widest angle is denoted as a grade 4, whilst 0 indicates 
a closed angle). Those with a grade of 0-1 were excluded. Media clarity was 
assessed for each eye and the lens graded according to the LOCS III grading 
scale (Chylack et al., 1993).  A volk lens was used to assess the retina.  
 Tropicamide 1% was instilled into both eyes. The participant was only dilated 
if the Van Herick grading assessed in the slit lamp examination fell within the 
limits of the eligibility criteria.  
 Auto refraction was carried out using the Topcon KR-7500. If a satisfactory 
auto-refraction result was unobtainable, the spectacle prescription from the 
participant’s spectacles or last eye examination was recorded instead. 
 Fundus photography and OCT were performed. Photographs of the retina 
(fundus) were obtained for each eye using the Topcon 3D-OCT 2000 (45° 
diameter photo centred on fovea) and digitally stored. The Topcon 3D-OCT 
2000 was also used to capture 5 OCT images of the study eye (Macular cube 
scan 20°-20° centred on fovea).  
 Visual function tests were performed: colour vision, flicker thresholds and dark 
adaptometry (as outlined in Sections 3.6.3.1 and 3.7.1.2). 
 Data collection environment and screen calibration 
One room was used for all psychophysical data collection for the duration of the trial. 
The room, based within the clinical research unit (CRU) of Bristol Eye Hospital, was 
identified as an effective environment for dark adaptation due to its lack of windows. 
Light seepage under the door was rectified via the installation of a light excluder in 
order to further enhance the testing environment. OCT and fundus images were taken 
in a neighbouring room. The luminance output of the LCD monitor used to present 
psychophysical stimuli was γ corrected every 6-8 weeks using established techniques 
102 
 
as described by Metha et al. (1993). The monitor was activated 30 minutes before 
threshold testing was performed in order to account for variability in output due to 
warm-up characteristics. Output luminance of the monitor with and without γ 
correction and warm-up characteristics are shown in Appendix III.  
 Staff training   
Each aspect of the data collection process was outlined to all affiliated CRU and 
retinal imaging unit (RIU) staff via a series of presentations delivered by the trial 
investigator from December 2014 until February 2015. Although the majority of 
baseline, monthly follow-up and final visits were carried out by the trial investigator, 
training was required for the BEH staff in case the trial investigator was absent for any 
reason. Although all staff members were introduced to the research study, one-to-one 
training was provided to the acting trial manager who was responsible for daily trial 
activity in the absence of the trial investigator. The trial manager was tutored on each 
data collection technique and shadowed the daily activity of the investigator on 5 
separate occasions during which screening, baseline and monthly follow-up visits 
were witnessed. Familiarisation with the intervention including troubleshooting, 
collection of objective data and maintenance was also witnessed. The investigator 
assessed the trial manager for competency by observing the trial manager perform 
each type of study visit. The trial manager was permitted to perform unsupervised 
study visits only when deemed competent by the investigator.  
3.4. Assessment of safety   
For detailed information regarding the safety monitoring procedures and the 
classification of adverse events the reader is directed to the protocol in Appendix II. 
 Conversion to nAMD  
One potential serious adverse event would be a conversion to nAMD in the study eye. 
An important aspect of the safety evaluation of the intervention was to ensure that it 
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did not increase the risk of progression to nAMD. Wong et al. (2008) carried out a 
meta-analysis of studies which looked at the progression to choroidal 
neovascularisation (CNV) in the fellow eye of people with unilateral nAMD at baseline. 
They reported that the cumulative 1 year incidence of CNV in the 426 patients enrolled 
in the 5 studies which evaluated this outcome was 12.2% (confidence intervals [CI], 
1.7%–30.6%). Therefore, an upper limit on the number of people expected to convert 
to nAMD per month was devised:  
Upper limit for conversion to nAMD from early/intermediate AMD: 
n x (30.6% / 12 months) 
 
Where n is the number of people in the trial who were using the light therapy light 
mask. It was deemed that should the percentage of participants using the light mask 
who develop nAMD exceed what might normally be expected (i.e. approximately 1% 
per month) we would notify the independent Trial Steering Committee, and the Device 
Manufacturer, who would notify the MHRA. Should the percentage exceed the upper 
confidence limit then the Trial Steering Committee would be contacted so that they 
could consider stopping the trial.  
3.5. Statistical considerations 
Given the potential benefit of participation, it was anticipated that the numbers of 
people withdrawing from the study from the intervention group would be low. By 
arranging follow-up appointments around scheduled visits to the nAMD clinic, we 
aimed to minimise drop-out within the control group. Data from a study involving 
diabetic patients and the same light mask intervention suggested that we would lose 
approximately 10% of people after 12 months due to lack of compliance or failure to 
attend follow-up appointments (Arden et al., 2011). It was also expected that further 
participants would withdraw for unrelated health reasons (Arden et al., 2011). 
Withdrawal from the study did not impact on patient care.  
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It should be noted that as a phase I/IIa proof-of-concept study this research was not 
powered to detect small effect sizes. In terms of the proportion of people showing 
disease progression, based on drusen volume and/or progression to advanced AMD, 
a sample size of 50 would allow for a 50% reduction in people showing progression 
to be detected at a probability level of 0.2, with a power of 80%. In terms of cone 
adaptation, based on parafoveal cone adaptation data from Gaffney et al., (2011), a 
sample size of 50 would allow a change in cone τ of 1 minute to be detected at a 
probability level of 0.05, with a power of 80%. This difference in cone τ is substantially 
smaller than the known effect of early AMD. Gaffney et al., (2011) reported a mean 
increase in cone τ of 2.85 mins compared to age-matched controls. In alignment with 
this we aimed to recruit 60 people which, allowing for 15% dropout through the year, 
would leave a final cohort of 51. 
 Randomisation 
Participants were randomly allocated to either a control or a treatment group. 
Randomisation was generated by a random number generator. Computer generated 
random permuted blocks of size 2, 4 and 6 stratified for grade of AMD were used to 
allocate interventions to participants. In stratification, patients are formed into risk 
groups (strata) based on 1 or more prognostic factors, and a separate randomisation 
is conducted for each stratum. This helps to ensure balanced groups and is 
particularly important in a small study such as this. Randomisation was stratified into 
3 layers (AMD grade 2, 3 or 4, according to the AREDS Simplified Severity Scale) 
(Ferris et al., 2005). The study investigator was provided with three piles of envelopes 
by the chief investigator in order to randomise the participant to either the intervention 
or control arm of the study. Each pile related to a different stratum of randomisation, 
i.e. grade 2, 3 or 4 of AMD, according to the AREDS Simplified Severity Scale. The 
envelopes in each pile were numbered, and contained the randomisation allocation 
for each participant. 
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3.6. Optimisation of outcome measures 
On the basis of the current literature regarding the usefulness of visual function tests 
as potential AMD biomarkers (as introduced in Section 1.3.6.6), three functional tests 
were chosen for inclusion in the ALight protocol: cone dark adaptation, 14 Hz flicker 
thresholds and colour discrimination. Although numerous studies have investigated 
the effect of AMD on various aspects of visual function, there are few longitudinal data 
available to validate these outcome measures as potential trial endpoints. Therefore, 
this study not only used the psychophysical tests to evaluate the effectiveness of the 
trial intervention, but also used the 12 month follow up period of the trial as an 
opportunity to evaluate the prognostic and predictive capacity of the tests, and a 
baseline cross-sectional study to evaluate the relationship between the outcome 
measures and the severity of the fundus changes.  
The following section outlines two pilot studies performed before recruitment for the 
ALight trial began to optimise and evaluate the psychophysical tests of visual function. 
The specific aims were: 
1. To check the test sequence and time of the experiments.  
2. To verify that a new handheld photopigment bleach source could be used 
reliably in a dark adaptation experiment. 
3. To optimise parameters of dark adaptation, flicker threshold and chromatic 
threshold measurement for use in the ALight clinical trial and cross-sectional 
study.  
 Pilot Study to evaluate the effect of bleach intensity on 
characteristics of the dark adaptation function 
As discussed in Section 1.3.6.5, dark adaptation parameters, including cone τ and 
time to RCB, have been identified as sensitive biomarkers for early AMD (Dimitrov et 
al., 2011; Gaffney et al., 2011). However, if assessment of dark adaptation is to be 
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employed as an outcome measure in a clinical trial, optimisation of the test 
parameters, such as bleach intensity, bleach duration and stimulus size, is essential, 
in order to maximise sensitivity to disease progression.  
 Selection of stimulus parameters 
When assessing the diagnostic ability of three different sized annular stimuli, Gaffney 
et al. (2011) concluded that an annular stimulus of 12° radius was optimal for cone 
dark adaptation assessment in early AMD, displaying 90% sensitivity and specificity.  
However, a smaller annular stimulus of 2° radius was recorded as displaying a greater 
difference in means between those with AMD and controls. The diagnostic accuracy 
of the smaller stimulus was compromised by the greater between subject variability 
in results, which was attributed by the authors to a greater impact of focal retinal 
abnormalities on thresholds when sampling a limited retinal area. However, in a study 
of disease progression rather than diagnostic capacity, the between subject variability 
is of less interest than the between session variability. The inter-session repeatability 
of dark adaptation was addressed by McKeague et al. (2014) who found the use of a 
2° spot stimulus to be more repeatable over two measurements than 7° and 12° 
annulus alternatives. When measuring cone τ it was determined that any change 
above the coefficient of repeatability (0.82) for this stimulus could be considered 
clinically significant. This number is considerably lower than the mean difference 
between healthy controls and those with AMD (McKeague et al., 2014).      
In a study involving 221 participants with AMD and 109 healthy controls Dimitrov et 
al. (2011) measured the diagnostic potential of dark adaptation characteristics using 
a 4° foveal stimulus and a 2° stimulus at 3.5° and 10° eccentricity. All three locations 
tested showed deficits in AMD participants when compared to controls. Dimitrov et al. 
(2011) found the 2° stimulus at 3.5° eccentricity to be optimal as it provided a high 
diagnostic value (determined as the area under the ROC curve) for the parameters of 
cone τ (AUC 0.86 ± 0.023), rod recovery rate (AUC 0.93 ± 0.016) and time to RCB 
107 
 
(AUC 0.86 ± 0.027). As the 2° radius stimulus allows quantification of cone recovery 
rate within 10 minutes (Gaffney et al., 2011) and displays good diagnostic potential 
and repeatability when compared to other alternatives (Dimitrov et al., 2011; 
McKeague et al., 2014) it has been adopted for use within this experiment.    
In addition to the stimulus area and size, the appearance of the dark adaptation 
function is also dependent on the intensity and duration of the pre-adapting bleaching 
light (Dimitrov et al., 2008; Gaffney et al., 2013). Gaffney et al. (2013) investigated the 
pre-adapting light intensity necessary to generate the maximal separation in the 
parameters of dark adaptation between those with early AMD and healthy controls. 
Participants were exposed to a 120s bleach of 3 adapting intensities termed low (71% 
and 51%), medium (84% and 74%) and high (91% and 90%) based on the percentage 
of photopigment (cone photopigment and rhodopsin, respectively) bleached. Their 
findings indicated that the medium and high intensities both provided equally good 
separation between groups, and sufficient data points to allow the time course of cone 
recovery to be monitored effectively. However, this study used a 12° radius annular 
stimulus. As a different retinal location will be targeted in the ALight trial (a circular 
region of 2° radius), the effect of bleach intensity needs further investigation before 
finalising the protocol.  
Another difference between Gaffney et al. (2013) and the current study is the source 
of the bleaching light. The findings reported by Gaffney et al. (2013) were generated 
using a Maxwellian View optical system which requires precise head alignment in 
order to ensure the accuracy of the photopigment bleach delivered. In contrast, the 
bleaching source used in the trial was a hand-held alternative. In the absence of the 
Maxwellian View system alignment must be achieved via instructing the subject to 
look directly at the centre of the bleaching source.  
This pilot experiment was designed in order to address the following aims: 
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1. To evaluate the effect of bleach intensity on dark adaptation parameters in 
healthy individuals using a 2° radius stimulus.  
2. To compare results with those collected from healthy individuals by Gaffney 
et al. (2013) using a 12° radius stimulus.  
3. To test the utility of a portable hand-held bleaching source. 
 Method and equipment 
Healthy participants were recruited from among staff or students of the School of 
Optometry and Vision Sciences, Cardiff University. Any potential participant was 
excluded if they had:  
 Ocular pathology: including narrow anterior chamber angles (≤grade 1 van 
Herrick), significant cataract (LOCS III graded, above grade 2 on any criterion), 
central corneal/media opacity, any posterior eye condition, glaucoma, history 
of prodromal symptoms of closed angle glaucoma.  
 Significant systemic disease known to affect visual function. 
 History of medication known to affect visual function.      
To assess eligibility prior to retinal function testing anterior (slit lamp biomicroscopy) 
and posterior ocular health (indirect Volk Fundoscopy) were assessed for each 
potential participant. A full ocular and general health history was also recorded. 
Measurement of intraocular pressure was performed prior to and following dilation. 
The School’s Research Ethics Committee approved the study, informed consent was 
obtained before data collection took place and all procedures were carried out in 
accordance with the tenets of the Declaration of Helsinki.  
 Experimental procedure  
For participants assessed at all bleach intensities, measurements were taken over 2 
separate days within a period of 2 weeks. All data could not be collected on a single 
visit due to the time required to perform repeated dark adaptation measurements. 
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Refractive correction for the test distance (140cm) was worn as required, and the non-
study eye was occluded. Participants were dilated with one drop of 1% tropicamide 
prior to dark adaptation (mean pupil diameter after dilation = 6.8mm).  
During the test procedure stimuli were presented on a calibrated, high-resolution 
monitor (NEC MultiSync PA241/W). The luminance of the monitor was γ-corrected in 
accordance with the method described by Metha et al. (1993). Cone dark adaptation 
thresholds were measured using a robust psychophysical method described in 
previous publications (Gaffney et al., 2011; 2012; 2013; 2014). The procedure is 
based on a ‘3 down, 1 up’ paradigm with a 0.2 second stimulus presentation time and 
a 0.6 second response window denoted in the MATLAB code found in Appendix IV. 
Thresholds were recorded in response to a 2° radius solid yellow circular stimulus 
(chromaticity coordinates, 0.429, 0.413) under software control (MATLAB, R2009a, 
The MathWorks Inc). To aid fixation a white cross of variable intensity was generated 
under the stimulus. The fixation cross was always 3 fold brighter than the stimulus 
(Figure 3.7).  
Participants were asked to wear goggles containing a 2.1 log unit neutral density filter, 
complete with side shields, throughout the duration of threshold measurement in order 
to minimise the distracting effect of light reflecting off the walls of the testing room. As 
the lower end of the linear luminance range approached, additional 2.1 ND and 1.8 
ND filters were applied to the monitor to ensure that its output remained in the linear 
range.  
Prior to commencement of threshold testing the subject was given verbal instructions 
and performed a training trial of 1 minute in order to familiarise themselves with the 
test. This training involved presentation of the test fixation target and suprathreshold 
stimuli without a photopigment bleach. The participant was deemed to have shown 
competency if they responded to all presentations (of varying brightness) without 
making any errors, i.e. missing a presentation or responding between presentations. 
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If the participant was unable to complete the training trial within three attempts they 
were deemed ineligible for the study. The tutorial session was repeated at the start of 
the second visit.   
A hand-held bleaching source consisting of a ‘white’ LED overlaid with a diffusing 
(LEE Filters 216 ‘white diffusion’) and amber filter (LEE Filters HT015 ‘deep straw’) 
was used to deliver a 120s photopigment bleach. The amber filter provided protection 
from potentially harmful short-wavelength blue light (Figure 3.8) and also reduced the 
scotopic retinal luminance in order to attain an approximately equivalent cone 
photopigment and rhodopsin bleach. The unit was mounted onto a modified Royal Air 
Force (RAF) rule in order to ensure a precise viewing distance of 23.5cm, thus 
resulting in a 12° diameter bleach of the central retina (Figure 3.9; Figure 3.10). The 
bleach source was calibrated using a photometer (LS-110; Konica Minolta., Osaka, 
Japan). The luminance of the device was initially measured with no filters in place, 
then with 0.6 and 1.2 ND filters. The bleach intensities that ensued were documented 
as high, medium and low. Table 3.1 shows them alongside the expected cone 
photopigment and rhodopsin bleach. 
To initiate threshold testing the desired bleach was applied for 2 minutes (Figure 
3.10). The order of bleach intensities used was randomised. Upon termination of the 
bleach, spectacles were instantly replaced if necessary and the 2.1 log unit ND 
goggles were positioned over the eyes. Immediately following this, dark adaptation 
was monitored continuously for 25 minutes. The subject was reminded at the start of 
this process to maintain their fixation towards the centre of the cross target and 
indicate perception of the stimulus via the hand-held keypad. Although fixation was 
not monitored, the examiner gave verbal encouragement to the participant at regular 
intervals in order to ensure alertness and compliance. An experimental timeline of 
dark adaptation visits is shown in Figure 3.11.  
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Figure 3.7. A representation of the participant’s view of the circular stimulus (left panel) and 
the fixation target alone (right panel) as seen on the NEC MultiSync PA24/W VDU monitor. 
 
Figure 3.8. Transmission spectrum of the bleaching source overlaid with a white diffusion (LEE 
filter 216) and amber filter (LEE filter HT015). The spectrum was obtained using a Specboss 
1201 Spectroradiometer (JETI Instruments, Germany). The multiple outlines of the spectrum 
represent repeated readings. 
 
 
 
 
 
 
 
Figure 3.9. A photograph of the bleaching source setup. The portable device was mounted 
onto a modified RAF rule and connected to a mains voltage supply for use. 
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Table 3.1. Bleach characteristics of the 3 intensities used, calculated using equations by 
Thomas and Lamb (1999) and Paupoo et al. (2000). Measurements reported do not take into 
account the Stiles-Crawford effect.  
 
 
Figure 3.10. The bleaching source was positioned in front of the study eye and held in place 
for 120s as seen in this photograph. Immediately after bleaching cessation the ND goggles 
were bought down over the participant’s eyes and threshold testing began. 
 
 
Figure 3.11. Experimental timeline for dark adaptation visits. Prior to dilation logMAR visual 
acuity was recorded at 4m and ocular health was verified. The timeline displays above shows 
activity related to the measurement of dark adaptation parameters across two visits (within 
two weeks apart). 
 
 Analysis  
A single exponential, double-linear model (see Equation 3.1; McGwin et al. [1999]) 
was fitted to the data on a least squares fit basis using the Solver function of Microsoft 
Bleach 
intensity 
Log photopic Trolands 
(duration: 120s,  
7mm pupil) 
Percentage cone 
photopigment bleach 
Percentage 
rhodopsin bleach 
 
HIGH 5.54 92.00 91.59 
MEDIUM 4.92 72.32 53.10 
LOW 4.37 37.91 19.81 
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Excel. Statistical analysis of cone τ, time to RCB and final cone threshold was 
undertaken using statistical software (SPSS, Version 20) in order to determine 
whether parameters differed significantly between bleach intensities. A Shapiro-Wilk 
test indicated that the data were not normally distributed hence non-parametric 
analysis via the use of a Kruskal-Wallis test and pairwise post-hoc analysis was 
applied. Median and inter-quartile range (IQR) values were also calculated. 
 
T(t) = (a + (b.exp(-t/τ))) + (c.(max[t – rcb,0])) + (d.(max[t – rrb,0])) 
Equation 3.1. T represents the threshold (log cd/m2) at time t after cessation of the bleach, a 
is the final cone threshold, b is the change in cone threshold from t=0. τ is the time constant of 
cone recovery, c and d represent the second and final slopes of rod recovery, max is a logic 
statement, rcb denotes time to RCB from t=0 and rrb denotes the time from bleach offset to 
the transition between c and d. 
 
 Results  
Thirteen healthy control participants took part in the study to evaluate the effect of 
bleach intensity on characteristics of the dark adaptation function. Mean age was 30.2 
years (range = 23 to 49yrs). Eleven of the 13 participants were assessed at all bleach 
intensities. Of the remaining 2, due to time constraints and unavailability to re-attend 
for further testing 1 participant (GR) provided data for the high and low bleach 
intensities only whilst the other (TM) provided data for the medium bleaching intensity 
only. In accordance with this data from 12 participants was analysed for each bleach 
intensity.    
The dark adaptation data for a typical participant are shown in Figure 3.12. Note that 
the rate of cone threshold recovery is slower and the time to RCB is later with 
increasing bleach intensity. When using the weaker bleach the rapid subsequent fall 
of threshold within the first half minute of measurement in all participants made data 
modelling difficult (Figure 3.13). Dark adaptation parameters for all participants are 
displayed in Table 3.2. Group median and IQR values for dark adaptation parameters 
are displayed in Table 3.3. Median values for each parameter at each bleaching 
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intensity are shown graphically in Figure 3.14. There was a significant difference in 
time to RCB between the highest bleach intensity and both the medium (P=<0.05) 
and low (P<0.05) intensities. There was no significant difference between bleach 
intensities for final threshold achieved (P>0.05). Cone τ was found to be significantly 
longer when using the highest bleach intensity level in comparison to the low (P<0.05) 
alternative.  
 
Figure 3.12. Typical dark adaptation curves recorded after exposure to three different 
photopigment bleach intensities. Each data set is represented by the raw data (squares high 
bleach, triangles medium bleach and circles low bleach) to which a best-fitting model has 
been applied (given by Equation 3.1). 
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Figure 3.13. Sample curves of high, medium and low intensity bleach for one participant (TC) 
with the first 10 minutes of data plotted in order to magnify the cone proportion of the data. 
The blue circles represent the raw data values by which the best-fitting model (black line) 
has been applied (given by Equation 3.1). Take note of threshold measurement over the first 
200 seconds, in which cone τ is recorded. The integrity of data modelling, on the basis of raw 
data values, can be seen to be more accurate for the high and medium bleach within this 
time frame. Due to the speed of recovery when using the low intensity bleach, few data 
points are available on which to fit the model. 
 
Table 3.2. Individual participant data for cone τ and time to RCB dark adaptation parameters. 
 
 
 
 
 Cone τ (mins) Time to RCB (mins) 
Study ID High Medium Low High Medium Low 
 
AB 
 
2.09 
 
1.67 
 
1.51 
 
11.27 
 
4.05 
 
3.91 
AN 1.68 1.70 0.52 12.26 7.29 4.20 
BF 1.60 1.17 0.55 9.87 7.56 6.00 
CE 1.73 1.47 0.72 9.78 7.00 4.67 
CJ 2.22 2.75 0.67 13.00 7.50 7.00 
KB 1.77 1.26 0.62 11.01 7.00 5.50 
LR 1.70 0.95 0.45 8.64 7.06 2.00 
LT 1.68 1.49 0.55 13.25 9.65 4.62 
NC 1.33 1.05 0.52 11.47 8.36 6.50 
SJ 1.90 1.60 0.45 12.10 7.64 3.00 
TC 1.45 1.24 0.55 10.92 6.00 5.00 
GR 1.12 - 0.44 9.89 - 5.50 
TM 
 
- 1.05 - - 5.74 - 
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Table 3.3. Comparison of median (inter-quartile range) of each bleach intensity used. 
 
 
Figure 3.14. Summary of median time to RCB (a), cone τ (b) and final threshold level (c) at 
each bleach intensity level. Whiskers denote the highest and lowest data points collected 
within each intensity. For any given parameter a bleach intensity denoted by an asterisk (*) 
demonstrated a significant difference to all other bleach intensities investigated.   
 Discussion 
The results suggested that bleaching levels of ≥70% cone photopigment and ≥51% 
rhodopsin (i.e. the medium and high bleach levels used in this study) were clinically 
viable for assessment of dark adaptation. Despite having the desirable characteristic 
of the shortest test duration to obtain parameters known to be affected in AMD, the 
weak bleach intensity was found most difficult to model as a result of the rapid 
recovery of threshold following cessation of the bleach. Such difficulty resulted in 
concerns about the integrity of the model outputs for the lowest bleach intensity, when 
compared to the high and medium intensity alternatives.  
Cone τ did not differ significantly between the upper two bleach intensities. The high 
bleach τ of 1.69 mins (101.4 secs) and the med bleach τ of 1.36 mins (81.6 secs) fall 
broadly into agreement with data published by Hollins and Alpern (1973). They 
reported that when using a long duration equilibrium bleach cone τ was around 105 
Bleach intensity Cone τ (mins) Final threshold (log cd/m2) Time to RCB (min) 
    
High 1.69 (1.56, 1.80) -2.23 (-2.34, -2.13) 11.14 (9.89, 12.14) 
Medium 1.36 (1.14, 1.62) -2.17 (-2.36, -2.02) 7.17 (6.75, 7.58) 
Low 0.55 (0.50, 0.63) -2.36 (-2.57, -2.24) 4.84 (4.13, 5.63) 
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seconds, regardless of the percentage of photopigment bleached (from 30% to 
100%). These published data, however, were obtained for one patient only.  
Measurement of time to RCB was possible for each participant at each bleach 
intensity. However, this parameter has been shown to occur later in an older cohort 
than used in the present study and in those with AMD (Gaffney et al., 2013). Due to 
its diagnostic capacity, the measurement of this parameter has been shown to be of 
importance (Owsley et al., 2016). Using a stimulus with a diameter and bleach 
intensity comparable to that of the high bleach intensity used in the present study 
Gaffney et al. (2011) recorded average time to RCB as being over 5 minutes longer 
in a healthy control group than that reported here (n=10, mean age 70.5yrs), and over 
9 minutes longer in those with early AMD (n=10, mean age 68.3yrs) than that found 
within this study (n=13, mean age 30.2yrs). This difference can be attributed to the 
age difference between the present cohort and that of Gaffney et al. (2011). The 
results suggest that dark adaptation to elicit rod parameters should be measured over 
a minimum period of 25 minutes in older adults and people with AMD, unless not 
permitted by participant fatigue.  
Cone final threshold, as expected, did not differ significantly between bleach 
intensities. The diagnostic value of the cone final threshold has been reported to be 
relatively poor (Owsley et al., 2001). Gaffney et al. (2011) found no significant 
difference in final threshold between control and AMD groups. Comparatively, the 
threshold reported by Gaffney et al. (2011) was higher in both the control (-1.92 log 
cd/m2) and AMD (-1.94 log cd/m2) groups than reported in the present study (-2.23 
log cd/m2). This was expected and can be attributed, once again, to the on-average 
40 year age difference between the study cohorts.  
In conclusion, the results indicate that the dark adaptation parameters of cone τ, cone 
final threshold, and time to RCB are measurable following the use of a simple hand-
held bleaching source. Based on current evidence regarding diagnostic capacity 
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(Dimitrov et al., 2011; Gaffney et al., 2011; 2013), cone τ and time to RCB were 
selected as outcome measures for the ALight trial. As the mean time to RCB for the 
early AMD cohort assessed by Gaffney et al. (2011) using a comparable stimulus was 
20.39mins a recording period of 25mins was used for the ALight trial. It was expected 
that this timeframe would allow time to RCB data to be attained in the ALight cohort 
without excessive participant fatigue.   
Results for the medium and high bleach intensities were consistent with other studies 
although direct comparison was not possible due to differences in cohort age (Gaffney 
et al., 2011) and stimulus size (Dimitrov et al., 2011). Overall the results suggested 
that either bleach intensity could be used for the ALight trial however, the high 
intensity was chosen to facilitate data modelling, particularly following bleach 
cessation when assessing cone τ.  
Despite this, the pilot study indicated that dark adaptation data collection in this 
manner is time consuming and requires considerable concentration. Those recruited 
to the ALight trial would be required to perform this test alongside a number of other 
visually demanding tasks in a single visit. As a number of the participants in this pilot 
study commented on the effect of fatigue, it was decided to modify the ALight protocol 
to include an extra dark adaptation recording session to ensure that the integrity of 
data collected was not compromised. In alignment with this, dark adaptation was 
initially performed following the ALight trial screening visit. If necessary, due to poor 
quality data (as attributable to participant fatigue) dark adaptation was repeated at the 
baseline visit.  
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3.7. Pilot study to collect data for flicker threshold and colour vision 
tests 
In addition to dark adaptation parameters, visual function measures of foveal flicker 
sensitivity and chromatic thresholds have also shown potential as biomarkers 
sensitive to the characteristics of early AMD (Neelam et al., 2009). The measurement 
of 14Hz flicker thresholds have been shown to distinguish healthy controls from those 
with early AMD (Mayer et al., 1991) because it targets the compromised retinal 
metabolism and blood flow in the presence of AMD (Mayer et al., 1991; Dimitrov et 
al., 2011). The Colour Assessment and Diagnosis (CAD) test has also been found to 
be a sensitive method of determining chromatic thresholds which may reflect 
photoreceptor disruption in AMD (Barbur et al., 2006; O’Neill-Biba et al., 2010). For 
further detail regarding these tests of visual function the reader is directed to Sections 
1.3.6.4. (temporal sensitivity) and 1.3.6.3. (colour vision).  
The aim of this experiment was to collect sufficient pilot data on normal subjects to 
ensure that the experimental methods, hardware and custom software scripts were 
sufficiently robust to include in the ALight trial.  
 Method and equipment 
Healthy control participants were recruited from the staff and students of the School 
of Optometry and Vision Sciences, Cardiff University. All subjects had no history of 
ocular or systemic disease known to affect visual function (the inclusion/exclusion 
criteria and assessment methods for eligibility are given in Section 3.6.2). The cohort 
consisted of the same participants (except participant TM) that were included in the 
study to evaluate the effect of bleach intensity on characteristics of the dark adaptation 
function (Section 3.6.1). There were no previously reported colour vision defects 
within the cohort. The School’s Research Ethics Committee approved the study, 
informed consent was obtained before data collection took place and all procedures 
were carried out in accordance with the tenets of the Declaration of Helsinki. 
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 Generation of stimuli 
Stimuli for both psychophysical tests were presented on a calibrated, high-resolution 
monitor (NEC MultiSync PA241/W). The monitor was calibrated with a 26cd/m2 test 
background luminance for CAD testing via the bespoke LUMCAL program as supplied 
by City Occupational Ltd. For the measurement of 14Hz flicker thresholds the 
luminance of the monitor was also γ-corrected in accordance with the method 
described by Metha et al. (1993).  
 Experimental procedure 
Both tests (CAD and flicker) were performed within a single session of testing 
following pupil dilation (1% Tropicamide). The eye with the best logMAR visual acuity 
at 4m was selected as the study eye, and the participant was seated 140cm directly 
in front of the monitor. Refractive correction was worn as necessary and the non-test 
eye was occluded. The CAD test was completed first, followed by a 15 minute 
recovery period before temporal flicker thresholds were assessed (Figure 3.15). 
 
Figure 3.15. Experimental timeline for performance of the Colour Assessment and Diagnosis 
(CAD) and flicker threshold tests. Prior to visual acuity measurement ocular health was 
verified. 
 
The Colour Assessment and Diagnosis Test (CAD) (Version 2.2.4. City Occupational 
Ltd., London, UK) was used to measure RG and YB chromatic sensitivity (Rodriguez-
Carmona et al., 2012). RG and YB chromatic thresholds were measured by using 
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coloured stimuli moving against an achromatic background. By employing dynamic 
luminance noise to mask the detection of any residual contrast cues, the test isolates 
chromatic thresholds along 16 directions of the CIE (x,y) chromaticity diagram. The 
dynamic luminance noise background (chromaticity coordinates 0.305, 0.323; mean 
luminance 26 cd/m2) comprised a checkerboard of 15 x 15 squares (total 3.3° 
diameter) which fluctuated randomly in luminance above and below the average 
background level. The luminance of each check was distributed with equal probability 
within ± 55% of the background luminance. The stimulus comprised of a colour-
defined checkerboard of 5 x 5 squares (total 1.1° diameter) which over a 600ms 
duration moved diagonally across the luminance noise in 1 of 4 possible directions. 
The 16 directions of colour space (6 red, 6 green, 2 blue, 2 yellow) assessed were 
selected to correspond to the RG (140-175°) and S-cone isolating (58-68°) confusion 
lines of the CIE chromaticity diagram. Determination of the final RG and YB threshold 
was based on a 2-down, 1-up staircase in which colour intensity was reduced (by an 
initial step size of 0.006 CAD units) until the stimulus was not distinguishable against 
the background. This staircase procedure was repeated for nine reversals. For each 
reversal the step size was reduced by 0.001 CAD units until a final step size of 0.002 
was reached. The chromatic distance in the CIE colour space for the last 4 staircase 
reversals was averaged in order to determine the final threshold.  
The participant was given verbal instructions regarding the test procedure and the 
four-alternative forced choice nature of the test. The participant was instructed to 
press one of the four buttons on a hand-held keypad which corresponded with the 
perceived direction of movement of the stimulus on the screen (Figure 3.16). Each 
stimulus presentation was followed by an audible ‘beep’ as an indication of when a 
response was expected. The participant was prompted to respond even if the direction 
of stimulus movement was not detected. Initially a screening programme lasting 1 
minute was run as a training and familiarisation exercise. Once a firm understanding 
122 
 
of test requirements had been demonstrated (deemed as a 100% correct response 
rate) the participant progressed onto the full threshold measurement program. Time 
to complete ranged from 12-20 minutes depending on response speed. Throughout 
the duration of the test the room was uniformly illuminated (69.2 cd/m2) and the 
monitor was mounted with a peaked hood to provide optimum conditions for colour 
accurate viewing.   
 
Figure 3.16. A representation of the participant’s view when performing the CAD test (left). 
The direction of movement seen was responded to using the red keypad buttons shown on 
the USB remote (right). 
 
Temporal sensitivity to flicker was measured using a well-established QUEST 
Bayesian adaptive procedure (Watson and Pelli, 1993; Brainard, 1997; Pelli, 1997). 
This method determines final threshold using the maximum likelihood estimate of 
threshold based upon the results of all previous trials (King-Smith et al., 1994). As per 
the code in Appendix V the QUEST procedure was implemented using routines 
available within MATLAB Psychophysics Toolbox (MATLAB, R2009a, The 
MathWorks Inc., Massachusetts, USA) to drive a go/no-go adaptive staircase 
(Brainard, 1997). The starting point for the final threshold estimate (40 trials) was 
determined from the results of the practice run (10 trials). Responses that occurred 
more than a second after stimulus offset were deemed as false-positives. The trial 
stimulus was situated in the centre of the screen and appeared as a 4° Gaussian blob 
(chromaticity coordinates, 0.305, 0.323; temporal frequency 14Hz) surrounded by a 
white circle to aid with fixation (Figure 3.17). The stimulus was presented to the fovea 
at random intervals for a duration of 2 seconds. The flickering stimulus was generated 
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by modulating a luminance increment according to a sinusoidal temporal profile. The 
mean luminance of the monitor was 48 cd/m2. Following verbal instructions on the 
test procedure and fixation requirements, a familiarisation trial of 1 minute duration 
was performed before data collection. The subject pressed a button on a hand-held 
keypad as soon as they perceived the stimulus.  
 
Figure 3.17. A representation of the participant’s view when performing the 14Hz flicker 
threshold test. The white circle provides a fixation target within which each flicker perceived is 
responded to using the keypad shown in Figure 3.16. 
 
The practice trial was repeated until the participant was able to demonstrate 
understanding of the test requirements, achieving two successive measurements 
within 1 standard deviation of each other with no more than 1 false positive over 10 
presentations. This allowed progression to the full trial of 40 presentations, taking 
approximately 4 minutes to complete. The mean threshold value for each test, along 
with its standard deviation and range, was determined. In order to compare the tests 
according to the dispersion of values around their mean the coefficient of variation 
(the ratio of the standard deviation to the mean) was also calculated.    
 Results 
Complete datasets were obtained and analysed from 12 participants. The age range 
of participants was from 23-48yrs (mean age = 28.7yrs). A sample flicker threshold 
dataset from one participant is shown in Figure 1.14. For the flicker assessment test, 
the solid blue line represents the final threshold achieved and the dashed lines either 
side denote the 95% confidence intervals. The 40 white circles represent the flickering 
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stimuli presented. Those in which the threshold is seen to elevate following 
presentation represent unseen stimuli. For the colour vision testing, threshold levels 
along 16 directions of colour space are represented by the coloured circles found 
within the larger grey ellipse of the CAD results diagram (Figure 1.11). As all circles 
fall within the boundary of the ellipse they are deemed to be within normal limits, 
hence the participant in question does not to have a colour deficiency. The flicker and 
colour contrast threshold data collected for each subject are presented in Table 3.4. 
Descriptive statistics relating to test thresholds are displayed in Table 3.5.  
Table 3.4. 14Hz Flicker and CAD threshold data as collected from each individual participant. 
 
 
 
 
 
 
 
 
Table 3.5. Comparison of mean threshold, threshold range and coefficient of variation between 
each test performed. 
 
 Discussion  
The chromatic sensitivity results obtained are in agreement with those of O’Neill Biba 
et al. (2010) who found the mean threshold value (± SD) within their control group 
(n=45, mean age = 56yrs) to be 1.47(± 0.17) for RG testing and 1.60 (± 0.15) for YB 
Study ID Flicker threshold 
RG threshold 
(CAD units) 
YB threshold 
(CAD units) 
 
AB -1.82 1.16 1.11 
AN -1.77 1.18 1.31 
BF -1.72 1.17 0.92 
CE -1.81 2.06 1.48 
CJ -1.89 0.96 1.10 
GR -2.00 1.30 1.35 
KB -1.81 1.85 1.89 
LR -1.74 1.32 1.41 
LT -1.70 2.22 1.85 
NC -1.83 1.35 1.28 
SJ -1.70 1.86 1.36 
TC 
 
-1.93 
 
1.29 
 
1.38 
 
Test (n=12) 
Mean threshold 
(+/- SD) 
Threshold range 
(max/min) 
Coefficient of 
variation 
 
14Hz Flicker 
 
-1.81 (±0.09) 
 
-0.30 (-1.70/-2.00) 
 
4.97 
CAD (RG) 1.48 (±0.41) 1.26 (2.22/0.96) 27.70 
CAD (YB) 
 
1.37 (±0.28) 
 
0.97 (1.89/0.92) 
 
20.53 
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testing. Both values fall within the statistically determined limits of the CAD test as 
based on analysis of 238 normal trichromats and 250 colour deficient observers by 
Barbur et al. (2006). In comparison, mean threshold values found for 18 participants 
at varying stages of AMD were documented outside the normal range as 5.58 and 
7.03 (RG and YB respectively) by O’Neill Biba et al. (2010).  
Even though flicker and colour vision parameters were not tested using the same units 
of measurement they may be compared with respect to their between-subject 
variability using the ‘coefficient of variation’ which expresses the standard deviation 
as a percentage of the mean. The least variable results were obtained when testing 
flicker sensitivity, followed by YB and finally RG colour contrast sensitivity. A higher 
level of between-subject variability can impact on the diagnostic capacity of a test. 
These results may help to explain the finding of Dimitrov et al. (2011) that 14Hz flicker 
threshold testing was better able to distinguish those with AMD from healthy controls 
(AUC ± SD, 0.84 ± 0.021), than colour threshold testing of both YB (AUC ± SD, 0.80 
± 0.020) and RG (AUC ± SD, 0.77 ± 0.026) parameters. Dimitrov et al. (2011) 
remarked that, within their cohort, between subject variation in chromatic thresholds 
may have been attributable to subtle lens opacities.  
As the ALight trial measures within subject changes over time the between-subject 
variability is of less importance than the inter-session repeatability of these tests. In a 
population of healthy participants (n=30, mean age ± SD: 36.3 ± 14.1) McKeague et 
al. (2014) found from coefficient of repeatability analysis (CoR ± SD) that the RG CAD 
threshold test (0.390 ± 0.13) was significantly more repeatable than the 14Hz flicker 
test (0.015 ± 0.005) when recorded on 2 occasions over 2 days. There was no 
significant difference between the coefficient of repeatability of the RG (0.39 ± 0.13) 
and YB (0.43 ± 0.14) CAD thresholds. Threshold values reported by McKeague et al. 
(2014) were comparable with those presented here (Table 3.6). This was expected 
due to the similarity in cohorts.  
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Table 3.6. Comparison of threshold values obtained by McKeague et al. (2014) and those 
presented here. Bracketed numbers show the standard deviation. 
 
 
Pragmatically the CAD and flicker tests were performed without issue by all 
participants. The cohort for the ALight trial was however much older and it was 
expected that the fast responses and dexterity required for the CAD test might cause 
difficulty for some individuals. It was thought that this could potentially increase the 
test time to over 15 minutes. On this basis, the protocol was amended such that 
participants would be instructed to take regular breaks after 15 minutes had elapsed 
in order to minimise the effect of fatigue and boredom. It was noticeable that 
participants were intentionally not blinking regularly when performing the 14Hz flicker 
test. This, on occasion, caused the sensation that the fixation target had temporarily 
disappeared thus participants were encouraged to blink as normal during threshold 
testing. Despite these minor concerns the pilot data collected was found to be 
comparable with published data and no issue was uncovered relating to the 
experimental methods, hardware or custom software scripts used which were 
sufficiently robust to include in the ALight trial.   
3.8. Conclusion 
This chapter began by introducing the original trial protocol. Additional information 
was provided regarding the intervention and protocol modifications implemented prior 
to trial inception. Amendments were made to the protocol with the aim of improving 
logistical aspects such as the participant recruitment pathway, data collection 
environment and staff training.  
 McKeague et al. 
(2014) Visit 1 
McKeague et al. 
(2014) Visit 2 
Pilot study 
cohort 
 
RG Threshold (CAD units) 
 
2.33 (±4.58) 
 
2.22 (±4.58) 
 
1.48 (±0.41) 
YB Threshold (CAD units) 1.42 (±0.56) 1.33 (±0.56) 1.37 (±0.28) 
14Hz Flicker (cd/m2) 
 
-1.85 (±0.012) 
 
-1.93 (±0.17) 
 
-1.81 (±0.09) 
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Both of the preliminary experiments described in this chapter resulted in the 
successful collection of pilot data from normal subjects. Dark adaptation data 
collected allowed optimisation of the bleaching source and timeframe of threshold 
measurement. It was also determined that the hand held bleaching source could be 
used in dark adaptation measurement. The usefulness of each test to monitor disease 
progression in AMD could not be determined from this pilot experiment. In order to 
address this, secondary aims of this PhD were to determine the relationship between 
each functional outcome measure and AMD severity in a cross-sectional evaluation 
of those with and without AMD, and to use the longitudinal trial data to assess the 
ability of dark adaptation, colour vision, and flicker thresholds to act as prognostic 
biomarkers for AMD progression. The results of the cross-sectional analysis are 
presented in Chapter 4.   
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Chapter 4. The capacity of four visual function tests to predict 
an increase in age-related macular degeneration severity   
Although hypoxia is implicated in AMD pathogenesis, the aetiology is multifactoral 
which increases the difficulty of developing targeted treatments. In accordance with 
this, current treatment is available only for those with nAMD. The early identification 
of individuals at the greatest risk of developing nAMD would enable targeted 
monitoring by clinicians. Furthermore, in planning clinical trials of interventions 
designed to prevent disease progression, identifying those individuals at greatest risk 
of progression enables an efficient study design to be implemented. This means that 
tests capable of predicting risk of disease progression are invaluable to both clinicians 
and researchers. This chapter details a cross-sectional study aiming to understand 
the prognostic capacity of a battery of psychophysical tests each of which has a body 
of evidence to support its relationship with AMD severity (Dimitrov et al., 2011; 2012).  
4.1. Introduction 
Currently, early and intermediate AMD are diagnosed by the presence of 
characteristic retinal features such as soft drusen and pigmentary abnormalities 
(Ferris et al., 2013). The standard approach used to determine AMD severity in both 
clinical and research settings is to grade the extent of these fundus changes using 
parameters such as size, number, appearance and location (Bird et al., 1995; Ferris 
et al., 2005; Davis et al., 2005; Ferris et al., 2013). However, the extensive longitudinal 
data provided by the AREDS trial led to the development of grading scales which not 
only allow the severity of AMD to be established, but also the 5-year risk of 
progression to advanced AMD to be determined (AREDS, 2005; Ferris et al., 2005). 
For example, the AREDS Simplified Severity Scale (Ferris et al., 2005) can be used 
to establish the risk of progression by summing risk factors (up to a maximum of 4) 
which include the presence of intermediate drusen in both eyes, the presence of large 
drusen or pigmentary abnormalities in either eye, and the presence of advanced AMD 
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in one eye (Ferris et al., 2005). The risk factors are summed across both eyes. The 
lowest and highest risk groups (0 risk factors and 4 risk factors) were estimated to 
exhibit a 0.5% and 50% chance, respectively, of progressing to advanced AMD over 
a 5 year period. However, the presence of drusen and pigmentary change alone is 
not sufficient to identify those likely to develop advanced disease (Dimitrov et al., 
2011). This is exemplified by the low rate of advanced disease manifestation in those 
over 50 years of age displaying early clinical characteristics (Sunness et al., 1989; 
Van Newkirk et al., 2000; Smith et al., 2001) and reflected in the low specificity 
(around 55%) of fundus changes to predict disease progression (Sunness et al., 
1989).  
Another approach to predicting risk of disease progression may lie in the evaluation 
of retinal function or OCT-derived anatomical biomarkers. At present, When 
investigating changes relating to AMD, OCT-derived measurements of retinal 
thickness are commonplace within clinical and research settings. Retinal layer 
segmentation tools such as the Iowa Reference Algorithms also allow the assessment 
of individual retinal layers of specific interest in relation to AMD pathogenesis such as 
the RPE and photoreceptor layer (Garvin et al., 2009; Antony et al., 2011). Drusen 
volume analysis has also shown potential as a structural AMD biomarker (Yehoshua 
et al., 2011; Abdelfattah et al., 2016; Schlanitz et al., 2017). To date, a number of 
visual function tests have also been identified as potential biomarkers of AMD. These 
include dark adaptation (Owsley et al., 2007; 2016; Dimitrov et al., 2008; 2011; 
Gaffney et al., 2011), flicker threshold (Mayer et al., 1992a; 1994; Dimitrov et al., 
2011) and chromatic sensitivity (Eisner et al., 1992; Arden and Wolf, 2004; O’Neill 
Biba et al., 2010). Longitudinal studies of colour-matching (Eisner et al., 1992), colour 
contrast sensitivity (Eisner et al., 1992; Holz et al., 1995), flicker threshold (Mayer et 
al., 1994; Luu et al., 2012) and dark adaptation (Owsley et al., 2016; Eisner et al., 
1992) indicate that these functional measures also have a prognostic value. This 
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suggests that relatively simple visual functional tests may be used to identify those at 
greatest risk of disease progression. Despite this, no published evidence is available 
to establish the magnitude of the increased risk of progression associated with a 
worsening performance in each of these tests.  
4.2. Aims 
The primary aim of this study was to evaluate the ability of dark adaptation, 14Hz 
flicker threshold, YB chromatic threshold and RG chromatic threshold tests to identify 
the likely risk of an increase in graded AMD severity . Five-year progression to nAMD 
risk was determined using the AREDS Simplified Severity Scale (Ferris et al., 2005) 
as a surrogate. The measures were chosen as candidate functional biomarkers on 
the basis of strong evidence supporting a relationship with disease severity (Dimitrov 
et al., 2011; 2012) and preliminary evidence of predictive capacity (Eisner et al., 1992; 
Holz et al., 1995; Mayer et al., 1994; Luu et al., 2012; Owsley et al., 2016). The study 
also had two secondary aims:  
3. To explore the relationship between the functional and structural outcome 
measures.  
4. To determine the relationship between disease severity and the observed 
functional and structural deficits.  
4.3. Methods 
Recruitment for this study took place at the BEH Clinical Research Unit from July 
2014 to August 2016. All participants were aged between 55 and 88 years of age and 
had a corrected ETDRS visual acuity in the test eye of 40 letters (logMAR 0.3, Snellen 
6/12) or better. A detailed eligibility criteria list is provided in Section 3.1.3 however, 
in brief, participants with bilateral advanced AMD, including drusenoid pigment 
epithelial detachment (DPED) and non-central GA were not eligible to participate in 
the study. Exclusion criteria also included ocular pathology other than macular 
disease, significant systemic disease or history of medication known to affect visual 
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function and cognitive impairment as determined using an abridged MMSE (Schultz-
Larsen et al., 2007).  
In order to maximise recruitment posters were displayed within the waiting areas of 
all departments within the eye hospital. All participants were asked if they would pass 
on leaflets to friends that may participate. Avon Local Optometric Committee was 
contacted and asked to distribute information (via e-mail) regarding the study to all 
practices within the Avon area. The local Macular Society was also informed of the 
research study and provided with posters, leaflets and information at a talk designed 
to raise awareness regarding research at BEH.     
 Participants  
One hundred participants were recruited to the study directly from BEH Medical 
Retinal Clinic. Sixty of those who took part were also participants in the ALight clinical 
trial addressed later in this thesis. All sixty within this cohort had early or intermediate 
AMD (as classified by the presence of soft drusen and/or focal pigmentary changes) 
in one eye and nAMD in their fellow eye (as confirmed by fluorescein angiography). 
The remaining 40 participants were normal or had early AMD in the study eye only, 
and were recruited from a list of research volunteers at Cardiff University Eye Clinic, 
clinic waiting rooms at BEH and from amongst the friends of those with nAMD enrolled 
onto the study. The AMD severity of all participants was graded (0-4 with increasing 
severity) in accordance with the AREDS Simplified Severity Scale (Ferris et al., 2005). 
The grading protocol is described in Section 3.3.3.2. In those with no or early AMD 
only, the eye with the best VA was designated as the test eye. In cases where VA and 
fundus status were the same, the right eye was assigned as the study eye. In the case 
of those with unilateral nAMD, the fellow eye (exhibiting signs of early AMD only) was 
selected for testing. All participants provided informed written consent prior to 
participation. The study was approved by the NHS Health Research Authority 
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National Research Ethics Service Committee North West – Greater Manchester 
South, and all procedures adhered to the tenets of the Declaration of Helsinki.  
 Experimental procedures  
The data from the 60 participants enrolled in the ALight trial were collected at the 
baseline visit as described in Section 3.3.3. The experimental procedure for the 40 
individuals who were not part of the larger trial is outlined here. The consent form and 
all templates used to record clinical data are shown in Appendix VI. Following a 
discussion of the participant information sheet, and provision of informed consent, all 
participants underwent a standardised examination procedure prior to undertaking the 
functional tests. These baseline tests included a clinical eye examination (slit lamp 
biomicroscopy of the anterior segment and indirect ophthalmoscopy), assessment of 
BCVA (4 metre logMAR), an assessment of cognitive function (MMSE; Schultz-
Larsen et al., 2007) and an interview regarding ocular history, medical history and 
medication. Pupillary dilation was achieved using 1% tropicamide and confirmed 
through assessment of the photopic pupil reflex. The same room was used for all 
visual function tests for which only the study eye underwent the visual function testing 
regimen.   
Each participant was seated 140cm directly in front of a calibrated high resolution LED 
monitor (NEC MultiSync PA24/W) when collecting dark adaptation, flicker and colour 
discrimination threshold data. Refractive correction was worn as required and the 
non-test eye was occluded. The order of tests used was randomised and all were 
performed on one visit. To prevent fatigue participants were given short breaks 
between tests and when necessary participants reattended to repeat a 
psychophysical test if completion was not possible at their initial visit. All repeat 
measurements were recorded within 4 weeks of initial assessment. Following visual 
function testing retinal images were obtained. The acquisition of SD-OCT images was 
performed using a Zeiss Cirrus SD-OCT 4000 (Carl Zeiss Meditec, Inc., California, 
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USA). Fundus photographs (30° diameter centred on the fovea) were taken using a 
Topcon 3D-OCT 2000 (Topcon Medical Systems Inc., New Jersey, USA) and digitally 
stored. All visual function tests were performed using the same methods and 
calibrated equipment as described in Chapter 3. For a detailed description of the dark 
adaptation (Section 3.6.3.1), chromatic threshold (Section 3.7.1.2) and flicker 
threshold (Section 3.7.1.2) testing regimen the reader is directed to the relevant 
bracketed section.  
 Examination of structural outcome measures   
The Cirrus HD-OCT instrument was used to acquire 5 images for each participant 
from which the mean drusen volume measurement was recorded. All images were 
macular cube scans (200 x 200mm3 A scans) covering a retinal area of 6 x 6mm2 (20° 
x 20° visual angle). A detailed description of the OCT acquisition and drusen volume 
measurement regimen is described in Section 3.3.3.1. Retinal thickness analysis was 
performed using OCT Explorer 4.0. This program is part of the Iowa Reference 
Algorithms (Retinal Image Analysis Lab, Iowa Institute for Biomedical Imaging, Iowa, 
USA) and is a publicly available, device-independent, graph theory-based tool for 
segmentation of 10 retinal layers in volumetric OCT images (Garvin et al., 2009; 
Antony et al., 2011). Of the 5 images taken per participant, the scan with the highest 
signal strength was chosen for automated retinal layer segmentation. If there were 
several scans of a similar quality then one was chosen randomly. Retinal layer 
thickness values were obtained for the foveal subfield and the inner and outer rings 
of a standard ETDRS grid (Figure 4.1). The thickness of each retinal layer within each 
subfield was summed to derive a total retinal thickness (corresponding to the distance 
from the inner limiting membrane to the outer boundary of the RPE). 
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Figure 4.1. ETDRS grid and example 10 intraretinal layer segmentation. (A) Standard ETDRS 
grid showing three subfields: foveal (black), inner (dark grey) and outer (light grey). (B) 
Screenshot of 10 layer (11 boundary) segmentation of a long-wavelength OCT image, 
produced by the Iowa Reference Algorithms. The left half shows the image prior to 
segmentation. Layers 1-10 (top to bottom, as defined by the software): retinal nerve fibre layer 
(RNFL); ganglion cell layer (GCL); inner plexiform layer (IPL); inner nuclear layer (INL); outer 
plexiform layer (OPL); outer plexiform layer-Henle fibre layer to boundary of myoid and 
ellipsoid of inner segments (OPL-HFL ~ BMEIS); photoreceptor inner/outer segments (IS/OS); 
inner/outer segment junction to inner boundary of outer segment photoreceptor/retinal pigment 
epithelial complex (IS/OSJ ~ IB-RPE); outer segment photoreceptor/retinal pigment epithelial 
complex (OPR); retinal epithelium (RPE) (Terry et al., 2016; copyright permission from PLOS 
One).      
 
 Statistical analysis  
All statistical analysis was performed in SPSS Statistics 20.0 (SPSS Statistics for 
Windows, R2011, IBM Corp., New York, USA). The functional measures used in this 
investigation may vary with age. Therefore, the first step was to analyse differences 
in age between graded severity groups using a one-way analysis of variance 
(ANOVA). The nominal level of statistical significance was set at α=0.05. Following 
this, to address significant differences between the groups, the second step was to 
make the data age independent. This was achieved using linear regression analysis 
to model the relationship between each functional outcome measure and age within 
the grade 0 AMD severity group (AREDS Simplified Severity Scale; Ferris et al., 
2005). The functional outcome values of each participant were adjusted according to 
the linear regression equation, to that of the mean age of the entire cohort (75.37 ± 
7.07 SD) (Figure 4.2). The drusen parameters were not age-adjusted as they are only 
associated with advancing disease.  
The Shapiro-Wilk test was used to assess distributional assumptions. Group 
comparisons between outcome measures were conducted using the one-way 
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analysis of variance (ANOVA) test with post-hoc Bonferroni testing (for normally 
distributed data) or the Kruskal-Wallis with pairwise Mann-Whitney U-test post-hoc 
comparisons (for non-normally distributed data). In order to account for multiple 
comparisons P-values were adjusted in accordance with the Holm-Bonferroni 
adjustment procedure (Holm, 1979). Standard and multiple linear regression analyses 
were conducted to explore the relationship between the structural (predictor variable) 
and functional (outcome variable) outcomes. Regression assumptions were tested in 
accordance with methods described by Altman (1991). This involved testing the 
distribution of the residuals (calculated as the actual outcome variable value minus 
the value predicted by the regression model) for normality (Figure 4.3). P, R2 and 
pseudo R2 values were determined to describe the significance of the regression 
model alongside the percentage of variance explained. 
 
Figure 4.2. Scatter plots for the control group (AREDS Simplified Severity Grade 0; Ferris et 
al., 2005) showing raw data (blue circles) for each outcome measure and age-adjusted data 
(orange circles). Linear regression analysis was used to model the relationship between each 
functional outcome measure (blue regression line) and correct the data to the average age of 
the cohort (orange regression line).  
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The predictive value of the visual function tests was estimated using ordinal 
regression analysis. Ordinal regression models identified as statistically significant 
(P<0.05) were used to determine odds ratios (calculated as the exponential of each 
coefficient estimate) for individual and combinations of outcome measures. The 
assumption of multicollinearity was verified using the test of parallel lines and 
coefficient estimates were verified as significant (P<0.05, based on Wald test statistic) 
prior to odds ratio calculation. Odds ratios determined equated to the odds of moving 
up an AMD severity grade based on 1 unit increase of the outcome measure. The 
corresponding risk of 5-year progression to nAMD associated with each severity 
grade was designated as grade 0 (0.4%), grade 1 (3.1%), grade 2 (14.8%), grade 3 
(35.4%), grade 4 (53.1%) in accordance with the AREDS Simplified Severity Scale 
(Ferris et al., 2005).  
 
Figure 4.3. Normality testing of residuals in order to satisfy linear regression assumptions 
(Altman, 1990). Standardised residuals obtained from a retinal thickness regression model are 
shown in the left panel. The standardisation process involved rescaling each variable to have 
a mean of zero and a standard deviation of 1. For each case shown, the Y-axis value 
represents its difference from the mean of the original variable in number of standard 
deviations. For example, a value of 0.5 indicates that the value for that case is half a standard 
deviation above the mean. Variables have been standardised in this manner to allow direct 
comparison of cases and simplify interpretation of results. The X-axis shows the predicted 
value of retinal thickness for each case as based on the regression model, This value has also 
been standardised. The normal P-P plot of the standardised residuals shown in the right panel 
suggests normality indicating the variability of residuals shown in the scatter plot was not 
sufficient to cause assumption violation.    
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4.4. Results  
The flow of participants through the study is shown in Figure 4.4. One hundred 
participants were recruited with AMD severity distributed from grade 0 to 4 (mean age 
75.37 ± 7.07 SD; 55% female). Participants with an AMD severity of grade 0 (0 risk 
factors) in accordance with the AREDS Simplified Severity Scale (Ferris et al., 2005) 
were designated as control participants. The characteristics of each AMD severity 
group are shown in Table 4.1. All other participants had either early/intermediate AMD 
only (1-4 risk factors), or advanced AMD in one eye and early/intermediate AMD in 
the fellow eye (2-4 risk factors). In those with unilateral nAMD, the number of 
intravitreal injections received at the time of recruitment ranged from 3 to over 20. 
Mean BCVA in the fellow eye ranged from 0.08 to 0.45 logMAR across all AMD 
severity grades.  
 
Figure 4.4. Flow diagram of cross sectional study participants. Specified ‘Grade’ relates to 
AMD severity as graded using the AREDS Simplified Severity Scale (Ferris et al., 2005). 
Those graded ≥2 also participated in the ALight clinical trial (results presented in Chapters 5 
and 6).   
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Significant differences were found between the mean age of the grade 0 group (69.58 
± 8.73) and the grade 2 (76.56 ± 8.29; P=0.037), 3 (78.65 ± 6.52; P=0.001) and 4 
(77.74 ± 5.37; P=0.006) groups. The relationship between age and each of the 
functional measures was verified as significant for each outcome measure within the 
control group (study-eye visual acuity, P=0.02; cone τ, P=0.01; 14Hz flicker threshold, 
P=0.05; red-green chromatic threshold, P=0.02; yellow-blue chromatic threshold, 
P=0.05). The functional data were therefore all corrected for the effect of age using 
the approach described earlier (Figure 4.2). The structural parameters were not age-
adjusted as linear regression showed no significant relationship between age in the 
control group and the retinal thickness of the foveal (P=0.166), inner (P=0.436) and 
outer (P=0.571) subfields.   
Table 4.1. Characteristics of each graded AMD severity group. Raw and age-adjusted means 
are provided for visual acuity measurements. “AREDS grade” refers to the number of risk 
factors assigned according to the AREDS Simplified Severity Scale (Ferris et al., 2005). 
 
 
 
 Retinal function and disease severity  
Cone τ, 14Hz flicker thresholds and chromatic thresholds were recorded for all 
participants. One participant was removed from red-green chromatic sensitivity 
analysis due to congenital protanopia as verified by the Ishihara test. In accordance 
with Shapiro-Wilk testing and as verified using normal Q-Q plots data were normally 
Participants Age 
Visual acuity (logMAR) 
Study Eye 
Visual acuity (logMAR) 
Fellow Eye 
AREDS 
grade 
N (% 
female) 
Mean 
(±SD) 
Mean 
(±SD) 
Age-
adjusted 
mean (±SD) 
Mean 
(±SD) 
Age-
adjusted 
mean (±SD) 
0 
19 
(52%) 
69.58 
(±8.73) 
-0.01 
(±0.07) 
-0.02 (±0.07) 
0.08 
(±0.12) 
0.05 (±0.15) 
1 
21 
(66%) 
74.33 
(±6.44) 
0.03 
(±0.14) 
0.03 (±0.14) 
0.20 
(±0.28) 
0.19 (±0.28) 
2 
18 
(44%) 
76.56 
(±8.29) 
0.06 
(0.15) 
0.06 (±0.16) 
0.30 
(±0.31) 
0.31 (±0.33) 
3 
23 
(56%) 
78.65 
(±6.52) 
0.08 
(0.12) 
0.08 (±0.12) 
0.45 
(±0.28) 
0.46 (±0.28) 
4 
19 
(58%) 
77.74 
(±5.37) 
0.11 
(0.11) 
0.11 (±0.11) 
0.45 
(±0.35) 
0.47 (±0.35) 
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distributed within each severity grade (Shapiro-Wilk, P>0.05) for the functional 
outcome measures (following log transformation).  
Significant differences between groups for each normally distributed outcome 
measure is shown in Figure 4.5. The mean RG chromatic threshold was significantly 
lower in the grade 0 group than grades 2 (P<0.001), 3 (P=0.001) and 4 (P<0.001). No 
significant difference in RG chromatic sensitivity was found between grades 2, 3 and 
4. However, the mean grade 1 threshold was significantly lower than grades 2 
(P=0.006) and 4 (P<0.001). Fewer significant differences were found when assessing 
YB chromatic threshold. The grade 4 group was found to have significantly higher YB 
thresholds than all other groups (grade 0, P<0.001; grade 1, P<0.001; grade 3, 
P<0.021), except grade 2 (P=0.683). Unlike RG thresholds there were no significant 
differences found between those graded 1-3. Mean cone τ values were significantly 
lower in grade 0 than grades 3 (P=0.033) and 4 (P<0.001), and in grade 1 when 
compared to all subsequent grades (grade 2, P=0.032; grade 3, P=0.001; grade 4, 
P<0.001). Mean 14Hz flicker threshold values showed fewer significant mean 
differences across graded severities than any other functional outcome measure. The 
average flicker threshold value was significantly higher for those with the highest 
graded AMD severity when compared to all other grades (grade 0, P<0.001; grade 1, 
P<0.001; grade 2, P=0.015; grade, P<0.001). There was no difference found between 
controls and those graded ≤3.   
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Table 4.2. Differences in mean as derived from raw data and age-adjusted mean thresholds 
across all grades of AMD severity. The small difference between means and age-adjusted 
means indicates a limited effect of age of the effect of each outcome measure.  
 
 
Figure 4.5. Graphs showing differences in age-adjusted means across AREDS grades for 5 
functional measures: visual acuity, red-green chromatic sensitivity, YB chromatic sensitivity, 
14Hz flicker threshold and cone τ. Significant differences between groups are denoted by the 
4 symbols used (asterisk, triangle, circle and diamond). A symbol above a specified P-value 
denotes a significant difference between that severity grade and all others with the same 
symbol. When a significant difference exists between one grade and multiple others the range 
of P-values is displayed. 
 
Red-Green Threshold 
(Log CAD Units) 
Yellow-Blue Threshold 
(Log CAD Units) 
Flicker Threshold 
(Log cd/m2) 
Cone τ 
(Log mins) 
AREDS 
Grade 
Mean 
(±SD) 
Adjusted 
Mean  
(±SD) 
Mean 
(±SD) 
Adjusted 
Mean (±SD) 
Mean 
(±SD) 
Adjusted 
Mean  
(±SD) 
Mean 
(±SD) 
Adjusted 
Mean (±SD) 
0 0.97 
(±0.35) 
1.11 
(±0.25) 
1.19 
(±0.44) 
1.30 
(±0.36) 
-3.71 
(±0.37) 
-3.55 
(±0.31) 
1.07 
(±0.50) 
1.29 
(±0.30) 
1 1.39 
(±0.67) 
1.43 
(±0.62) 
1.43 
(±0.51) 
1.46 
(±0.48) 
-3.63 
(±0.45) 
-3.60 
(±0.43) 
1.14 
(±0.51) 
1.18 
(±0.50) 
2 2.06 
(±0.69) 
2.06 
(±0.67) 
1.86 
(±0.57) 
1.87 
(±0.51) 
-3.22 
(±0.72) 
-3.25 
(±0.49) 
1.55 
(±0.36) 
1.53 
(±0.39) 
3 1.84 
(±0.47) 
1.82 
(±0.42) 
1.73 
(±0.55) 
1.70 
(±0.55) 
-3.33 
(±0.20) 
-3.38 
(±0.24) 
1.67 
(±0.15) 
1.62 
(±0.16) 
4 2.33 
(±0.70) 
2.33 
(±0.67) 
2.17 
(±0.39) 
2.16 
(±0.38) 
-2.72 
(±0.80) 
-2.82 
(±0.23) 
1.89 
(±0.34) 
1.86 
(±0.35) 
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 Retinal structure and disease severity  
No data were omitted from the analysis of drusen area, volume and retinal thickness. 
Measurements of retinal thickness were normally distributed and as such were not 
log transformed. Drusen data were found not to be normally distributed even after log 
transformation, hence non-parametric statistics were used to analyse and describe 
these data. For those graded 0-2 median drusen volume and area measurements 
were found to be 0.00 (Table 4.3). As shown graphically in Figure 4.6 those graded 
≥3 were found to have significantly larger drusen volume and area when compared to 
those graded ≤2. Retinal thickness data are provided in Table 4.4. Due to the imaging 
protocol chosen OCT image quality did not permit individual retinal layer 
segmentation. However, measurements of total retinal thickness were possible. When 
assessing retinal thickness, mean differences existed between severity groups at the 
foveal (P=0.040) and inner (P=0.001) subfield regions. The mean foveal subfield was 
found to be significantly thicker in those graded 0 when compared to those graded 4 
(P=0.04). No significant differences in thickness were found between grades 0-3. 
Similarly, grade 4 subjects had a significantly thinner mean inner-subfield zone than 
those graded 0 (P=0.001), 1 (P=0.015) and 3 (P=0.018) (Figure 4.7). 
Table 4.3. Median and inter-quartile-range (IQR) values for drusen characteristics. 
 
 
 
 
 
 
 
 
 
 Drusen Volume (mm3) Drusen Area (mm2) 
AREDS grade 3mm median (IQR) 5mm  median (IQR) 3mm  median (IQR) 5mm  median (IQR) 
0 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 
1 0.00 (0.00, 0.00) 0.00 (0.00, 0.01) 0.00 (0.00, 0.02) 0.00 (0.00, 0.10) 
2 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.05) 0.00 (0.00, 0.06) 
3 0.01 (0.01, 0.03) 0.02 (0.01, 0.04) 0.38 (0.21, 0.69) 0.56 (0.32, 1.14) 
4 0.01 (0.01, 0.02) 0.03 (0.01, 0.04) 0.40 (0.15, 0.55) 0.80 (0.41, 1.16) 
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Table 4.4. Mean and standard deviation values for 3 retinal thickness zones: foveal, inner and 
outer subfields. 
Figure 4.6. Boxplots for each structural outcome measure showing distribution of data across 
graded AMD severities. Black circles show outliers (calculated as 3 times above IQR). 
Significant differences between groups (P<0.01) are denoted by the symbols used (asterisk, 
triangle and white circle). When the same symbol is denoted by more than two groups each 
group has a significant difference with at least 1 other group denoted by the same symbol. 
One drusen volume outlier (GP15:1.66/1.74mm3 is not shown as their data extends beyond 
axis boundaries). A negative y-axis origin has been chosen in order to aid visualisation of the 
minimum value for all structural outcomes (0.00). 
 
 
Retinal thickness foveal 
subfield (microns) 
Retinal thickness inner 
subfield (microns) 
Retinal thickness outer 
subfield (microns) 
AREDS 
Grade 
Mean (±SD) Mean (±SD) Mean (±SD) 
0 288.26 (±24.28) 1331.13 (±56.65) 1147.95 (±54.71) 
1 282.61 (±31.01) 1306.72 (±90.28) 1148.74 (±71.99) 
2 272.15 (±21.47) 1264.59 (±91.40) 1093.87 (±67.16) 
3 278.93 (±29.99) 1303.57 (±78.94) 1139.57 (±54.62) 
4 261.75 (±29.22) 1219.33 (±99.74) 1112.75 (±73.44) 
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Figure 4.7. Graphs showing differences in means across AREDS grades for 3 subfields of 
retinal thickness: foveal, inner and outer. Significant differences between groups are denoted 
by the three symbols used (asterisk, triangle and circle). 
 
 Functional and structural outcome relationship 
Standard linear and multiple regression were conducted (Table 4.5) to determine the 
relationship between functional and structural outcome measures. According to 
standard linear regression analysis the only variable which was a significant predictor 
(P<0.05) of drusen volume (3mm radius around fovea, R2 0.06, P=0.035) and area 
(R2 0.09, P=0.006) was cone τ (Figure 4.8). Despite this, according to the R2 
parameter of the model, cone τ was only able to predict <10% of the variation in 
drusen volume and area. When retinal thickness was assessed, independent 
predictors for mean foveal thickness (flicker threshold, R2 0.06, P=0.035), mean outer 
retinal thickness (YB chromatic sensitivity, R2 0.12, P=0.002) and mean inner retinal 
thickness (cone τ, R2 0.13, P=0.001; YB chromatic sensitivity, R2 0.22, P<0.001; flicker 
threshold, R2 0.18, P=<0.01) were found. Models containing multiple parameters were 
also found to be significant predictors of mean inner retinal thickness. The most 
significant multivariate model to predict mean inner retinal thickness (adjusted R2 
0.30, P<0.001) included the parameters of YB chromatic sensitivity (P=0.018), cone 
τ (P=0.020) and flicker threshold (P=0.033). In comparison, a model containing just 
the parameters of YB chromatic sensitivity and cone τ was also found to be a 
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significant predictor of mean inner retinal thickness (adjusted R2 0.28, P<0.001) 
however it explained slightly less variance. 
Table 4.5. Linear and multiple linear regression results. Data are shown only for significant 
models (P<0.05 model fit). Where models contain more than one test of visual function a 
coefficient estimate and its corresponding 95% confidence intervals (CI) are shown for each 
test within the model.    
 
 
Figure 4.8. Scatter plots showing significant relationships between structural and age-adjusted 
functional tests.  
 
 Outcome measures as AMD predictors  
According to the ordinal regression analysis, cone τ (pseudo R2 0.35, P<0.001) and 
YB chromatic sensitivity (pseudo R2 0.16, P<0.001) were found to be independent 
predictors of increased AMD severity (Table 4.6). The predictive capacity of cone τ 
and YB chromatic sensitivity together was higher still (pseudo R2 0.39, P<0.01). When 
                                  Variable predicted β coefficient 
95% CI bounds 
(lower, upper) 
P R2 
Cone τ Drusen area (3mm2) 0.329 0.095, 0.563 0.006 0.09 
Cone τ Drusen volume (3mm3) 5.151 0.404, 9.898 0.035 0.06 
Cone τ Inner retinal thickness -0.002 -0.003, -0.001 0.001 0.13 
YB sensitivity Outer retinal thickness -0.003 -0.004, -0.001 0.002 0.12 
YB sensitivity Inner retinal thickness -0.003 -0.004, -0.002 <0.001 0.22 
Flicker threshold Inner retinal thickness -0.002 -0.004, -0.001 <0.01 0.18 
Flicker threshold Foveal thickness -0.004 -0.009, 0.000 0.035 0.06 
YB sensitivity and Inner retinal thickness -64.500 -99.733, -29.267 <0.001 0.28 
cone τ  -54.815 -98.892, -10.742   
YB sensitivity and Inner retinal thickness -46.340 -84.570, -8.117 <0.001 0.30 
cone τ and  -51.548 -94.704, -8.399   
flicker threshold  -39.870 -76.391, -3.350   
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both tests were used simultaneously odds ratios showed that with every log minute 
increase in cone τ and every CAD unit increase, the odds of moving up a severity 
grade are 2.5 and 20 times higher, respectively. For a participant progressing from 
severity grade 3 to 4 this equates to a 5-year progression risk increase from 35.4% to 
53.1% in accordance with the AREDS Simplified Severity Scale (Ferris et al., 2005). 
Therefore, they are 2.5 times more likely to have a 17.7% increased risk of 5-year 
progression to nAMD based on 1 log minute increase in cone τ. Flicker threshold was 
only a significant predictor when used in combination with YB chromatic sensitivity 
(pseudo R2 0.27, P<0.001). RG chromatic sensitivity was rejected as a significant 
predictor by all ordinal regression models. Foveal thickness was the only significant 
structural predictor (P=0.047) however it explained far less of the variance (pseudo 
R2 0.05) than cone τ and was rejected by all multivariate models.    
Table 4.6. Ordinal regression results. Data are only shown for significant models (P<0.05 
model fit, P<0.05 coefficient estimate, P>0.05 test of parallel lines). P values <0.05 show that 
at least one coefficient in the model is a significant predictor of increasing disease severity 
based on the AREDS Simplified Severity Scale. A coefficient estimate is shown for each test 
incorporated within the regression model (as ordered in the first column). The P-value provided 
for each β coefficient shows the significance of that coefficient (as based on the Wald test 
statistic) in estimating an increase in AREDS Simplified Severity grade (Ferris et al., 2005).  
 
                                                                   β coefficient 1 β coefficient 2 
 P 
Pseudo 
R2 
Estimate 
(P-value) 
Odds 
ratio 
95% 
Confidence 
interval 
Estimate 
(P-value) 
Odds 
ratio 
95% 
Confidence 
interval 
Cone τ 
 
<0.001 
 
0.35 
 
3.352 
(<0.001) 
 
28.56 
2.022 –  
4.681 
 
 
  
YB sensitivity 
 
<0.001 
 
0.16 
 
1.408 
(0.001) 
 
4.09 
 
0.607 – 
2.209 
 
 
  
Retinal 
thickness: 
fovea 
 
0.047 
 
0.05 
 
-0.014 
(0.044) 
 
1.00 
 
-0.029 – 
0.000 
 
 
  
YB sensitivity 
and cone τ 
 
<0.001 
 
0.40 
 
0.916 
(0.034) 
 
2.50 
 
0.069 – 
1.763 
 
3.018 
(<0.001) 
 
20.45 
 
1.670 – 
4.366 
 
YB sensitivity 
and flicker 
threshold 
<0.001 
 
0.27 
 
0.867 
(0.054) 
 
2.38 
 
-0.140 – 
1.748 
 
1.587 
(0.002) 
 
4.89 
 
0.568 – 
2.607 
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4.5. Discussion   
In order for clinicians and those undertaking clinical trials to identify high risk patients 
for closer monitoring the identification of visual function tests that may enhance the 
prediction of disease progression in those with early/intermediate AMD would be 
valuable. Although the hierarchy of early AMD changes based upon visual function 
tests has been established previously (Dimitrov et al., 2012) such functional outcomes 
have not previously been utilised to predict risk of progression. In the present study, 
using the AREDS Simplified Severity Scale as a surrogate, the best predictor of an 
increase in graded AMD severity was found to be cone τ. When compared to all other 
vision function tests, cone τ was better able to predict an increase in AMD severity. 
Out of the remaining 3 functional tests, YB chromatic sensitivity also showed some 
promise in predicting AMD progression based on severity grading, particularly when 
used in combination with other visual function tests. In comparison, flicker threshold 
and RG chromatic sensitivity showed only limited capacity and were least useful.   
The present findings are in agreement with Dimitrov et al. (2012) who performed a 
cross-sectional study to assess the relationship between clinical macular changes 
and retinal function in 293 participants of varying AMD severity and 64 controls. The 
adaptational tests (cone and rod recovery) investigated by Dimitrov et al. (2012) were 
found to show a rapid decrease in functional outcomes at the earliest stage of AMD. 
The functional deficit exhibited continued to worsen with the manifestation of 
intermediate and soft drusen and remained stable thereafter, at a low-level of function 
following the onset of advanced disease. Therefore, it was suggested that 
adaptational tests would be valuable in identifying those with the earliest form of AMD. 
In comparison, steady-state measurements of visual function such as 14Hz flicker 
threshold and blue chromatic threshold have been shown to decrease consistently as 
clinical grading increases in severity (Dimitrov et al., 2012). Therefore, it was 
concluded that steady-state thresholds were particularly useful for monitoring AMD 
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progression over time. In light of the findings of the present study, it might be 
suggested that these outcomes are less effective as prognostic indicators.       
When considering previous longitudinal studies that have examined endpoints 
predictive of progression to late AMD the present findings are consistent with that of 
Eisner et al. (1992). Eisner et al, (1992) used a battery of tests (including flicker 
threshold) and found that foveal dark adaptation rate and S-cone mediated colour-
matching were the best predictors of nAMD development. Similarly, the strong 
performance of cone τ in the present study is also in agreement with a previous study 
by Owsley et al. (2016) who, by measuring rod dark adaptation, showed that those 
with delayed dark adaptation at baseline were twice as likely to have AMD in that eye 
when reassessed after 3 years. Owsley et al. (2017) also reported that rod-mediated 
dark adaptation may slow in intermediate AMD over 2 years and as such could be 
useful as a functional endpoint in proof-of-concept studies and clinical trials on 
intermediate AMD.  
The overall delay in dark adaptation in AMD can be attributed to impaired outer retinal 
function. That is, the intimate relationship between photoreceptor outer segments and 
the RPE is fundamental to the regeneration of visual pigment molecules following 
photoisomerisation. Crucially, production of 11-cis retinal by the RPE is the rate 
limiting step in the regeneration of visual pigment molecules and hence dark adaption 
rate (Lamb and Pugh, 2004). AMD and the rate limiting set in the dark adaptation 
process share the same anatomical locus, the RPE cell, and it is for this reason that 
measures of dark adaptation are consistently associated with AMD, even at its earliest 
stages (Ambati et al., 2003). 
The poor predictive capacity of red-green chromatic sensitivity in comparison to 
yellow-blue sensitivity is also consistent with current evidence as based on a 
longitudinal study of 47 subjects with macular drusen reported by Holz et al., (1995). 
The vulnerability of the blue cone pathway to retinal disease has been attributed to 
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the S-cone receptors and corresponding ganglion cells (Hood and Greenstein, 1988; 
Hood et al., 1984; Cho et al., 2000). The limited dynamic response range of the S-
cone receptors compared to L and M counterparts has been postulated as a factor 
resulting in their increased susceptibility to pathological disturbance, such as the 
hypoxia and inflammation implicated in AMD pathogenesis (Hood et al., 1984). 
Conversely, the loss could also be due to structural changes that occur to the 
photoreceptors in early AMD (Curcio et al., 1996; Jackson et al., 2002) or alterations 
in the post-receptoral retinal mechanisms (Greenstein et al., 1992).  
The current findings suggest that the usefulness of flicker sensitivity as a prognostic 
biomarker for AMD progression based on graded severity is limited. This conclusion 
appears to be at odds with a report that flicker threshold is decreased in eyes that 
eventually develop GA or choroidal neovascularisation (Mayer et al., 1994; Luu et al., 
2012). However, the study undertaken by Mayer et al, (1994) included a relatively 
small cohort (n=16 subjects with AMD, n=20 controls). Secondly, comparison with the 
more robust longitudinal study conducted by Luu et al. (2012) is difficult as ‘flicker 
perimetry’ using a different frequency stimulus positioned at different retinal locations 
to those in the present study was implemented. Although the present findings suggest 
that flicker threshold is not likely to be a good predictor of the onset of advanced 
disease, based on other attributes the test has been identified a useful clinical 
biomarker (Dimitrov et al., 2011). Despite having a lower diagnostic capacity than 
cone recovery rate, flicker threshold testing was found to be a useful clinical biomarker 
when factors such as reproducibility, test difficulty and test-time were considered 
(Dimitrov et al., 2011). This conflicting evidence suggests that flicker threshold cannot 
be excluded as a potentially useful biomarker for AMD progression until further 
longitudinal investigation has been conducted.   
A good functional biomarker would also be able to monitor disease progression with 
greater sensitivity than the widely used measure of visual acuity. Although visual 
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acuity displayed potential to differentiate between those with grade 0 AMD severity 
and those with the highest AMD severity grading, the tests that showed the largest 
difference between severity groups, and therefore may have the greatest potential to 
monitor disease progression were cone τ and chromatic sensitivity. These findings 
are consistent with a previous study by Dimitrov et al. (2011) who examined the 
diagnostic capacity, reproducibility and clinical applicability of a battery of visual 
function tests in 221 subjects with early AMD and 109 controls. Dimitrov et al. (2011) 
reported that the biomarker with the best diagnostic capacity to distinguish those with 
early AMD from controls was cone recovery rate. However, comparison of colour 
threshold with the present study is confounded given that Dimitrov et al. (2011) 
measured this using a staircase paradigm based on equiluminous foveal red and blue 
2° diameter Gaussian blobs. Such a method is unable to mask the detection of any 
residual luminance contrast signals that may be present. In comparison, the CAD test 
uses dynamic luminance contrast noise to mask the detection of confounding signals 
allowing for greater precision when isolating colour thresholds (Birch et al., 1992; 
Barbur et al., 1994; 2004).  
When considering retinal thickness, due to the imaging protocol chosen OCT image 
quality did not permit analysis of individual retinal layers. Although retinal morphology 
and macular OCT imaging have previously been shown to correlate well, the 
separation of adjacent tissues at a retinal level is restricted by the resolution of the 
OCT image, particularly when the neighbouring tissues have matching relative 
reflectivity such as the RPE and choroid, or the photoreceptor outer segments and 
photoreceptor nuclei (Toth et al., 1997). Other drawbacks of OCT imagining which 
may have impacted on image quality in the present study included: refractive index or 
media opacification effects, optical attenuation with increasing tissue depth and the 
misrepresentation of surface contours used to define total retinal thickness by the 
image processing algorithm (Toth et al., 1997).  
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Cone τ and YB chromatic sensitivity displayed the closest relationships with the 
structural measure of retinal thickness. Using OCT analysis a number of studies have 
evaluated retinal thickness in eyes with early/intermediate AMD (Camacho et al., 
2017; Yang et al., 2016; Lee and Yu, 2015; Yenice et al., 2015; Rogala et al., 2015; 
Savastano et al., 2014; Wood et al., 2011; Schuman et al., 2009; Kaluzny et al., 2009; 
Malamos et al., 2009) and advanced AMD (Blair et al., 2010; Kashani et al., 2009; 
Yuda et al., 2010; Zhang et al., 2014). Wood et al. (2011) reported a reduction of 
mean retinal thickness at the fovea and at a number of extrafoveal points in those 
with early AMD (n=16) compared to age-matched controls (n=16). Other studies 
exploring retinal thickness in early AMD have documented focal thinning localised to 
drusen location but no evidence of a generalised reduction across the macular region 
(Rogala et al., 2015; Schuman et al., 2009; Kaluzny et al., 2009; Malamos et al., 
2009). Localised thinning of the ganglion cell layer (Camacho et al., 2017; Lee and 
Yu, 2015; Yenice et al., 2015; Savastano et al., 2014) and photoreceptor layer 
(Schuman et al., 2009; Kaluzny et al., 2009) has also been found in early and 
intermediate AMD. The importance of Photoreceptor layer thickness measurement is 
further supported by the finding of an association between decreases in photoreceptor 
layer thickness in those with early AMD and a deterioration of retinal 
electrophysiological activity (Yang et al., 2016). In addition, the overall change in 
retinal thickness in those with GA has also been attributed to photoreceptor loss as 
assessed in human donor eyes (Curcio et al., 1996).  
Due to the increased intraretinal fluid and pigment epithelial detachment, retinal 
thickness analysis as performed in the present study (using the standard IOWA 
reference algorithm approach) is prone to segmentation error in those with nAMD 
(Zhang et al., 2014). Alternatively an automated 3D method of retinal segmentation 
has been reported by Zhang et al. (2014) which can accurately quantify the outer 
retinal-subretinal layer thicknesses in the presence of fluid relating to nAMD. This 
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method, which is currently being assessed in a larger population, facilitates the 
investigation of thickness changes in the photoreceptor layer of those with nAMD 
whereas previous studies have targeted the retinal nerve fibre layer (Yuda et al., 
2010) and outer-nuclear layer (Kashani et al., 2009).  
Although further investigation of the individual intraretinal layer thicknesses and their 
relationship to functional outcomes in those with AMD is necessary, the findings of 
the present study in conjunction with current evidence suggest that any change of 
visual function associated with thinning of the macular region, especially in those with 
early AMD, may be a candidate biomarker to reflect an increase in graded disease 
severity.   
Drusen volume and area measurement allowed clear differentiation between 
participants with early/intermediate and advanced disease grades. The lack of 
variation in drusen volume for those graded 0-2 was likely caused by the insensitivity 
of the Zeiss Cirrus Advanced RPE Analysis Software or the image protocol used. The 
elevation map generated by the software apparently permits measurement of drusen 
area and volume elevations >20μm (Gregori et al., 2011). It is suspected that the on-
board Zeiss Cirrus drusen analysis software used in this study was not sensitive 
enough to identify small RPE deformations and therefore failed to detect drusen 
<20μm, as well as flat drusen or subretinal drusenoid deposits that are located above 
the RPE. Those with graded severity ≥3 tended to feature larger, easily measurable 
drusen, whilst those with lower grades tended to have drusen of a size which was not 
registered by the imaging software.  
A limitation in this study was the reliance on the AREDS Simplified Severity Scale 
(Ferris et al., 2005) as a surrogate for risk progression to advanced AMD. Although 
the scale is based on large scale clinical trial data, the predicted progression risk is a 
marker for AMD progression and as such cannot be directly interpreted as being equal 
to the actual progression. In addition, multiple tests of significance were conducted to 
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discern relationships between outcome measures and an increase in AMD graded 
severity. Although steps were taken to reduce the likelihood of Type I error, repeated 
testing does increase the risk that significant results arose by chance alone. The study 
is strengthened by its large sample size, of which 60% of participants were recruited 
from a robust clinical trial cohort (McKeague et al., 2014). Also, the robust outcome 
measures tested each relate to a body of evidence supporting their use as effective 
AMD biomarkers.  
4.6. Conclusion   
In conclusion, alongside the aforementioned aims in Section 4.2 this chapter has 
addressed secondary aim 4 (Section 1.5) of this PhD which was to establish the 
relationship between baseline functional biomarker outcomes and severity of AMD. 
The identification of two different visual function testing modalities as independent 
predictors of increased AMD graded severity implies that cone τ and YB chromatic 
sensitivity may provide different information about the underlying pathological 
processes in AMD. This may be valuable when used alongside clinical estimation of 
severity as based on fundus changes and further advocates the use of visual function 
testing in AMD patients. However, this study evaluated cross-sectional data and 
evaluated the ability to predict risk of increased severity based on the fundus 
appearance graded using the AREDS Simplified Severity Scale (Ferris et al., 2005). 
Whilst this approach has identified promising candidate biomarkers, there is a need 
for a longitudinal evaluation of these functional measures over a period of years in 
order to definitively quantify the risk of progression associated with a change in these 
parameters. Similarly, whilst the significant difference in mean results between AMD 
grades might suggest that these tests are sensitive to disease progression, it is only 
through longitudinal evaluation that this hypothesis can be tested. Longitudinal testing 
as such would improve functional test selection for clinical trials investigating potential 
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new AMD treatments. An overview of one such clinical trial, as pertaining to this 
thesis, is provided in the next chapter.  
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Chapter 5. Overview of ALight trial implementation and 
intervention safety 
To date, there have been three longitudinal studies which have reported on the safety 
and acceptability of night-time light therapy (Arden et al., 2010; 2011; Sahni et al., 
2016). Over 6 and 12 month periods Arden et al. (2010; 2011) reported no difficulty 
in sleeping or mood alteration associated with the light therapy. Similarly, over a 3 
month period Sahni et al. (2016) found no major safety concerns, although they did 
report a small impairment to daytime alertness and a moderate negative effect on 
wellbeing (Sahni et al., 2016). Although these studies have assessed the acceptability 
of sleep mask based night-time light therapy, they targeted the treatment of diabetic 
maculopathy (Arden et al., 2010; Arden et al., 2011; Sahni et al., 2016). As AMD is a 
condition that manifests over the age of 55 (Klein et al., 2004) the cohort investigated 
during the ALight trial allows the acceptability of light therapy to be assessed in an 
older population. Information regarding clinical trial implementation and intervention 
safety in a cohort with AMD will be useful not only in future longitudinal studies aiming 
to investigate the impact of light therapy on progression of this disease, but also for 
assessing light therapy as a potential long-term treatment for AMD and other 
pathologies in an ever ageing population.  
This chapter begins by providing an overview of key aspects of the clinical trial, such 
as participant characteristics and recruitment. The chapter goes on to describe an 
evaluation of the safety and acceptability of the Noctura 500 light mask intervention 
during the ALight trial, including an analysis of compliance data, and concludes by 
describing withdrawals from the clinical trial.   
5.1. Recruitment and participants  
This section provides details regarding the recruitment of participants to the ALight 
trial which ran from July 2014 to November 2016. Specifically, there is an overview of 
patterns of recruitment and a description of a modification made to the protocol that 
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was designed to ensure that the recruitment target (n=60) was met. Participant 
characteristics are also described. For a detailed overview of the methods for the trial 
prior to its inception the reader is directed to Chapter 3 and to the published trial 
protocol (McKeague et al., 2014a) shown in Appendix II. 
 
Figure 5.1. Timescale showing monthly (a) and cumulative (b) projected (black) and actual 
(blue) recruitment figures. The asterisk shows the point in time at which the protocol was 
amended to improve recruitment. 
 
 
Figure 5.1 shows the predicted (n=6 per month over 10 months) and actual (n per 
month ± SD, 4 ±2.79 over 17 months) recruitment timescale. Over the course of the 
trial, 160 patient information sheets (PIS; Appendix VII) were distributed (n per month 
± SD, 9 ± 5.6). The reasons given by those who declined to participate are 
documented in Figure 5.2. Over a third of those who declined to participate stated that 
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they did not want to wear a mask whilst sleeping (n=36). Nineteen were deterred by 
the duration of study appointments as they had others dependent on them or relied 
on others for transport to and from the hospital. Twelve were happy with the current 
standard level of care and eleven did not want the additional psychological strain of 
being involved in a clinical trial. The participants featured in the ‘other’ category did 
not wish to participate due to comorbidity issues or impending operations. Thirteen 
potential participants were identified as eligible using medical notes, and issued with 
a PIS, however further assessment revealed ineligibility.  
 
Figure 5.2. Bar chart displaying number of PIS distributed and reasons for decline in 
participants. 
 
5.2. Recruitment enhancement for clinical trial  
The lower than projected recruitment rate 4 months after trial inception not only 
resulted in a protocol amendment (to the eligibility criteria), but also prompted the 
original recruitment strategy (Section 3.1.4) to be further developed in order to 
maximise the number of participants receiving information about the trial. On a weekly 
basis the investigator was tasked with reviewing the eligibility of the entire list of 
patients attending the following week’s nAMD clinic. Each day, the nAMD clinic patient 
list consisted of those attending the injection clinic and those booked into the Retinal 
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Imaging Unit. Potential eligibility, at this stage, was determined on the basis of NHS 
medical records. Lists of potentially eligible participants were distributed amongst the 
CRU, Retinal Imaging Unit and Medical Retina Unit staff. In addition, an email 
detailing the same information was sent to all staff within the CRU. This was done to 
ensure that eligible patients were not missed in the busy clinic. CRU staff were 
encouraged to actively search for the specified patient at the designated appointment 
time if for any reason they had not been contacted by the reception staff upon the 
patient’s arrival. Using this approach, it was possible to ensure that longstanding 
hospital patients were being informed of the study as well as new referrals to the 
department. 
The recruitment process is summarised in Figure 5.3. Upon arrival of the patient, staff 
based either at reception or within the Retinal Imaging Unit were advised to alert the 
study investigator or a member of the CRU immediately so that the potential 
participant could be provided with verbal and written information about the trial. At this 
stage, the potential participant was also allowed to examine the light-mask 
intervention.  
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Figure 5.3. Flow diagram summarising distribution of patient information leaflets throughout 
the Bristol Eye Hospital AMD clinic. 
 
5.3. Participant characteristics  
Figure 5.4 shows the flow of participants through each stage of the ALight trial. The 
cohort in this study overlapped with that presented in Chapter 4, previously described 
characteristics are briefly mentioned however differences between the present cohort 
and that of the previous study are described in detail. The target of 60 participants 
were recruited from the BEH Medical Retina Clinic (average age ± SD, 77.65 ± 6.72; 
53% female). Each participant was reviewed on a monthly basis over a 1 year period 
(+/- 1 month; average time on study ± SD, 372 ± 18.59 days). Case report forms 
(CRFs) for each study visit are shown in Appendix VIII. All those recruited had early 
or intermediate AMD (Ferris et al., 2013) defined by the presence of intermediate or 
large soft drusen and/or focal pigmentary changes in one eye and, nAMD in their 
fellow eye (as confirmed by fluorescein angiography). The number of unilateral 
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intravitreal injections received at the time of recruitment ranged from 3 to 36 (mean ± 
SD, 8.16 ± 8.00). All participants were aged between 55 and 88 years of age (mean 
age ± SD, 77.74 ± 6.76). BCVA ranged from 0.26 to -0.14 logMAR in the study eyes 
(mean BCVA ± SD, 0.09 ± 0.12) and 1.06 to -0.14 logMAR (mean BCVA ± SD, 0.39 
± 0.30) in the fellow eyes.  
 
Figure 5.4. Consolidated standards of reporting trials (CONSORT) diagram showing the flow 
of participants through each stage of the ALight trial.  
 
The grading of retinal images has been described in Section 3.3.3.2. Due to the 
presence of advanced AMD in one eye and early/intermediate AMD in the fellow eye, 
severity grades ranged from 2-4 (grade 2, n=18; grade 3, n=22; grade 4, n=20) of the 
AREDS Simplified Severity Scale (Ferris et al., 2005; Figure 5.5). During the course 
of the trial no participant displayed increased lenticular opacification beyond 1 LOCS 
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grade. Mean LOCS gradings (± SD) at baseline were: nuclear opalescence (1.5 ± 
1.1), nuclear colour (1.68 ± 1.25), cortical cataract (1.0 ± 0.9) and posterior 
subcapsular cataract (0.5 ± 0.7). Eleven had an intraocular lens implant (8 bilateral, 3 
monocular). No participant underwent cataract extraction within 6 months prior to 
study enrolment. Two were current smokers (mean pack years ± SD, 28.13 ± 29.17), 
30 previously smoked (mean pack years ± SD, 24.43 ± 19.28) and 18 were regularly 
taking ocular supplements (mean years taken ± SD, 1.95 ± 0.96). A full breakdown of 
participant baseline characteristics is provided in Appendix IX. Table 5.1 provides 
descriptive characteristics of each randomisation group.  
 
Figure 5.5. Study eye fundus photographs from participants with varying AMD severity grades. 
In all cases participants had nAMD in the fellow eye, which meant they were attributed 2 risk 
points from the non-study eye in addition to risk points attributable to large drusen and 
pigmentary change in the study eye. Severity grades 2 (KW010028), 3 (JC010004) and 4 
(GP010015) are shown from left to right. Severity was graded in accordance with the clinical 
manifestation of drusen and pigmentary change: Grade 2, drusen <125µm only; grade 3, 
drusen/pigmentary changes ≥125µm only; grade 4, drusen and pigmentary changes ≥125µm 
(Ferris et al., 2005).   
 
Table 5.1. Table of baseline descriptive statistics for ALight clinical trial participants. 
 
                                                 Intervention                                                                                                     Control
 
Number of participants 
 
30 (60 % female) 
 
30 (53% female) 
Mean Age (±SD) 78.30 (± 6.56) 77.17 (± 6.95) 
AREDS grade 2 (N) 9 9 
AREDS grade 3 (N) 13 9 
AREDS grade 4 (N) 8 12 
Mean BCVA Study Eye  
(logMAR ± SD) 
0.10 (± 0.12) 0.08 (± 0.12) 
Mean BCVA Fellow Eye 
(logMAR ± SD) 
0.38 (± 0.27) 0.39 (± 0.32) 
Ocular supplement history 
(mean years taken ±SD) 
0.93 (± 1.29) 0.32 ± 0.63 
Smoking history  
(mean pack years ±SD) 
13.89 (± 20.07) 12.42 (± 18.50) 
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5.4. Research appointment scheduling and protocol violation  
During the course of the trial, a number of protocol violations arose relating to 
research appointment scheduling and the collection of drusen volume data. A total of 
701 research appointments were scheduled over a 29 month period (73 screening, 
60 baseline, 521 monthly and 47 final appointments) equating to approximately 700 
hours. All appointments were carried out by trained study investigators, with over 95% 
of all appointments being undertaken by the primary investigator (DGR). The total 
number of study visits taking place in the trial per month ranged from 2 to 51 with no 
participant returning within 4 weeks of their last monthly follow-up visit. The number 
of monthly follow-up appointments performed peaked at a little over 40 between 
months 15 (September 2015) to 17 (November 2015). During this period a 
combination of baseline, monthly follow-up and final visits were being performed. 
Recruitment was completed by December 2015 resulting in a drop of study visits 
overall, however the monthly follow-up rate remained high. Final visits were initiated 
from June 2015 onwards, 12 months after the first participant was randomised. Half 
of all final visits were performed between June and October 2016 with the final 
participant completing their 12 month study cycle on 29th November 2016. For a visual 
representation of the study visit schedule throughout the trial the reader is directed to 
Figure 5.6.      
The reliance on the BEH nAMD Clinic appointment schedule resulted in participants 
being seen every 4-6 weeks as opposed to monthly as originally planned. The mean 
frequency of follow-up visits (days ± SD) was 35 (± 2.06) days across the entire cohort 
with a range of 21 to 93 days. This resulted in the majority of participants (n=38) 
completing their 12 month study period with fewer than the expected 11 follow-up 
visits prior to their final visit. The mean number of follow-up visits per participant (n ± 
SD) was 9.50 (± 1.00). Forty-six percent of participants completed 10 of more follow-
ups. The fewest monthly appointments performed for 1 participant was 7 owing to 
162 
 
their hospital appointment schedule and existing medical health conditions requiring 
intervention during the course of the study.  
Final follow-up visits were carried out for all participants that did not withdraw from the 
trial. For 6 participants (4 control, 2 intervention) final appointments were conducted 
outside the proposed timescale of 12 months (± 4 weeks) due to scheduling issues 
arising from the hospital appointment structure. The intervention participants within 
this group were 6 and 7 days over the 12 months (± 4 week) schedule and continued 
to wear the mask through this additional time period. Despite these deviations from 
the planned structure it is worth noting that the mean number of active days (n ± SD) 
in the study for both the control (372 ± 18.59) and intervention (372 ± 14.94) 
participants showed only minimal deviation from the original target of 365 days.  
The second cause of protocol violations resulted from a technical issue with the Zeiss 
Cirrus HD-OCT. Due to hardware malfunction the instrument was unusable for a 9 
week period from May-July 2016. As a result, drusen volume data were not collected 
over 2 consecutive monthly follow-up visits for 24 participants. During this period, end-
of-study appointments were still conducted in accordance with the participant 
timescale specified in the protocol. Following the end-of-study visit, mask wear 
ceased and missing data were collected as soon as possible following OCT repair. 
The mean delay in drusen volume measurement for the 5 participants (4 intervention, 
1 control) affected by this issue was 7.20 (± 2.89) weeks post final study visit.    
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Figure 5.6. Plots depicting the number of screening (a), baseline (b), monthly follow-up (c) and 
final (d) assessments performed monthly throughout the duration of the trial. 
 
5.5. Safety and acceptability of the intervention  
A concern regarding the use of low-level night-time light therapy is potential sleep 
disturbance. This may occur because a subgroup of retinal ganglion cells containing 
the photopigment melanopsin has been found to be responsible for mediating light-
dark cycles and melatonin secretion (Lyubarsky et al., 1999; Berson et al., 2002; 
Hattar et al., 2002). Studies that have investigated the nightly use of low-level light 
therapy (Arden et al., 2010; 2011; Sahni et al., 2016) aimed to investigate the effect 
in those with diabetic macular oedema, rather than AMD. In addition to this, the 
methods of suppressing the rod-circulating current and delivering light therapy are not 
all comparable with the present study (Figure 5.7). Therefore, it could not be assumed 
that the safety and tolerance to light therapy would be as well received by the 
participants in this study as it was by those in previous reports. As the illuminance 
used in the present study has the potential to suppress melatonin secretion by 50-
60% (Brainard et al., 2001) the safety and acceptability of the intervention was 
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monitored throughout the duration of the trial via a number of mechanisms, each of 
which are introduced in this section.   
 
Figure 5.7. Photographs showing the difference in light therapy delivery as used by Arden et 
al. (2011) (left panel) and in the present study (right panel). The mask used by Arden et al. 
(2011) utilises four LEDs attached to plastic housing which was enclosed in a thick cotton 
cover and held in place by an elastic headband. In comparison, the sleep mask utilised in the 
present study uses OLEDs as an illumination source and is secured to the head via an 
adjustable velcro strap attached to a padded, synthetic housing.   
 
 Aims 
This section presents results regarding the following specific aims of the trial: (i) to 
assess the safety of the intervention and (ii) to determine the acceptability of the sleep 
mask within a cohort of those with AMD. In order to address this overarching objective 
the following specific aims were established:  
i. To report the number and cause of adverse events for each study group and 
identify any relationship with the intervention.  
ii. To determine differences in sleep quality and total hours slept between the 
intervention and control groups.   
iii. To report changes (and associated reasons) to nightly compliance data over 
the duration of the trial and seasonally for the intervention group.     
iv. To report subjective feedback regarding the intervention from those within the 
intervention group.  
v. To report the number and causes of withdrawals for each study group and 
identify any relation to the intervention. 
165 
 
 Methods  
Throughout the course of the clinical trial the safety of each participant was monitored 
by the recognition, documentation and appropriate management of any AEs or SAEs. 
For more information regarding the classification of AEs the reader is directed to the 
protocol in Appendix II. The relationship of any SAE to the intervention was 
determined by the chief investigator following accrual of any additional information 
needed to make an informed decision. Information relating to sleep disturbance, 
discomfort, changes to wakefulness during the day and number of hours slept per 
night were collected on a monthly basis using the PSQI. The PSQI was chosen due 
to its well-validated supporting internal consistency (Cronbach’s alpha 0.80) (Buysse 
et al., 1989; Carpenter and Andrykowski, 1998) and discriminative validity (Carpenter 
and Andrykowski, 1998; Backhaus et al., 2002) across a variety of clinical and healthy 
populations.  
Mask compliance data were collected as specified in Section 3.2. In brief, compliance 
data were collected at each monthly follow-up visit from a chip housed within the mask 
itself. The compliance data recorded within the chip were based on a capacitive 
sensor which logs when the mask is in contact with the face. The mask was connected 
to bespoke computer software (PPX Works, Polyphotonix Medical, UK) which 
extracted the data and displayed them graphically and in the form of daily, weekly and 
monthly tables of hours mask wear. Throughout the duration of the trial a monthly 
semi-structured interview for those within the intervention group allowed the collection 
of verbal feedback regarding their mask wear experience. Withdrawals were made as 
necessary in accordance with the onset of nAMD in the study eye or at participant 
request. 
 Analysis  
Analysis was performed using IBM SPSS Statistics (SPSS Inc. SPSS for Windows, 
Version 20.0. Chicago, USA). The main analysis comprised descriptive statistics to 
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summarise safety concerns (adverse events and serious adverse events). The 
distribution of continuous data was assessed using the Shapiro-Wilk test. In 
accordance with the present consensus regarding Likert scale analysis (Sullivan and 
Artino, 2013; Norman, 2010; Carifio and Perla, 2008; De Winter and Dodou, 2010), 
questionnaire data were analysed with appropriate parametric and non-parametric 
tests based on data distribution. Sleep disturbance, as assessed using the PSQI, was 
scored using the methods described by Buysse et al. (1989). This scoring system 
uses the 19 individual PSQI items to generate 7 component scores, each reflecting a 
different component of sleep quality. Summation of the 7 component scores allowed 
the derivation of a global sleep score, with higher values reflecting greater sleep 
impairment.  
Differences between groups for baseline, change in sleep quality (specified as change 
in global score from month 1 to month 12 of the study) and number of hours slept per 
night were compared using an independent samples t-test. Similarly, the independent 
samples t-test was also used to assess differences between the baseline global PSQI 
score of those who completed the full study duration and those who were withdrawn. 
Comparisons between number of hours slept before and during mask wear for the 
intervention group were made using the paired t-test. Seasonal variation in mask 
compliance was assessed using the 2016 northern hemisphere meteorological 
calendar in order to designate seasonal start and end dates (Met Office, 2017). 
Seasons were designated as: spring (1st March–31st May), summer (1st June–31st 
August), autumn (1st September–30th November) and winter (1st December–29th 
February).  
For those within the intervention group, differences in monthly compliance over the 
duration of the trial and seasonal differences in compliance were investigated using a 
one-way ANOVA test. In accordance with the current consensus on randomised 
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controlled trials baseline characteristics between groups were not analysed (Roberts 
and Torgerson, 1999; Egbewale, 2015).  
 Results  
 Safety of the intervention  
All 60 participants enrolled in the ALight trial were included in the analysis of 
intervention safety. During the course of the study, 33 mild/moderate AEs were 
recorded (Table 5.2). Most AEs occurred during winter (December-February) and 
fewest during spring (March-May). The reasons for each AE were assigned into three 
categories; ocular, general health and falls. All AEs were graded for severity and 
relatedness to the intervention, as described in the protocol.  
Eight ocular AEs were recorded (4 control, 4 interventions; 24% of total AEs recorded) 
of which 2 occurred as a direct result of ranibizumab injection (MA010002 and 
PS010047). Ocular AEs recorded for intervention participants resulted in minor 
disruption to compliance in which mask wear was suspended for a maximum of 1-2 
nights. Nineteen AEs (58% of total recorded AEs) were related to GP diagnosed 
general health issues; a third of which were attributed to cold/flu and 
sickness/diarrhoea symptoms. One participant (RG010035) reported a period of 4 
night’s non-compliance, citing nasal pressure caused by the mask leading to 
increased breathing difficulty during a period of cold/flu symptoms. Six participants 
(18% of total recorded AEs) suffered falls, all of which occurred during daylight hours. 
One mask wearer within this category required surgical intervention resulting in a 
period of sporadic compliance over a 2-week period.  
The relationship of events to the study intervention was assessed by the chief 
investigator using the terms: associated or not associated (see the protocol in 
Appendix II for further details). Mask wear was deemed not to be associated with any 
reported adverse events. All ocular manifestations, although potentially aggravated 
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by mask wear, were a result of pre-existing ocular pathology within the eligibility 
criteria or occurred shortly after an intraocular injection. The proportion of participants 
in the intervention group who converted to nAMD was lower than the mean predicted 
conversion rate of 1% of per month (Section 3.4.1). Falls suffered by intervention 
participants occurred in daylight hours and all remaining adverse events recorded 
related to general health conditions commonly found within the age range of the 
cohort.   
Table 5.2. Summary of AEs recorded throughout the data collection period. 
 
Study ID Date Severity Reason Description Study Arm 
 
MA010002 
 
Sep-14 
 
Moderate 
 
Ocular 
 
conjunctival ulcer 
 
Intervention 
JN010005 Dec-14 Moderate Muscular pain Shoulder pain Control 
JN010005 Dec-14 Moderate General health Cystitis Control 
MA010002 Dec-14 Mild Ocular Dry eye Intervention 
JC010004 Jan-15 Mild Ocular Epiretinal membrane Control 
RG010035 Jul-15 Mild General health Cold/flu symptoms Intervention 
RH010024 Jul-15 Mild Fall Outdoors (daylight) Control 
RJ010021 Jul-15 Moderate Fall Outdoors (daylight) Intervention 
ML010036 Aug-15 Moderate Fall Outdoors (daylight) Intervention 
JC010011 Oct-15 Moderate General health Cold/flu symptoms Control 
CG010025 Nov-15 Moderate General health Shortness of breath Control 
PS010047 Nov-15 Moderate Ocular Stye Intervention 
JH010039 Dec-15 Moderate General health Gout Control 
ML010036 Dec-15 Mild Fall Outdoors (daylight) Control 
AW010051 Jan-16 Moderate General health Ankle swelling  Control 
AW010060 Jan-16 Moderate General health Ankle swelling  Intervention 
JW010017 Jan-16 Moderate Muscular pain Leg pain Control 
JW010043 Jan-16 Mild Ocular Epiretinal membrane Control 
AN010020 Feb-16 Moderate Fall Indoors (daylight) Control 
PS010047 Feb-16 Mild General health Cystitis Intervention 
PB010058 Mar-16 Moderate General health Cough Control 
AH010054 Jun-16 Moderate General health Sickness/diarrhoea Control 
JH010039 Jun-16 Mild General health Gout Control 
AW010048 Jul-16 Moderate General health Cold/flu symptoms Control 
AW010048 Jul-16 Mild Ocular Dry eye Control 
CE010059 Jul-16 Moderate Fall Indoors (daylight) Control 
DR010052 Jul-16 Moderate Muscular pain Neck pain  Control 
HB010038 Jul-16 Moderate Ocular blunt trauma Control 
MM010045 Jul-16 Mild Muscular pain Foot pain  Control 
RH010045 Jul-16 Moderate General health Sickness/diarrhoea Intervention 
PS010047 Aug-16 Mild Ocular 
Conjunctival 
haemorrhage 
Intervention 
AH010054 Sep-16 Moderate General health Sickness/diarrhoea Control 
AW010060 Sep-16 Moderate General health Hiatus hernia Intervention 
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Nine serious adverse events took place during the course of the clinical trial (4 ocular 
and 5 general health related, see Table 5.3). Three participants (1 intervention, 2 
controls) developed nAMD in their study eye and were withdrawn accordingly. For 1 
participant (CA010016), mask wear was suspended for a month due to a retinal 
detachment following ranibizumab administration. General health issues that arose 
included undiagnosed heart disease and routine hip surgery. Two SAEs documented 
within a short time frame relate to a control participant (JW010023) who died shortly 
before completing their full study period. 
Table 5.3. Summary of serious adverse events recorded throughout the data collection period. 
 
 Acceptability of the intervention: compliance data 
Twenty intervention participants completed the study period (± 1 month). The masks’ 
12 week lifespan resulted in each participant receiving 5 masks in total over 1 year at 
various intervals. Due to reliance on the hospital AMD clinic timetable it was not 
possible to arrange a final study visit exactly 12 months after baseline therefore the 
number of days of mask wear over the study period differed for each participant. The 
mean number of night’s worn (± SD), taking into account nights of complete non-
compliance, was 372 (± 15). An example of monthly compliance data collection is 
shown in Figure 5.8 and final compliance data are shown in Table 5.4.  
Study ID Date Reason Description Study Arm 
 
EA010007 
 
Nov-14 
 
Ocular 
 
nAMD in study eye 
 
Control 
MA010002 Nov-14 General health Heart disease Intervention 
CA010016 Aug-15 Ocular Retinal detachment Intervention 
MH010029 Sep-15 Ocular nAMD in study eye Control 
BP010040 Oct-15 Ocular nAMD in study eye Intervention 
CA010016 Nov-15 General health Hip surgery Intervention 
AH010054 Dec-15 General health Heart disease Control 
JW010043 Aug-16 General health Cancer Control 
JW010043 Aug-16 General health Deceased Control 
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For those who completed the entire study duration, compliance data collected directly 
from the mask reported an average of 2067 (± 591) hours mask wear (± SD), taking 
into account nights of complete non-compliance, per participant over an average of 
372 (± 15) days. This equated to 5.60 hours of mask wear per night or to 69% (± 19%) 
of the maximum achievable compliance (100% based on 8 hours of nightly mask 
wear). Monthly PSQI data specifying number of hours slept per night did, however, 
show that only a quarter of mask wearers reportedly slept 8 hours per night on 
average over the study duration. In order to derive a more realistic compliance rate, 
the compliance data were also assessed monthly by dividing each participant’s 
average number of mask hours worn per night by their reported average number of 
hours slept per night (as specified by the PSQI response). The average compliance 
calculated for each participant across the 12 months was then averaged across 
participants to derive a final mean compliance rate of 78% (± 23%). The reported 
mean hours (± SD) slept per night as subjectively recorded from the PSQI was 7.19 
(± 0.89) and the average nightly hours mask wear (± SD) as per objective mask data 
was 5.63 (± 1.54). No significant difference (one-way ANOVA with repeated 
measures, P>0.05) in mean hours of mask use per month was found over the study 
duration i.e. according to the number of months enrolled in the trial (Figure 5.9).  
To explore seasonal variation, mean hours mask wear per participant were derived 
for each season in accordance with the 2016 northern hemisphere meteorological 
calendar (Met Office, 2017). The mean nightly hours worn (± SD) across all mask 
wearers (n=20) was highest during winter (5.73 ± 1.67), followed by summer (5.62 ± 
1.77), spring (5.53 ± 1.98) and autumn (5.22 ± 1.67). No significant difference in mean 
hours of mask use per season was found over the study duration (one-way ANOVA 
with repeated measures, P=0.33). 
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Figure 5.8. Twelve-week objective compliance data as collected directly from the masks of 2 
participants. The left panel shows a compliant wearer (JG010014). The right panel shows a 
wearer reporting regular mask displacement throughout the night (MN010003). 
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Table 5.4. 12 month (±1 month) compliance data for the 20 intervention participants who 
completed the trial. All times are given in hours. Mean hours slept per night is derived from 
subjective feedback (PSQI questionnaire), total days worn and mean nightly hours mask wear 
are derived from objective mask compliance data.   
 
Figure 5.9. Means plots for average nightly hours mask wear each month over a 1 year period. 
Error bars represent 95% confidence limits. 
Study ID 
Total  
days 
worn 
Total  
wearing 
time 
Compliance  
rate (%) 
Mean hours 
slept per 
night (±SD) 
Mean nightly 
hours mask 
wear (±SD) 
      
MN010003 383 1253.43 40.91 6.83 (± 0.42) 3.65 (± 2.10) 
FC010009 370 2514.73 84.96 8.00 (± 1.33) 6.80 (± 1.91) 
CS010012 364 2250.07 77.27 5.80 (± 1.30) 6.18 (± 1.65) 
JG010014 400 2935.90 91.75 8.20 (± 0.25) 7.30 (± 1.69) 
CA010016 393 2105.87 66.98 6.35 (± 0.40) 5.90 (± 3.21) 
JB010019 364 2249.40 77.25 7.25 (± 1.27) 6.25 (± 2.41) 
RJ010021 387 1925.47 62.19 7.58 (± 0.36) 4.93 (± 3.27) 
RH010024 357 1720.87 60.25 8.55 (± 0.77) 4.95 (± 3.45) 
KW010028 388 2716.30 87.51 7.90 (± 0.30) 7.15 (± 1.79) 
DB010031 356 2203.20 77.36 6.40 (± 0.60) 6.22 (± 1.58) 
AB010032 374 2250.13 75.20 6.98 (± 0.41) 6.03 (± 2.11) 
SG010033 363 2191.77 75.47 7.55 (± 0.45) 5.97 (± 1.62) 
RG010035 376 186.27 6.19 8.30 (± 0.32) 0.47 (± 0.76) 
WB010037 353 1985.23 70.30 6.08 (± 0.30) 5.62 (± 2.00) 
VB010042 399 2408.07 75.44 7.93 (± 0.16) 5.95 (± 1.63) 
RH010045 364 1970.97 67.68 8.10 (± 0.42) 5.37 (± 2.19) 
GL010046 356 2047.07 71.88 6.18 (± 0.40) 5.77 (± 2.39) 
PS010047 357 2120.47 74.25 6.50 (± 0.47) 5.95 (± 2.14) 
JL010056 364 1588.50 54.55 7.40 (± 0.64) 4.25 (± 2.76) 
AW010060 373 2714.13 90.96 5.87 (± 0.56) 7.28 (± 0.89)   
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 Acceptability of the intervention 
Subjective feedback regarding mask wear from those within the intervention group is 
introduced in detail in this section. Participants reported issues relating to mask 
comfort, design and disturbance to habitual routine throughout the trial in their monthly 
semi-structured interviews. Figure 5.10 provides an overview of negative participant 
feedback relating to the intervention.  
Figure 5.10. Negative mask wear feedback divided into three groups; comfort (green), design 
(orange) and sleep disruption (blue). Numbers denote the number of participants that reported 
each observation. 
 
Of the original 30 mask wearers, 10 cited discomfort as a result of temporal pressure 
caused by mask wear when sleeping in a sideways posture. This issue contributed to 
the withdrawal of 3 participants and was reported most commonly by physically 
smaller participants who also cited issues with the mask size in general. One 
participant (GL010046) was able to successfully adopt a new sleeping posture to 
avoid this issue. Another source of discomfort arose as a result of contact between 
the mask housing and the eyelids/lashes (n=2). The irritation attributed to this 
sensation caused increased tearing in one participant resulting in damp mask fabric 
and skin friction. Pressure on the nasal bridge was experienced by 9 mask wearers, 
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3 of which were eventually withdrawn. The nasal pressure resultant from mask weight 
was reported to cause bridge indentation following overnight usage (n=2) and 
disrupted nasal breathing (n=2), particularly in the presence of cold/flu symptoms. All 
discomfort issues were reported on a constant basis for the duration of the trial. In 
order to alleviate nasal pressure a number of participants modified their masks (Figure 
5.11) 
 
Figure 5.11. Photograph of mask modifications as performed by participants in an attempt to 
improve comfort. The padding applied in (a) was performed by a number of participants using 
cotton wool and folded fabric. As verified by the trial investigator this modification did not inhibit 
effective compliance data collection or light therapy administration. In contrast the modification 
displayed in (b) was potentially damaging the mask at a functional level. The mask wearer in 
(b) was eventually withdrawn due to persistent mask discomfort. 
 
One participant (JG010014) encountered no discomfort, however subjectively 
reported increased periorbital darkening 2 months following initiation of mask wear. 
As this event was isolated, ophthalmic examination revealed no underlying 
pathological cause and the symptom did not worsen with continued wear. It was 
therefore not attributed to the intervention. Despite having no specific complaint of 
physical discomfort, 3 participants were unable to use the intervention on a nightly 
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basis as they became anxious with the concept of mask wear, preferring not to be 
visually enclosed upon awakening. This problem continued beyond 2 months for only 
1 participant (RG010035) who described a ‘claustrophobic’ sensation encountered 
during mask usage.  
The synthetic housing used for the mask was repeatedly reported to cause two issues 
relating to temperature and odour. Six participants cited the fabric as a cause of facial 
overheating. Although seasonal, this effect was a common complaint for all 
participants demonstrating a compliance <65% of the maximum achievable annually. 
New fabric housing was also described as emitting a ‘chemical’ smell for up to 1 week 
post initial usage. Despite causing some participants to wash the mask housing this 
reported issue was always temporary.            
Loss of compliance as a result of mask displacement throughout the night was a 
common finding. Eight of the 30 original mask wearers reported waking up without 
the mask in position in at least 1 monthly follow-up appointment. 2 participants 
(MN010003 and JL010056) cited this as the primary reason for reduced compliance. 
Both participants also reported that tightening the mask fit until displacement ceased 
resulted in increased frontal/nasal pressure beyond tolerance. All participants who 
repeatedly reported displacement felt that once affixed the strap strength alone was 
adequate to prevent mask dislocation via general head movement during sleep. 
Displacement was instead speculated to be resultant of subconscious manual 
removal.  
No mask malfunction was reported throughout the duration of the trial. Monthly 
inspection revealed damage to the fabric housing only as a result of usage (Figure 
5.12). Participants were regularly given extra fabric sleeves to use if they felt wear 
and tear to the current mask housing was sufficient to warrant changing. No issues 
arose regarding activation of the mask. Two participants who reported nasal 
discomfort returned their pods with bridge damage (Figure 5.12). This issue did not 
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disrupt mask function despite the potential for connectivity damage between 
eyepieces. 
 
Figure 5.12. Photograph of (a) housing, (b) pod and (c) bridge damage as a result of usage. 
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 Sleep disturbance questionnaire data 
No major disruption to falling asleep or increased daytime lethargy was reported for 
any participant. One participant experienced a sustained increase in dream/nightmare 
regularity after initiating mask wear which subsided after a 2 month period. At first 
exposure, the light level was tolerated well by the majority of participants. Described 
sensations of glare (RH010045) and dazzle (RG010035) were found to subside within 
an 8-week period after which no further issues relating to luminance were reported. 
Continuing nightly exposure to low-level light therapy post 8 months resulted in the 
most compliant wearers (n=2) describing the illumination as ‘comforting’, aiding their 
ability to fall asleep. Three participants reported buying non-illuminating sleep masks 
for post-trial use attributing their improved sleep habits to the introduction of mask 
wear.   
In addition to the subjective feedback, further analysis regarding sleep disturbance 
was conducted on the PSQI data of the 47 participants (27 controls, 20 intervention) 
who completed the full study cycle. No significant difference was found between the 
study groups for the mean baseline global score (independent samples t-test; P=0.16) 
suggesting that neither group contained more inherently poor sleepers. Mean 
baseline and 12 month global scores for each group are shown in Table 5.5. At the 
12 month stage no significant difference was found in the proportion of each group 
designated as a ‘poor’ sleeper in accordance with the PSQI global score (control, 
59%; intervention, 60%; Chi squared test, P=0.46). Similarly, over the study duration 
there was no significant difference in PSQI global score change between groups 
despite a higher proportion of mask wearers (65%) than controls (41%) reporting 
greater sleep disturbance after 12 months (independent samples t-test, P=0.19). 
Usable post-baseline PSQI data were only available for 8 of the 10 withdrawn mask 
wearers as 2 intervention participants did not surpass their 1 month follow-up. No 
significant difference was found between the baseline PSQI score of those who 
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remained within the study and those who were withdrawn (independent samples t-
test, P=0.29).  
There was no significant difference in the subjectively reported mean number of hours 
slept per night (± SD) for the mask wearers (7.19 ± 0.89) and the controls (6.78 ± 
1.20) over the study duration (independent samples t-test, P=0.36). There was also 
no significant difference between mean hours slept before (7.23 ± 0.93) and after 
(7.17 ±1.07) mask wear (matched pairs t-test, P=0.49) or in mean hours slept at 
baseline (7.20 ± 1.12) and final (7.28 ± 1.22) study visits (matched pairs t-test, P=0.77) 
for the intervention group.  
Table 5.5. Monthly mean global PSQI scores for participants who completed the full study 
period. Global scores shown represent the sum of mean monthly component scores relating 
to subjective sleep quality (component 1), sleep latency (component 2), sleep duration 
(component 3), habitual sleep efficiency (component 4), sleep disturbances (component 5), 
use of sleeping medication (component 6) and daytime dysfunction (component 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mean PSQI global score (±SD) 
Month Intervention Control 
 
Baseline 
 
3.97 (± 2.27) 
 
5.40 (± 3.32) 
1 5.38 (± 3.81) 5.56 (± 3.49) 
2 4.79 (± 2.89) 5.64 (± 3.82) 
3 5.30 (± 2.60) 6.04 (± 3.39) 
4 5.11 (± 2.14) 5.29 (± 3.17) 
5 5.57 (± 2.90) 5.80 (± 3.56) 
6 5.33 (± 2.70) 6.25 (± 4.13) 
7 5.93 (± 2.95) 5.45 (± 3.42) 
8 6.06 (± 3.51) 5.63 (± 3.73) 
9 6.11 (± 3.48) 6.38 (± 3.66) 
10 5.82 (± 3.32) 6.04 (± 3.69) 
11 5.05 (± 3.17) 6.20 (± 3.76) 
12 5.10 (± 2.65) 5.59 (± 3.32) 
1-12 5.35 (± 2.95) 5.79 (± 3.57) 
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 Withdrawals from the study 
Thirteen participants were withdrawn throughout the course of the trial (3 control, 10 
intervention). As the trial follow-up visits were conducted in conjunction with 
scheduled hospital appointments, no participants were withdrawn due to repeated 
failure to attend. Of the control subjects 2 developed nAMD in their fellow eye and 1 
died within 12 months of randomisation. The reasons for intervention withdrawals are 
detailed in Table 5.6. Thirty-three per cent of all intervention participants withdrew 
from the study. Seventy per cent of all intervention withdrawals occurred within 65 
days of randomisation with only 2 intervention participants unable to complete less 
than 1 month of mask wear. Consistent with the semi-structured questionnaire 
feedback, the majority of withdrawals relating to mask wear were caused by temporal 
and bridge discomfort. The mean number of mask wear nights before withdrawal did 
not differ significantly between those who reported temporal (53 days) and bridge (47 
days) discomfort.  
Analysis of the characteristics between those withdrawn (n=13) and those who 
completed the entire study duration (n=47) was performed in order to investigate any 
potential bias in the study caused by the withdrawn cohort. This was done to establish 
whether the results had been skewed in a more favourable direction by the withdrawal 
of participants for whom the intervention was having either no effect, or an adverse 
effect. The baseline characteristics of the withdrawn and completed study groups are 
shown in Table 5.7. Independent samples t-test analysis showed no significant 
difference between the age (P=0.94), ocular supplement history (P=0.12), smoking 
history (P=0.52) or baseline VA (P=0.28) of those withdrawn and those who 
completed the entire study duration. Similarly, there was no difference in gender 
balance between the groups (chi-squared test, P=0.36).   
 
 
180 
 
Table 5.6. Mask wearer withdrawal timescale and primary reason for ceased participation. 
 
Table 5.7. Baseline characteristics of participants who were withdrawn and those who 
completed the full study period of 12 months. Standard deviation values are shown in brackets. 
 
5.6. Conclusion  
This chapter has described the implementation of the ALight trial, provided 
information on trial logistics, participant characteristics and reports the results of a 
study designed to determine the safety and acceptability of nighttime light mask wear. 
Challenges relating to recruitment, appointment scheduling and the day-to-day 
operation of a longitudinal clinical trial investigating AMD have been described. Such 
information may be useful for future longitudinal studies aimed at assessing AMD.  
In the present study, the mask was well tolerated by 90% of participants. Minor issues 
relating to brightness shortly after commencing mask wear were found to subside in 
concordance with the Troxler effect (Martinez-Conde et al., 2004). Reports of 
“glairiness” did not pose an issue beyond 2 months and no participant withdrew citing 
luminance level as a key contributing factor. The main reason for withdrawal was 
Study ID 
Date 
randomised 
Date 
withdrawn 
Days on  
study 
Mask wear 
(hours) 
Reason for 
withdrawal 
      
MJ010001 11/07/2014 05/08/2014 25 85.80 Overheating 
JE010010 03/12/2014 03/01/2015 31 142.00 Temporal discomfort 
MA010002 06/10/2014 06/01/2015 92 137.50 Bridge discomfort 
GW010018 22/04/2015 27/04/2015 5 21.33 Bridge discomfort 
GF010034 20/07/2015 01/09/2015 43 20.30 Bridge discomfort 
BP010040 13/07/2015 28/10/2015 107 591.50 Conversion to nAMD 
GC010055 20/10/2015 22/12/2015 63 310.90 Temporal discomfort 
MP010057 24/11/2015 22/12/2015 28 37.43 Psychological 
PC010050 02/11/2015 05/01/2016 64 31.23 Temporal discomfort 
BJ010041 25/08/2015 25/01/2016 153 582.73 Eyelid/lash irritation 
 
 Withdrawn Completed study 
   
N 13 47 
Grade 2 (n) 3 15 
Grade 3 (n) 6 16 
Grade 4 (n) 4 16 
Age (± SD) 77.15 (± 8.25) 77.34 (± 7.06) 
Ocular supplement history (years taken ± SD) 1.08 (± 1.30) 0.50 (± 1.12) 
Smoking history (pack years ± SD) 19.66 (± 16.36) 11.35 (± 18.97) 
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mask discomfort of which 60% was attributed to issues with bridge or temporal 
discomfort. The overall withdrawal rate as a result of mask issues alone (26%) was in 
agreement to that reported for a similar age cohort (21%) in the one other study that 
has also used a sleep mask containing an OLED device as a potential therapy for 
retinal disease (Sahni et al., 2016). From month 1 to 3 the number of participants 
withdrawn per month due to mask-issues was equal (n=2) suggesting no ‘critical-
period’ of habitualisation immediately after the initiation of mask wear. However, as 
the majority (75%) of withdrawals caused by mask-issues occurred within 64 days 
post randomisation, future studies may expect a low withdrawal rate beyond 3 months 
wear. The mask itself was found to be a robust method of delivering light therapy with 
no malfunction or operational issues reported throughout the duration of the trial. 
The compliance rate of 70% was similar to that reported by Sahni et al. (2016) (76%) 
when a similar intervention was assessed in those with diabetic macular oedema 
(n=15) and healthy controls over 2 age groups (18-30 years, n=45 and 50-70 years, 
n=24). The mean age (± SD) of the older group was comparable with the present 
study (77.65 ± 6.72). Sahni et al. (2016) reported that the compliance within their older 
cohort was better and more consistent over time than their younger cohort. In the 
present study, disruption to compliance was minimal and primarily caused by 
ranibizumab administration. The complaints relating to mask comfort reported by 
those who completed the full 12 month study duration were not reflected in the self-
reported PSQI analysis of sleep quality when baseline and final data was compared. 
For the majority of mask wearers, PSQI data suggested that any discomfort 
encountered relating to the mask was not sufficient to have a significant impact on 
sleep quality. This, in combination with a similar mean number of reported hours slept 
per night for both the intervention (7hrs 7mins) and control (6hrs 47mins) groups, 
suggests that sleep quality was not substantially affected by mask wear.  
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Although the level of retinal illuminance used had the potential to suppress the rod 
circulating current by 40% (Thomas and Lamb, 1999) whilst having a minimal effect 
on melatonin production as influenced by the photoreceptive melanopsin-containing 
ganglion cells (Brainard et al., 2001; Berson et al., 2002), there was a possibility that 
the nightly delivery of light therapy could disrupt circadian rhythm (see Section 3.2.3). 
In accordance with the PSQI, which was included as a means of evaluating self-
reported sleep quality, the nightly delivery of low-level light therapy had no negative 
impact on any sleep component assessed including sleep quality, duration or latency. 
Although this is in agreement with other studies that reported no serious adverse 
events associated with mask wear (Arden et al., 2010; 2011; Sahni et al., 2016) it is 
not in agreement with the small impairment to daytime alertness reported by Sahni et 
al. (2016). Direct comparison is however confounded given several differences in the 
design of the current study. In the study by Sahni et al. (2016) the mean age of 
participants was substantially lower (45.18 years) than the present study (77.74 
years), the masks were only worn for 3 months as opposed to the 12 month duration 
of the present study and daytime dysfunction was measured using response time as 
opposed to the PSQI. It can be suggested that the cohort assessed by Sahni et al. 
(2016) was more likely to be in full-time employment and, as a result, more likely to 
appreciate daytime dysfunction than the primarily retired cohort of the present study. 
Participants in the present study also wore the mask 4 times longer hence were given 
greater time to become accustomed to sleeping in the device.  
The results described here provide evidence that the use of an OLED sleep mask is 
an acceptable and safe method of delivering nightly low-level light therapy. Although 
it must be noted that the number of withdrawals along with the high incidence of 
discomfort reported suggest that a proportion of individuals will find mask wear 
intolerable. The next chapter presents results of the analysis of the magnitude of the 
effect of light therapy on AMD progression.   
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Chapter 6. ALight trial magnitude of treatment effect  
This chapter presents results relating to the magnitude of the effect of low-level night-
time light therapy as delivered using a sleep mask on AMD progression in the ALight 
trial cohort. Functional (dark adaptation, chromatic sensitivity and flicker sensitivity), 
structural (drusen volume) and subjectively-reported (visual function and quality of 
life) changes are reported. Firstly, the results describe the impact of low-level night-
time light therapy, compared to no intervention, on disease progression in early and 
intermediate AMD. Secondly, the effect of low-level night-time light therapy on retinal 
function, subjectively reported outcome measures and ranibizumab retreatment rate 
in the fellow eye is described.  
6.1. Introduction  
There is a critical need to evaluate potential therapeutic interventions aimed at treating 
AMD prior to the onset of the advanced stages of GA and nAMD. Presently, ageing 
retinal function has shown to be improved with near infrared light 
(Sivapathasuntharam et al., 2017) and an LED based multi-wavelength treatment 
(photobiomodulation therapy) has been shown to improve functional outcomes in 
those with early/intermediate AMD (Merry et al., 2016). In addition, two phase III 
clinical trials are also underway investigating a potential new GA treatment 
(CHROMA, 2014; SPECTRI, 2014) however, to date, the only treatment currently 
available is for those with the neovascular form of the disease. For the majority of 
individuals with intermediate AMD or GA no such treatment exists. The potential 
treatment introduced in this PhD was developed in response to evidence implicating 
hypoxia in AMD pathogenesis (see Chapter 2). The availability of oxygen at a retinal 
level can be increased by the inhalation of a greater volume of oxygen or manipulation 
of metabolic demand. As the retina is most metabolically active under scotopic 
conditions any approach aimed at preventing full dark adaptation at night could 
potentially reduce the need for oxygen, thereby delaying progression of conditions 
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with a hypoxic aetiology (Arden et al., 2011). In practice, this effect can be achieved 
on a nightly basis via the provision of low-level light therapy. To date, a number of 
studies have assessed the impact of low-level light therapy in those with diabetic 
macular oedema (Arden et al., 2010; 2011; Sahni et al., 2016). These studies have 
shown an improvement in chromatic sensitivity and a reduction in diabetic retinal 
oedema in those who underwent light therapy in comparison to controls. Both of which 
were attributed to the prevention of night-time hypoxia (Arden et al., 2011; Sahni et 
al., 2016). This PhD sought to establish if the same intervention would have a 
therapeutic effect on people with early and intermediate AMD.     
6.2. Aims  
The primary aim of the ALight trial was introduced in Section 1.5. Briefly the aim was 
to assess the impact of low-level night-time light therapy, compared to no intervention, 
on AMD progression. Disease progression was defined on the basis of two co-primary 
outcome measures: 
i. The proportion of people showing disease progression in the eye with early or 
intermediate AMD. Disease progression was defined as the onset of advanced 
AMD or increase in drusen volume beyond test-retest 95% confidence 
intervals.  
ii. The rate of retinal adaptation (time taken for photoreceptors to recover their 
sensitivity after being exposed to a bright adapting light).   
Secondary aims addressed in this chapter were to establish the effect of low-level 
night-time light therapy on:  
i. The change in drusen volume over 12 months.  
ii. The number of ranibizumab injections required in the fellow eye over 12 
months.  
iii. The change in chromatic sensitivity and 14Hz flicker threshold over 12 months.  
iv. The change in self-reported quality of life and visual function over 12 months. 
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v. The ability of all clinical tests to act as prognostic biomarkers for AMD 
progression.  
vi. The ability of all clinical tests to act as predictive biomarkers for low-level night-
time light therapy in AMD.    
6.3. Methods  
For a detailed description of the ALight trial methods the reader is directed to the 
published trial protocol (McKeague et al., 2014) or the relevant sections throughout 
this thesis: eligibility criteria (Section 3.1.3), withdrawal criteria (Section 3.1.5), 
assessment of safety (Section 3.4), randomisation (Section 3.5.1), fundus grading 
(Section 3.3.3.2), experimental procedure (Section 3.6.3 and 3.7.1) and examination 
of structural outcome measures (Section 3.3.3.1).   
In brief, the data presented relate to the participants who completed the trial. The 
baseline assessment (Section 3.3.3) involved the collection of drusen volume data 
(via optical coherence tomography: 5 Zeiss Cirrus OCT 2000 images, 6x6mm macular 
cube scans centred on the fovea), fundus photographs (Topcon OCT 2000 45° 
photographs centred on the fovea), BCVA, computer-based tests of visual function 
(chromatic thresholds, 14Hz flicker threshold and dark adaptation), and self-reported 
quality of life (EQ-5D) and visual function (VFQ-48) data. Following successful 
completion of the visual function tests, the participant was randomised to the 
intervention or control arm of the study. On a monthly basis, participants within each 
study group attended a short, follow-up appointment during which OCT images and 
ranibizumab retreatment data were collected. The final visit was conducted 12 months 
post-randomisation. At the final visit, data relating to retinal function were collected in 
the same manner as per baseline visit. The reader is directed to the relevant 
appendices for an example of the PIS (Appendix VII) consent form and CRFs 
(Appendix VIII) relating to this study.  
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In order to expand on the magnitude of effect analysis post-hoc data relating to the 
AMD status of participants who showed no disease progression during the trial was 
reviewed 6 months following their end-of-study visit (Appendix X). In addition, post-
hoc testing was performed on the baseline difference of visual function between those 
who remained and those who withdrew from the trial. This was done to establish any 
potential bias in the study caused by the withdrawn cohort and to address the 
possibility that results had been skewed in a more favourable direction by the 
withdrawal of participants for whom the intervention was having either no effect, or an 
adverse effect.  
6.4. Statistical analysis  
All analysis was performed using IBM SPSS Statistics (SPSS Inc. SPSS for Windows, 
Version 20.0. Chicago, USA). There was no interim analysis. However, conversions 
to nAMD in the treated eye were monitored for safety reasons. This study was 
designed as a phase I/IIa proof of concept study and so was designed to estimate the 
magnitude of any potential therapeutic effect, rather than to detect small effect sizes.  
Given the phase I/II nature of the trial, the main analysis comprised descriptive 
statistics to summarise the demographic characteristics and outcome measures of 
the two study arms. The primary outcome measure, disease progression, was based 
on the rate of retinal adaptation and also on nAMD onset or an increase in drusen 
volume beyond test-retest 95% confidence intervals (Gregori et al., 2011). The highly 
reproducible algorithm for drusen volume change as developed by Gregori et al. 
(2011) states that the change in drusen volume within a 3mm radius circle centred on 
the fovea of a given eye would only be significant if the new measured drusen volume 
were smaller than: [(baseline volume)1/3 – 0.025]3 or larger than [(baseline volume)1/3 
+ 0.025]3. Substitution of 0.025 with 0.028 allows for the calculation of confidence 
intervals for drusen volume measured within a 5mm radius circle centred on the fovea. 
In accordance with the consensus relating to randomised controlled trials, differences 
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in baseline characteristics between groups were not assessed (Roberts and 
Torgerson, 1999; Egbewale, 2015).  
Prior to analysis, guidance on appropriate analysis techniques was sought from an 
experienced statistician based in the South East Wales Trials Unit. To compare the 
proportion of people showing disease progression in each study arm, individual chi-
squared tests relating to drusen volume change and onset of nAMD were performed 
initially. Following this, a stratified Mantel-Haenszel test was used. In order to address 
the assumption of odds ratio homogeneity prior to Mantel-Haenszel analysis, a 
Breslow-Day statistic was derived. The normality of the distribution of data was 
assessed using the Shapiro-Wilk test. For normally distributed data, the ANCOVA test 
was carried out to compare the change in cone τ, BCVA and the number of 
ranibizumab retreatments between the two arms across the duration of the trial, when 
controlling for covariates age, gender differences (binary controlled as 0 or 1 
depending on sex per group), vitamin supplement intake (controlled by number of 
years taken per group), history of smoking (controlled by overall pack years until date 
of assessment per group), and baseline data relating to each outcome measure.    
Data that remained non-parametric even after log transformation were the change in 
drusen volume, 14Hz flicker threshold and chromatic thresholds. For these outcomes 
the Kruskal-Wallis test was performed to analyse and compare the change in the 
outcome measures over 12 months between the two groups. Note that all analysis 
apart from the ranibizumab retreatment rate relates to the eye with early/intermediate 
AMD.  
Questionnaire data were analysed with appropriate parametric (ANCOVA) or non-
parametric (Kruskal-Wallis) tests (according to data distribution). Self-reported visual 
function was assessed using the VFQ-48 scoring system (Stelmack and Massof, 
2007). The scoring system allowed the derivation of a ‘person measure’ for each 
subject, with smaller values corresponding to a greater deficit in self-reported visual 
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function. Self-reported health related quality of life data were assessed using the EQ-
5D (3 level version; EuroQol Group, 1990).  This consisted of two questions. The first 
question, known as the EQ-5D self-classifier, consisted of five items for which an 
index-based ‘summary score’ was calculated using an algorithm developed from a 
general UK population based validation study (Dolan, 1997; Rabin and De Charro, 
2001). The summary score is typically interpreted along a continuum with a lower 
score reflecting poorer self-reported quality of life. For the second question, the 
subjects rated their health using a 20 centimetre visual analogue scale (VAS) that 
ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). 
VFQ-48 and EQ-5D data remained non-parametric even after log transformation 
hence these were assessed using the Kruskal-Wallis test.  
A post-hoc analysis (not specified in the published protocol) was carried out to 
investigate the change over 12 months in the total retinal thickness (Kruskal-Wallis), 
visual acuity (ANCOVA) and AMD status as based on clinical severity between 
groups. Retinal thickness values were derived from the on-board Zeiss Cirrus SD-
OCT 4000 retinal thickness algorithm which specifies total thickness for three 
subfields of the ETDRS grid (Figure 3.6). In addition, a comparison of the baseline 
characteristics and the computer-based visual function tests of those who were 
withdrawn and those who remained for the entirety of the study duration was also 
conducted. In order to investigate the prognostic capacity for AMD progression of the 
visual function tests ROC curves were constructed for each test plotting the sensitivity 
for AMD progression against the false-positive rate (1-specificity). The AUC was used 
to express the diagnostic capacity of each test. A post-hoc assessment of AMD status 
was also conducted 6 months after trial closure via review of hospital medical records.    
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6.5. Results 
 Participant characteristics 
Twenty-one intervention and 29 control participants either completed the trial or 
withdrew as a result of nAMD, and are included in the magnitude of effect analysis 
(Table 6.1). Those that completed the full study period (20 intervention, 27 control) 
are included in the secondary outcome analysis. Fifty percent of the intervention group 
and 41% of the control group who completed the entire study duration were recruited 
within their ranibizumab loading phase.  
Table 6.1. Table of baseline descriptive statistics for participants who completed the 1 year 
study duration and are included in the magnitude of effect and secondary outcome analysis. 
 
 Disease progression on basis of change in drusen volume or 
onset of nAMD 
Characteristics relating to the change in drusen volume of the 50 participants who are 
included in the magnitude of effect analysis are shown in Table 6.2. Thirty-three 
percent (n=7) of intervention and 41% (n=12) of control participants were found to 
exhibit an increase in drusen volume beyond the 95% test-retest confidence intervals 
within a circle of 5mm diameter centred on the fovea. Five percent (n=1) of 
intervention participants and 7% (n=2) of control participants progressed to nAMD 
during the course of the study and were withdrawn. When combined with those who 
showed significant drusen growth, 38% (n=8) of the intervention group and 48% 
(n=14) of the control group showed disease progression over the course of the trial. 
 Intervention Control 
Number of participants 
Mean age (±SD) 
21 
78.43 (±7.03) 
29 
77.00 (±7.02) 
Gender balance 43% female 48% female 
Mean BCVA study eye (ETDRS letter score ±SD) 0.09 (±0.13) 0.07 (±0.12) 
Mean BCVA fellow eye (ETDRS letter score ±SD) 0.40 (±0.28) 0.39 (±0.33) 
Ocular supplement history (mean years taken ±SD) 0.76 (±1.38) 0.33 (±0.63) 
Smoking history (mean pack years ±SD) 12.43 (±20.21) 12.68 (±18.77) 
Ranibizumab injection history (mean number ±SD) 8.45 (±8.94) 8.07 (±7.45) 
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Although the proportion of people showing disease progression was reduced in the 
intervention group this did not reach statistical significance when onset of advanced 
AMD and increased drusen volume were assessed individually using a chi-squared 
test (drusen volume, χ2 = 0.34, P=0.39 [Table 6.3]; onset of nAMD, χ2 = 0.10, P=0.62 
[Table 6.4]) or combined and analysed using the Mantel-Haenszel test (common odds 
ratio = 0.76, P =0.50 [Table 6.5]). 
Table 6.2. Drusen volume characteristics of each study group. Percentages given relate to 
total number in each cohort included in the magnitude of effect analysis (intervention, 21; 
control, 29). Measurements were classified as showing significant growth/shrinkage using 
test- retest confidence intervals (CI) as derived from Gregori et al. (2011).   
 
Table 6.3. Tabulated variables for assessment of disease progression (as based on nAMD 
onset) using the chi-squared test of independence. 
 
 
 
 
 
 
 
Table 6.4. Tabulated variables for assessment of disease progression (as based on increase 
of drusen volume beyond 95% test-retest confidence intervals) using the chi-squared test of 
independence. 
 
 
 
 
 
 
 
 
 
 
 Intervention Control 
Change in drusen N (%) Mean (±SD) N (%) Mean (±SD) 
 
Growth 
 
8 (38%) 
 
0.012 (±0.006) 
 
16 (55%) 
 
0.018 (±0.030) 
Growth beyond 95% CI 7 (33%) 0.013 (±0.005) 12 (41%) 0.027 (±0.035) 
Shrinkage 5 (24%) 0.036 (±0.047) 5 (17%) 0.018 (±0.024) 
Shrinkage beyond 95% CI 5 (24%) 0.036 (±0.047) 4 (14%) 0.022 (±0.025) 
No change 
 
7 (33%) 0.000 (±0.000) 
 
6 (21%) 0.000 (±0.000) 
Study Arm Onset of nAMD Frequency 
Intervention 
Yes 1 
No 20 
Control 
Yes 2 
No 27 
χ2 statistic 0.10 
P 0.62 
Study Arm Increase drusen 
volume 
Frequency 
Intervention 
Yes 7 
No 14 
Control 
Yes 12 
No 17 
χ2 statistic 0.34 
P 0.39 
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Table 6.5. Tabulated variables for assessment of disease progression (as based on increase 
of drusen volume beyond 95% test-retest confidence intervals and onset of nAMD) using the 
Mantel-Haenszel Test. 
 
 
 Disease progression on the basis of cone dark adaptation  
Data relating to the assessment of disease progression on the basis of change in 
cone τ are displayed in Figure 6.1 and Table 6.6. At baseline, the mean cone τ was 
0.61 minutes faster in the intervention cohort than the controls. When measured again 
after 12 months, the average cone τ of the mask wearers was 1.59 minutes slower 
than initially recorded. A similar change was exhibited by the control group albeit by 
a smaller increment of 0.70 minutes. No significant difference in cone τ was found 
between the study groups at either baseline or the final visit. Despite this, analysis 
showed that the mean overall change of cone τ (±SD) in the control group (0.66 ±0.49 
mins) was significantly less (P=0.018) than the intervention group (1.66 ±0.61 mins) 
when adjusted for covariates as shown in Figure 6.1. Therefore, cone τ increased 
significantly more in the mask wearing group over 12 months than it did for the control 
group.  
 
 
 
Study Arm Onset of nAMD (n) 
Significant increase 
in drusen volume (n) 
Frequency 
Intervention 
Yes (1) No (14) 15 
Yes (1) Yes (7) 8 
No (20) No (14) 34 
No (20) Yes (7) 27 
Control 
Yes (2) No (17) 19 
Yes (2) Yes (12) 14 
No (27) No (17) 44 
No (27) Yes (12) 39 
Odds ratio 0.76 
P 0.50 
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Figure 6.1. Means plots showing change in cone τ (a) and visual acuity (b-c) over 12 months. 
Plots (d) and (e) show the number of anti-VEGF injections administered over the study 
duration for the entire study cohort (d) and those recruited within their loading phase only (e). 
Black circles represent total injections (ranibizumab and aflibercept) and white circles 
represent those treated only with ranibizumab for the study duration. Whiskers denote 95% 
confidence intervals. 
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Table 6.6. Cone τ characteristics between study groups. Baseline and final mean cone τ are 
shown alongside the mean change prior to and after ANCOVA correction for differences in 
age, vitamin supplement intake, smoking history and baseline cone τ. The P-values specified 
relate to the significance of the difference in mean cone τ between study groups for each row. 
Cone τ measurements are given in minutes.     
 
 
 
 
 
6.6. Secondary outcome measures 
The secondary outcome measures (drusen volume, chromatic threshold and 14Hz 
flicker threshold data) were not normally distributed, even after log transformation. 
Hence, the Kruskal-Wallis test was used to evaluate change (baseline to 12 months) 
in each parameter. The results of this analysis are presented in Table 6.7. A number 
of outliers across all functional tests were identified, each of which has been specified 
in Figure 6.2. No evidence suggested that any of the outliers occurred as a direct 
result of any AE, mechanical fault or poor quality OCT scans. Information relating to 
the outliers was collected by the study investigator throughout the trial. Information of 
particular interest included:  
 CA010016 encountered a number of health issues throughout the duration of 
the study resulting in general and ocular (non-study eye) surgery.  
 CS010012 was increasingly anxious for a large proportion of the study 
(including the collection of final result data) due to the unexpected and sudden 
ill health of her partner. 
 MB010023 OCT scans were reviewed by a hospital ophthalmologist at the 
time of nAMD diagnosis. In agreement with the study investigator hospital 
 
Intervention 
(mean ±SD) 
Control 
(mean ±SD) 
P 
 
Baseline 
 
5.27 (± 1.81) 
 
5.88 (± 1.58) 
 
0.219 
Final 6.86 (± 2.64) 6.58 (± 2.13) 0.689 
Change over 1 year 1.60  (± 1.17) 0.70 (± 1.50) 0.031 
ANCOVA corrected change 
 
1.66  (± 0.61) 0.66 (± 0.49) 0.018 
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records suggest that the study eye exhibited only dry AMD changes in the form 
of drusen and pigmentary abnormality.     
As there was no evidence of a mistake and the outlier values were plausible analysis 
was performed on the entire dataset (Altman, 1991).   
Spearman correlation analysis showed no significant correlation between baseline 
results and 12 month change for RG chromatic threshold (control correlation 
coefficient = 0.129, P=0.520; intervention correlation coefficient = -0.211, P=0.373), 
YB chromatic threshold (control correlation coefficient = -0.120, P=0.550; intervention 
correlation coefficient = 0.150, P=0.950), flicker threshold (control correlation 
coefficient = -0.170, P=0.933; intervention correlation coefficient = 0.251, P=0.286) or 
baseline drusen volume (control correlation coefficient = 0.348, P=0.076; intervention 
correlation coefficient = -0.139, P=0.559) (Figure 6.2). Therefore no correction for 
difference in baseline status between groups was required.      
Table 6.7. Twelve month change in non-parametric outcome measures for each study group. 
Medians alongside inter-quartile range (bracketed) values are shown. For each functional 
outcome measure shown a larger threshold relates to poorer retinal function. The EQ-5D 
scores are based on the summary index score and the visual analogue scale score (0% 
relating to worst imaginable health state and 100% relating to best imaginable health state). 
For functional outcomes a larger value represents a decrease in retinal function. For the 
structural outcomes a negative value represents a reduction in drusen volume or retinal 
thickness over 12 months. A higher EQ-5D summary index score reflects an increased self-
reported quality of life whereas a larger VFQ-48 person measure shows fewer self-reported 
visual function issues. Total retinal thickness values relate to the three subfield areas of the 
ETDRS grid.    
 
Outcome measure Intervention (IQR) Control (IQR) 
 
Drusen volume (mm3) 
 
0.00 (0.00, 0.01) 
 
0.00 (0.00, 0.01) 
14Hz flicker threshold (cd/m2) 0.004 (0.001, 0.053) 0.001 (-0.006, 0.007) 
RG chromatic threshold (CAD units) -0.01 (-1.79, 2.84) 0.91 (-0.49, 2.17) 
YB chromatic threshold (CAD Units) 
EQ-5D summary index score 
0.245 (-0.23, 1.49) 
0.00 (-0.22, 0.00) 
0.170 (-0.31, 1.49) 
0.00 (-0.06, 0.00) 
EQ-5D visual analogue scale % 1.25 (-5.00, 6.25) 1.00 (-4.00, 10.00) 
VFQ-48 person measure score 3.42 (2.92, 3.65) 3.25 (2.65, 3.42) 
Retinal thickness: central subfield (microns) -7.50 (-11.25, -2.00) -2.00 (-7.50, 2.00) 
Retinal thickness: inner subfield (microns) -4.63 (-7.50, -1.56) -4.25 (-5.75, -2.13) 
Retinal thickness: outer subfield (microns) -2.38 (-3.88, -1.13) -2.50 (-5.63, -0.25) 
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Over 12 months the median change in drusen volume (IQR) was the same for the 
intervention and control groups (0.000 [0.00, 0.01] mm3). The largest increase 
reported within the control group was 0.12mm3. This was 6 times larger than the peak 
increase reported by any intervention participant (0.02mm3). In the intervention group, 
the median change in RG chromatic threshold over 12 months (IQR) showed an 
overall improvement by 0.01 (-1.79, 2.84) CAD units for mask wearers whereas the 
control group exhibited an overall decline of 0.91 (-0.49, 2.17) CAD units. The 
opposite was found when assessing YB chromatic thresholds where the median 
decline in function was 0.08 CAD units greater for mask wearers (YB chromatic 
threshold [IQR], 0.25 [-0.23, 1.49] CAD units) than controls (YB chromatic threshold 
[IQR], 0.17 [-0.31, 1.49] CAD units). The median change in 14Hz flicker threshold 
(IQR) over 12 months corresponded to a decline in function for both the intervention 
(0.004 [0.001, 0.053] cd/m2) and control groups (0.001 [-0.006, 0.007] cd/m2).  
Analysis of median change in secondary outcome measures relating to visual function 
showed no significant difference between study groups (Kruskal-Wallis: drusen 
volume [P=0.66], RG chromatic threshold [P=0.46], YB chromatic threshold [P=0.79], 
14Hz flicker threshold [P=0.10]) over the 12 month period (Figure 6.3). 
At baseline, all participants were on a structured ranibizumab treatment regimen at 
BEH. This consisted of a loading phase (3 injections over 3 months) immediately after 
nAMD diagnosis followed by monthly assessment and subsequent injection as 
necessary. During the course of the study ranibizumab use was ceased in favour of 
aflibercept for 7 participants (4 intervention, 3 control). Twenty-one participants (10 
intervention, 11 control) were recruited within their initial ranibizumab loading phase. 
Table 6.8 shows the injection characteristics of each study group. At baseline the 
average number of injections administered across the entire cohort was 8 (± 8.20). 
When all participants were included (from both ranibizumab and aflibercept regimens) 
the mean (± SD) number of injections administered over 12 months was slightly higher 
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in the intervention (5.30 ± 2.57) than the control (4.37 ± 2.91) group, although a higher 
number of intervention participants switched treatment regimen resulting in a 3-
injection loading dose of aflibercept. No significant difference was found between the 
mean (± SD) total number of anti-VEGF injections received by the intervention (5.28 
± 2.54) and control (4.38 ± 2.91) groups despite non-mask wearers receiving on 
average 1 fewer anti-VEGF injection over a 12 month period (ANCOVA: P=0.30). As 
shown in Figure 6.1 this finding was also evident when considering those from each 
group who were retained on ranibizumab only (ANCOVA: P=0.57) and those who 
were recruited within their 3 month ranibizumab loading phase (ANCOVA: P=0.27) 
(Table 6.8). ANCOVA analysis relating to ranibizumab administration between the 
groups was performed specifying age, gender, vitamin supplement intake and history 
of smoking and baseline data relating to each visual function test as covariates.  
 
Figure 6.2. Scatter plots showing change of chromatic threshold, flicker threshold and drusen 
volume as a function of baseline data for all ALight clinical trial participants who completed the 
12-month study period. Mask-wearers (intervention) are represented by black circles and non-
mask wearers (controls) are represented by white circles. Outliers have been specified with 
the participant ID that they relate to. 
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Visual function (VFQ-48) and quality of life (EQ-5D) data are shown in Table 6.7. A 
large proportion (80%) of the entire cohort reported an overall improvement in self-
reported visual function over the duration of the study in accordance with the VFQ-48 
questionnaire. There was, however, no evidence of a significant difference between 
groups (Kruskal-Wallis: P=0.32) (Figure 6.3). The median change (IQR) in EQ-5D 
scores for the intervention and control groups was 0.00 (-0.22, 0.00) and 0.00 (-0.06, 
0.00), respectively. This change was not significantly different between groups 
(Kruskal-Wallis: P>0.05). When using the EQ-5D visual analogue scale (0% relating 
to worst imaginable health state and 100% relating to best imaginable health state) 
the median change in health state was an increase from 85-88% in the control group 
and 80-83% in the intervention group over the study duration. There was no significant 
difference in the change of quality of life between study groups when analysing the 
visual analogue scale score (Kruskal-Wallis: P=0.85). 
Table 6.8. Table showing mean number of anti-VEGF injections received by participants in 
each group over the duration of the ALight clinical trial. At the time of randomisation all 
participants enrolled into the clinical trial were on a ranibizumab treatment regimen. Data within 
the table relating to each study arm are divided into ‘entire group’ (the total number of 
intervention/control participants to complete the entire study duration) and ‘loading phase’ 
(data relating only to those who were recruited during their ranibizumab loading phase). 
‘Ranibizumab only’ refers to those who were retained on a ranibizumab treatment regimen for 
the duration of their participation within the clinical trial. ‘Treatment regimen changed’’ refers 
to those for whom their treatment regimen was changed from ranibizumab to aflibercept during 
the course of their participation within the clinical trial. ‘Ranibizumab pre-randomisation’ refers 
to the mean number of ranibizumab injections received prior to randomisation. ‘Mean total 
injections’’ refers to the mean combined total of ranibizumab and aflibercept injections 
administered over the study duration for each study arm. ‘Mean ranibizumab’ refers only to 
those who were retained on a ranibizumab regimen for the duration of the clinical trial and 
denotes the mean number of ranibizumab injections administered for each study arm over the 
study duration. ‘Mean total injections/ranibizumab (ANCOVA)’ relates to corrected mean 
values obtained following ANCOVA analysis specifying age, smoking history, vitamin 
supplement intake and number of injections at baseline as covariates. Standard deviations are 
shown in brackets.    
 
 Intervention (n±SD) Control (n±SD) 
 Entire 
group 
Loading 
phase 
Entire 
group 
Loading 
phase 
Ranibizumab only 16 8 24 10 
Treatment regimen changed 4 2 3 1 
Ranibizumab pre-randomisation 8.45 (±8.94) 3.00 (±0.00) 8.07 (±7.45) 3.00 (±0.00) 
Mean total injections 5.30 (±2.57) 5.40 (±2.27) 4.37 (±2.91) 3.73 (±2.76) 
Mean total injections (ANCOVA) 5.28 (±0.77) 5.40 (±0.95) 4.38 (±0.67) 3.73 (±1.51) 
Mean ranibizumab  4.44 (±2.03) 4.43 (±1.77) 3.67 (±2.22) 3.10 (±1.91) 
Mean ranibizumab (ANCOVA) 4.23 (0.74) 4.86 (±0.86) 3.80 (±0.55) 3.10 (±0.93) 
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Figure 6.3. Boxplots showing 12 month change in RG chromatic threshold (a), YB chromatic 
threshold (b), 14Hz flicker threshold (c), drusen volume (d), VFQ-48 person measure (e) and 
EQ-5D instrument VAS validated score (f). Median is shown as the horizontal black line within 
the box. The box boundaries represent upper and lower quartiles with range minima and 
maxima at ends of vertical lines. Outliers (outside 2 inter-quartile ranges) of the median are 
shown as single points. For change in drusen volume 3 outliers (2 control: -0.058; 0.120 and 
1 intervention: -0.120) have not been included in order to aid visualisation. 
 
6.7. Post-hoc analyses 
No significant difference (P>0.05) was found between the withdrawn and remain study 
groups for any visual function test. Data relating to retinal thickness measurements 
for the ETDRS subfields are displayed in Table 6.7. Assessment of thickness change 
over 12 months between study groups showed that the median reduction in thickness 
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was significantly greater in the central subfield of mask wearers when compared to 
controls (Kruskal-Wallis: P=0.044). No significant difference (P>0.05) was found when 
considering the median change of the other subfields. 
As logMAR visual acuity is still used as a primary diagnostic tool within the hospital 
setting, this functional measure was also assessed for the study eye on a post-hoc 
basis. Over the course of the study a mean loss (± SD) of 4 (± 9) letters in the 
intervention and 3.5 (± 4.5) letters in the control group was found. This change was 
not significantly different between the two groups (ANCOVA: P=0.69) (see Figure 
6.1). The change in AMD as based on clinical severity grading was also investigated. 
During the course of the trial the AMD severity of 2 intervention and 2 control 
participants increased by at least 1 AREDS Simplified Severity Scale grade. As the 
number of participants exhibiting a change in AMD severity as based on clinical 
grading was so few no statistical analysis was performed on this outcome measure.  
6.8. Prognostic and predictive capability of visual function tests  
Twenty-nine control participants were included in the ROC analysis of prognostic 
capability of the visual function tests. The control participant omitted was withdrawn 
during the study due to general health issues. The ROC curves for each test of retinal 
function assessed are shown in Figure 6.4. All parameters assessed at baseline 
showed limited capability to discriminate participants who went on to show 
progression from those who didn’t. Cone τ yielded the highest area under the curve 
(AUC ± standard error) of 0.53 (± 0.11). This equated to an approximate 60% 
sensitivity and 40% specificity of the mean cone τ (5.88 mins). The other parameters 
did not exceed an area under the curve of 0.5, indicating that the prognostic capacity 
was no better than chance alone. The predictive capacity of the tests as biomarkers 
for low-level light therapy was not investigated as there was no statistically significant 
treatment effect.  
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Figure 6.4. Receiver operating characteristic curves for cone τ (a), flicker threshold (b), yellow-
blue chromatic threshold (c) and red-green chromatic threshold (d). Each plot shows the 
sensitivity of the parameter to disease progression in AMD against the false detection rate (1-
specificity for all 29 participants). 
 
6.9. Discussion  
The findings of this exploratory study suggested that low-level night-time light therapy 
had no effect on disease progression in patients with early/intermediate AMD over 12 
months. A greater proportion of controls (48%) than mask wearers (38%) showed 
disease progression over the duration of the trial, where progression was defined by 
either an increase in drusen volume (beyond 95% test-retest confidence intervals) or 
the onset of advanced AMD in the study eye. Whilst this difference failed to reach 
statistical significance, it must be noted that this was an exploratory study and as such 
was not powered to detect small differences between study groups.  
The use of OCT-derived drusen volume measurement as a surrogate for disease 
progression was based on recent published evidence that drusen volume shows an 
overall pattern of growth for people with early/intermediate AMD over time 
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(Abdelfattah et al., 2016; Schlanitz et al., 2017; Yehoshua et al., 2011). The proportion 
of the intervention (35%) and control (44%) participants for which drusen volume 
increased significantly over the 12 month follow up period was roughly in agreement 
with that expected (48%) on the basis of published data (Yehoshua et al., 2011). The 
slightly higher than expected proportion of participants in the control group showing 
an increase in drusen volume could be attributable to the fact that all participants in 
this study had unilateral nAMD, and might therefore be considered to be at higher risk 
of progression than a randomly selected cohort with non-exudative AMD (Schlanitz et 
al., 2017; AREDS, 2005). This is reflected in the fact that none of Yehoshua’s cohort 
of 143 people with drusen progressed to nAMD within the 12 month follow up, 
compared to 3 participants in the current cohort of 60.   
In the present study a greater proportion of individuals in both groups showed drusen 
shrinkage (25% intervention, 15% controls) than had previously been reported 
(Yehoshua et al., 2011). This may, again, reflect a more advanced disease state in 
the ‘early/intermediate AMD’ eyes enrolled in the current study compared to 
Yehoshua et al. (2011), as a spontaneous regression of drusen appears to occur prior 
to the onset of advanced AMD (Schlanitz et al., 2017; Abdelfattah et al., 2016; Sallo 
et al., 2009). For the purposes of this trial, drusen shrinkage was not included as an 
outcome measure as it was not possible to distinguish between regression preceding 
late stage AMD and regression which may indicate a reduction in disease severity. 
However, there was no significant difference (chi-squared test, P=0.72) in the 
proportion of people (intervention, 25%; control, 19%) showing drusen shrinkage 
between groups. The post-hoc review of AMD status 6 months after the final visit also 
showed that none of the intervention participants who displayed significant drusen 
shrinkage throughout the trial progressed to nAMD up to 18-months post 
randomisation.     
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The findings of the present study show a 5% conversion rate to nAMD over a 12 
month period for those with early/intermediate AMD at baseline.  This is lower than 
the published rate of the same outcome (12.2%) as based on a meta-analysis of five 
studies of eyes free of advanced disease at study inception (Wong et al., 2008). Direct 
comparison with the published rate may be confounded as a number of participants 
included in the present study were taking an antioxidant supplement based on the 
AREDS formula (AREDS, 2001). Although, the exact impact of this possible 
confounding factor is unclear as the effect of the AREDS formula is based on one 
large trial of which the generalisability of the findings to other populations is unknown 
(Evans and Lawrenson, 2017).   
In the present study, the only outcome measure to show a significantly different 
change over 12 months between the study groups was dark adaptation. There is an 
emerging body of evidence to suggest that dark adaptation is a sensitive biomarker 
of AMD (Eisner et al., 1987; 1991; Midena et al., 1997; Owsley et al., 2001; 2007; 
2016; Binns and Margrain, 2007; Dimitrov et al., 2008; 2011; 2012; Gaffney et al., 
2011; Jackson et al., 2014b), although there are limited longitudinal data to show the 
sensitivity of the test to disease progression (Eisner et al., 1992; Owsley et al., 2016; 
2017) particularly when used over 1-year as opposed to a 2-year period (Owsley et 
al., 2017). The significant increase in cone τ seen in the intervention group when 
compared to the controls suggests that dark adaptation was selectively impaired in 
the treatment group. However, there is no published data regarding the long-term 
effect of reducing the rod-circulating current on the dynamics of cone adaptation. 
Hence, although the delayed dark adaptation metric may herald the progression of 
AMD, we cannot rule out the possibility that it is a consequence of disrupting retinal 
physiology. Although none of the changes in dark adaptation manifested in an 
increase in self-reported difficulty when moving from high to low illumination the VFQ-
48 questionnaire is not sensitive to this aspect of visual function. A better alternative 
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to investigate this trait would be a questionnaire specific to low luminance such as the 
32-item Low-Luminance Questionnaire (Owsley et al., 2006).  
Despite the non-significant change in BCVA, a large proportion (80%) of the entire 
cohort reported an overall improvement in self-reported visual function over the 
duration of the study in accordance with the VFQ-48 questionnaire. This was not the 
case with self-reported quality of life as recorded using the EQ-5D instrument which 
showed no significant change. The primary reason for the improvement in self-
reported visual function is likely to be continued anti-VEGF treatment as opposed to 
the intervention, as the effect was seen in both study groups. To date, a number of 
studies have reported an improvement in patients’ vision-related quality of life after 
they started receiving anti-VEGF treatment for nAMD (Liew et al., 2015; Finger et al., 
2013; 2014; Inoue et al., 2014). However, the positive impact of anti-VEGF treatment 
on a patient’s vision-related quality of life was found to be dependent on improvement 
in visual acuity (Senra et al., 2016). In these studies, vision-related quality of life 
included not only aspects related to the use of vision in activities of everyday life but 
also mental health and social functioning. Therefore, a link has been suggested 
between VA and patients’ perceptions of quality of life, functioning, and mental health 
(Senra et al., 2016). Such a link was not found in the present study however it is 
possible that comorbidities of the elderly ALight trial cohort, such as arthritis and 
osteoporosis, could have had a negative effect on quality of life (Mitchell and Bradley, 
2006).   
Although this trial found no significant effect of the therapy on progression of 
early/intermediate AMD, previous studies have suggested that the therapy is effective 
at improving retinal function (Arden et al., 2010; 2011) and reducing macular thickness 
(Arden et al., 2011) in those with diabetic macular oedema. Although both conditions 
are hypothesised to have a hypoxic aetiology this difference in effectiveness may be 
due to differing pathogenesis, as diabetic retinopathy primarily affects the inner rather 
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than the outer retinal circulation. In accordance with the current treatment regimen 
ranibizumab was issued on the basis of subretinal or intraretinal fluid without stable 
vision. In the present study, the potential influence of light therapy on the ranibizumab 
retreatment rate was found to be statistically not significant over a 12 month period. 
This analysis, however, was confounded by the implications of including those who 
switched to aflibercept and those who were not recruited within their loading phase.  
Both study groups were found to show an overall decrease in retinal thickness (within 
a 6mm diameter circle centred on the fovea) over the course of the study. This is 
consistent with evidence suggesting that those with early/intermediate AMD have a 
generalised thinning of the macular region (Wood et al., 2011) compared to age-
matched controls. The primary source of reduced retinal thickness in 
early/intermediate AMD has been attributed to thinning of the photoreceptor 
(Schuman et al., 2009; Kaluzny et al., 2009) and ganglion cell (Camacho et al., 2017; 
Lee and Yu, 2015; Yenice et al., 2015; Savastano et al., 2014) layers, particularly in 
regions overlying drusen (Rogala et al., 2015; Schuman et al., 2009; Kaluzny et al., 
2009; Malamos et al., 2009).    
Although retinal segmentation was not utilised in the present study to investigate intra-
retinal changes, when considering total retinal thickness the retina thinned 
significantly more in mask wearers when compared to controls within the central 
subfield (1mm diameter circle centred on the fovea). Due to poor reproducibility of 
thickness measurements between OCT instruments of varying manufacturers, direct 
comparison of the change in retinal thickness found in the present study to that in the 
wider literature is not possible. This issue is primarily attributable to the different 
analysis algorithms used to set retinal boundaries within each OCT instrument (Giani 
et al., 2010; Kiernan et al., 2008). The finding of the present study could potentially 
be confounded by a number of causes. These include the effect of multiple 
comparisons increasing the risk of type I error, the effect of axial length which was not 
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accounted for (Song et al., 2010; Szigeti et al., 2015) and the possibility that some of 
the control group had retinal thickening attributable to incipient nAMD. 
None of the visual function tests were able to predict AMD progression. This finding 
is not consistent with the potential biomarkers identified in Chapter 4, or with previous 
longitudinal reports assessing the usefulness of dark adaptation (Owsley et al., 2016) 
and flicker threshold (Mayer et al., 1994) as prognostic tools for AMD progression. 
Flicker threshold has been found to be reduced in eyes that eventually develop GA or 
nAMD (Mayer et al., 1994), however its efficacy as a marker for early disease onset 
or progression has not been established. It is hypothesised that the prognostic 
capability of flicker threshold measurement relies upon morphological changes to the 
L- and M- cone mechanisms as a result of AMD. These changes are postulated to 
cause the foveal cones to behave more like those within more peripheral retinal 
locations where they are less densely packed, have larger receptive fields and 
sensitivity loss at low temporal frequencies (Mayer et al., 1994). Alternatively, rod-
mediated dark adaptation has been reported as a prognostic biomarker for early AMD 
(Owsley et al., 2016). The delay in dark adaptation has been attributed to impaired 
outer retinal function through changes that occur to structures underlying the retina, 
such as the photoreceptors, Bruch’s membrane and the retinal pigment epithelium in 
AMD. For further detail on this process the reader is directed to Section 1.3.6.5. The 
poor prognostic performance of the visual function tests in the present study may be 
attributed to the relatively small cohort compared to the aforementioned longitudinal 
studies. In order to adequately establish the prognostic capacity of each test of visual 
function a much larger cohort would be required.  
A weakness to the clinical trial was that an eligibility criteria change was required to 
improve the recruitment rate during the clinical trial (Section 5.1) thus reducing the 
power of the analysis with respect to number of injections in the eye with nAMD. It is 
also worth noting that throughout the study it was not possible to control variation in 
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pupil size between each intervention participant. Therefore the light therapy dosage 
each participant received may have varied slightly. For example, based on pupil 
measurements reported by Winn et al, (1994) the average pupil diameter for the 
youngest and oldest intervention participants during mask wear can be estimated as 
5.5mm and 4.2mm, respectively. Assuming an average lid transmission of 1% this 
equates to a discrepancy in dosage of 20 scotopic Td per night between the 2 
participants. Furthermore, when a possible difference in lid transmission between the 
participants is also considered the discrepancy in dosage may further increase. The 
effect of this discrepancy cannot be ruled out as a contributing factor to differences in 
the overall effect of light therapy between participants within the intervention cohort.   
The strengths of this study include the robust randomised controlled trial design, the 
successful masking of treating ophthalmologists, the high level of compliance, and 
the relatively low rate of withdrawal after the initial period of adaptation.  
This study has collected important information about the safety and acceptability of 
the device in this patient cohort and the potential magnitude of the treatment effect for 
powering future trials. In conclusion, a larger cohort would be required to determine 
whether the lack of intervention effect on risk of AMD progression was a chance 
finding. Further work is also required to determine the potential effect of the treatment 
on subsequent progression to nAMD. Such future work, alongside a comprehensive 
discussion of this thesis, is presented in the following chapter.  
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Chapter 7. Discussion and future work 
The overarching aim of the work presented in this thesis was to collect preliminary 
phase I/IIa proof of concept data about low-level night-time light therapy from people 
with early and intermediate AMD. The following chapter summarises the work in more 
detail. 
7.1. Summary of thesis  
Chapter 1 provided an overview of normal retinal structure and physiology in photopic 
and scotopic conditions. Current literature concerning the risk factors, 
pathophysiology, classification, treatment and clinical investigation of AMD was also 
reviewed. The concept of hypoxia in the AMD pathogenesis was introduced. Evidence 
regarding the fragile balance between metabolic demand and oxygenation of the 
retina, especially under dark-adapted conditions, was explored and attributed to the 
rod mediated dark current. 
Chapter 2 reported a systematic literature review conducted to evaluate the role of 
hypoxia in the pathogenesis of AMD. The review identified direct evidence through 
the emergence of hypoxia-inducible factor (HIF) that hypoxia is evident at some stage 
during the pathogenesis of AMD (Kvanta et al., 1996; Lopez et al., 1996; Sheridan et 
al., 2009; Inoue et al., 2007). Indirect evidence was suggestive that the source of 
hypoxia resides in diminished choroidal circulation (Grunwald et al., 2005; Metelitsina 
et al., 2008). Considering that the macula is an area with a high oxygen demand and 
a fragile oxygen balance it seems reasonable to conclude that a consequence of 
irregularity in choroidal haemodynamic disruption would be hypoxia. However, there 
was no direct evidence from the review implicating hypoxia as a causative factor in 
the pathogenesis of AMD, or at what stage during the disease process it manifests. 
In addition, it could not be concluded whether the disturbance of choroidal circulation 
evidenced in AMD is unequivocally the source of hypoxia.  
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Chapter 3 detailed the study design for the ALight clinical trial, a prospective, 
longitudinal, randomised controlled trial to assess the impact of low-level night-time 
light therapy on the progression of early/intermediate AMD. In addition to elaborating 
and presenting amendments to the published protocol (McKeague et al., 2015), two 
pilot studies that aimed to optimise the parameters used within the main study were 
also reported. The results of the chapter indicated that the technique, parameters and 
equipment used to assess dark adaptation, chromatic sensitivity and flicker threshold 
prior to trial inception were clinically viable.  
In chapter 4, the predictive capacity of the outcome measures used in the ALight trial 
was explored in the form of a cross-sectional study. Two different visual function tests 
(cone τ [pseudo R2 0.35, P<0.001] and YB chromatic sensitivity [pseudo R2 0.16, 
P<0.001]) were identified as independent predictors of increased AMD graded 
severity. When both tests are used simultaneously to predict an increase in AMD 
severity, odds ratios calculated show that with every log minute increase in cone τ 
and every CAD unit increase, the odds of moving up a AREDS Simplified Severity 
Scale grade (Ferris et al., 2005) are 2.5 and 20 times higher, respectively.   
The finding supports the theory that a different underlying pathological process during 
AMD progression is responsible for dark adaptation and chromatic sensitivity deficits. 
These tests have been revealed as possible predictive biomarkers (Owsley et al., 
2016; 2017; Eisner et al., 1992), however, as introduced in Section 6.8 following 
longitudinal evaluation dark adaptation, chromatic sensitivity and flicker threshold 
showed poor prognostic capacity for AMD progression during the ALight trial. Despite 
this, the poor performance of these visual function tests during the ALight trial may be 
attributed to the relatively small cohort compared to the aforementioned longitudinal 
studies. Therefore, the usefulness of these tests as AMD biomarkers is still unclear. 
Future clinical trials investigating potential new AMD treatments would benefit from 
further longitudinal evaluation of these potential biomarkers.     
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Chapter 5 provided an overview of the implementation of the ALight Clinical Trial. The 
safety and acceptability of the intervention was of particular focus. By examining the 
number of adverse events, subjective feedback and compliance data of the trial 
participants it was concluded that the use of an OLED sleep mask is an acceptable 
and safe method of delivering low-level night-time light therapy.  
Chapter 6 presented the results relating to the magnitude of the effect of low-level 
night-time light therapy as delivered using an OLED sleep mask. These results formed 
the major findings of this thesis and as such are discussed in more detail below. 
7.2. Key findings  
The key findings of this thesis are presented with a view to addressing the original 
aims as specified in Section 1.5.  
 Effect of low-level night-time light therapy on AMD 
progression  
The findings in relation to the primary objective suggested that low-level night-time 
light therapy, although well tolerated, had no effect on AMD progression. Although a 
greater proportion of controls (48%) than mask wearers (38%) showed disease 
progression over the duration of the trial, the study was exploratory and not powered 
to detect small differences between study groups. In addition to disease progression 
during the trial, a greater proportion of the control group (10%) than mask wearers 
(0%) also progressed to nAMD within 6 months after their end-of-study visit (Appendix 
X). Post-hoc analysis of baseline data showed that only RG chromatic threshold was 
a significant individual predictor of nAMD development over 18 months (binary logistic 
regression, R2 = 0.25, P=0.05). Presently, no longitudinal study has investigated the 
usefulness of CAD-measured chromatic sensitivity as an AMD biomarker. These 
findings suggest that conversion to nAMD rates and effectiveness of the intervention 
≥12 months may be worth exploring further in future studies.     
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Progression as based on the rate of retinal adaptation (time taken for the 
photoreceptors to recover their sensitivity after being exposed to a bright adapting 
light) showed a significant increase in cone τ in the intervention group when compared 
to the controls. The interpretation of this finding is not clear. It may represent a risk of 
increased rate of progression in the treatment arm (Eisner et al., 1992; Owsley et al., 
2016). However, the finding that more participants from the control than the treatment 
arm showed increase in drusen volume or conversion to nAMD during the trial, and 
that more control participants converted to nAMD in the 6 months following the trial 
suggests that the intervention did not cause an increased risk of disease progression. 
It is possible that the delay in cone adaptation reported is a consequence of the long-
term prevention of dark adaptation as opposed to AMD progression. At present, there 
is a deficit in the literature surrounding this as the two other longitudinal studies that 
have implemented similar methods of dark current suppression in a cohort of those 
with diabetic macular oedema did not measure dark adaptation parameters. Similarly, 
there is no evidence to clarify the effect of long-term light adaptation status on dark 
adaptation.   
 Acceptability of the intervention  
Despite the limited impact on AMD progression the results of this thesis provide 
evidence that the use of an OLED sleep mask is an acceptable and safe method of 
delivering low-level night-time light therapy. The compliance rate (70%) was 
comparable with another study that utilised a similar intervention in a cohort of those 
with diabetic macular oedema (Sahni et al., 2016) and there were no serious adverse 
events or negative impact on sleep patterns to suggest safety concerns for future 
trials.  
Although the use of an OLED sleep mask has been designated as an acceptable 
method of low-level night-time light therapy delivery there were a number of 
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withdrawals, and a high incidence of discomfort reported. During the course of the 
trial a number of design modifications were suggested to the mask which included: 
i. Replacement of the synthetic material with a softer, lighter, natural fibre 
alternative to reduce overall mask weight.  
ii. Perforation of mask housing or replacement with breathable material to 
prevent overheating. 
iii. Tailoring fit by manufacturing the mask housing in a number of sizes.  
iv. Incorporating memory foam into the housing to improve comfort through 
enhanced personalisation. 
v. Modifying the strap fastener to prevent adhesion with bedding and hair.  
vi. Applying a forehead buffer to alleviate pressure on bridge of nose by extending 
mask further outwards from the face.    
vii. Redesigning access to the light sensor so the mask can be activated without 
removal from fabric sleeve.  
viii. Enhancing the activation sensor location or colour to improve visibility.  
 
These design modifications have since been relayed to the manufacturer and 
incorporated into the next generation OLED mask (Figure 7.1) prior to prospective 
implementation in future studies.   
 
Figure 7.1. Photograph of the next generation OLED sleep mask housing as modified using 
feedback from the ALight study. 
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 Effect of low-level night-time light therapy on secondary 
outcome measures  
The findings relating to the secondary aims of this thesis were discussed in detail in 
section 6.6. Briefly, there was no evidence that low-level night-time light therapy had 
a positive effect on: the ranibizumab retreatment rate, change in drusen volume, 
change in health related quality of life (EQ-5D instrument) or change in visual function 
(as based on chromatic thresholds, 14Hz flicker threshold and ETDRS visual acuity). 
Although, 80% of the entire cohort reported an overall improvement in self-reported 
visual function over the duration of the study (in accordance with the VFQ-48 
questionnaire) no significant difference between groups was found for this outcome 
measure. 
 Prognostic capacity of visual function tests for AMD 
progression  
The evidence in this report suggests that none of the functional tests assessed at 
baseline were able to accurately predict disease progression during the 12 month 
follow up. Cone τ was the only measure to show an AUC exceeding 0.5, i.e. superior 
to chance alone at distinguishing between those who went on to progress in disease 
status, and those who did not. This finding is not consistent with previous longitudinal 
reports assessing the usefulness of dark adaptation (Owsley et al., 2016; 2017) and 
flicker threshold (Mayer et al., 1994) as prognostic tools for AMD progression. The 
predictive capability of dark adaptation parameters was recently evidenced in a 
longitudinal study by Owsley et al. (2016) who, by measuring rod dark adaptation, 
showed that those with delayed function at baseline and an otherwise normal retinal 
appearance were twice as likely to have AMD in that eye when reassessed after 3 
years. In addition, both cone and rod dark adaptation parameters have also been 
found to show concordance with clinical macular changes in early/intermediate AMD 
(Dimitrov et al., 2012) further underlining the usefulness of this test. In comparison to 
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the results of the aforementioned studies, the poor performance of the visual function 
tests in the present longitudinal study may be attributed to the relatively small cohort 
(n=29). In order to adequately establish the prognostic capacity for nAMD onset of 
each test of visual function it would have been useful to have studied a larger cohort 
and to have followed them up for longer.  
The cross-sectional analysis introduced in Chapter 4 showed that when using the 
AREDS Simplified Severity Scale as a surrogate for disease progression (Ferris et 
al., 2005) dark adaptation was the best predictive biomarker for increased AMD 
graded severity. Yellow-blue chromatic sensitivity also showed promise and as such 
is a useful test to supplement cone τ measurement. However, unlike dark adaptation, 
the predictive capacity of this measurement is not strengthened by a robust 
longitudinal study (Owsley et al., 2016; 2017). RG chromatic threshold and 14Hz 
flicker threshold were least useful as predictive biomarkers. This finding is contrary to 
current evidence suggesting that flicker threshold is found to be decreased in eyes 
that eventually develop GA and choroidal neovascularisation (Mayer et al., 1994; Luu 
et al., 2012). These differences can be attributed to the small cohort (n=36) of Mayer 
et al. (1994) and the different stimulus used by Luu et al. (2012) when compared to 
the present study. The finding that none of the visual function tests were accurately 
able to predict disease progression in the longitudinal component of this thesis is 
contrary to the identification of cone τ and YB chromatic sensitivity as independent 
predictors of increased AMD graded severity, as based on the cross sectional analysis 
conducted in Chapter 4. However, when considering the longitudinal analysis the 
sample size analysed (n=29) was far smaller than that of the cross-sectional study 
(n=100). In accordance with the lack of effect on AMD progression, the predictive 
capacity of the visual function tests as biomarkers for low-level night-time light therapy 
was not investigated.     
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7.3. Future work 
 Investigation of delayed dark adaptation cause 
The precise cause of the delay in dark adaptation exhibited by the mask wearers of 
the present study is unclear. Longitudinal evaluation of a cohort of healthy participants 
could aid in further interpreting the present results. Such a study would involve a 
cohort of normals age-matched to the ALight trial cohort. Participants would be 
supplied with OLED light-emitting masks to wear nightly during sleep. Dark adaptation 
would be measured prior to mask wear and on a monthly basis until the end of the 
study period. This would determine any overall and progressive effect of dark current 
suppression on the rate of cone τ in those without AMD. Also, comparison of the 
change in cone τ (from baseline to final measurement) with the ALight cohort would 
suggest whether a delay in dark adaptation was related to suppression of the dark 
current or to the progression of AMD. In addition to this, a review of dark adaptation 
for the ALight trial intervention group would determine the permanency of the deficit 
found in the present study. 
 Anti-VEGF retreatment rate 
The analysis of the ranibizumab retreatment rate in the present study was confounded 
by the implications of including those who had competed their initial loading phase 
and for those whom the treatment regimen was altered mid-trial. There is a strong 
rationale to support the presence of hypoxia in nAMD (see Chapter 2) and the present 
study has demonstrated acceptability and safety of the intervention. Therefore a 
future study specifically designed to investigate anti-VEGF retreatment rates in those 
with nAMD may still be valuable. It is, however, worth noting that in designing such a 
study the ‘treat and extend’ anti-VEGF administration programme will likely need to 
be considered as opposed to the standard monthly dosing regimen. 
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 ALight follow-up study 
The Alight trial was designed as an exploratory, proof of concept study. Although there 
was no evidence of an effect on disease progression the intervention was found to be 
safe and tolerable and, importantly, the absence of evidence is not evidence of no 
effect. In order to further investigate the effect of low-level night-time light therapy on 
AMD and build on the results of the ALight trial it is sensible to suggest a larger study, 
with a longer follow-up period utilising the same intervention. Post-hoc sample size 
calculations suggest that an approximate sample size of 381 per group would be 
required to power a future study to detect an effect of the magnitude seen in this 
exploratory trial (with 80% power, P=0.05) at 12 months. It is also worth noting that if 
nAMD conversions at 18-months are considered 59% of controls and 38% of the 
intervention group showed AMD progression (Appendix X). Powering a study to 
detect this magnitude of difference (80% power, P=0.05) would require an 
approximate sample size of 85 per group. When considering AMD progression over 
time using 18-month post-hoc data, the rate of progression (based on a significant 
increase in drusen volume or onset of nAMD) for participants within the intervention 
and control groups was 0.50 and 0.94 per month. Projected figures based on these 
progression rates show 57% (n=12) of the intervention group and 79% (n=23) of the 
control group displaying progression over 24 months. Powering a study to detect this 
magnitude of difference (80% power, P=0.05) would require an approximate sample 
size of 67 per group.               
7.4. Final remarks 
In conclusion, this exploratory study provides evidence that the use of an OLED sleep 
mask is an acceptable and safe method of delivering nightly low-level light therapy. A 
larger cohort would be required to determine whether the intervention has any effect 
on the progression of AMD. As AMD is a complex condition with a multi-factorial 
aetiology the development of a treatment is extremely difficult. Taking into account 
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the current global prevalence of AMD and the number of those who are presently 
registered as sight impaired or severely sight impaired as a result of AMD the need 
for a treatment aimed at preventing onset or progression is paramount. To that effect, 
it is hoped that the information here will not only inspire new thoughts regarding 
pathogenesis, but also aid in the design of future clinical trials aiming to drive us ever 
closer to a world where sight loss as a result of AMD no longer exists.   
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Appendix I. Table of studies included in literature review 
 
Title Participants Methods Results Conclusion Notes 
Reduced 
choroidal 
foveolar blood 
flow in eyes with 
increasing AMD 
severity 
(Grunwald et al., 
2005). 
189 in total 
 
26 control eyes.  
 
163 eyes with early 
AMD characteristics 
divided into 3 
subgroups: 
 
(1) 56 eyes of 
drusen >63μm and no 
RPE changes.  
 
(2) 88 eyes of 
drusen >63μm and 
some RPE 
hyperpigmentary 
changes.  
 
(3) 19 eyes of 
drusen >63μm and 
CNV in non-study eye 
(13 of which had RPE 
hyperpigmentary 
changes in the study 
eye also). 
 
Laser Doppler flowmetry (LDF) 
used to assess foveolar 
choroidal blood velocity, volume 
and flow. Laser diode beam 
670nm, intensity 20mW, probing 
laser beam diameter 200μm 
 
3 continuous 30s measurements 
of choroidal circulation taken per 
eye of which 12s of stable 
measurement was selected for 
analysis. 
 
Differences in mean circulatory 
parameters assessed by 
analysis of variance and test of 
linear trend. 
 
Choroidal blood velocity (average): 
Controls (0.43). AMD 1 (0.38). AMD 2 
(0.38). AMD 3 (0.37) arbitrary units. 
Increased risk of CNV was associated 
with decreased velocity (linear trend 
test). 
 
Choroidal blood volume (average): 
Controls (0.26). AMD 1 (0.25). AMD 2 
(0.23). AMD 3 (0.20) arbitrary units.  
 
Choroidal blood flow (average): 
Controls (9.80). AMD 1 (7.78). AMD 2 
(7.49). AMD 3 (6.54) arbitrary units. 
Increased risk of CNV was associated 
with decreased flow (linear trend test).  
 
Linear trend of velocity and flow remain 
statistically significant when adjusted for 
age and hypertension (important as 
increasing age causes decreased flow in 
controls). 
Decreasing choroidal blood flow 
with increasing AMD features. 
 
Result suggests foveolar choroidal 
blood flow is lower than normal in 
eyes with AMD and correlates to the 
fundus features associated with risk 
of CNV development i.e. choroidal 
blood velocity, volume and flow all 
decrease progressively with an 
increase in severity of AMD 
features.  
 
Results are suggestive that 
disturbances in the choroidal 
circulation could hinder the normal 
diffusion of substances across the 
RPE-Bruch’s membrane complex 
thus promoting an ischaemic 
environment.  
 
Author points out that loss of PRs 
during AMD may result in a reduced 
oxygen demand and decreased 
choroidal flow.  
 
Also changes to the intensity 
and coherence of laser light 
produced by AMD can 
theoretically affect the 
hemodynamic 
measurements, the 
comparison of LDF relative 
blood flow measurements 
between normal and AMD 
eyes is open to question. 
 
Compares study to those 
measuring pulse amplitude 
however relationship 
between choroidal blood 
flow and pulse amplitude is 
not clearly established. 
Regulation of 
sub-foveal 
choroidal blood 
flow in age-
related macular 
degeneration 
(Pournaras et 
al., 2006). 
56 eyes in total  
 
1 eye of each 
participant used, split 
over 3 groups: 
 
(1) 19 ‘young’ controls 
(age 24-44yrs) 
 
(2) 24 controls (age 
50-84yrs) with mild 
Laser Doppler flowmetry used to 
assess changes in foveolar 
choroidal blood velocity, volume 
and flow induced by increased 
perfusion pressure (achieved 
through isometric exercise).  
 
Measurements were taken at 3 
points: rest, standing and 
squatting.  
 
Squatting induced a significant increase 
in perfusion pressure (20-23%) that was 
similar in all groups.  
 
Measurements at the end of squatting as 
follows:  
 
Choroidal blood velocity (average): 
Young controls (3.0), elderly controls 
(5.7), AMD (7.3) arbitrary units. 
 
New vessels lack ability to regulate 
increased blood flow in nAMD. 
 
An acute systemic increase in BP 
(perfusion pressure) does not 
induce a significant change in 
choroidal blood flow in young or 
elderly subjects with early AMD. 
However in the presence of nAMD 
blood flow increases significantly. 
 
Highlights again that LDF 
data may be corrupted by 
changes in the laser light-
scattering properties of 
sampled (AMD) tissue – 
hence physiological stimulus 
of exercise is used in this 
study. Exercise is used in 
order to eliminate tissue 
scatter as cause of error 
with LDF (LDF subfoveal 
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macular pigmentary 
disturbances.  
 
(3) 23 subjects (age 
45-86yrs) with 
subfoveal CNV 
caused by AMD.  
Choroidal blood volume (average): 
Young controls (1.3), elderly controls (-
2.9), AMD (0.5) arbitrary units. 
 
Choroidal blood flow (average): 
Young controls (7.3), elderly controls 
(6.7), AMD (12.4) arbitrary units. 
 
Measurements for group 1 and 2 were 
not significantly different from baseline 
(before squatting). In the AMD blood 
volume and (significantly) blood flow 
increased following the exercise when 
compared to group 2.  
 
During exercise BP in the 
ophthalmic artery increases in 
parallel with that of the brachial 
artery. Therefore to find no increase 
in choroidal flow from before to after 
exercise (as with group 1 and 2) 
indicates a vascular resistance 
against the new perfusion pressure 
(brought about by either contraction 
of arteriole smooth muscle or 
contraction of pericytes surrounding 
the capillaries). 
 
The results suggest choroidal 
dysregulation of the AMD group 
which would allow over-perfusion in 
nAMD leading to increased 
exudation and bleeding. 
 
choroidal flow is largely 
constant in healthy 
volunteers in spite of 
changes in perfusion 
pressure caused by 
exercise). 
 
Author states that: new 
vessels have immature 
fenestrated endothelial cells, 
inadequate numbers of 
pericytes and inadequate 
sites of contact between 
endothelial cells and 
pericytes hence control of 
vascular diameter is poor. 
 
Delayed 
macular chorio-
capillary 
circulation in 
age-related 
macular 
degeneration 
(Zhao et al., 
1995). 
42 eyes in total.  
 
34 eyes with AMD (dry 
or nAMD, any stage of 
progression).  
 
8 Age-matched 
controls.  
Scanning laser ophthalmoscope 
(SLO) fluorescein video-
angiography used.  
 
The retina was divided into 8 
sections for analysis. 
Choriocapillary filling time was 
recorded in each sector (the 
time between the initial choroidal 
filling and the time at which 
choriocapillary filling was 
demonstrable in the entire 
sector).  
 
Filling time was correlated with 
the participant’s drusen number, 
size, type, area and degree of 
confluence.  
 
Areas of slow filling by neo-
vascularisation complexes were 
not considered when assessing 
the presence of delayed 
choriocapillary circulation. 
Macular choriocapillary filling time was 
prolonged in AMD.  
 
Mean macular filling time for controls 
was 1.71s. Mean macular filling time for 
AMD participants was 3.29s. 5s was 
deemed as a delayed filling time (mean 
normal macular choriocapillary filling time 
plus 3 standard deviations), this was met 
by 26% of the AMD eyes tested.  
 
Delayed choroidal filling in AMD was 
widespread and not confined to the 
macular region. Filling was more delayed 
nasally to the fovea (as opposed to 
temporally), inferiorly to the fovea (as 
opposed to superiorly) and near the 
fovea (as opposed to in the periphery). 
 
A greater incidence of GA of the RPE 
was found in AMD eyes with delayed 
choroidal filling (statistically significant 
when age corrected). Also a trend 
towards a higher incidence of CNV in 
AMD causes delayed choroidal 
filling which is proportional to drusen 
characteristics 
 
Results suggest clinically evident or 
hydrophobic drusen deposits impair 
bi-directional metabolic exchange 
across Bruch’s membrane 
culminating in CC atrophy. The 
biochemical characteristics of the 
drusen may cause more impediment 
in one direction i.e. CCs decline but 
RPE preserved. In these eyes it is 
hypothesised the CC atrophy 
triggers a wound healing response 
to the ischaemia leading to CNV.  
 
Eyes with delayed choroidal filling 
had less, but more confluent drusen 
in the inner subfield. Therefore the 
composition of the confluent drusen 
could be used to identify those 
predisposed to delayed filling (this is 
opposite to Paulikoff et al. 1990, the 
author speculates due to study 
Author comments on 
previous fluorescein 
angiographic analysis of 
choroidal filling times stating 
the short vascular filling 
time, fast outflow of 
fluorescein from the 
capillaries and frame speed 
of 1 photo per second limits 
precise analysis of filling 
times with this technique. A 
SLO gives 60 frames per 
second to improve this and 
provides better resolution of 
the short choriocapillary 
filling time.  
 
Areas of blocked choroidal 
fluorescence such as the 
xanthophyll containing 
foveal areas and RPE 
hyperpigmentation could not 
be analysed hence it is 
possible that the incidence 
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AMD eyes with delayed choroidal filling 
was found (not statistically significant).    
 
design, populations or disease 
severity).  
 
Less fluorescence of the inner 
subfield drusen in eyes with delayed 
filling suggests hydrophobic drusen 
(likely to impede the exchange of 
metabolites between the RPE and 
CCs).  
 
of delayed filling has been 
under-estimated.  
 
Results similar to Pauleikoff 
et al. (1990). 
 
Color Doppler 
imaging of 
choroidal 
circulation in 
patients with 
asymmetric age-
related macular 
degeneration 
(Üretman et al., 
2003). 
52 eyes in total 
 
26 participants who 
had dry AMD in one 
eye and nAMD in the 
fellow eye. 
Laser Doppler flowmetry of the 
ophthalmic artery, nasal 
posterior ciliary artery and 
temporal posterior ciliary artery 
was performed in order to 
assess the blood flow velocity 
(peak systolic and end diastolic) 
alongside vessel pulsatilities and 
resistivity. 
It must be remembered that these 
comparisons are between dry AMD and 
nAMD eyes (not controls).  
 
In eyes with CNV, systolic and diastolic 
velocities were lower for each vessel with 
the exception of systolic velocity of the 
nasal posterior ciliary artery. 
 
In eyes with CNV, the pulsativity and 
resistivity index was higher for each 
vessel to a statistically significant degree. 
 
Decreased perfusion in nasal and 
temporal posterior ciliary arteries in 
nAMD more-so than dry AMD 
 
Results indicate that impaired 
choroidal blood flow could contribute 
to the pathophysiological process of 
CNV in eyes with AMD by 
predisposing the retina to ischaemia 
and hypoxia.  
 
It is still only speculated as to 
whether impaired blood flow plays a 
causative role in CNV development 
or whether it is secondary to CNV 
development.  
 
Author states that all 
differences found in velocity 
were not statistically 
significant. 
Retrobulbar 
circulation in 
patients with 
age-related 
maculopathy 
(Dimitrova et al., 
2002). 
22 eyes for study (1). 
42 eyes for study (2).  
 
44 participants with 
exudative AMD 
recruited over both 
trials alongside 32 
age-matched controls. 
 
11 with early AMD 
(drusen >63µm and/or 
atrophy of the RPE 
<175µm).  
 
33 with late AMD ( 7 
had PED, 18 had 
2 separate trials: 
(1) Study of retrobulbar 
circulation in stages of AMD 
(2) Study of retrobulbar 
circulation in patients with 
unilateral exudative AMD 
 
Color doppler imaging used to 
measure peak systolic velocity, 
end diastolic velocity, pulsatility 
and resistivity in the central 
retinal, posterior ciliary and 
ophthalmic arteries.   
 
 
In the posterior ciliary artery the 
pulsatility and resistivity (1.13 and 0.66) 
were significantly higher in the late AMD 
group than in the controls (0.97 and 
0.61) this was statistically significant. No 
such difference was found within the 
other vessels analysed. 
 
No significant differences found between 
early AMD participants and controls.  
 
In unilateral exudative AMD participants 
the end diastolic velocity was lower in the 
posterior ciliary artery of the fellow eye 
(2.48) when compared to the exudative 
(2.64) and control group (3.11). The 
pulsatility and resistivity index of this 
Circulatory dysfunction of the 
posterior ciliary artery was found 
(therefore the choroid) which may 
be related to AMD pathology.  
 
Irregularities in the retrobulbar 
circulation are not present in early 
AMD however manifest in later 
stages of the disease.  
 
Author speculates that increased 
scleral rigidity with AMD progression 
causes increased resistivity to 
choroidal blood flow and as a 
consequence a decrease in end 
diastolic velocity/increase in 
pulsatility and resistivity. 
Author adds that results for 
central retinal artery 
circulation are reliant on 
blood pressure/ posture 
during measurement hence 
cannot be relied upon when 
comparing between trials.  
 
Results consistent with Mori 
et al., 2001.  
 
Choroidal circulation in 
fellow eyes of unilateral 
nAMD is also compromised 
hence studies should not 
use them as a 
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CNV, 8 had disciform 
scarring).  
 
vessel was also higher for the exudative 
eye (1.15 and 0.67) when compared to 
both the fellow eye (1.14 and 0.66) and 
controls (0.97 and 0.61) however this 
was found not to be statistically 
significant.  
 
 
.  
representative of true 
circulation in early AMD. 
Ocular blood 
flow velocity in 
Age-related 
Macular 
Degeneration 
(Friedman et al., 
1995). 
50 eyes in total (age 
range 50-87, 75yrs 
median).  
 
23 eyes with nAMD.  
27 eyes with dry AMD 
(soft drusen without 
the presence of RPE 
detachment of CNV).  
 
74 aged-matched 
controls.  
Color Doppler imaging used to 
measure blood flow velocity 
(mean peak systolic and end-
diastolic) and vessel pulsatility in 
the ophthalmic artery, central 
retinal artery and vein, temporal 
and nasal short posterior ciliary 
arteries and the four vortex 
veins.  
Vessel pulsatility was found to be higher 
in participants with AMD (statistically 
significant for the nasal short posterior 
ciliary artery and central retinal artery).   
 
The pulsatility of the arteries that perfuse 
the eye is higher with the presence of 
AMD: Subjects whose pulsatility 
measures were in the upper tertile for the 
temporal short ciliary artery, central 
retinal artery and the nasal short 
posterior ciliary artery were 3, 3 and 11 
times more likely to have AMD than 
those in the lower tertile.  
 
Systolic and diastolic velocities tended to 
be lower in patients with AMD across all 
age groups (statistically significant for the 
temporal short posterior ciliary artery and 
central retinal artery). 
 
It is suggested that the higher 
pulsatility, combined with a lower 
end diastolic velocity, is evidence of 
an increase in the resistance of the 
short posterior ciliary arteries 
(indicating a decrease in the 
compliance of the choroidal vessels, 
combined with a decrease in their 
calibre in the presence of AMD).  
 
The author suggests that the 
decrease of compliance of the 
choroidal vessels is initiated by 
deposition of lipid in the 
sclera/Bruch’s membrane resulting 
in decreased perfusion (ischaemia), 
higher intravascular pressure or 
both which leads to impaired RPE 
transport, then drusen accumulation 
etc.  
 
IOP, hypertension, pulse pressure 
and smoking variables were found 
not to be significantly associated 
with AMD status. 
    
Author states that the 
pulsatility index is derived 
from the ratio of diastolic to 
systolic velocity and is less 
dependent on Doppler 
angle, machine settings, 
physiological conditions 
(hypertension) than 
measurements of absolute 
velocity.  
 
See Figure 4 for proposed 
sequence of AMD 
pathogenesis. 
 
Drusen and 
‘Choroidal filling 
defects’: a 
cross-sectional 
survey 
(Staurenghi et 
al., 1992).  
126 eyes in total 
 
68 eyes with hard 
drusen (<50μm, round 
lesions with sharply 
defined borders). 
Average age 65yrs. 
 
58 eyes with soft 
drusen (>50μm, ill 
Cross sectional study. 
 
Retrospective data taken from 
participants recruited to an 
ongoing case-control study.  
 
Fluorescein-angiography images 
analysed in order to categorise 
drusen and identify choroidal 
filling defect. 
 
19.1% (13 of 68) Participants with hard 
drusen had a choroidal filling defect. 50% 
(29 of 58) participants with soft drusen 
had a choroidal filling defect.  
 
No delayed filling correlation was found 
associated with IOP, hypertension or 
diabetes.  
 
A significant difference between the 
mean ages of the 2 groups was found. 
Results suggest an association 
between soft drusen and a choroidal 
filling defect.  
 
Eyes with abnormal choroidal filling 
tend to have fewer drusen that are 
less densely distributed in the 
central region (within 1600μm of the 
fovea).  
 
A deficiency of blood flow in 
this area not related to AMD 
(a true choroidal filling 
defect). 
 
A decrease in the effusion 
(flow) of dye from the 
choroidal capillaries. 
 
Lower penetration of dye 
into Bruch’s membrane due 
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defined borders). 
Average age 72yrs. 
 
Also FFA 
characteristics used to 
diagnose. 
 
Those with both were 
designated into the 
group of their 
predominant drusen 
type.  
Choroidal filling defect defined 
as adjacent areas, extending 
over at least 2 disk areas of 
choroidal hypofluorescence still 
evident at the end of the venous 
laminar phase.  
 
This had no bearing on the mean age of 
participants with choroidal filling defects 
(69yrs hard drusen and 68yrs soft 
drusen).  
 
The prolonged choroidal filling 
phase observed using FFA is likely 
to be associated with hydrophobic 
material in Bruch’s membrane 
leading to an overall thickening of 
the layer. Evidence suggests this 
causes difficulty with metabolite 
transportation from the RPE to the 
choroid and results in choriocapillary 
irregularity.  
 
Author recognises that the criteria 
used (the appearance of a 
prolonged choroidal filling phase 
during FFA) cannot be used to 
diagnose a perfusion defect with 
100% certainty as it could be 
caused by:  
 
to altered composition 
(hydrophobic drusen altering 
the diffusion characteristics 
and binding properties of 
fluorescein). 
Pulsatile ocular 
blood flow study: 
decreases in 
exudative age-
related macular 
degeneration 
(Mori et al., 
2001).  
90 eyes in total. 
 
10 participants with 
dry AMD,  
 
11 participants with 
nAMD. 
 
69 age-matched 
controls. 
 
Participants with 
hypertension were 
included in the study.  
Pulsatile ocular blood flow 
(POBF) and pulse amplitude 
(PA) taken with participants in 
sitting position using a 
computerised tonometer (gives a 
measurement of total choroidal 
blood flow). The mean of 5 
pulses was recorded. 
 
Also recorded was: 
systolic/diastolic blood pressure, 
IOP (Non-contact tonometer), 
refractive error 
(Autokeratorefractometer) and 
axial length (A-scan biometric 
ultrasound).   
 
 
 
 
Participants with nAMD had a lower PA 
(median 1.2mmHg) than those with dry 
AMD (median 2.2mmHg) and controls 
(2.0mmHg).  
 
Participants with nAMD had a lower 
POBF (median 372.7μl/min) than those 
with dry AMD (607.0μl/min) and controls 
(547.4μl/min). 
 
30% decrease in POBF for nAMD 
participants when compared to controls 
and those with dry AMD.  
 
No significant differences in PA or POBF 
were found between those with dry AMD 
and the controls.  
 
No significant differences were found in 
age, systolic and diastolic blood 
pressures, IOP, refractive error and axial 
length between AMD and control 
participants. 
 
The total choroidal flow is lower in 
participants with nAMD, hence 
results correlate with those finding 
lower blood flow velocity in the short 
posterior ciliary arteries.  
 
Thickening of Bruch’s membrane 
(associated with prolonged filling 
time observed in FFA) may induce 
increased vascular resistance of the 
choroid and decreased choroidal 
blood flow, leading to ischaemia. 
 
Choroidal blood flow was found to 
be lower in the centre of the fovea 
for participants with dry AMD (when 
compared to controls) by Grunwald 
et al., 1998. These results do not 
correlate and suggest that only local 
choroidal flow in the centre of the 
fovea may decrease however total 
choroidal flow does not.  
Results do not correlate with 
Lang et al. 1994. The author 
suggests axial length was 
not accounted for by Lang et 
al., 1994. When a POBF 
decrease was reported for 
dry AMD participants.  
 
 
Decreased total choroidal 
flow may induce CNV via 
angiogenic factor induced by 
hypoxia. Stated by Chen et 
al. 2001. The disease 
activity of the nAMD is 
unknown: disciform scar or 
active CNV?  
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Presumed 
macular 
choroidal 
watershed 
vascular filling, 
choroidal 
neovascularisati
on and systemic 
vascular disease 
in patients with 
age-related 
macular 
degeneration 
(Ross et al., 
1998). 
94 eyes in total.  
 
74 patients with age-
related macular 
degeneration (mean 
age 75.1yrs) 
 
20 age-matched 
controls (referred for a 
uniocular condition 
and underwent 
videoangiography on 
their ‘healthy’ fellow 
eye).  
 
Eyes with dry AMD 
were classified as 
having multiple 
drusen, GA or both 
(17.6% of AMD 
cohort).  Eyes with 
nAMD were classified 
as having CNV, PED 
or both (82.4% of 
cohort).  
 
Retrospective study of randomly 
selected indocyanine green 
videoangiograms (25mg dye in 
1.25ml solvent followed by 5ml 
saline flush). Images taken 
every 2s for 30s and then 
intermittently for 30mins.  
 
The record of each participant 
was assessed, including results 
of a complete ocular 
examination, FFA, contact lens 
biomicroscopy and current 
systemic medication (used to 
derive info on hypertension, 
diabetes, coronary disease and 
vascular disorders).  
41 of 74 AMD eyes (55.4%) exhibited 
presumed macular choroidal watershed 
vascular filling (PMWF) versus 3 of 20 
(15%) control participants (none of which 
displayed PMWF near or adjacent to the 
fovea).  
 
Hypertension was noted in 24 of 41 
(58.5%) participants with AMD and 
PMWF versus 9 of 33 (27.3%) 
participants with AMD and no PMWF.  
 
No significant difference was found when 
comparing the incidence of coronary 
heart disease, hypertension, vascular 
disease and diabetes in the AMD versus 
control groups. 
 
5 of 13 (38.5%) eyes with dry AMD 
versus 36 of 61 (59.0%) eyes with nAMD 
exhibited PMWF of which 33 of 41 
(80.5%) exhibited PMWF through or 
adjacent to the fovea.  
 
Of the 41 participants with AMD and 
PMWF 36 (87.8%) had CNV. In 33 
(91.7%) the CNV arose from the 
watershed zone or its margin. 
 
Results of previous angiographic 
studies indicate that the 
choriocapillaries consist of lobular 
beds, each acting as an 
independent unit with no functional 
adjoining connection of blood 
streams. Results documented here 
suggest watershed zones represent 
areas susceptible to ischaemia.  
 
Numerous watershed zones of the 
short posterior ciliary arteries and 
vortex veins meet at the highly 
metabolically active macular. 
Combined with a high pressure 
gradient and rapid blood flow this 
area is particular vulnerable to 
hypoxic assault.  
 
Participants with dry AMD and large 
PMWF zones may be at a higher 
risk of CNV development, 
destruction of these zones or 
improvements to their flow may aid 
in preventing AMD progression. 
 
Data supports theory that underlying 
systemic vascular disease such as 
hypertension further augments the 
tendency for PMWF in the presence 
of AMD.  
 
Indocyanine green results of 
Hayashi and Laey. 1985. 
May be corrupted by poor 
eligibility criteria.  
 
Diabetes showed a negative 
correlation with PMWF. 
Possibly explained by 
diabetic systemic autonomic 
neuropathy, which can 
involve ocular uveal 
sympathetic pathways. 
(Choroidal sympathetic 
denervation could alter 
microvascular perfusion 
gradients or increase 
choroidal blood flow, thus 
minimising ischaemia and 
the tendency for PMWF).  
 
Study limited by low number 
of controls and participants 
with systemic complications 
of a vascular origin.  
 
Author suggests AMD 
pathogenesis theory (page 
76).  
 
Changes of 
retinal capillary 
blood flow in 
age-related 
maculopathy 
(Remsch et al., 
2000).  
47 eyes in total 
 
10 eyes with early 
AMD (drusen >63μm 
and/or RPE atrophy 
<175μm) 
 
13 with nAMD. 10 with 
end stage AMD 
(fibrotic scarring) 
 
HRF two-dimensional confocal 
scanning laser Doppler 
flowmetry used to record retinal 
capillary blood volume, flow and 
velocity in 6 retinal sectors (I-IV 
over foveal region, V-VI outside 
vascular arcades) 
 
Classification based on 
ophthalmic examination, FFA.  
Systemic vascular disorder was 
excluded.  
Participants with early AMD showed no 
significant change in choroidal volume, 
flow or velocity in any sector when 
compared to controls.  
 
Participants with nAMD showed 
significantly higher flow in areas I, II and 
IV and higher volume in areas III and IV 
when compared to controls. 
 
Participants with end-stage (fibrotic) 
AMD showed a reduction of velocity in 
Results show a marked disturbance 
of retinal capillary blood flow in 
participants with nAMD (raised 
blood flow) and end-stage AMD 
(reduced perfusion).  
 
Early vascular abnormalities cannot 
be used as a risk factor for AMD 
development in children of those 
currently affected.  
Author remarks that this 
technique cannot be 
compared directly to 
conventional laser Doppler 
flowmetry.  
 
Raised blood flow could be 
due to auto-regulative 
vascular response due to 
compromised metabolism, 
hence cannot be used as an 
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14 normal eyes of 
children of participants 
with AMD (Mean age 
46yrs, versus mean 
age of AMD 
participants of 72yrs) 
 
 
Heart rate, blood pressure and 
IOPs monitored.  
 
sectors II and IV and a reduction of 
volume and flow in sectors I-IV.  
 
In children of AMD participants in 
changes were found when compared to 
the control group. 
 
AMD pathogenesis model 
with complete certainty.  
Evolution of 
age-related 
macular 
degeneration 
with choroidal 
perfusion 
abnormality 
(Piguet et al., 
1992) 
96 eyes in total (all 
over 57yrs old). 
 
46 had drusen in both 
eyes. 
 
50 had drusen in one 
eye and dry or nAMD 
in the fellow eye. 
 
Participants recruited 
from an existing 
longitudinal study of 
AMD had visible 
drusen and underwent 
FFA. GA and PED 
were not included in 
this study. 
Cross sectional study in which 
fluorescein angiography (FFA) 
was used. 
 
As opposed to normal rapid 
filling, abnormal choroidal 
perfusion was classified as a 
continuous area of prolonged, 
patchy choroidal fluorescence 
during the transit phase of the 
angiogram  
 
This pattern of choroidal filling is 
characteristically seen in 
participants with known 
choroidal hypoperfusion as part 
of a general vascular disorder.  
 
A long choroidal filling phase was 
identified in 32 eyes (normal dye transit 
in 64 eyes). 
 
The number of new lesions associated 
with vision loss (a reduction of 2 Snellen 
lines or more) was significantly greater in 
eyes with prolonged choroidal filling (12 
of 32 [37.5%], P<0.1) than in those with 
normal perfusion (9 of 64 [14%] ).  
 
17 of the 32 eyes (53.1%) with prolonged 
choroidal filling had GA whereas 9 of the 
64 eyes (14%) with normal dye transit 
had GA (P<0.001).  
 
Newly developed GA caused vision loss 
in 7 of the 32 eyes (21.9%) with 
prolonged choroidal filling. CNV 
manifested in 4 eyes with prolonged 
choroidal filling (12.5%) and 7 eyes with 
normal dye transit (10.9%). 
  
Evidence suggests that eyes with 
prolonged choroidal filling are more 
at risk of vision loss (through the 
development of GA) than those 
without the clinical sign.  
 
During early stages nAMD causes a 
greater degree of visual loss 
however it is expected that long 
term vision loss caused by 
progressive GA can be more 
detrimental.  
 
 
Failure of the RPE to deliver 
diffusible substances to the choroid 
may result in the choriocapillaries 
being unable to change from a 
sinusoidal system to a tubular 
arrangement (seen in most capillary 
beds). 
The age, gender and period 
of review were not 
statistically significant. 
 
The degree of vision loss 
was on average 3 lines with 
newly developed GA and 5 
lines with CNV.  
 
Potential pathway 
suggested: slow filling of the 
choriocapillaries indicates a 
change in blood flow likely to 
be brought about by the 
accumulation of deposits in 
Bruch’s membrane which 
impair metabolic exchange.  
Pulsatile ocular 
blood flow in 
asymmetric 
exudative age 
related macular 
degeneration 
(Chen et al., 
2001). 
74 eyes in total 
 
37 participants 
categorised into 3 
groups:  
 
(1) 21 with drusen in 1 
eye and nAMD in the 
fellow eye, 
 
(2) 9 with a disciform 
scar in 1 eye and 
drusen in the fellow 
eye,  
Pulsatile ocular blood flow 
(POBF) was performed using an 
OBF tonometer on a seated 
participant.  5 pressure pulses 
were also averaged in order to 
determine the pulse amplitude 
(PA).  
 
IOPs were also measured using 
contact tonometry.  
 
Blood pressure was taken and 
ocular perfusion pressure (OPP) 
was calculated.  
Group 1 nAMD eyes had higher POBF 
than their fellow eyes with drusen only 
(when corrected for IOP and OPP).  
 
Eyes with disciform scarring in group 2 
had lower POBF than their fellow eyes 
with drusen only. 
 
The IOP and OPP showed no significant 
difference between the fellow eyes of 
groups 2 and 3 but marginal significant 
difference between the eyes in group 1. 
 
POBF was different between the 
fellow eyes of the individuals was 
asymmetric nAMD.  
 
Because the calculated OPP was 
not seen to be different between the 
2 eyes in a single subject, it is 
speculated that the discrepancy in 
POBF may originate in a more distal 
vessel i.e. the retrobulbar vessels or 
the eye wall itself.  
 
The asymmetric pulsation found 
could have 2 causes: the pulsatile 
Author states POBF 
measures choroidal 
circulation and contribution 
from retinal blood flow is 
negligible. However, there is 
still a contribution. Krakau. 
1995. and Langham et al. 
1989 give more detail on the 
floors of this technique.  
 
Author recognises POBF is 
not a flawless technique: the 
components of pulsatile 
blood flow to the total blood 
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(3) 7 with a disciform 
scar in 1 eye and CNV 
in their fellow eye. 
 
Strict and numerous 
criteria stated for 
grading AMD and 
eligibility. 
 
 No statistically significant differences 
found between age, sex or blood 
pressure between the groups.  
 
The correlation of POBF to the CNV 
lesion size was insignificant.   
components of the choroidal blood 
flow are dynamically influenced 
during the development of nAMD. A 
disciform scar may replace an active 
CNV, disorganise the 
choriocapillary-Bruch’s membrane 
complex and damage the outer 
retina (thus decreasing the need 
and supply of the choroidal vessels 
in this eye). Reversely eyes with 
active CNV are likely to attract more 
blood flow to feed the new vessel 
growth. Alternatively increased 
asymmetrical scleral rigidity is more 
pronounced in the CNV eyes of 
group 1 and drusen eyes of group 2 
(unlikely).  
 
flow is unclear and ranges 
from 50-80%.  
 
There is high inter-individual 
variation and factors such as 
age, sex, hypertension, 
blood velocity, blood 
viscosity may affect 
readings.  
 
Results of group 3 possibly 
corrupted by 2 participants 
with leaking disciform scars 
and CNV in their fellow eye.  
 
Topographic 
variation of the 
choroidal 
watershed zone 
and its 
relationship to 
neovascularisati
on in patients 
with age-related 
macular 
degeneration 
(Mendrinos and 
Pournaras, 
2009). 
50 eyes in total. 
 
ICG video-angiograms 
reviewed of 50 
participants (20 male, 
30 female).  
 
Mean age was 78.7yrs 
(range 55-94yrs).  
 
AMD was classified 
via reviewing the FFA 
of each participant. All 
forms and stages of 
nAMD were included. 
Cases of AMD with no 
clearly visible WZ 
were not used. 
 
CNV Graded using the 
Treatment of age-
related macular 
degeneration with 
photo-dynamic 
therapy study group. 
1999. Scale.  
Cross sectional retrospective 
study using digital indocyanine 
green (ICG) video-angiography 
 
WZ zones were classified due to 
shape:  
 
Stellate pattern: consists of a 
vertical portion (corresponding to 
the WZs between the medial 
and lateral PCAs) associated 
with multiple, smaller, triangular 
zones (corresponding to the 
WZs between the branches of 
the lateral PCA).  
 
Vertical WZ only: running 
vertically through the ONH and 
fovea. 
 
Angle-shaped WZ: running at an 
angle through the ONH and 
fovea.  
CNV occurred within the WZ in 88% of 
participants. In the remaining 12% CNV 
occurred at the WZ margin.  
 
Stellate pattern (60% participants): the 
triangular WZs are seen to meet in the 
centre of the macular. CNV occurred 
within the centre of these WZs in all 
cases.  
 
Vertical WZ only (36% participants): 
CNVs were located in the area at which 
the WZ passes through the fovea in 
66.7% of cases. In the remaining cases 
the CNV was found at the temporal 
margin of the WZ and extended towards 
the fovea.  
 
An occult CNV was found in 13 of 50 
participants (1 with an angle-shaped WZ, 
5 with a vertical WZ and 7 with a stellate 
pattern).  
 
Predominantly classic CNV was found in 
15 of 50 participants (5 with a vertical 
WZ and 10 with a stellate pattern).  
A part of every watershed zone 
involved the macular region (even if 
it did not course through the fovea 
directly). 
 
The area at which WZs meet is an 
area of relatively poor blood flow 
supply and is consequently most 
vulnerable to ischaemic disorders. 
As in the majority of participants 
WZs met at the macular region it is 
this area that is anatomically 
predisposed to chronic ischaemia 
more than any other part of the 
posterior choroid.  
 
Combined with: 
Delayed filling and lowered 
perfusion pressure of the macular 
vasculature could predispose to 
AMD.  
 
Findings agree with Hayashi and De 
Laey (1985), Ross et al. (1998). and 
Giovanni et al. (1994) however this 
study only incorporated participants 
Anatomically the choroidal 
blood supply comes from 2 
posterior ciliary arteries 
(PCAs). In vivo studies on 
the choroidal vascular bed 
show that the PCAs and all 
their choriocapillary branch 
are segmentally structured 
and thus behave like end-
arteries (individually 
supplying only one portion of 
tissue). Each choriocapillaris 
lobule functions as an 
independent unit with no 
anastomoses with adjacent 
lobules. The borderline area 
between territories of 2 end-
arteries is defined as a 
watershed zone (WZ). 
 
Author states ICG is a highly 
protein-bound dye that 
provides enhanced imaging 
of the choroidal vessels in 
comparison to fluorescein 
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Minimally classic CNV was found in 6 of 
50 participants (1 with a vertical WZ and 
5 with a stellate pattern).  
 
with nAMD (hence higher 
percentages of CNV found in 
relation to WZs). Also no control 
group used and technique requires 
subjective interpretation of the 
angiogram to determine WZ 
boundaries. 
 
which rapidly leaks out of 
the vasculature. 
 
Quantification of 
choroidal blood-
flow parameters 
using 
indocyanine 
green video-
fluorescence 
angiography and 
statistical picture 
analysis (Prünte 
and Niesel, 
1988).  
 
10 eyes in total. 
 
5 participants with dry 
AMD (determined by 
the presence of hard 
drusen, 
hyperpigmented RPE 
and RPE atrophy) 
 
5 age-matched 
controls.   
  
ICG Videoangiography.  
 
A solution of 0.3 mg/kg ICG was 
dissolved in 0.02 ml/kg of water 
and injected into the cubital vein.  
 
Picture processing analysis 
software was used in order to 
enhance the obtained images.  
 
The arteriole filling time was delayed in 
those with AMD (P<0.05).  
 
The capillary peak filling time was 
delayed in those with AMD (P<0.01).  
 
Control participants displayed a lower 
coefficient of variance of grey values 
(CVG) indicating a higher perfusion rate.  
 
The reduced perfusion found of 
AMD participants is likely to be due 
to morphological changes caused 
by the disease.  
 
More research is necessary to 
determine specifics of choroidal 
disruption. 
 
Localised 
reticular 
pseudodrusen 
and their 
topographic 
relation to 
choroidal 
watershed 
zones and 
changes in 
choroidal 
volumes (Alten 
et al., 2013).  
60 eyes in total. 
 
30 patients (22 
females, 8 males) of 
mean age 76.7yrs. 
 
30 age-matched 
controls.  
 
Participants were only 
eligible if they 
displayed reticular 
pseudodrusen (RPD) 
smaller than 10mm2 in 
the macular area.  
 
Signs of conventional 
soft or hard drusen, 
CNV, PED or GA were 
excluded.  
Multiple techniques used. 
 
Fundoscopy, fundus auto 
fluorescence (FAF), infrared 
reflectance (IR) and fluorescein 
angiography (FFA) were used to 
determine eligibility.  
 
Indo-cyanine green angiography 
(ICG) used to classify shape of 
WZ.  
 
Confocal scanning laser 
ophthalmology (cSLO) was used 
to quantify the area affected by 
RPD.  
 
Spectral domain-optical 
coherence tomography (SD-
OCT) was used to calculate 
choroidal volume and thickness. 
WZs were detected in 83.3% of RPD 
eyes and 40% of controls. A stellate 
pattern was present in 40%, a vertical 
WZ was present in 44% and an angle-
shaped WZ was present in 16.0% of 
RPD eyes studied.  
 
Correlation between the presence and 
localisation of RPD with the pattern of 
WZ was unable to be made due to lack 
of numbers.  
 
Mean retinal area affected by RPD was 
7.45mm2. This area was localised fully or 
partially within the WZ of 22 out of 25 
study eyes (88.0%).  
 
Mean choroidal volume was reduced 
significantly in the study group 
(4.49mm3) versus the controls 
(5.85mm3). P<0.05.  
 
RPD development and progression 
may be driven by ischaemia starting 
with diffuse loss of small choroidal 
vessels and submacular choroidal 
thinning (confirmed by the presence 
of WZs combined with reduced 
choroidal volume and thickness). 
 
Areas of RPD were never situated 
nasally to the ONH and most 
frequently found superiorly to the 
fovea. The author speculates that 
RPD are likely to originate from rod 
rather than cone PR metabolism 
due to their position in the outer 
macular.  
 
 
RPD are most frequently 
found between the superior 
fovea and superior temporal 
arcade (visible via cSLO, 
FAF, IR and SD-OCT). They 
have a punctate white/grey 
appearance close to the 
fovea (as opposed to yellow, 
ill-defined drusen). An 
average RPD diameter is 
between 50-400μm.   
 
Subjective interpretation of 
WZ via ICG is not ideal.  
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Mean choroidal volume and choroidal 
thickness in the area most affected by 
RPD were both diminished to 0.85mm3 
and 171μm when compared to the same 
area within controls (1.11mm3 and 
225μm).  
 
The association 
between drusen 
extent and 
foveolar 
choroidal blood 
flow in age-
related macular 
degeneration 
(Berenberg et 
al., 2012).  
239 eyes in total. 
 
157 participants with 
AMD (mean age 
71yrs).  
 
Mean systolic blood 
pressure 137mmHg, 
mean diastolic blood 
pressure 75mmHg. 
 
CNV in the study eye 
(and any other ocular 
pathology) was 
excluded. 
Foveolar blood flow velocity, 
volume and flow measured 
using laser Doppler flowmetry.  
 
670nm diode laser beam with 
20mW intensity (beam diameter 
200µm). 3 continuous 30s 
measurements of the choroidal 
circulation were obtained of 
which a stable 12s section was 
used for analysis. 
 
Individual druse area, total 
drusen area and shortest 
distance between the druse 
edge and the fovea 
measurements were recorded 
by specially developed fundus 
camera software and assessed 
manually by a grader.  
 
Total number of drusen within 3000µm of 
the foveola ranged from 1-846 (median 
126). Total drusen area ranged from 
0.001mm2-9.62mm2 (median 1.65mm
2). 
Average druse area ranged from 
0.001mm2-0.097mm2 (median 0.01mm2). 
 
For every 1- mm2 increase in total drusen 
area, volume decreased by 0.0061 
(P=0.03) and flow decreased by 0.23 
(P=0.049). Association after age 
adjustment became less strong. 
 
For every 0.01- mm2 increase in average 
druse area, the volume decreased by 
0.0149 (P=0.001) and flow decreased by 
0.495 (P=0.003). Remained statistically 
significant after adjustment for age 
(P=0.004) and (P=0.017).   
 
The number of drusen was not 
significantly associated with choroidal 
circulatory measurements.   
 
Results suggest that in participants 
with dry AMD, eyes with a larger 
extent of drusen, as measured by 
total drusen area and average druse 
area, tend to have decreased 
choroidal blood volume and flow 
(which suggests that the area 
covered by drusen may be an 
important determinant of disease 
risk). 
 
Results indicate as drusen coalesce 
with advancing AMD there is a 
larger negative effect on choroidal 
blood volume and flow. A reduction 
of choroidal blood flow may also 
propagate drusen formation as it 
slows the removal of waste products 
from the RPE-Bruch’s complex.  
 
Results indicate that total drusen 
area is more correlated with 
decreased flow than actual number 
of drusen.  
Advantage of manual 
assessment of drusen: 
better discernment of drusen 
versus non-drusen, 
decreased false positives 
and false negatives.  
 
Advantage of computer 
assessment of drusen: 
reduced grading time, 
improved quantitative data, 
use of technical advances in 
digital image manipulation.  
 
There is a possibility that 
blood flow measurements 
are affected directly by the 
presence of drusen i.e. 
drusen interfere with laser 
Doppler blood flow 
measurement. 
Association of 
risk factors for 
choroidal 
neovascularisati
on in age-
related macular 
degeneration 
with decreased 
foveolar 
choroidal 
circulation (Xu et 
al., 2010). 
298 eyes in total. 
 
269 study eyes in total 
from 204 non-
exudative participants 
recruited (mean age 
71yrs) of which 55.9% 
were female.  
 
6.4% were current 
smokers. 44.6% had a 
history of systemic 
hypertension. 61.8% 
Laser Doppler flowmetry 
measurements from the centre 
of the foveola were performed to 
obtain data on blood velocity, 
volume and flow.  
 
Measurements were taken on a 
seated participant using a 
670nm laser beam (20mW 
intensity). Blood pressure and 
IOP (Goldmann tonometry) data 
was also taken.  
 
A significant inverse correlation was 
observed between age and choroidal 
blood flow and volume (P<0.0001 for 
both). Patients with increasing age tend 
to have lower choroidal blood flow and 
volume (maintained following adjustment 
for all other risk factors).  
 
A significant inverse correlation was 
observed between spherical correction 
and choroidal blood flow (P=0.006) and 
volume (P=0.04). Patients with more 
The results of the study indicate flow 
and volume (but not velocity) 
decrease with age. This is likely due 
to age-related changes in capillary 
structure (decreases in lumen 
diameter and choriocapillary 
density).  
 
Systemic hypertension does appear 
to be related to irregularities in 
choroidal blood flow. It is speculated 
that hypertension may contribute to 
AMD pathogenesis through 
No significant correlation 
between choroidal blood 
flow and actual blood 
pressure at the time of 
measurement was found. 
 
No correlation with race, eye 
colour or kidney disease 
was found however the 
author states this is not 
conclusive due to small 
numbers of participants 
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had a history of 
cardiac disease. 8.8% 
had a history of kidney 
disease. 58.4% had 
RPE hypertrophy.    
 
29 Controls used from 
previous study of 
which one eye used in 
each (Grunwald et 
al.1998).  
Structured questionnaire used to 
obtain information on age, 
gender, race, smoking, medical 
history, eye colour and family 
history of AMD. 
hyperopia tended to have lower choroidal 
blood flow and volume.  
 
Patients with a history of hypertension 
had choroidal blood volume (0.21 AU) 
and flow (6.94 AU) which were 
significantly lower than those observed in 
patients without hypertension (0.25 
[P=0.007] and 7.97 [P=0.003] AU). 
 
Patients with RPE hypertrophy had 
average choroidal blood volume (0.22) 
and flow (6.94) which were significantly 
lower than those of eyes without 
hypertrophy (0.25 [P=0.01] and 7.78 
[P=0.04] AU).  
 
promoting an ischaemic 
environment (leading to WZ hypoxia 
and CNV).  
 
RPE hyperpigmentation was 
associated with decreased blood 
flow, it is suggested that hypoxia 
may play a role in the formation of 
RPE changes through moderating 
RPE proliferation and migration.  
within the cohort of which 
these sub-categories apply.  
 
No association with 
smoking, cardiac disease or 
gender was found however 
the author states this is likely 
to be connected with the 
involvement of other 
pathogenic mechanisms that 
are not related to ischaemia 
or hypoxia i.e. oxidative 
damage and inflammatory 
pathways. 
Age-related 
macular 
degeneration: 
choroidal 
ischaemia? 
(Coleman et al., 
2013). 
69 eyes in total.  
 
52 patients recruited: 
18 controls, 23 dry 
AMD, 28 nAMD.  
High resolution ultrasound  
 
(20mHz ultrasound scans on 
each eye using a B-scan 
immersion technique). A 
prototype instrument of the 
authors design was used (based 
on a wavelet analysing 
technique and passing data 
through VDU based software for 
analysis). 
 
Fundus photography, OCT and 
ICG was measured in order to 
identify AMD type.  
 
Technique able to separate visible areas 
of tissue from areas of fluid via their 
boundaries. 
 
In dry AMD, the wavelet descriptors 
showed a reduction in boundary contrast 
meaning decreased fluid to tissue ratio 
when compared to control eyes 
(indication of choroidal ischaemia in dry 
AMD).  
 
In nAMD there was an increased 
boundary enhancement which could be 
caused by an enhanced blood supply or 
other causes such as inflammation of 
microvascular anomalies.   
 
Results confirm a principal 
correlation of dry AMD and 
choroidal dysfunction. It is 
hypothesised that ischaemia, 
primarily of Sattler’s layer of the 
choroid, exists in nearly all cases of 
dry AMD. This smooth muscle 
endothelial dysfunction of the 
terminal arterioles would reduce the 
production of nitric oxide (a 
messenger molecule produced by 
the endothelium) leading to 
dysfunction.   
 
Alternatively the arteriolar damage 
may be caused by parasympathetic 
neuronal deterioration leading to 
reduced perfusion of the 
extracellular region surrounding the 
RPE.  
 
Author speculates that 
pharmaceutical agents such 
as sildenafil, tadalafil and 
niacin could aid with 
increased choroidal 
perfusion and delay AMD 
pathogenesis.  
Morphometric 
analysis of 
Bruch's 
membrane, the 
choriocapillaris, 
and the choroid 
120 eye in total.  
 
25 eyes with 
advanced AMD.  
 
95 controls.  
Histological analysis.  
 
After fixation in formaldehyde a 
horizontal tissue block of the 
ONH and macular was 
The changes  relating to normal ageing  
were recorded as:  
 
An increase in Bruch’s membrane from 
2.0μm to 4.7μm on average. A decrease 
of choriocapillaris from 0.75 (1st decade) 
Results indicate that capillary 
density diminished in a linear 
fashion with increasing age. The 
reason for this is unknown. In eyes 
with AMD the decrease in capillary 
density and diameter was 
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in aging 
(Ramrattan et 
al., 1994).  
dehydrated and embedded in 
paraffin.  
 
7μm thick sections were then 
stained for light microscopy 
analysis. Measurements 
included thickness of Bruch’s 
membrane, lumen diameter and 
choroidal thickness at the fovea.   
to 0.41 (10th decade). A decrease in 
choriocapillaris diameter from 9.8μm (1st 
decade) to 6.5μm (10th decade).   
 
With regards to normal and pathological 
macular differences:  
 
The thickness of Bruch’s membrane did 
not significantly differ from normal in 
areas of basal laminar deposit or GA. It 
was however thinner in areas of 
disciform scarring.  
 
Choriocapillaris diameter was 
significantly decreased in areas of GA 
and disciform scarring. 
 
significantly larger than comparable 
normal counterparts.  
 
The presence of basal laminar 
deposits, GA or disciform scarring is 
associated with a reduction of 
choriocapillary density most likely by 
induced hypoxia derived from 
interference with diffusion across 
the RPE – PR complex.   
 
Results suggest that the 
choriocapillaris diameter is not 
related to the thickness of Bruch’s 
membrane hence an alternate 
theory based on increased weight of 
Bruch’s applying pressure onto the 
vasculature below can be dispelled. 
  
Histologic and 
morphometric 
analysis of the 
choroid, Bruch’s 
membrane, and 
the retinal 
pigment 
epithelium in 
post-mortem 
eyes with age-
related macular 
degeneration 
and histologic 
examination of 
surgically 
excised 
choroidal 
neovascular 
membranes 
(Spraul et al., 
1999) 
80 eyes in total.  
 
19 eyes with dry AMD.  
 
21 eyes with nAMD.  
 
40 controls.  
Histological analysis.  
 
Eyes were opened horizontally 
and examined via the use of a 
dissection microscope in order 
to diagnose as dry AMD, nAMD 
or control.  
 
The ONH and macular were 
removed, dehydrated in ethyl 
alcohol and 5μm thick sections 
were stained with acid-schiff 
before being slide mounted.  
 
The presence and severity of 
basal laminar deposit (BLD) was 
assessed alongside the number 
and type of drusen, thickness of 
the RPE, Bruch’s membrane 
and the choroid. The density and 
diameter of capillaries and 
choroid vessels was also noted.  
 
As a secondary investigation the 
same procedure and 
The density of large choroidal vessels 
was significantly reduced in both the 
nAMD (13.6 vessels mm-1) and dry AMD 
(3.5 vessels mm-1) when compared to 
controls (0.51 vessels mm-1) however 
this was only significant for veins 
(P<0.001).  
 
Choriocapillary density was increased in 
the AMD groups: nAMD (0.61), dry AMD 
(0.63) in comparison to controls (0.51).  
 
A significant difference was found 
between the AMD and control group 
regarding the amount of BLD present. No 
such difference was found between AMD 
groups.  
 
The difference in drusen found (in terms 
of the percentage of eyes within each 
group was as follows:  
 
Hard drusen: nAMD (73%), dry AMD 
(77%), controls (57%).  
 
The presence of AMD in any form 
results in increased BLD. Excess 
BLD is likely to disrupt the fragile 
balance of RPE derived factors 
required for healthy vasculature 
maintenance by hindering diffusion 
across Bruch’s membrane.  
 
Results with regards to thickness 
correlate with Ramrattan et al. 
(1994). The result suggests that 
deposition of BLD within Bruch’s 
membrane does not cause a 
significant change in its thickness.  
 
Choriocapillary findings differ to 
Ramrattan et al. (1994) however the 
choriocapillary characteristics 
measured in this study were in the 
majority from eyes at less advanced 
stages of AMD. As a result it has 
been determined that in early AMD 
the choriocapillaris appear to be 
relatively unchanged.  
 
BLD is a material composed 
mostly of wide spaced 
collagen embedded in a 
granular matrix associated 
with membrane bound 
structures and fibronectin. It 
may be produced by 
damaged RPE cells.  
 
Read pg 529 for more 
information on pathogenesis 
theory.  
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measurements were applied to 
surgically removed CNVM’s.   
 
Soft drusen: nAMD (64%), dryAMD 
(62%), controls (3%).  
 
More Bruch’s membrane breakages 
were documented in nAMD than dry 
AMD or control groups.  
 
No difference in RPE thickness was 
found between the groups.  
 
Soft, diffuse and large drusen 
alongside BLD are associated with 
development of AMD. Calcification 
and fragmentation of Bruch’s 
membrane appears synonymous 
with nAMD development. 
Increased 
scleral rigidity 
and age-related 
macular 
degeneration 
(Friedman et al., 
1989).  
58 eyes in total.  
 
29 patients with AMD 
most of which had 
either a disciform scar 
or drusen and 
pigmentary changes.  
 
50 age-matched 
controls.  
 
 
Contact Tonometry.  
 
Goldmann, Perkins (to verify 
Goldmann reading) and Schiotz 
tonometry performed on each 
participant.  
 
Initially an ultrasound A-scan 
was performed in order to 
determine axial length and 
fundus photos were taken to 
grade the AMD.  
 
Scleral rigidity was estimated 
using a Friedenwald nonogram2 
by graphically plotting the 
applanation IOP. 
 
IOP in those with AMD was slightly lower 
on average than controls (not 
significant).  
 
Schiotz scale readings were lower in 
those with AMD when compared to 
controls and when paired with IOP 
readings the combination resulted in the 
difference of scleral rigidity (of both eyes) 
between the 2 groups being statistically 
significant (RE: P=0.0003, LE: P=0.009).  
 
Mean standard deviation of Perkins was: 
AMD (RE: 0.023, LE: 0.024).  
 
Mean standard deviation of Scleral 
rigidity was: AMD (RE: 0.018, LE: 0.020).  
 
 
The author proposes that in AMD 
the blood flow within the intra-scleral 
portion of the vortex veins is 
compromised (Friedman et al., 
1977) resulting in increased scleral 
rigidity.  
 
 
 
Diagram available within the 
journal regarding proposed 
pathogenesis of AMD as 
speculated by Friedman et 
al. (1989). 
Ocular rigidity in 
patients with 
age-related 
macular 
degeneration 
(Pallikaris et al., 
2006).  
76 eyes in total  
 
One eye of 32 
participants with AMD 
(16 nAMD and 16 dry 
AMD). Mean age 
69yrs.  
 
44 age-matched 
control participants. 
Mean age 65yrs.  
 
Any pathology known 
to interfere with 
Ocular rigidity measurement. 
 
An ocular rigidity measurement 
device was used to measure the 
pressure-volume relation and 
the ocular rigidity coefficient of 
each participant whilst 
undergoing cataract extraction.  
 
200µl of salt solution was 
injected through the limbus into 
the anterior chamber in 4.5µl 
steps whilst the subsequent IOP 
rise was measured in intervals 
up to 30mmHg.   
A rigidity coefficient was calculated as 
the slope of the pressure versus volume 
of salt solution curve (pressure range of 
10-30mmHg).  
 
No statistically significant difference in 
ocular rigidity was found between those 
with and those without AMD (when both 
nAMD and dry AMD groups are merged).  
 
Rigidity coefficient:  
AMD: 0.0142µl-1. Control: 0.0125µl-1. 
P=0.255.  
 
The findings indicate increased 
scleral rigidity in nAMD only. This 
has the potential to hamper vortex 
vein flow leading to increased 
choriocapillary resistance and 
induced hypoxia.  
 
Another possible cause of AMD 
development is speculated to initiate 
with RPE damage.   
 
The author states that the study is 
limited by the fact that participants 
had undergone photodynamic 
therapy prior to cataract extraction. 
Results do not correlate with 
Friedman et al. (1989) as no 
sig difference was found 
between AMD and control 
participants. Difference likely 
due to study design i.e. 
Friedman et al. (1989) using 
a non-invasive method of 
scleral rigidity measurement.  
 
Also Friedman et al. (1989) 
used a cohort likely to be 
over-representing those with 
nAMD as opposed to dry 
AMD. 
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aqueous drainage was 
ineligible.  
 The average ocular rigidity 
measurements were significantly higher 
in nAMD participants than controls 
(P=0.014) and in nAMD than those with 
dry AMD (P=0.004).  
 
This has the potential to influence 
ocular rigidity measurements. 
 
Deep retinal 
vascular 
anomalous 
complexes in 
advanced age-
related macular 
degeneration 
(Hartnett et al., 
1996).  
24 eyes in total. 
 
14 with a retinal 
vascular anomalous 
complex (RVAC) : 11 
participants were 
characterised as 
having a RVAC (mean 
age 79yrs). 
3 additional patients 
developed a RVAC 
over the course of 
research and were 
subsequently 
included. Of the 14 
with a RVAC, 13 also 
had a PED and 8 had 
an intra-retinal 
haemorrhage.. 
 
10 age-matched 
participants with PED 
and CNV but no 
RVAC. 
 
Cross sectional retrospective 
study using fluorescein 
angiography (FFA).  
 
Patients were selected from a 
computer search of records. 
Their FFAs were reviewed in 
order to determine the presence 
of a retinal vascular anomalous 
complex (RVAC) via secondary 
filling after the choroidal 
arterioles. 
 
RVACs were identified by the 
evidence of at least 1 dipping 
retinal arteriole into a deep 
vascular complex or at least 1 
arteriole descending into a deep 
retinal space to a vascular 
communication.  
 
PEDs that developed were similar in size 
and position to areas of drusen. ICG 
displayed a delay in choroidal filling 
adjacent to areas of drusen. 
 
Intraretinal haemorrhages, 
microaneurysms or telangiectatic vessels 
were found in 12 eyes, 11 of which had a 
RVAC.  
 
3 of the 14 participants had either 
cardiovascular disease or hypertension 
and 2 had NIDDM (without signs of 
diabetic retinopathy).  
Findings suggest evidence of 
disease at the RPE-Bruch’s 
membrane level consistent with the 
emergence of a hypoxic 
environment via the accumulation of 
drusen. This is suggested as the 
precursor to RVAC development 
(and the following CNV as seen in 
nAMD). 
 
Results point towards an early 
alteration in the macular retinal 
vasculature in which the RVAC is 
likely to be a latter result.  
 
 
The presence of a PED may provide 
an additional hypoxic challenge by 
further removing the choroidal 
circulation from the outer retina.  
An RVAC is an anomalous 
leaking vascular structure, 
found in the deeper retina 
(which is normally devoid of 
vessels). It is fed by 1 or 
more retinal arterioles. 
 
Media opacities, small pupils 
and IOLs in the elderly 
cohort made viewing of 
some RVACs difficult.  
 
 
Refractive error 
and choroidal 
perfusion 
characteristics in 
patients with 
choroidal 
neovascularisati
on and age-
related macular 
degeneration 
(Böker et al., 
1993) 
106 eyes in total. 
 
186 study eyes who 
had CNV secondary to 
AMD (mean age 
71yrs) were collected 
of which 80 were 
removed due to lack of 
(or poor quality) 
fluorescein 
angiograms.  
 
Fluorescein angiography used to 
confirm presence of CNV 
membrane and reviewed for the 
determination of choroidal 
perfusion characteristics 
(classified as prolonged 
fluorescence during the transit 
phase).  
 
Refractive error was taken to be 
the spherical equivalent of the 
last refraction value that had 
been obtained prior to the 
The risk for development of CNV 
increased with an increasing degree of 
hyperopia.  
 
Results show that an eye with a 
refractive error of +3.00-4.00D is 6.2 
times more likely to develop nAMD than 
an emmetropic eye.  
 
Eyes within the +3.00D-+4.00D subgroup 
were found to be at most risk for nAMD 
development when compared to others 
(refraction range from +6.00 to -6.00D).  
Results suggest that the hyperopic 
eye has a statistically significantly 
increased risk of developing AMD.   
 
As the sclera ages it becomes 
increasingly rigid, this has the 
potential to compromise the 
choroidal circulation by obstructing 
venous outflow. An obstruction of 
the choroidal veins will lead to an 
increase in choroidal vascular 
pressure which could ultimately 
contribute to CNV formation.  
The finding is supported 
further by the fact that the 
prevalence of hyperopia 
recorded during the study 
was likely to have been a 
low estimate (due to nuclear 
cataract induced myopic 
shifting of the cohort).  
 
Those ineligible included: 
dry AMD, degenerative 
myopia, angioid streaks  
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90 participants had 
unilateral CNV, the 
remaining had bilateral 
CNV.  
 
Healthy controls used 
(no number specified) 
from a general 
German population 
based study. 
participants symptoms relating 
to AMD (as nAMD is likely to 
cause a hyperopic shift).  
 
 
Myopic refractive error had little impact 
on the relative risk of developing CNV.  
 
Participants afflicted with bilateral nAMD 
tended to be older (mean age 73.1yrs) 
than those with unilateral CNV (mean 
age 70.9yrs. This was statistically 
significant, P=0.027). 
 
Abnormal choroidal perfusion was 
identified in 66.4% of angiograms 
reviewed.  
 
 
This theory is supported by 
increased age in the bilateral nAMD 
participants. In hyperopic, shorter 
eyes the effects of scleral stiffening 
combined with a slightly thicker 
sclera lead to increased venous 
outflow obstruction when compared 
to myopic and emmetropic eyes. 
 
Delayed filling of choroidal vessels 
probably indicates a change in 
blood flow. This may manifest 
secondary to Bruch’s membrane 
thickening and the appearance of 
drusen.  
 
Uses good diagram of 
possible pathogenesis by 
Friedman et al., 1987. 
Choroidal filling 
in age-related 
macular 
degeneration: 
indocyanine 
green 
angiographic 
findings 
(Giovannini et 
al., 1994).  
177 eyes in total.  
 
103 with nAMD. 42 
with dry AMD (mean 
age >70yrs).  
 
32 age-matched 
controls.  
 
2 observers used for 
grading and analysis.   
Indocyanine green 
videoangiography used 
(alongside FFA to aid diagnosis) 
 
VDU based software applied to 
analyse data and increase the 
definition of each image 
obtained.  
 
The earliest part of the 
angiography (the choroidal 
blush) was used to evaluate 
filling. A lack of a ‘blush’ at the 
centre of the macular during 
filling is indicative of poor 
perfusion within this area.  
A statistically significant difference with 
regards to delayed choroidal filling was 
observed between those with and 
without AMD (P<0.005): 
 
In 59% of AMD participants delayed 
choroidal filling was observed.  
 
In 23% of control participants delayed 
choroidal filling was observed. 
 
71% of CNVs seen were present at WZs.  
 
52% of CNVs grew inside or at the 
margin of areas displaying delayed filling. 
 
Results suggest a relationship 
between delayed choroidal filling 
and the presence of AMD. 
 
There was no significant difference 
between the filling pattern of those 
with classic and occult CNV hence a 
filling pattern alone cannot be used 
to determine the proposed AMD 
subtype that may develop.  
 
Results further underline 
correspondence between CNV 
development and WZs. This 
emphasised inadequate choroidal 
circulation in those with nAMD. 
Delayed filling sites are likely to 
represent areas of ischaemia and 
could be target by laser therapy to 
delay AMD progression.  
 
Author states that ICG is a 
more accurate tool to assess 
choroidal filling that FFA. 
Using FFA it was difficult to 
differentiate between 
delayed filling due to 
blockage of fluorescence by 
deposits within Bruch’s 
membrane. ICG uses infra-
red investigation hence can 
better penetrate the barrier 
posed by Bruch’s 
membrane.  
Choroidal blood 
flow and 
progression of 
age-related 
macular 
degeneration in 
82 eyes in total.  
 
41 participants with 
unilateral nAMD were 
enrolled. Their fellow 
Laser Doppler flowmetry (785nm 
beam) and laser interferometry 
used in this observational 
longitudinal study. 
 
Of 37 participants 17 developed CNV 
over the course of the study and 20 did 
not. 
 
Lower choroidal blood flow (P=0.0071), 
higher AMD grade and lower PA 
Analysis showed that blood flow and 
PA are risk factors for the 
development of CNV. This suggests 
that a lower choroidal perfusion is a 
risk factor for development of nAMD 
 
 
This study used 2 
independent methods of 
assessing blood flow. 
Metelitsina et al. (2008) only 
276 
 
the fellow eye in 
patients with 
unilateral 
choroidal 
neovascularisati
on (Boltz et al., 
2010).  
eyes (the study eye) 
were used as controls.  
 
37 participants 
completed the study. 6 
of which had systemic 
hypertension, 8 of 
which were current 
smokers and 9 of 
which were past 
smokers).  
 
Study eyes were 
graded according to 
the ‘Age-related 
maculopathy staging 
system’ based on 
fundus photos. 
 
Participants were 
excluded if they had 
diabetes, glaucoma or 
lens opacification of a 
degree that affected 
blood flow 
measurements. 
FFA was used to confirm the 
absence of CNV in the non-
exudative eye.  
 
Study ran over 3 years. Each 
participant underwent a 
screening visit (to check for 
eligibility) and a maximum of 7 
study visits (where blood 
pressure, pulse rate, blood flow, 
blood volume, PA and contact 
IOP measurements were taken). 
 
  
 
(P=0.0068) had statistically significant 
influences on the development of CNV. 
 
Also it was suggested that the more 
advanced the nAMD in the study eye 
was in direct relation to the risk of CNV 
development in the fellow eye.  
 
Systemic blood pressure and IOP 
showed no significant correlation with 
CNV development.  
in the fellow eye of participants with 
unilateral CNV.  
 
A higher grading of CNV also 
correlates with a risk of 
development of CNV in the fellow 
eye.  
 
Author notes that a comparable 
study by Metelitsina et al. (2008) 
had a wide inclusion criteria 
(typically ophthalmic features of 
AMD and no signs of CNV) hence 
the proportion of eyes that 
developed AMD in their study was 
much smaller.  
 
Follow-up times were also more 
variable hence Metelitsina et al. 
(2008) observed a small increase in 
hemodynamic parameters over time 
in those eyes in which CNV did not 
develop (whereas a continuous 
decline has been suggested by this 
study, possibly due to the smaller 
number of participants who did not 
develop CNV).  
 
used laser Doppler 
flowmetry which is 
susceptible to scattering 
properties of the tissue in 
question and also the media 
(laser interferometry can aid 
in overcoming this).   
Retinal 
haemodynamics 
in patients with 
age-related 
macular 
degeneration 
(Sato et al., 
2006).   
33 eyes in total.  
 
25 participants with 
AMD (all sub types 
graded via the AREDS 
scale).  
 
9 age-matched 
controls.  
 
All participants 
underwent an 
ophthalmic 
examination (IOP, VA 
and a health-check) at 
screening.  
Laser Doppler flowmetry used to 
measure vessel diameter, 
velocity and flow in the major 
temporal retinal arteries.  
 
A red 675nm beam was used to 
determine the velocity. 50 
measurements were recorded 
per second for 2 seconds.  
 
The pulsatility ratio (PR), 
pulsatility index (PI) and 
resistivity index (RI) were 
calculated from velocity traces.  
Values of PR (7.7), PI (1.8) and RI (0.84) 
were significantly higher in AMD 
participants than in controls (4.2, 1.4 and 
0.75 respectively).  
 
There was no significant difference found 
in the mean velocity, diameter or flow 
between all levels of AMD and the 
controls.  
 
Mean velocity in mm/s was: 31.9 in 
controls, 34.5 in early, AMD and 29.5 in 
nAMD.  
 
Diameter in µm was: 106 in controls, 110 
in early AMD and 120 in nAMD.  
Typically an increased PR, PI and 
RI are an indication of increased 
vascular resistance to flow and/or 
decreased vascular compliance (in 
which case flow would also be 
reduced, which was not found in this 
study). 
 
 These results point towards a more 
generalised circulatory abnormality 
proximal to the eye, specifically it is 
likely that participants with AMD 
have a stiffer, less compliant arterial 
vasculature leading to the eye (and 
that the loss of compliance of these 
larger blood vessels is due to age-
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Those with additional 
ocular disease or a 
history of ocular 
operation were 
excluded.  
 
Flow in µl/min was: 8.4 in controls, 10.7 
in early AMD, and 10.2 in nAMD.  
 
related degenerative changes in 
collagen and elastin).  
 
Results indicate that AMD and 
cardiovascular disease share the 
same modifiable risk factors. 
Treatments aimed at preventing 
systemic arterial rigidity may also 
slow or prevent the onset of AMD.  
 
Functional loss 
in age-related 
Bruch’s 
membrane 
change with 
choroidal 
perfusion defect 
(Chen et al., 
1992).  
14 eyes in total.  
 
8 eyes of 8 
participants identified 
as having delayed 
choroidal filling from 
FFA.  
 
6 controls with visible 
drusen but no vascular 
abnormality.  
 
The fundus 
appearance, visual 
acuity and age range 
(mean 63-64yrs) was 
similar in all 
participants.  
Fluorescein angiography was 
used to identify the presence 
prolonged choroidal filling 
phase.  
 
Dark adapted static perimetry 
was performed on 8 eyes with 
prolonged choroidal filling and 6 
eyes with a similar number of 
drusen but no manifest choroidal 
perfusion abnormality. Each 
participant was dark adapted for 
45 minutes.  
 
Scotopic threshold was 
measured using a Humphrey 
automated perimeter (central 30-
2 programme with background 
illumination off and a size V blue 
stimulus presented) and using 
fine matrix mapping (a VDU 
based threshold test).  
 
In eyes without delayed perfusion no 
discrete areas of increased threshold 
were found. In contrast, 7 of the 8 eyes 
with delayed filling displayed discrete 
areas of scotopic threshold elevation (up 
to 3.4 log units). These areas 
corresponded to regions of perfusion 
abnormality.  
 
On fine matrix mapping, eyes with 
normal choroidal filling had a mean 
scotopic threshold above normal of 0.7 
log units (7dB) beyond 5° from fixation. 
Eyes with choroidal perfusion 
abnormality showed a mean background 
threshold above normal of 1.0 log unit 
(10dB). 7 of these 8 eyes also had 
discrete areas of scotopic threshold 
elevation above normal of 1.8 (18dB) to 
3.4 log units (34dB).  
 
The area of depressed sensitivity always 
corresponded with the area of slow 
choroidal filling when fine matrix mapping 
and FFA results were compared.   
 
Eyes with the angiographic sign of 
slow choroidal filling have a higher 
threshold than eyes with normal 
choroidal filling.  
 
These participants had a similar 
fundus appearance and VA to the 
controls however reported more 
readily the need for increased light 
intensity for reading and slow 
recovery of vision after exposure to 
bright light.   
 
The results suggest that a more 
diffuse pigment epithelial or retinal 
dysfunction must be present either 
as a result of, or as a precursor to 
the accumulation of deposits within 
Bruch’s membrane. It is suggested 
that the drusen might account for 
both the perfusion abnormality and 
functional loss by acting as a 
diffusion barrier between the RPE 
and choroid. 
Small number of participants 
in this study.  
 
 
 
Choroidal 
perfusion 
abnormality with 
age-related 
Bruch’s 
membrane 
change 
100 eyes in total.  
 
115 participants 
(all >60yrs age) were 
recruited of which 100 
met the eligibility 
criteria of drusen in 
both eyes or unilateral 
Fluorescein angiography (FA) 
was used to analyse the 
presence of delayed choroidal 
filling. 
 
Filling was deemed abnormal if 
there was seen to be a 
continuous area of prolonged, 
26 of the 100 eyes displayed a prolonged 
choroidal filling phase (PCFP), the other 
74 were classified as having normal 
circulation characteristics. There was no 
statistically significant difference in age 
or sex of both groups.  
 
Results suggest that angiographic 
appearance of the choroidal 
perfusion is modified in some AMD 
participants.  
 
The angiographic appearance 
cannot be assumed to imply a 
perfusion deficit alone as this may 
Author explains FA dye can 
adhere to deposited 
molecules within Bruch’s 
membrane which slows the 
speed of its diffusion and 
gives a false impression of 
delayed filling.  
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(Pauleikhoff et 
al., 1990).  
nAMD/PED and 
drusen in the fellow 
eye.  
 
patchy choroidal fluorescence in 
the transit phase of the FA 
extending over at least 5 disc 
diameters.  
 
Fundus photos were collected in 
order to analyse drusen 
characteristics (within 1600µm of 
the fovea, classified by number 
and density).  
 
Eyes with a PCFP tended to have few 
drusen of less density in the macular 
area when compared to those without a 
choroidal defect (65.4% of eyes with a 
PCFP had >20 drusen centrally in 
comparison to 81.1% of eyes without a 
PCFP also 0% of eyes with a PCFP had 
confluent drusen in comparison to 31.1% 
of eyes without a PCFP). 
 
No significant difference was found in 
size/fluorescence or density/number of 
drusen in the peripheral retina.   
 
be caused by accumulated deposits 
in Bruch’s membrane.  
 
It can only be speculated as which 
clinical sign if causative of AMD 
pathogenesis (reduced perfusion or 
increased Bruch’s thickness).  
Foveolar 
choroidal 
circulation and 
choroidal 
neovascularizati
on in age-
related macular 
degeneration 
(Metelitsina et 
al., 2008).  
193 eyes in total.  
 
135 participants with 
dry AMD of any grade 
(none of which 
displayed CNV at the 
time of enrolment) 
were recruited. Mean 
age was 70yrs.  
 
Longitudinal, 
prospective study in 
which participants 
were reviewed at 
various intervals: 101 
were reviewed at 1yr, 
89 at 2 years, 87 at 3 
years, 59 at 4 years 
and 27 at 5 years. 
 
Participants were 
screened for other 
ocular diseases before 
being enrolled into the 
study.    
Laser Doppler flowmetry was 
used to determine foveolar 
choroidal blood velocity, volume 
and flow.  
 
A 670nm diode laser beam of 
intensity 20mW was used to 
obtain blood flow readings. 
 
All measurements, including 
fundus photography, IOP and 
blood pressure were taken at 
baseline and follow-up visits.  
CNV developed in 28 of 18 participants 
eyes during the course of the study.  
 
Baseline measurements of mean 
foveolar volume and flow in those who 
developed CNV were 24% (P<0.0001) 
and 20% (P=0.0007) lower than that 
observed in the 165 eyes in which CNV 
did not develop. There was no 
statistically significant difference in 
velocity of these groups.  
 
In the eyes that developed CNV foveolar 
volume and flow decreased annually on 
average by 9.6% and 11.5% before the 
formation of CNV, whereas in the eyes 
that did not, they increased by 6.7% 
(P=0.006) and 2.8% (P=0.004).  
 
In eyes in which CNV developed 
perfusion pressure (P=0.04) and drusen 
size (P=0.004) were increased when 
compared to those who did not develop 
CNV.  
 
Eyes with lower baseline flow were found 
to be more likely to show visual loss of 3 
or more lines when compared to eyes 
with a higher baseline flow (P=0.005).  
 
The results suggest that decreases 
in the choroidal circulation 
(particularly foveolar volume and 
flow) precede the development of 
CNV.  
 
The results strongly suggest that 
ischaemia has a role in the 
pathogenesis of AMD. The study 
suggests that a decrease in the 
delivery and diffusion of oxygen or 
metabolites may have a role (or be 
a causative factor) in the formation 
of CNV by triggering the formation 
of hypoxia-inducible genes i.e. 
VEGF.  
 
 
 
 
Study results agree with 
those of: 
 
Mori et al., 2001; 
Chen et al., 2001 ;  
Üretmen et al., 2003 ;  
Rigas et al., 2004. 
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Color Doppler 
imaging 
discloses 
reduced ocular 
blood flow 
velocities in non-
exudative age-
related macular 
degeneration 
(Ciulla et al., 
1999). 
50 eyes in total.  
 
25 participants with 
dry AMD (mean age 
73yrs) were compared 
to 25 age-matched 
control subjects (Mean 
age 70.2yrs). 
 
Participants were 
eligible if they 
displayed: soft 
drusen >63µm, 
hyper/hypopigmentatio
n of the RPE or GA. 
Anyone with signs of 
nAMD were excluded 
from this study.  
 
Participants were also 
excluded if they 
showed a history of 
diabetes, ophthalmic 
artery/venous 
occlusion, additional 
ocular disease or 
hypertensive 
retinopathy  
Colour Doppler imaging  
was used to measure peak 
systolic and end-diastolic 
velocity in the ophthalmic, 
central retinal and 
nasal/temporal posterior ciliary 
arteries.  
 
A resistivity index (RI) was 
calculated from the peak systolic 
and end-diastolic velocity.  
 
Participants initially underwent 
tests to identify BCVA (logMAR), 
IOP (Goldmann) and FFA (in 
order to ensure no nAMD). 
All velocities are recorded in cm/s. Cut-
off for P was 0.0125. 
 
Nasal posterior ciliary artery results: 
mean end-diastolic velocity 1.45 with 
AMD and 1.95 in controls (25% decrease 
with AMD. P=0.0012, highly significant). 
Peak systolic velocity 6.02 with AMD and 
7.34 in controls (18% decrease with 
AMD. P=0.00175 nearly significant). The 
resistivity index showed no significant 
difference.  
 
Temporal posterior ciliary artery results: 
mean end-diastolic velocity 1.54 with 
AMD and 1.88 in controls (18% decrease 
with AMD. P=0.0160 nearly significant). 
Peak systolic velocity 6.47 with AMD and 
7.07 in controls (P=0.1733 not 
significant). The resistivity index showed 
no significant difference.  
 
Central retinal artery results: mean end-
diastolic velocity 1.37 with AMD and 1.95 
in controls. No significant difference in 
peak systolic velocity recorded. The 
resistivity index was 0.83 with AMD and 
0.76 in controls (P=0.0007).  
 
No correlation was found between BCVA 
and velocity or area of RPE 
mottle/drusen and velocity however 
these measurements are of ‘bulk’ 
choroidal flow and not specifically the 
macular region. 
 
No differences were found between the 
groups for the ophthalmic artery.  
 
There was no statistically significant 
difference in age, BCVA or IOP of the 
subjects from both groups.  
 
Results suggest that there are 
retrobulbar vascular changes 
(decreases in flow velocity), 
particularly in the nasal and 
temporal posterior ciliary arteries in 
the presence of AMD.   
 
In the posterior ciliary arteries 
(which supply the choroid) it was 
found that participants with AMD 
displayed a trend towards lower 
peak systolic and end-diastolic 
velocity.  
 
The findings of the central retinal 
artery may point to a secondary 
autoregulatory response in which 
retinal perfusion decreases in this 
vessel due to the decreased 
metabolic requirements (caused by 
RPE atrophy) during AMD.  
 
Classic pathogenesis theory quoted: 
Ageing of RPE causes accumulation 
of metabolic debris which leads to 
progressive engorgement of the 
RPE cells and to drusen formation. 
This in turn leads to dysfunction of 
the RPE which causes choroidal 
vasculature decline due to loss of 
angiographic factors. 
 
Alternate theory proposed: 
Scleral thickening and 
stiffening via the deposition 
of lipid with age causes 
impaired choroidal perfusion 
which in turn adversely 
affects the metabolic 
transport function of the 
RPE.  
 
Finding with regards to RI do 
not correlate to Friedman et 
al., 1997.  Differences may 
be due to the broader 
eligibility criteria used (both 
dry and nAMD).  
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Choroidal 
perfusion 
perturbations in 
non-neovascular 
age related 
macular 
degeneration 
(Ciulla et al., 
2001). 
21 AMD and 21 
controls.  
 
AMD patients:  
Over 50yrs with soft 
drusen >63 microns, 
hyper/hypopigmentatio
n or GA in fellow eye. 
nAMD in study eye.  
 
Controls:  
No AMD, diab ret, 
ocular pathology.  
   
ICG angiography.  
 
Images processed in 6 locations 
including and around macular. 
 
Area dilution analysis: Speed of 
which ICG enters choroidal 
vasculature measured via 
plotting dilation curves.  
No difference in perfusion characteristics 
in controls.  
 
Speed of 10% filling time was longer in 
AMD Px’s than in normals for 4 
perifoveal regions.  
 
Speed of 63% filling time was longer in 
AMD Px’s than in normals for 4 
perifoveal regions (this remained 
significant when other 2 peripapillary 
regions also included in analysis).  
 
Subjects with AMD showed 
significant delays and heterogeneity 
of filling within perifoveal region 
when compared to age-matched 
controls.  
 
This indicates changed relating to 
vasculature in AMD show 
preferential involvement of 
perifoveal choroid.  
 
Subretinal 
neovascular 
membranes 
associated with 
choroidal non-
perfusion and 
retinal ischemia 
(Melrose et al., 
1987).  
1 eye described in 
detail throughout the 
paper.  
 
 
Case document of a 
75yr old woman 
suffering from 
systemic 
hypertension, arthritis 
and confluent drusen 
(without the 
appearance of 
subretinal 
haemorrhage) in her 
RE. Her left macular 
was scarred from 
previous nAMD.  
Fluorescein angiography was 
used for assessment following 
hospital based diagnosis of the 
patient (based on symptoms of 
central vision loss and 
ophthalmologist evaluation).    
Angiography displayed a normal 
choroidal and retinal filling pattern except 
for marked choroidal non-perfusion in the 
foveal region (which appeared early and 
persisted through all stages of the 
angiogram).  
 
The eye was treated with krypton-laser-
photocoagulation in order to try and 
prevent disciform scarring.  
 
Results indicate poor foveolar 
choroidal perfusion in association 
with nAMD. It is speculated that the 
cause may be linked to occlusion of 
the short posterior arteries 
secondary to spasm, oedema or 
direct injury.   
 
The case is consistent with studies 
showing a higher incidence of CNV 
in the fellow eye of patients with a 
history of nAMD.  
 
The author also speculates that the 
patient’s light complexion and blue 
irides were also in agreement with 
studies suggesting caucasians are 
at a high risk of AMD development.  
 
Documented in the style of a 
case-report hence minimal 
detail provided.  
 
First documented evidence 
of localised choroidal non-
perfusion and associated 
CNV.  
 
In final paragraph the author 
indicates that 200 AMD 
cases have been reviewed. 
No numbers are provided 
with regards to results 
however.  
 
A fluorescein 
and indocyanine 
green 
angiographic 
study of 
choriocapillaries 
in age-related 
macular disease 
(Pauleikhoff et 
al., 1999). 
100 eyes in total.  
 
12 Participants had 
early AMD only 
(classified by bilateral 
soft drusen).  
 
88 participants had 
early AMD and nAMD 
in their fellow eye.  
 
Fluorescein angiography was 
used to identify a distinct area of 
slow and patchy choroidal 
hypofluorescence during the 
early phase.  
 
Indocyanine green video-
angiography (ICG) was used to 
identify a distinct area of 
reduced diffuse background 
During early AMD a prolonged choroidal 
filling phase (PCFP) was observed in 
26% of eyes using FFA and 32% of eyes 
using ICG.  
 
The predominant ocular characteristic 
associated with PCFP was the presence 
of localised areas of RPE atrophy. This 
was found in 28% of eyes with PCFP 
and only 6% without PCFP (P=0.005).  
 
A PCFP can be interpreted as a 
sign of reduced choroidal perfusion 
in AMD. A change in the diffusional 
characteristics of Bruch’s membrane 
is the speculated cause.  
 
Subsequently a PCFP can be used 
as a risk factor for GA development. 
To what extent PCFP contributes 
toward loss of VA due to AMD is 
unknown, but the sign could be 
ICG confirmed as more 
accurate that FFA with 
regards to identifying PCFP.  
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Mean age of 
participants was 
72.6yrs.  
 
 
fluorescence during the early 
phase.  
 
Drusen characteristics (number, 
size, density and fluorescence), 
BCVA and AMD status of the 
fellow eye was also 
documented.  
A PCFP was associated with confluent 
drusen, of which 66% of eyes with PCFP 
displayed (P=0.01) and RPE atrophy 
patches (P=0.005) in the study eye. Eyes 
with PCFP tended to have a higher 
density of drusen inside 1600µm around 
the fovea. (P=0.01).  
 
There was also an association between 
PCFP and GA in the fellow eye (P=0.03).   
 
used as a clinical indicator of visual 
prognosis.  
 
 
Foveal 
electroretinogra
ms and 
choroidal 
perfusion 
characteristics in 
fellow eyes of 
patients with 
unilateral 
neovascular 
age-related 
macular disease 
(Remulla et al., 
1995).  
67 eyes in total. 
 
67 patients with 
unilateral nAMD (age 
61-89) recruited from 
a larger group study 
investigating 
prevalence of CNV 
and ERG implicit 
times.  
 
Exclusion criteria 
included media 
opacification 
significant enough to 
impact on fundus 
appearance.   
Fluorescein angiogram used to 
identify delayed choroidal filling 
(characterised by a non-uniform 
fluorescence extending over at 
least 5 disc diameters of the 
posterior pole persisting through 
the onset of the venous phase).  
  
Foveal ERGs were elicited with 
a 4° white stimulus flickering at 
42Hz presented by a hand held, 
dual beam stimulator 
ophthalmoscope. Responses 
were monitored with a CL 
electrode and quantified by 
Fourier analysis with regards to 
amplitude and implicit time  
 
The mean for foveal cone ERG implicit 
time was 38.3ms for participants with 
delayed filling and 37.0ms for those 
without filling defects (This was 
statistically significantly. P=0.0167).  
 
ERG implicit times averaged 1ms slower 
(P=0.0167) and were more likely to be 
delayed (P=0.0078) in eyes with 
abnormal choroidal perfusion (retained 
when corrected for age, acuity and 
drusen extent). 
 
42% of eyes studied displayed a 
choroidal perfusion defect. Participants 
with prolonged choroidal perfusion had a 
tendency to have more extensive 
macular drusen.   
 
ERG implicit time was positively 
correlated to the extent of macular 
drusen (which was also almost 
significantly associated with poor 
choroidal perfusion).  
 
Prolonged choroidal perfusion was 
associated with a foveal cone ERG 
implicit time that was slower or more 
likely to be delayed.  
 
Results suggest the focal ERG can 
be added to impaired sensitivity in 
the dark and slowed dark adaptation 
as an objective measure of retinal 
malfunction related to AMD.  
 
It is hypothesised that the 
angiographic finding in participants 
with AMD is reflective of outer 
retinal ischaemia, resulting in foveal 
cone ERGs of normal amplitude but 
delayed implicit time.  
 
Occlusion of the 
posterior ciliary 
artery. I. Effects 
on choroidal 
circulation 
(Hayreh and 
Baines, 1972).  
 
85 eyes in total. 
 
In-vivo 85 rhesus 
monkey eyes.  
 
 
Fluorescein angiography (FA) 
was used in order to assess the 
macular choroidal circulation 
following induced arterial 
occlusion. 
 
Lateral orbitotomy was 
performed in order to gain 
During lateral and medial PCA 
occlusions, the filling of the choroid 
supplied by the occluded artery was 
found to be delayed and incomplete.  
 
The delayed filling observed was specific 
to the occluded vessel i.e. neighbouring 
areas of choroidal vasculature supplied 
The results indicate that a reduction 
in perfusion pressure in an end 
artery i.e. the PCAs has the 
potential to leave the macular in a 
hypoxic state. Any pathology that 
has the potential to interrupt 
choroidal blood flow (such as AION 
In a corresponding review 
article (Hayreh. 1990) the 
author states from other 
studies that WZs between 
the choriocapillary lobules 
are arranged in a 
honeycomb formation and 
that WZs exist between 
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access to the posterior ciliary 
arteries (PCAs) which were 
cauterised (occluded) near the 
site of entry into the eyeball.  
 
The lateral PCA was occluded in 
31 eyes. The medial PCA was 
occluded in 17 eyes and all 
PCAs were occluded in 37 eyes.  
by additional vessels were unaffected by 
the occlusion.  
Following PCA occlusion in all cases the 
retinal circulation remained unaffected 
 
No specific details provided or statistical 
analysis documented.  
 
or senile degeneration) may have a 
pathogenesis involving ischaemia.   
 
Due to the nature of the filling the 
author speculates about watershed 
zones (WZs) between each 
segmental area of delay. The WZs 
location and number depend on the 
number of PCAs and short PCAs 
present and also their anatomical 
position.  
 
Watershed zone (WZ) definition: the 
border between the territories of 
distribution of any 2 end arteries 
(e.g. the nasal and posterior short 
ciliary arteries). 
 
every aspect of the choroidal 
vasculature arrangement i.e. 
the PCAs and the short 
PCAs. The short PCAs and 
the choriocapillaries etc.  
Changes in the 
choriocapillaris 
associated with 
senile macular 
degeneration 
(Kornzweig, 
1977).  
107 eyes in total.  
 
All eyes were attained 
post mortem.  
 
26 eyes with 
established AMD, 5 
with early AMD and 76 
age-matched controls.  
 
All measurements 
were taken with a 
micrometer.  
Histological Analysis.  
 
The retina and choroid were 
removed from the globe and 
placed in 7.5% buffered formalin 
solution for fixation.  
 
Then both were transferred into 
3% trypsin solution and 
incubated at 38°C for 30mins (in 
order for the choroid to lose its 
pigment).  
 
The specimen was then placed 
into a petri dish and the larger 
choroidal vessels were removed. 
Bruch’s membrane was dried 
onto a slide and stained with 
Schiffs (PAS) reagent and 
counterstained with hematoxylin 
in order to allow measurement of 
the finer choroidal vasculature.  
 
Choriocapillary appearance in controls: 
A visible network of closely packed 
capillaries separated by inter-capillary 
septa (a dividing line of tissue). Lumen 
width ranged from 20-28 microns and 
septa width from 8-12 microns.  
 
Choriocapillary appearance in the 
presence of AMD:  Thickening of the 
inter-capillary septa was noted 
(diameters between 20-24 microns were 
recorded). Narrowing of the lumen was 
also documented (12-20 microns).  
 
There appeared to be loss of cellular 
content of the capillaries with many 
lacking nuclei and only being sustained 
by the thickened septa. Distinct areas of 
capillary atrophy were observed in 59% 
of AMD eyes reviewed.  
 
It is suspected that septa thickening 
and lumen narrowing is likely to 
have an impact on oxygen 
availability to the macular. In effect, 
a condition of hypoxia may develop 
which can lead to atrophy of the 
RPE via disrupting the 
photoreceptor cone cell function.  
 
Visible areas of atrophy may also 
contribute by causing focal hypoxia.  
  
 
Relationship 
between RPE 
and 
11 in total. 
 
Histological analysis  
 
GA patient: 
Area outside atrophic zone: 92% RPE 
coverage, 72% vascular area, 13.9μm 
Different pathogenesis for dry and 
nAMD.  
 
Take into consideration the 
small sample size. 
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choriocapillaries 
in Age-related 
macular 
degeneration 
(McLeod et al., 
2009). 
3 age-matched 
controls,  
 
5 subjects with GA, 
 
3 subjects with nAMD.  
 
 
Post-mortem analysis of the 
choroid. Globes opened at 
limbus and AC removed, then 
photographed with a digital 
microscope camera to assess 
pigmentary changes in retina 
(RPE atrophy) and CNV 
scarring. 
 
Choroids then dissected from 
sclera and assessed for alkaline 
phosphatase (APase) activity. 
Overlying pigment bleached with 
H2O2 and monitored daily until 
underlying CC visible. 
Photographs then taken and 
analysed with computer assisted 
morphometric technique.  
capillary diameter (all comparable with 
controls). At border of atrophic zone: 
38.1% RPE coverage, 52.3% vascular 
area, 10.3μm capillary diameter (all 
reduced). 
 
In atrophic zone: 1.8% RPE coverage, 
38.0% vascular area, 7.9μm capillary 
diameter (all severely reduced).  
 
nAMD patient: 
1mm peripherally from CNV: 95.9% RPE 
coverage, 39.6% vascular area, 13.9μm 
capillary diameter (RPE coverage and 
capillary diameter comparable with 
controls, vascular area severely 
reduced).  
 
Linear relationship between loss of RPE 
and CCs in GA. Linear relationship 
between loss of RPE and CC diameter in 
GA. Loss of fenestrations in endothelium 
of constricted CCs suggesting functional 
changes.  
 
RPE removal causes CC atrophy 
likely as CCs require bFGF, VEGF, 
endothelin-1 and insoluble 
molecules to maintain endothelial 
integrity). 
 
For dry AMD this correlates with 
theory of RPE atrophy initiating 
secondary PR and CC loss (CC 
either constricts and loses 
fenestrations or degenerates to 
atrophy).  
 
For wet AMD results correlate with 
theory of choroidal vascular 
insufficiency preceding RPE 
dysfunction. Choroidal blood flow 
impairment leads to foveal 
ischaemia and then to 
neovascularisation in wet AMD.  
 
Quantifying 
changes in RPE 
and choroidal 
vasculature in 
eyes with age-
related macular 
degeneration 
(McLeod et al., 
2002). 
6 eyes in total.  
 
Both eyes of 2 donors 
with AMD and 1 
control donor (aged 
70yrs).  
 
1 donor (aged 84yrs) 
had systemic 
hypertension and a 10 
year history of GA 
(RE) alongside a 
disciform scar (LE). 
 
Another donor (Age 
95yrs) had 
cardiovascular 
disease and was 
registered sight 
Histological Analysis. 
 
The retina and choroid was 
dissected from the sclera and 
incubated in alkaline 
phosphatase (APase).  
 
Pigment was then bleached with 
30% H2O2 until the underlying 
vasculature was visible (at which 
point the tissue was slide-
mounted).  
 
Computer assisted image and 
metamorphic analysis was then 
performed. A photomicroscope 
was used to take 1x1mm images 
which were enhanced for 
definition and clarity.  
Regions of GA eyes with complete RPE 
atrophy demonstrated a substantial loss 
of choroidal blood vessels (only 42.7% 
vascular area found at the posterior 
pole).  
 
A 100% loss of RPE in eyes with GA was 
associated with a 51% mean decrease of 
vascular density in that area. Capillaries 
that remained within these regions were 
found to have constricted lumens 
(statistically significant P<0.0001, no 
figures provided).  
 
Analysis of the disciform scar revealed 
that underlying new vessels were highly 
constricted.  
 
Control subject results: 
The normal ageing changes that 
occur within the choroid, Bruch’s 
membrane, RPE and 
photoreceptors become pathologic 
as a result of AMD related histologic 
changes.  
 
The density of choroidal capillaries 
decreases considerably with age 
and substantially more in the 
presence of AMD.   
 
Results indicate that atrophy of RPE 
is more severe than loss of 
choriocapillaries. Loss of RPE does 
not result in complete underlying 
capillary loss (however surviving 
capillaries are less functional which 
Removal of the retina and 
choroid from the eyecup 
may could mechanical loss 
of RPE. Similarly eyes with 
extended death-to-
enucleation times (>20hrs) 
may have artificial RPE loss 
also.  
 
The percentage RPE area 
may be underestimated in 
the subjects with GA as 
unhealthy (but still functional 
RPE) may have no pigment 
and, therefore, would have 
been excluded from the 
analysis.  
 
284 
 
impaired due to GA 
(RE) and advanced 
dry AMD (LE). 
 
 99-100% of RPE intact. 87.2% vascular 
area at the posterior pole which 
decreased to 78.9% at equator areas.  
 
has the potential to result in 
ischaemia).  
 
Results correlate well with 
Ramrattan et al. (1994).  
Effects of 
hypoxia on 
retinal 
pigmented 
epithelium cells: 
protection by 
antioxidants 
(Castillo et al., 
2002). 
Cultured RPE cells of 
bovine origin.  
 
Bovine eyes obtained 
from a local abattoir, 
placed on ice and 
transferred to the 
laboratory for RPE 
culture within 2hrs.  
 
Undefined number of 
source eyes 
documented. 
 
In Vitro RPE model.  
 
The RPE cells were accessed 
via resection of the retina. The 
tissue was then incubated for 
45mins at 37°C with collagenase 
followed by further incubation 
with trypsin-EDTA. The 
remaining suspension was 
concentrated via centrifugation 
and cultivated for 7-10days 
before being plated out for 
analysis. 
 
A percentage of healthy RPE 
cells cultivated were then 
incubated for 72hrs at 3% O2 in 
order to induce hypoxia. Before 
incubation some cells were 
introduced to 300µm of vitamin 
C (VC) or 10mM of N-
acetylcysteine (NAC) 
antioxidant. 
 
RPE apoptosis was revealed via 
a Hoechst staining agent. 
 
Hypoxic ATP and normoxic ATP were 
1.5 and 2.5µM/25,000 cells respectively 
(P<0.001).  
 
Cells treated with antioxidant prior to 
hypoxia displayed increased ATP 
availability when compared to cells not 
treated with VC or NAC. As a result a 
significantly lower number of apoptotic 
cells were found when RPE cells were 
treated with VC or NAC. 
 
The induction of apoptosis (nuclear 
fragmentation) by hypoxia was confirmed 
by the typical DNA smear on agarose gel 
electrophoresis.  
 
 
Incubation of RPE cells under 
hypoxia induced a reduction of 
intracellular ATP via the increase of 
lactate dehydrogenase (LDH).  
 
The results indicate that hypoxia 
can cause cell death of RPE 
through an oxidative stress-related 
mechanism. 
 
The data suggests that RPE cells 
suffer apoptosis when normal aging 
changes are accompanied by 
hypoxia. 
 
The effect of VC and NAC 
introduction appeared to have a 
protective function against free 
radical attack triggered via hypoxia. 
This is likely to be due to improved 
protection of mitochondrial 
membranes.    
 
 
 
Hypothermia 
reduces 
secretion of 
vascular 
endothelial 
growth factor by 
cultured retinal 
pigment 
epithelial cells 
(Coassin et al., 
2010). 
Cultured RPE cells 
(unspecified species 
of origin).  
 
The ARPE-19 strain 
was used.  
In Vitro RPE model.  
 
RPE cells (ARPE-19 strain) 
were grown in culture for up to 5 
days under normoxic (20% O2) 
and hypoxic (1% O2) conditions 
at temperatures ranging from 
27°C to 40°C.  
 
Conditions were achieved using 
an incubating chamber via which 
gas could be introduced and 
temperature modified.  
Hypothermia reduced RPE cell 
metabolism in a temperature dependant 
fashion. Metabolism was reduced by 
31% and 17% at 27°C and 34°C when 
compared to cells grown at 37°C 
(P<0.0001).  
 
Hypothermia also reduced VEGF 
secretion which was reduced by 38% at 
34°C when compared to cells cultured at 
37°C (P<0.0001). Conversely VEGF 
secretion was significantly increased by 
A hypoxic environment (such as that 
made possible by AMD 
pathogenesis) resulted in increased 
VEGF secretion.  
 
Hypothermia decreases both VEGF 
secretion and cellular metabolism of 
cultured RPE cells.  
 
Temperature manipulation is 
suggested as a possible treatment 
of AMD via reducing the energy 
consumption of the suffering 
It is unknown as to whether 
hypothermia inhibits or 
promotes the secretory 
pathways of other growth 
factors which may influence 
RPE activity e.g. 
inflammatory factors (HIF-1).  
 
The safety of temperature 
manipulation has not been 
investigated long term and 
would be difficult to achieve 
in an ocular model. If 
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VEGF levels were measured by 
the enzyme-linked 
immunosorbent assay (ELISA) 
and cell metabolic activity was 
measured by a fluorescent cell 
metabolic assay.  
 
32% at 40°C when compared to those 
grown at 37°C (P<0.0001).  
 
Hypoxia increased VEGF secretion by 
84% at 37°C when compared to cells 
cultivated under normoxic conditions 
(P<0.0001).  
 
Hypothermia decreased the hypoxia 
induced VEGF secretion by 30% at 34°C 
compared to cells grown under hypoxic 
conditions at 37°C (P<0.0001).  
 
photoreceptors, reducing the 
metabolic activity of the RPE and as 
a result minimising VEGF secretion. 
This could be achieved by cooling 
the choroidal circulation.  
successful chronic reduction 
of VEGF secretion could 
result in capillary atrophy.  
Role of hypoxia 
and extracellular 
matrix-integrin 
binding in the 
modulation of 
angiogenic 
growth factors 
secretion by 
retinal 
pigmented 
epithelial cells 
(Moussa et al., 
1999). 
Cultured RPE cells of 
human origin. 
 
Undefined number of 
source eyes 
documented. 
 
96 samples of RPE 
cells were cultured in 
Dulbecco’s modified 
Eagle’s medium and 
demonstrated to be a 
pure population before 
manipulation.  
In Vitro RPE model.  
 
Refer to paper for specific detail 
on method. RPE cells were 
transferred into 96 well plates 
and incubated at room 
temperature for 60mins in order 
to set into position.  
 
Extra-cellular matrix (ECM) 
protein was added to all samples 
of which 48 were subjected to 
either normoxia (20% O2) or 
hypoxia (1% 02) within a 
humidified incubator.  
 
RPE cells maintained under hypoxic 
conditions showed a time-dependent 
linear increase in VEGF in their media.  
 
There was significantly more VEGF 
present (2 fold) under hypoxic conditions 
when compared to normoxic samples 
(P<0.01).  
 
A decrease of FGF2 was also recorded 
under hypoxic conditions. 
 
Under normoxic conditions there was an 
initial rise in VEGF in the sample which 
reached a plateau after 24hrs.  
Exposing RPE cells to hypoxic 
conditions results in the up-
regulation of VEGF.  
 
Thickening of Bruch’s membrane is 
due in part to accumulation of type 
IV collagen. This could disrupt the 
adhesion of RPE cells to their 
basement membrane and contribute 
to their dysfunction. 
Integrins are receptors that 
mediate the attachment 
between a cell and its 
surroundings.  
 
Hypoxia increases VEGF 
mRNA by a combination of 
upregulation of transcription 
and increased mRNA 
stabilization. 
Effect of hypoxic 
stress in RPE 
cells: Influence 
of antioxidant 
treatments 
(Bellot et al., 
2001). 
Cultured RPE cells of 
rabbit origin.  
 
Donor eyes were 
immediately incubated 
in Dulbecco’s modified 
Eagle’s medium 
following enucleation. 
Sheets of RPE layer 
In Vitro RPE model.  
 
The RPE cells were cultured in 
flasks (of which the purity of cell 
culture was verified via 
morphology testing). 
 
The cultures were separated 
and exposed to 1 of 2 oxygen 
LDH activity in the culture medium 
significantly increased when RPE cells 
were incubated under hypoxic conditions 
(P<0.05).  
 
The intracellular content of ATP 
(recorded in mmol/25,000 cells) was 
reduced under hypoxic conditions (0.20) 
when compared to normoxia (1.30).   
Most damage occurred when RPE 
cells were incubated within 
ischaemic conditions (hypoxia and 
glucose deprivation). 
 
Hypoxia induces LDH activity and 
ATP reduction which has the 
potential to cause apoptosis (as 
LDH is an enzyme that aids 
in the production of energy. 
Its levels tend to rise in 
response to cellular 
damage.  
 
Experimentally induced 
ischaemia has the potential 
to create oxygen-free 
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were removed from 
the eyecup and 
incubated in 0.1% 
trypsine and EDTA 
solution for 90mins.  
 
 
levels (21% or 3% O2). Half the 
cultures were treated with 
glucose and half were incubated 
without glucose (in order to 
simulate an ischaemic 
condition).  
 
Lactate dehydrogenase (LDH) 
activity and ATP cell content 
was used to determine the 
damage sustained by the RPE 
cells under each condition.   
 
3 culture subgroups were 
treated with 1 of 3 antioxidants 
(thioproline, vitamin C or trolox) 
prior to hypoxic exposure. 
 
 
DNA fragmentation of the hypoxic cells 
was demonstrated using an agarose gel 
electrophoresis test.  
 
Thioproline significantly prevented LDH 
activity (and ATP reduction) in hypoxic 
(1.25) and ischaemic cells (1.40) when 
compared to controls (0.30 and 1.1).  
 
Vitamin C did significantly prevented 
LDH activity and ATP reduction in 
ischaemic (hypoxia + glucose 
deprivation) but not purely hypoxic 
conditions. 
 
Trolox had no effect on LDH release or 
ATP levels under any condition.  
 
demonstrated by the DNA 
fragmentation).  
 
Certain antioxidants appear to have 
a protective effect upon the RPE 
however more research is 
necessary to identify the optimum 
subtype.  
 
radicals which in turn can 
induce apoptosis.  
Vascular 
endothelial 
growth factor-A 
is a survival 
factor for retinal 
neurons and a 
critical 
neuroprotectant 
during the 
adaptive 
response to 
ischemic injury 
(Nishijima et al., 
2007).  
Rat animal model.  
 
Male pigmented Long-
Evans rats used.  
In-vivo animal model.  
 
Transient ischaemia was 
induced in the RE by surgical 
constriction of the optic sheath 
for 60minutes. 
 
VEGF-A isoforms (120 and 164), 
placental growth factor-1 (PIGF-
1) and VEGF-E were 
administered intravitreally. FA 
was used to visualise vascular 
leakage.  
 
The eyes were then enucleated 
so that the VEGF levels could be 
determined by immunosorbent 
assay.  
 
3µl of a VEGF neutralising 
antibody was also injected 
intravitreally into a sample of 
rats once per week over 6 
weeks. 
 
The number of apoptotic cells peaked at 
12 and 24 hours after transient 
ischaemia (following the reperfusion of 
the ganglion cell and inner nuclear layer). 
Few apoptotic cells were found in the 
outer nuclear layer (due to its blood 
supply from the choroidal vasculature).  
 
Intraocular injection of VEGF-A just after 
reperfusion reduced apoptosis in the 
retina (in a dose-dependent manner). At 
24 hours after reperfusion the number of 
apoptotic cells were reduced by 51.2% 
by the VEGF120 isoform (20pmol, 
P<0.01) when compared to the control 
group.  
 
A 20pmol dose of VEGF164 reduced the 
number of apoptotic cells by 46.7% 
(P<0.01) 12hrs after ischaemic assault.  
 
 
 
VEGF-A has an initial anti-apoptotic 
effect on vascular endothelial cells 
under duress. Treatments aiming at 
reducing VEGF levels may cause 
secondary damage via eradicating 
its natural neuro-protective function.  
 
Exposure to the two most prevalent 
VEGF-A isoforms is effective in 
protecting neuronal cells in both the 
ganglion cell layer and inner nuclear 
layer after ischaemic assault.  
 
VEGF164 usage was seen to cause 
vascular leakage however hence 
the isoform is too potent for use as a 
neuro-protectant against AMD.  
Documented details 
available on the retinal effect 
of ischaemia. See page 5 
‘Exogenous VEGF-A 
reduces long-term 
ischaemia-induced retinal 
damage’.  
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Hypoxic 
regulation of 
vascular 
endothelial 
growth factor in 
retinal cells 
(Aiello et al., 
1995) 
Cultured RPE cells of 
bovine origin.  
 
Some human donor 
cells also used.  
 
 
In Vitro RPE model.  
 
All cells were cultured in 
Dulbecco’s modified Eagles 
medium and exposed for various 
periods to 0% O2.  
 
Hypoxia was achieved via a 
VDU controlled incubator 
 
RNA expression of VEGF was 
evaluated using northern blot 
analysis. 
 
Retinal endothelial growth 
assays (Hoechst-33258 dye) 
were used to assess the VEGF 
specific proliferative potential.  
In a normoxic state the retinal pericytes, 
RPE cells and endothelial cells produced 
low levels of VEGF. Normoxic and 
hypoxic values were: 
 
Retinal pericytes: normoxic (0.1), hypoxic 
(0.9).  
RPE cells: normoxic (0.075), hypoxic 
(0.2).  
Endothelial cells: normoxic (0.05), 
hypoxic (0.4) 
(Units unknown).  
 
Retinal endothelial cells expressed less 
VEGF than RPE cells (P=0.1) and 
pericytes (P=0.1).  
 
VEGF expression was 6.1 and 2.5 fold 
greater in pericytes than RPE and 
endothelial cells respectively.   
 
VEGF expression was first noted at 
<10% O2 and was maximum at <5% O2 
for exposures up to 24hrs. Increased 
VEGF expression was first recorded after 
4hrs and reached a maximum value at 
18hrs.  
 
VEGF is a likely candidate for 
mediating retinal neovascularization 
(arising from ischaemic ocular 
disorders). VEGF mRNA expression 
is stimulated by hypoxia, likely to be 
pathologically induced by poor blood 
flow perfusion. 
 
Retinal pericytes, endothelial and 
RPE cells all have the potential to 
induce VEGF production. 
 
The author suggests laser 
photocoagulation of VEGF 
neutralising antibodies in order to 
prevent ocular neovascularization.   
 
VEGF levels were reversed in all 
cells by reinstitution of normoxia and 
reached a normative level within 
24hrs.   
 
 
 
Sustained 
delivery of a 
HIF-1 antagonist 
for ocular 
neovascularisati
on (Iwase et al., 
2013).  
Mouse and rabbit 
animal model.  
 
The experiment used 
Doxorubicin (DXR) 
and Daunorubicin 
(DNR) which inhibit 
HIF-1 and perturb 
retinal function as 
demonstrated by ERG 
testing.  
 
Pathogen free 
C57BL/6 mice were 
used and Dutch belted 
rabbits.  
In-vivo animal model.  
 
DXR was diluted into a 
nanoparticle polymer 
(synthesised by centrifugation). 
It was then delivered via 
intraocular injection in order to 
reduce HIF response and 
prevent CNV formation.  
 
Eyes were analysed at 1, 4, 7 
and 14 days after injection. At 14 
days the total area of CNV was 
measured following fluorescein 
perfusion.  
 
VEGF levels were reduced significantly 
in those treated with DXR.  
  
10µm DXR administered to mice was 
found to suppress VEGF formation for 35 
days. The same amended dose in 
rabbits caused 105 days of VEGF 
suppression).  
 
The CNV and retinal NV area was 
significantly reduced in mice that were 
administered DXR after 14 days when 
compared to controls.  
 
Laser induced CNV results: 
Anti-VEGF shows a benefit in 
preventing the progression of ocular 
neovascularization however it 
doesn’t result in regression.  
 
Anti-VEGF combined with anti-
platelet derived growth factor 
(PDGF-B) has resulted in regression 
suggesting that combination 
treatment shows promise.  
 
The author suggests that the 
suppression of HIF-1 is comparable 
to a combination therapy as HIF 
activity is not specific to the 
transcription of just one protein.  
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CNV was induced in a number 
of mice via laser-
photocoagulation of Bruch’s 
membrane.  
 
A number of mice were placed in 
75% O2 7 days after birth and 
returned to normoxia at day 12 
in order to induce retinal 
neovascularization (NV).   
 
Control area (0.02mm2), 10mg DXR area 
(0.005 mm2). P<0.001. 
 
Hypoxia induced retinal NV results: 
Control area (1.5 mm2), 1mg DXR area 
(0.5 mm2). P<0.001.  
 
See paper for full figures (substantial).  
 
 
The results also confirm a strong 
role for HIF in AMD pathogenesis. 
DXR pending results of further 
testing on concentration may act as 
a promising treatment or alternative 
to ranibizumab.  
Geldanamycin, 
a HSP90 
inhibitor, 
attenuates the 
hypoxia-induced 
vascular 
endothelial 
growth factor 
expression in 
retinal pigment 
epithelium cells 
in vitro (Wu et 
al., 2007).  
Cultured RPE cells of 
human origin. 
 
RPE cell line (R-50) 
was cultivated 
overnight and 
distributed into 6 well 
plates.  
In Vitro RPE model.  
 
After cultivation the RPE was 
moved into a hypoxic chamber 
where it was exposed to 1% O2 
conditions for 48hrs.  
 
A cell proliferation assay was 
used to identify the effect of 
hypoxia on cell growth. An 
immunosorbent (ELISA) assay 
was used to identify VEGF and 
bFGF release from the RPE.  
 
A selection of samples were pre-
treated with geldanamycin (GA) 
1hr prior to hypoxic exposure. 
 
The cultured RPE cells under hypoxic 
conditions showed no obvious cell death 
as seen by morphological observation 
and cell proliferation assay.  
 
The hypoxic environment caused a 3.4 
fold increase in the level of VEGF 
production when compared to original 
levels. VEGF concentration was 
documented as 500 and 900pg/ml in the 
control group in comparison to 900 and 
1500pg/ml in the study group (after 24 
and 48hrs hypoxic exposure). P<0.05.   
 
bFGF levels showed no significant 
change in levels under hypoxic 
conditions.   
 
Samples pre-treated with GA displayed 
reduced expression levels of VEGF. 
 
The results indicate that VEGF 
expression is dependent on HSPs 
(particularly HSP90).  
 
Hypoxia was found to cause an 
increase in VEGF expression which 
under the artificial environment may 
have induced an anti-apoptotic 
effect.  
 
The author speculates that the 
HSP90 inhibitor (GA) induces 
reduction of HIF-1α levels and its 
downstream transcriptional activity 
(resulting in decreased VEGF 
expression). 
 
Using a HSP90 inhibitor as a 
clinically therapeutic agent for 
nAMD may be viable pending on 
further testing.  
  
The study results conflict 
with that of Castillo et al. 
2002 and Osborne et al. 
1997 in which hypoxia 
induced apoptosis was seen 
in cultured RPE cells after 
72hrs. A longer timescale 
may have given results that 
conform and the difference 
in RPE cell line used could 
have caused the conflicting 
results.  
 
 
Hypoxia/ 
Reoxygenation 
induces CTGF 
and PAI-1 in 
cultured human 
retinal pigment 
epithelium cells 
(Fuchshofer et 
al., 2009). 
Cultured RPE cells of 
human origin.  
 
The study aimed to 
investigate how 
hypoxia/re-
oxygenation affects 
connective tissue 
growth factor (CTGF), 
plasminogen activator 
inhibitor-1 (PAI-1), 
Lab based: immunoblot and 
immunoassay analysis used.  
 
Cultured RPE cells were kept in 
a hypoxic chamber and exposed 
to 1% O2 for 12.36hrs before a 
24hr reoxygenation period.  
 
The expression of various 
proteins was assessed by 
No changes were notable at a 
microscopic level between the 
morphology of normoxic and hypoxic 
cells.   
 
Exposure to hypoxia caused a marked 
increase in the CTGF protein level (2.8 
fold increase when compared to 
controls).  
 
Hypoxia increases the expression of 
CTGF and PAI-1 at a transcriptional 
level. This can be prevented via the 
blockage of HIF-1 activity and 
reduced via antioxidant usage.  
 
The results indicates that the 
process of hypoxia/re-oxygenation 
increases pro-fibrinogenic factors 
and ECM components of RPE cells, 
leading to speculation that hypoxia 
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collagen type IV and 
fibronectin.  
immunohistochemistry (Northern 
and Western blot analysis).  
 
Actinomycin D was added in 
order to examine whether 
hypoxia induced transcription of 
CTGF to PAI-1.  
 
Cells were prevented from HIF-1 
activation by the addition of 
siRNA in a number of samples. 
Coenzyme Q10 and ascorbic 
acid (antioxidants) were 
introduced to a number of 
samples.  
 
The PAI-1 protein level expression also 
increased following hypoxic exposure. A 
1.7 and 2.5 fold increase was found after 
12 and 24hrs.  
 
Following re-oxygenation levels of 
CTGF, PAI-1 and HIF-1 all showed a 
marked increase when compared to 
controls. Blocking HIF-1 expression 
prevented the increase in CTGF and 
PAI-1 previously observed under hypoxic 
conditions.  
 
The introduction of antioxidants caused a 
reduction of CTGF and PAI-1 mRNA 
expression by 2.2 and 1.8 fold in 
comparison to untreated samples.  
 
may play a role in ECM deposit 
accumulation (drusen formation) 
seen during AMD.  
 
Increase CTGF expression found in 
CNV membranes is likely due to 
hypoxia mediated activation of 
VEGF and transforming growth 
factor.  
Concerted 
inhibition of HIF-
1 alpha and-2 
alpha 
expression 
markedly 
suppresses 
angiogenesis in 
cultured RPE 
cells (Nakajima 
et al., 2013) 
Cultured RPE cells of 
human origin. 
 
 
Lab based: immunoblot and 
immunoassay analysis used.  
 
Human ARPE-19 cells were 
cultured and introduced to 
hypoxia via the usage of an 
AnaeroPack chemical (0.1% O2).  
 
Cell damage was quantified by 
measuring levels of LDH (an 
indicator of cell death and 
membrane breakage). A LDH 
cytotoxicity detection kit was 
utilised.  
 
VEGF activity was also detected 
using an immunoassay. HIF 
protein was identified using 
immunoblotting.  
Hypoxia caused HIF-1α increase until 
the 24hr stage and HIF-2α increase until 
the 36hr stage. In correlation with HIF 
stabilization VEGF levels were also 
raised (After 24hrs hypoxic exposure 
levels were significantly raised when 
compared to controls). 
 
VEGF mRNA was inhibited by nearly 
50% when HIF-1α activity was blocked 
using si-RNA. VEGF levels were not 
affected by the blocking of HIF-2α. 
However a combination block of both 
HIF-1α and HIF-2α gave the largest 
reduction in VEGF levels.  
 
VEGF release levels (in 
pg/VEGF/ml.medium): after 24hrs 
normoxia (250), hypoxia (500) and after 
48hrs normoxia (600), hypoxia (1900).  
 
The increased level of HIF isoforms 
during hypoxia is likely to be due to 
inhibition of O2 dependent 
proteasomal degradation.  
 
Increased HIF-1α stabilisation 
induces increased VEGF 
transcription. Both HIF isoforms 
seem to be important in the 
upregulation of angiogenic factors 
during hypoxia.  
 
Inhibition of HIF-1α alone or a 
combination HIF inhibition may have 
the potential to be useful in targeted 
therapy however HIF is an important 
inducer of protein autophagy and 
RPE clearance hence this method 
would have to be approached with 
caution. 
The author states that HIF-1 
is the ‘master switch’ for 
control of cellular responses 
in hypoxia. HIF-1 isoforms 
are short lived under 
physiological conditions due 
to their hydroxylation by HIF 
prolylase. In hypoxia HIF 
isoforms stabilise and 
mediate angiogenesis or cell 
proliferation/survival 
processes.  
Expression of 
hypoxia-
inducible factor -
1 alpha and -2 
alpha in human 
6 eyes in total.  
 
6 eyes of 6 nAMD 
participants (aged 65-
86yrs) were assessed 
Lab based: immunoassay 
analysis used.  
 
This was not a post-mortem 
study. Each participant 
HIF-1α and/or HIF-2α were detected in 5 
of 6 CNVM’s analysed. Half of the total 
endothelial cells and all macrophages 
(located in the stroma) were found to 
have both HIF isoforms.  
The results suggest that HIF-1α 
and/or HIF-2α play a role in VEGF 
up-regulation and CNVM formation 
under hypoxic conditions. 
 
HIF is a transcription factor 
that activates the expression 
of pro-angiogenic gene 
VEGF in response to 
hypoxia. 
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choroidal 
neovascular 
membranes 
(Inoue et al., 
2007).  
for the expression of 
HIF isoforms within 
their CNVM’s.  
 
 
underwent ocular surgery 
(submacular) in order to allow 
the CNVM to be obtained 
following its classification using 
FA.  
 
Once obtained the CNVM was 
tested for HIF presence 
(unspecified specifics of assay).  
 
 
  
HIF was not detected within RPE 
cells raising the suspicion that 
another mechanism causes VEGF 
up-regulation at this location.  
Expression of 
hypoxia-
inducible factor -
1 alpha and -2 
alpha in human 
choroidal 
neovascular 
membranes 
associated with 
age-related 
macular 
degeneration 
(Sheridan et al., 
2009).  
12 surgically excised 
subfoveal CNVM’s 
used.  
 
The CNVM’s were 
obtained from 9 
participants with AMD 
and 3 with punctate 
inner choroidopathy 
(PIC).  
 
26 control participants 
were also recruited.  
Lab based: histological and 
immunoassay analysis used. . 
 
Specimens were fixed with 
formalin and embedded in wax. 
5mm sections were then cut, 
mounted on slides, de-waxed 
and stained for histological (with 
haematoxylin and eosin) or 
immunohistochemical analysis.  
 
  
HIF-1α was detected in 7 of 12 
specimens (5 AMD and 2 PIC). HIF-2α 
was detected in 8 of 12 specimens (8 
AMD).  
 
Within the outer retina of CNVM 
(containing capillaries and endothelial 
cells) both isoforms of HIF were found in 
10 of 12 specimens. Within the inner 
retina (containing RPE and 
macrophages) both isoforms of HIF were 
found in 5 of 10 specimens.  
 
HIF-1α was less than HIF-2α expression. 
The presence of at least one HIF isoform 
was found in 10 of 12 CNVM’s caused by 
AMD.  
 
HIF-1α was found in the RPE of 55% of 
samples.  
 
The presence of VEGF was found in all 
12 samples and tended to be co-
localised with HIF.  
The results suggest that the central 
RPE cells are exposed to hypoxic 
insult during AMD pathogenesis. 
Blocking HIF activity has a potential 
therapeutic use however may lead 
to impaired wound healing. Also this 
action does not impact on the 
underlying disease pathway and 
hence will not resolve the disease 
activity (and promote a sustained 
hypoxic environment via preventing 
new vessel growth).  
 
The results confirm that hypoxia 
induces the expression of pro-
angiogenic factors through the HIF 
transcriptional complex and that 
both HIF isoforms appear to have 
the ability to transcribe VEGF. 
 
Expression of HIF in RPE cells 
suggests that at some stage during 
AMD pathogenesis the RPE is 
hypoxic.  
 
Less long term hypoxia (due to the 
acute nature) of PIC onset may 
result in reduced HIF-2α. AMD 
pathogenesis seems more chronic 
in progression when compared 
hence HIF levels differ. Also fewer 
PIC samples were collected hence 
the results are less reliable.   
Morphological analysis 
displayed that study and 
control eyes had a similar 
and distinctive cellular 
distribution consisting of a 
relatively avascular, fibrous 
stromal core to the CNVM 
and a peripheral zone rich in 
cells.  
 
Outside of this RPE 
degenerates and 
macrophages were found 
scattered throughout the 
tissue neighboured by 
capillaries and endothelial 
cells. 
 
This result differs from 
others as both HIF isoforms 
were found in-situ, not just 
HIF-1α  only which has been 
documented in cultured RPE 
cells.   
 
The author states that the 
fact that anti VEGF 
injections are required to be 
repeated may indicate that 
the underlying hypoxic 
signal behind AMD 
pathogenesis remains 
present.  
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Retinal oxygen 
metabolism in 
exudative age-
related macular 
degeneration 
(Geirsdottir et 
al., 2014). 
166 eyes in total.  
 
46 eyes of 46 nAMD 
participants and 120 
eyes of 120 healthy 
controls were used. All 
participants were 
Caucasian.  
 
nAMD participants had 
not undergone any 
treatment prior to 
clinical testing. Those 
with longstanding 
AMD (disciform 
scarring) or additional 
ocular/systemic 
pathology were not 
eligible.  
  
Microperimetry and OCT used. 
 
Oximeter used to provide 
oxygen saturation readings of 
the retinal circulation (not the 
choroid).  
 
Pre-trial measurements of blood 
pressure, finger pulse oximetry, 
IOP and heart rate were taken 
alongside a questionnaire 
regarding medical history and 
smoking status.  
 
A dual-wavelength non-invasive 
retinal oximeter (Oxymap T1) 
was used to record 
measurements of oxygen 
saturation via a light wavelength 
and absorption methodology.  
 
Images provided were analysed 
by Oxymap Analyzer software.  
No difference was found between the 
arteriolar oxygen saturation between the 
AMD participants and the healthy 
controls (P=0.16).  
 
There was a statistically significant 
oxygen saturation difference found within 
the venuoles of the AMD and control 
groups, with the saturation being higher 
in the presence of AMD.  
 
In healthy individuals, venous oxygen 
saturation decreases by 0.16 percentage 
points for each year of age, while in 
AMD, the oxygen saturation increases by 
0.40 percentage points per year.  
 
The arteriovenous difference decreases 
with age in AMD, while it increases in 
healthy individuals.  
 
Alternatively similar results may be as a 
consequence of less O2 demand by the 
damaged retinal tissue. 
 
The results suggest that retinal 
oxygen metabolism may be 
abnormal in patients with nAMD.  
 
Venous oxygen saturation appeared 
to be higher in the presence of AMD 
and continued to increase with age.  
 
Arteriovenous difference in oxygen 
saturation was less in AMD 
participants indicating that less 
oxygen is being extracted from the 
retinal vessels in the presence of 
AMD. This reduced oxygen 
saturation (assuming blood flow is 
not increased) results in less oxygen 
reaching the macular tissues.  
 
The data indicates that the retinal 
circulation is contributing less 
oxygen to the retina in AMD when 
compared to normal eyes. The 
oxygen consumption of the retina is 
likely to be abnormally low with 
nAMD.  
 
High oxygen saturation in vessels 
may reflect reduced oxygen delivery 
from vasculature to tissue as with 
results found in the presence of 
diabetic retinopathy (Hardarson and 
Stefánsson, 2012).  
 
The author provides a good 
breakdown of studies 
performed: (Grunwald et al., 
1998; Metelitsina et al., 
2008; Boltz et al., 2010; 
Sato et al., 2006; and 
Remsch et al., 2000).  
 
The control group in this 
study was not age-matched 
to the study group and only 
vessels equal to or larger 
than 8 pixels could be 
measured due to the 
reliability of the oximeter 
(small vessels would’ve 
provided more accurate 
results).  
 
The author also suggests 
that another explanation for 
reduced oxygen delivery to 
tissue may be related to 
capillary non-perfusion and 
vessel wall thickening. 
Hypoxia-induced 
metabolic stress 
in retinal 
pigment 
epithelial cells is 
sufficient to 
induce 
photoreceptor 
degeneration 
(Kurihara et al., 
2016)  
In vivo analysis using 
mouse and human 
cultivated RPE cells 
and functional analysis 
(ERG) using mouse 
models to 
demonstrate effect of 
induced hypoxia on 
photoreceptors 
 
 
Electroretinography was 
performed on dark adapted, 
anaesthetised mice engineered 
to have choriocapillary defect. 
The defects exhibited were then 
compared to the retinal damage 
as induced by hypoxia 
(immunochemical analysis).   
 
Human RPE cells with induced 
hypoxia (3% oxygen chamber) 
Mouse model:  
1st signs of hypoxia (HIF reactivity) was 
noticed 6/12 post induction. Hypoxia in 
RPE induced severely distended basal 
infoldings, accumulation of lipid droplets 
within RPE cells, RPE cell hypertrophy 
and progressive thickening of  
Bruch’s membrane (9/12 post induction) 
 
Human RPE:  
Chronic HIF-2alpha mediated 
metabolic stress in RPE cells is 
enough to induce PR dysfunction 
and/or degradation.  
  
How this occurs:  
Hypoxia alters the RPE secretome 
(secretions). Hypoxic RPE shut 
down glucose and lipid oxidation 
(restoration)  and commit to 
glycolysis (breaking down glucose 
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were also assessed for retinal 
damage. RPE cells were also 
modified to induce HIF 
stabilization and assessed for 
retinal damage.   
HIF target gene VEGF-A was 
upregulated after exposure to low 
oxygen. Hypoxia triggered CC 
vasodilation.  
 
Removing VHL Causes RPE lipid droplet 
accumulation within 3/7. Severely 
distended basal infolding and increased 
thickness of BM occurred after 14/7.  
 
The effect of RPE hypoxia caused 
sensory defects. PR degeneration was 
observed along with significant functional 
impairments of both rod and cone driven-
pathways   
 
for energy). This allows RPE to gain 
energy more quickly however 
doubles their glucose intake. Since 
RPE is main supplier of glucose to 
neurosensory retina this impacts 
photoreceptor function and survival.   
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Appendix II. ALight trial published protocol 
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Appendix III. Calibration of a LCD monitor 
Prior to calibration the luminance output of the monitor was non-linear. Therefore the 
output was ‘Gamma corrected’ to ensure linear output in accordance with the methods 
described by Metha et al. (1993). In brief, a ‘Gamma model’ was fitted to the non-
linear luminance output using the Excel Solver function (Figure App II.1). This allowed 
the derivation of output luminance as a function of grey scale monitor output. Direct 
measurement of the luminance output of the monitor at various grey scale values 
allowed the calculation of the grey scale value needed to give a desired luminance. 
This allowed the derivation of a ‘Gamma function’ (Table App II.1) which when applied 
to the LCD monitor resulted in a linear luminance output.     
Figure App II.1. Pre- (triangle) and post- (circle) calibration luminance output of the LCD 
monitor.  
Table App II.1. Gamma function values calculated throughout the duration of the ALight clinical 
trial.  
 
 
 
 
 
  
 
 
 
 
Date Gamma Function 
 
08/07/14 
 
2.230375 
31/10/14 2.215787 
12/12/14 2.223671 
26/01/15 2.210972 
25/02/15 2.221308 
24/03/15 2.223629 
21/04/15 2.218070 
19/05/15 2.209280 
30/06/15 2.221618 
14/07/15 2.227637 
02/09/15 2.221134 
18/11/15 2.191009 
27/01/16 2.175951 
23/02/16 2.188395 
04/04/16 2.215031 
07/06/16 2.231966 
08/08/16 2.209406 
12/10/16 
 
2.222900 
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Appendix IV. Dark adaptation MATLAB code  
DARK ADAPTATION EXPERIMENT – Alight trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                            
%First written 3/3/90 by Tom Margrain.  
%This version was modified on 13/5/14 by T.Margrain and G.Robinson. 
%This version is specific to the 4 degree target used for the Alight 
trial.  
%The Programme is set up for dilated Px at 140cm. DA over 25mins 
%Calibration is for the NEC MultiSync PA241w Monitor. 
  
clear all 
  
%1st step: input coordinates and sizes for fixation cross and spot 
stimulus: 
 
%Stimulus specifics: 
%How many pixels of the monitor equate to 1 retinal degree at 140cm? 
%How large (in retinal degrees) will the stimulus be? 
%Spot positioning (1st and 3rd numbers = horiz, 2nd and 4th = vert)  
pixelsPerDegree=88.86;  
SpotSize=4;  
SpotSize=(SpotSize*pixelsPerDegree)/2; 
offsetCenteredspotRect = [960-SpotSize, 600-SpotSize, 960+SpotSize, 
600+SpotSize];  
SurroundRectInner = [960-SpotSize-10, 600-SpotSize-10, 
960+SpotSize+10, 600+SpotSize+10]; 
  
%Fixation cross specifics: 
%What thickness/size/colour [R,G,B] will the fixation cross be? 
LineThickness = 7; 
LineLength=600; 
LineSpectrum = [256 256 256];  
 
%2nd step: input specifics of the test prior to bleach: 
 
%How long will the test run? 
durationInSeconds = 1500; 
%How will the programme know when a button has been pressed (a response 
given)?     
KbName('UnifyKeyNames');  
%Which VDU screen will be used? Which window will the test run in?  
try 
whichScreen = 0; 
window = Screen(whichScreen, 'OpenWindow'); 
white = WhiteIndex(window); % pixel value for white colouring in this 
window 
black = BlackIndex(window); % pixel value for black colouring in this 
window 
%What sounds will be used throughout the test?  
correctSound = sin(2*pi*100*[0:0.00125:2.0]); 
incorrectSound = sin(2*pi*40*[0:0.00125:2.0]); 
NewFilterSound = sin (2*pi*200*[0:0.00125:10.0]);   
%Dark adaptation specifics: 
%Step-size is based on 4-2 staircase method used by Dimitrov et al. 
(2011).  
incrementStep = 0.4; 
SpotLuminance = 1.95; 
%How can you escape the programme in event of an error? 
escapeKey = KbName('ESCAPE'); 
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%Set up a various counters to record data throughout the test: 
response = 0;  
responseCounter = 0; %Counts patients responses throughout test 
reversalCounter = 1; %Counts number of reversals (reset after each 
threshold) 
DarkAdptCounter = 0; %Counts number of times a DA threshold is recorded 
presentationCounter=1; %Counts total number of presentations shown 
dataCounter=1; %Counts total number of reversals shown 
thresholdCounter = 1;%Counts total number of threshold points 
 
%Set up filter parameters: 
%The 2nd and 3rd ND filters are set as 0 until put into place 
AdjustmentFilter1 = 1.2; %This is the optical density of the first ND 
filter. 
AdjustmentFilter2 = 0; %This is the optical density of the second ND 
filter  
AdjustmentFilter3=0; %This is the optical density of the third ND 
filter 
 
%Create a line to flag when the stimulus is reaching its lowest 
luminance for a 2nd time during threshold testing: 
SecondNDFIlterFlag = 0; 
resultTime = 1; 
resultThreshold = 1; 
BreakFlag=0; 
     
%Create a window at the start of the experiment in which instructions 
can be displayed: 
Screen(window, 'FillRect', 0);     
%Write experiment details and instructions into the created window 
Screen('DrawText', window, 'DARK ADAPTATION VERSION 2 12-05-14', 700, 
800, white); 
Screen('DrawText', window, '10s to start bleach', 800, 400, white); 
Screen(window, 'Flip');  
%Inform the investigator when to apply the bleaching source 
WaitSecs (10);     
Screen ('DrawText', window, 'Start bleach now', 800, 400, white); 
Screen(window, 'Flip'); 
WaitSecs (60); 
%Inform the investigator when half the bleaching time has subsided 
Screen('DrawText', window, '1 minute complete, the beep will sound 
when 10s remain', 600, 400, white); 
Screen(window, 'Flip'); 
WaitSecs (50); 
%Inform the investigator (via a beep) when there is 10s of bleaching 
time left 
cf = 750;                   % This is the carrier frequency (Hz). 
sf = 15050;                 % This is the sample frequency (Hz). 
d = 1.0;                    % This is the duration (s). 
n = sf * d;                 % This is the number of samples. 
s = (1:n) / sf;           % This prepares the sound data from the 
video card.  
s = sin(2 * pi * cf * s);   % This is the sound modulation 
sound(s, sf);              % This presents the sound from the sound 
card. 
pause(d + 0.5);             % This ends the sound.  
WaitSecs (10); 
%Inform the investigator when threshold testing is to begin 
Screen ('DrawText', window, 'Press any key to begin', 750, 800, 
white); 
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Screen('DrawText', window, 'Bleach finished', 800, 400, white); 
Screen(window, 'Flip');  
%Wait until a key is pressed before the testing begins and hide the 
mouse cursor 
KbWait;  
Screen('HideCursorHelper', window); 
 
%3rd step: set up procedures following bleach – before threshold 
testing begins 
     
%Set up a timer to record duration of testing from when 1st key is 
pressed  
startTime = now; 
durationEachThreshold = 1; 
numberOfSecondsRemaining = durationInSeconds;  
SecondsRemaining = durationEachThreshold; 
     
%Calibrate the screen as soon as the 1st key is pressed  
MinScreenLum = 0.12;  
GammaFunc = 2.227637; 
MaxScreenLum = 99.36; 
  
%Now start the experiment loop (i.e. threshold testing via 4-2 
staircase) 
fprintf('Experiment started'), 
%Record what time threshold testing began and for how long it proceeds 
StartExptSecs = GetSecs;  
while GetSecs - StartExptSecs < durationInSeconds   
%Ensure that threshold testing re-enters the experiment loop and 
doesn’t stop until commanded 
stopRule = 1;  
while stopRule > 0  
  
%Calculate the grey scale required for desired spot luminance 
%To do this raise spot luminance by the power of 10 to ‘un-log’ it 
GammaCorrectSpotLum = 255*(((10^SpotLuminance)-
MinScreenLum)/MaxScreenLum)^(1/GammaFunc);  
 
%Make the fixation cross 3x brighter than the spot stimulus 
LineSpectrum = [GammaCorrectSpotLum*3.0; GammaCorrectSpotLum*3.0; 
GammaCorrectSpotLum*3.0];  
 
%Write the spot luminance on the corner of the screen in blue text 
Screen('DrawText', window, ['GammaCorr: ' num2str(SpotLuminance,4)], 
1700, 1100, [0,0,240]);  
 
%Ensure the fixation cross is visible before and after the stimulus 
appears 
Screen('DrawLine', window, [LineSpectrum], 960-LineLength, 600, 
960+LineLength, 600 ,LineThickness);  
Screen('DrawLine', window, [LineSpectrum], 965, 600-LineLength, 965, 
600+LineLength ,LineThickness);  
 
%4th step: begin stimulus presentation for threshold testing 
 
%Create the spot stimulus – with fixation cross lines superimposed 
Screen('FillOval', window, [GammaCorrectSpotLum GammaCorrectSpotLum 
0], offsetCenteredspotRect);  
Screen('DrawLine', window, [LineSpectrum], 960-LineLength, 600, 
960+LineLength, 600 ,LineThickness);  
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Screen('DrawLine', window, [LineSpectrum], 965, 600-LineLength, 965, 
600+LineLength ,LineThickness) 
%Present the stimulus  
Screen(window, 'Flip');  
%After 200ms remove the stimulus but keep fixation cross lines. 
WaitSecs (0.2);  
%Write the spot luminance on the corner of the screen in blue text 
again 
Screen('DrawText', window, ['GammaCorr: ' num2str(SpotLuminance,4)], 
1700, 1100, [0,0,240]); 
%Ensure the fixation cross remains even after the stimulus has 
disappeared  
Screen('DrawLine', window, [LineSpectrum], 960-LineLength, 600, 
960+LineLength, 600 ,LineThickness); 
Screen('DrawLine', window, [LineSpectrum], 965, 600-LineLength, 965, 
600+LineLength ,LineThickness);  
Screen(window, 'Flip'); 
%Record the exact time at which the stimulus was taken off the screen. 
ResponseSecs = GetSecs;  
 
%5th step: record responses to stimulus presentation  
%Record if any key has been pressed during stimulus presentation 
while 1 
[ keyIsDown, timeSecs, keyCode ] = KbCheck; 
if keyIsDown                    
 
%If the ESC key is pressed then break the loop and end the programme 
if keyCode(escapeKey)  
BreakFlag=1; 
break 
end 
 
%If the patient pressed a key within a given timescale then record a 
‘correct response’ 
if (timeSecs - ResponseSecs)<0.6; 
response = 1;  
sound(correctSound) 
 
%If the patient pressed a key too late then record an ‘incorrect 
response’ 
else 
response = -1;  
sound (incorrectSound) 
break 
end     
 
%Avoid kbcheck reporting multiple events as loop is repeated 
while KbCheck;  
end  
break 
end 
  
%If no response is made by the patient to the stimulus... 
%Record the time and how long it has been since a presentation 
SecsNow = GetSecs; 
timeSincePresentation = (SecsNow - ResponseSecs); 
if timeSincePresentation > 1; 
%This means that the patient did not identify the stimulus (response 
incorrect) 
response = -1;  
break 
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end 
end  
%If the ESC key is pressed then break the loop and end the programme 
if BreakFlag==1  
break 
end 
             
%Record the time and brightness of each presentation made 
presentationTime(presentationCounter)= (GetSecs - StartExptSecs); 
presentationThreshold(presentationCounter)= SpotLuminance-
AdjustmentFilter1-AdjustmentFilter2-AdjustmentFilter3; 
presentationCounter = presentationCounter + 1; 
             
%Adjust the next stimulus presented based on the response given 
%If there is a correct response:        
if response > 0;  
if incrementStep > 0.0; %Indicates the threshold was raised on the 
last presentation 
%Record the time and brightness of the current threshold (to which a 
correct response has been given) 
resultTime (thresholdCounter) = (GetSecs - StartExptSecs); 
resultThreshold (thresholdCounter) = SpotLuminance-AdjustmentFilter1-
AdjustmentFilter2-AdjustmentFilter3; 
thresholdCounter = thresholdCounter + 1; 
stopRule = -1; %Indicates to the programme that a correct answer has 
been logged and a threshold has been recorded 
end 
%Ensure that the next presentation given is reduced in brightness by 
0.3 log units 
incrementStep = -0.3; 
WaitSecs (0.5+(2*(rand(1.0)))); 
End 
 
%If there is an incorrect response:        
if response < 0; 
incrementStep = 0.1; 
WaitSecs (rand(1.0)); 
end 
%Ensure that the next presentation is increased brightness of 0.1 log 
units  
SpotLuminance = SpotLuminance + incrementStep;   
if SpotLuminance > 2 
SpotLuminance = 2; 
end 
 
%6th step: Reset stimulus intensity when minimum luminance is reached  
if SpotLuminance < -0.5; 
SecondNDFIlterFlag = SecondNDFIlterFlag + 1;  
%Make a sound to alert the investigator a new filter is required 
sound (NewFilterSound) 
% Ensure the programme knows if this is the 1st or 2nd filter being 
brought down 
if SecondNDFIlterFlag == 1  
%By what value will the brightness be attenuated by the filter? 
AdjustmentFilter2 = 2.1; 
%How long does the investigator have to bring the filter down? 
WaitSecs (10.0) 
%Reset the stimulus intensity to maximum brightness with filter in 
place 
SpotLuminance = SpotLuminance + AdjustmentFilter2; 
end 
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%Repeat process with a 1.8ND filter if patient reached minimum 
brightness again 
if SecondNDFIlterFlag == 2  
AdjustmentFilter3 = 1.8; 
WaitSecs (10.0) 
SpotLuminance = SpotLuminance + AdjustmentFilter3;  
end    
end 
end %This ends the search for a threshold 
 
% What happens if the esc key is pushed during this? 
if BreakFlag==1  
break 
end      
end  
 
%7th step: Generate results 
 
%Bring the cursor back 
Screen('ShowCursorHelper', window); 
 
%Converts row of presentation times and threshold values into column 
format 
presentationTime = presentationTime (:);% 
presentationThreshold = presentationThreshold (:);  
%Plot every recorded presentation graphically 
plot(presentationTime, presentationThreshold,'b*') 
xlabel('Time(s)') 
ylabel('Log Threshold') 
axis ([0 1500 -5 1.5]) 
hold on 
%Converts row of correct-response times and correct-response threshold 
values into column format 
resultTime = resultTime(:); 
resultThreshold = resultThreshold(:); 
%Plot every recorded correct-response graphically 
plot(resultTime, resultThreshold,':ko')  
%Fit the final exponential curve to the data 
Starting = [1.2,5,40];  
options=optimset('Display','off');       
Estimates=fminsearch(@myfitExp,Starting,options,resultTime,resultThr
eshold); 
fT = Estimates(1) 
iT = Estimates(2) 
Tau =Estimates(3) 
ExpFitTime =0:2.0:300; 
ExpFitThreshold = Estimates(1)+((Estimates(2)-Estimates(1))*exp(-
ExpFitTime./Estimates(3))); 
plot(ExpFitTime, ExpFitThreshold,'r-','LineWidth',2) 
  
%Close the window now that the data has been collected and graphically 
plotted 
Screen('CloseAll'); 
     
%Output all the data to Excel spreadsheet 
presentationData = [presentationTime, presentationThreshold] 
thresholdData = [resultTime, resultThreshold] 
ExpFitTime=ExpFitTime(:); 
ExpFitThreshold=ExpFitThreshold(:); 
%What folder shall the results be sent to? 
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xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\Dark 
Adaptation Results.xls', presentationData,'Model','A14');  
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\Dark 
Adaptation Results.xls', thresholdData,'Model','D14'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\Dark 
Adaptation Results.xls', fT,'Model','H3'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\Dark 
Adaptation Results.xls', iT,'Model','H2'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\Dark 
Adaptation Results.xls', Tau,'Model','H4'); 
catch 
Screen('CloseAll'); 
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Appendix V. Flicker threshold MATLAB code 
% 14 Hz FLICKER THRESHOLD: For Alight Trial use 
% 
% This programme uses a YES/NO, QUEST driven staircase to determine 
contrast  
% thresholds for a flickering gaussian blob.  
% The code is adapted from Gaboiumdemo, kbDemo and QuestDemo. 
% Ver. 1: T.Margrain (28-11-12).  
% Modified for the Alight trial by T.Margrain and G Robinson (Mar 
2014) 
% This version uses a 14Hz Gaussian blob set for 2 degrees at 140cm 
% viewing distance (Alight monitor: NEC Multisync PA241W) 
 
% Modifications from V1 include: 
% 'simple gamma correction' code obtained online from 
% AdditiveBlendingForLinearSuperpositionTutorial.  
% Lines of code that were not used before include:  
% PsychImaging('AddTask', 'General', 'EnablePseudoGrayOutput') - this 
line 
% lets us call up all screen output in the range 0-1 (0-100%) rather 
than 
% grey scale.  
% PsychImaging('AddTask', 'FinalFormatting', 
'DisplayColorCorrection',  
% 'SimpleGamma'); 
% This line sets up simple gamma correction in the video output 
'pipeline' 
% PsychColorCorrection('SetEncodingGamma', win, gamma); So, all 
output is 
% gamma corrected automatically. 
% This version also allows the 'blob' to occupy a 0-1 range rather 
than 
% 0-0.5 (line 130). It also changes the slightly misleading variable 
% "contrast" to the more accurate "luminance" i.e. the output is 
threshold 
% luminance (lines 167, 173). The final output (threshold) is log 
luminance  
% as a fraction of the max screen luminance in cd/m2. 
 
 
% Step 1: Set up all the relevant parameters 
% How many trials?  
clear all 
trialsDesired = 40;% How many trials?  
wrongRight={'wrong','right'}; % What is correct response? 
stimFreq = 14; % What is temporal frequency of flickering in Hz? 
KbName('UnifyKeyNames'); % Allows keypad press to be recorded as a 
response 
escapeKey = KbName('ESCAPE'); % Ensures prog can be stopped if 
necessary 
format compact 
avgfps = []; 
contrastPresent = []; 
falsePositive = 0; % Counts number of false positive responses 
LineSpectrum = [256 256 256]; % Draw a line (colour [R,G,B] 
LineLength =200; 
LineThickness=5; 
AssertOpenGL; 
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% This programme uses Psychophysics QUEST routines to determine 
threshold 
% to get these to work it is necessary to provide information about 
the 
% threshold we are looking for in particular an initial guess at the 
% threshold and the standard deviation 
% Provide our prior knowledge to QuestCreate, and receive the data 
structure % "q". 
participant=[]; 
while isempty(participant) % Display message to input subjects name 
    participant=input('Subjects name please: ', 's'); 
end 
tGuess=[]; 
while isempty(tGuess) % Display message to input an estimate of 
threshold 
    tGuess=input('Estimate threshold (e.g. -1): '); 
end 
tGuessSd=[]; 
while isempty(tGuessSd) % Display message to input an estimate of SD 
    tGuessSd=input('Estimate the standard deviation of your guess, 
above, (e.g. 2): '); 
end 
pThreshold=0.82; 
beta=3.5;delta=0.01;gamma=0.5; 
% beta controls the steepness of the psychometric function (Typically 
3.5). 
% delta is the fraction of trials on which the observer presses 
blindly. %(Typically 0.01). 
% gamma is the fraction of trials that will generate response 1 when  
% intensity==-inf. 
q=QuestCreate(tGuess,tGuessSd,pThreshold,beta,delta,gamma); 
q.normalizePdf=1; % This adds a few ms per call to QuestUpdate, but 
otherwise the pdf will underflow after about 1000 trials. 
  
% Introduce try and catch failsafe to rescue code in event of prog 
crash 
try 
 
% Select screen with maximum ID for output window: 
screenid = max(Screen('Screens')); 
 
% Open a fullscreen, onscreen window with gray background. Enable 
32bpc 
% floating point framebuffer via imaging pipeline on it, if this is 
possible 
% on your hardware while alpha-blending is enabled. We need alpha-
blending 
% here to superimpose the gabor blob on the background. The programme 
will 
% abort if your graphics hardware is not capable of any of this. 
PsychImaging('PrepareConfiguration'); 
PsychImaging('AddTask', 'General', 'FloatingPoint32BitIfPossible'); 
 
% Enable bitstealing aka PseudoGray shader: This line is needed so 
that 
% subsequent screen output is in the range 0-1 i.e. up to 100% of 
screen % output. No need to call grey levels.  
% It also increases the number of grey scales that can be generated 
PsychImaging('AddTask', 'General', 'EnablePseudoGrayOutput'); 
 
% Set up the final video output pipeline to include gamma correction 
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PsychImaging('AddTask', 'FinalFormatting', 'DisplayColorCorrection', 
'SimpleGamma'); 
 
% Finally open a window according to the specs given with above 
% PsychImaging calls, clear it to a background color of 0.5 aka 50% 
% luminance: 
[win, winRect]=PsychImaging('OpenWindow',screenid, 0.5); 
WaitSecs (0.5); 
 
% Apply the gamma correction to all outputs to the screen. The default 
value % here is gamma = 2 however Grant to update monthly throughout 
Alight trial 
gamma = 1 / 2.227637; 
PsychColorCorrection('SetEncodingGamma', win, gamma); 
WaitSecs (1); 
  
% Enable alpha-blending, set it to a blend equation useable for linear 
% superposition with alpha-weighted source. This allows to linearly 
% superimpose gabor patches in the mathematically correct manner, 
should 
% they overlap. Alpha-weighted source means: The 'globalAlpha' 
parameter in 
% the 'DrawTextures' can be used to modulate the intensity of each 
pixel of 
% the drawn patch before it is superimposed to the framebuffer image, 
i.e. 
% it allows to specify a global per-patch contrast value: 
Screen('BlendFunction', win, GL_SRC_ALPHA, GL_ONE); 
  
% Query frame duration: We use it later on to time 'Flips' properly 
for an 
% animation with constant framerate: 
ifi = Screen('GetFlipInterval', win); 
  
% Create a gabor patch: This is 184x184 pixel matrix that has periperal  
% values around zero and a central value of 1. The gray scale range 
of the  
% monitor is 1 at the centre of the gabor. 
[x,y] = meshgrid(-100:100, -100:100); 
whiteBlob = (exp(-((x/40).^2)-((y/40).^2))); 
   
% Create blob movie, first determine frame rate 
rate = 1/ifi; 
  
% Determine number of frames avaliable for a given stimulus frequency 
framesAvaliable = rate/stimFreq; 
  
% Determine the step size to get through 360 degrees (1 cycle) in the 
% number of frames avaliable 
step = 360/framesAvaliable; 
  
% Set up degrees, start a zero and increment in the loop according to 
the 
% step size 
x=-180; 
  
% Get the time at the very start to record the total experimental time 
exptStart = Screen('Flip', win); 
  
% Introduce experiment, wait for signal to start 
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%Screen('FrameRect', win ,[0,128,0], [540,300,740,500],1); 
Priority(2);% Update the priority for Matlab i.e. Avoid interference 
from OS 
 
% Give instructions to the patient 
Screen('DrawText', win, 'PUSH THE BUTTON WHEN YOU SEE THE CENTRE OF 
THE CIRCLE FLICKER', 550, 283, [1,1,1]); 
 
% Draw a white oval to use as a fixation target 
Screen('FrameOval', win, [LineSpectrum], [760,400,1160,800]); 
Screen ('Flip', win); 
WaitSecs (4); 
Screen('HideCursorHelper', win); 
Screen ('Flip', win); % Flipping removes the text from the screen 
  
 
 
 
 
% Step 2: Start main experiment loop (threshold testing begins) 
 
for k=1:trialsDesired; 
Screen('FrameOval', win, [LineSpectrum], [760,400,1160,800]); 
Screen ('Flip', win); 
% First pick up the threshold recommended by QUEST 
tTest=QuestQuantile(q); % Recommended by Pelli (1987). 
  
% Unlog tTest, this ensures that the luminance of the stimulus is 
controlled 
luminance = 10^tTest; 
  
% Generate the textures to be displayed during each frame, assume 60Hz 
so 
% going from 1 to 120 will be a 2s presentation 
for i=1:120; 
 
%Need to change contrast to a fraction 
Blob = whiteBlob * (luminance) * sind(x); 
gabortex(i)=Screen('MakeTexture', win, Blob, [], [], 2); 
x=x+step; 
end; 
  
% Wait a random period of time before giving the presentation 
randomdelay = rand*6; 
StartSecs = GetSecs; 
timeNow=0; 
while timeNow <randomdelay   
SecsNow = GetSecs; 
timeNow = (SecsNow - StartSecs); 
 
% Command the keyboard to check for input 
[ keyIsDown, timeSecs, keyCode ] = KbCheck;  
 
% if a key is pushed: 
if keyIsDown  
falsePositive = falsePositive+1; % Count the incorrect responses  
Beeper(400) % Sound to indicate response 
while KbCheck; end % this avoids KbCheck reporting multiple events 
end 
end 
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% Was the stimulus seen or not seen?            
response = 0;  
count = 0; % This is needed to count the number of presentations 
vbl = Screen('Flip', win); 
tstart = vbl; % records the time the main presentation loop started 
for i=1:120; 
Screen('DrawTexture', win, gabortex(i),[],[],45); 
Screen('FrameOval', win, [LineSpectrum], [760,400,1160,800]); 
 
% Check the frame presentation time, does it always match the frame 
refresh  
% rate? 
vbl = Screen('Flip', win, vbl + ifi/2); 
lastTime = vbl; 
count = count+1; % Will count up to 120 
 
% check for keyboard for a correct response during presentation 
[ keyIsDown, timeSecs, keyCode ] = KbCheck;  
if keyIsDown % if a key is pushed this is what to do 
response=1; % flags a correct response  
break % breaks out of the presentation loop 
end 
end; 
     
% Clear the screen of any residual gabor and get time stamp 
tend = Screen ('Flip', win); % records the time the presentation 
stopped 
Screen('FrameOval', win, [LineSpectrum], [760,400,1160,800]); 
Screen ('Flip', win); 
 
% Check frames per second for this trial, store result in array avgfps 
avgfps(k) = count / (tend - tstart); 
     
% Now get the participants response 
ResponseSecs = GetSecs;% gets the time the stimulus was flipped out 
             
% Wait for a response for three seconds, if in the 1st second = correct 
while 1 
[ keyIsDown, timeSecs, keyCode ] = KbCheck; % Did they push a button? 
if keyIsDown % This bit of code is only executed if a button is pushed 
if (timeSecs - ResponseSecs)<1; % Was their response in time? 
response = 1; %this 'flag' means the response was correct 
Beeper (1000) % make a 'beep' sound to indicate correct response 
recognised 
                 
else 
response = 0; %this means the response was incorrect (in this case 
too slow) 
Beeper (600) % make a different sound to indicate response too slow 
falsePositive = falsePositive+1;% counts the incorrect responses 
break 
end 
  
while KbCheck; end % this avoids KbCheck reporting multiple events 
break 
end 
  
% Now, if no button was pressed 
SecsNow = GetSecs; 
timeSincePresentation = (SecsNow - ResponseSecs); 
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% If no response within 1s of stimulus, its missed, get out of loop 
if timeSincePresentation > 4;  
break 
end % waiting for response or time up 
end 
  
% Print the results for this particular trial 
fprintf('Trial %3d at %5.2f is 
%s\n',k,tTest,char(wrongRight(response+1))); 
LuminancePresent(k)=tTest; 
  
% Now update the QUEST routines with the last threshold value (this 
is all in % logs) and let it know if the participant responded 
correctly (1) or  
% incorrectly (0) 
 
% Add the new datum (actual test intensity and observer response) to 
the  
% database 
q=QuestUpdate(q,tTest,response);  
end 
 
% Step 3: Obtain and export results 
  
% Display cursor again now threshold testing has finished 
Priority(0);% Resest normal priority 
Screen('ShowCursorHelper', win); 
  
% Ask Quest for the final estimate of threshold. 
t=QuestMean(q); % Recommended by Pelli (1989) and King-Smith et al. 
(1994). 
sd=QuestSd(q); 
fprintf('Final threshold estimate (mean±sd) is %.2f ± %.2f\n',t,sd); 
  
% Determine total experimental time 
exptEnd = Screen('Flip', win); 
exptTotal = exptEnd - exptStart 
  
% Print out the number of false positives 
falsePositive 
  
% Close onscreen window, release all resources: 
Screen('CloseAll'); 
  
% Plot results onto graph for quick viewing 
figure(1) 
k=1:trialsDesired; 
plot (k,avgfps) 
xlabel ('Trial') 
ylabel ('Frames / sec') 
  
% Plot the stimuli presented 
figure(2) 
k=1:trialsDesired; 
plot (k,LuminancePresent, 'ob') 
xlabel ('Trial') 
ylabel ('Log luminance') 
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% Transfer all the key data to Excel 
LuminancePresent = LuminancePresent(:); % This changes the vector from 
a row to a column 
trialNumber = k(:); 
today = now; % this represents the current date and time in Excel 
name ={participant}; 
% Where to transfer the data to? 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', today,'Sheet1','B3');  
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', today,'Sheet1','B4'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', name,'Sheet1','B5'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', exptTotal,'Sheet1','E3'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', trialNumber,'Sheet1','A8'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', LuminancePresent,'Sheet1','B8'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', t,'Sheet1','E4'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', sd,'Sheet1','E5'); 
xlswrite('c:\Users\CAD User\Desktop\Grant\Matlab results\14Hz Flicker 
Results.xls', falsePositive,'Sheet1','E6'); 
 
% The following code allows the source error to be identified if the 
programme does not run 
 
catch  
Screen('CloseAll'); 
rethrow(lasterror); 
psychrethrow(psychlasterror);  
end 
 
 
 
 
 
 
 
 
 
 
 317 
 
Appendix VI. Cross sectional study consent form and CRFs 
 
School of Optometry 
Cardiff University 
Maindy Road 
Cardiff 
CF24 4LU 
Study Title:  Low-Level Night-Time Light Therapy for Age-Related Macular 
Degeneration 
Protocol:  11/01/15; Version: 16 
Names of Researchers: Dr Alison Binns 
          Dr Tom Margrain 
          Mr David Grant Robinson     
1. I confirm that I have read and understand the Alight 
participant information sheet dated 04/03/15. I have had the 
opportunity to consider the information, ask questions and 
have had these answered satisfactorily.  
2. I understand that my participation is voluntary and I am free 
to withdraw at any time without giving reason, without my 
medical care or legal rights being affected. 
3. I agree that my details can be used by the research team and 
understand that my personal details will be treated as 
STRICTLY CONFIDENTIAL. 
4. I agree to take part in the study in accordance with the terms 
set out in the consent form and ALight information sheet. 
5. I would like to receive a summary of the research findings at 
the end of the study. 
 
Name of Patient Date Signature 
   
Name of person taking consent Date Signature 
   
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
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PART A: Patient Details 
 
Today’s date    /   /     
 d d  m m  y y y y 
 
Patient’s surname                   
Patient’s first name                   
 
Patient’s date of birth    /   /     
 d d  m m  y y y y 
 
Patient’s address             
 
           
 
           
Patient’s telephone 
number 
 
          
PART B: Explain study; ask if patient wants to take part 
 
 Yes  No 
     
Has the patient read the study information sheet?       
     
Has a full explanation of the study been provided?     
     
 
PART C: Audit Information 
 
 
 
 
 
 
Gender   Male   Female 
 
Ethnicity  White  Black / Black British   
     
  Asian / Asian 
British 
 Other Ethnic Group (please specify) 
_____________________________ 
 
Patient ID         
 
 
 
Does the patient want to 
take part?  
 Yes, consent  Need more time, review at  
next clinic 
   
 No  
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PART A: Patient ID 
 
        
 
Study Eye (please tick 
appropriate box) 
Right                 
Left 
  
 
Part B: Screening evaluation 
 
 Right Eye Left Eye 
 
LOCS III Grade 
NC  NC  
NO  NO  
C  C  
P  P  
Fundus Appearance   
AMD Status (early, nAMD, 
GA) 
  
Drusen volume   
Van Herick Grade (Please tick 
appropriate box) 
G1 G2 G3 G4 G1 G2 G3 G4 
     
   
AREDS Simplified Grade 
(Please tick appropriate box) 
G0 G1 G2 G3 G4 
     
 
Visual Acuity Right Eye Left Eye 
BCVA (ETDRS number of 
letters) 
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PART C:  
a) Check inclusion criteria Yes  No 
     
The patient is between 55-88 years old      
     
The patient has visual acuity better than 40 letters in study eye      
     
The patient has grade 0 or grade 1 AMD (AREDS simplified scale)       
     
The patient can speak and understand English 
    
 
If NO for any box above, the patient needs to be excluded: Skip to Part E 
 
b) Check exclusion criteria 
 
Yes 
  
No 
     
The patient has ocular pathology other than macular disease      
     
The patient has a Van Herrick angle of 1 or 0     
     
The patient has significant systemic disease known to affect visual 
function (e.g. diabetes, Parkinson’s disease, Alzheimer’s disease). 
    
     
The patient has cognitive impairment (MMSE)     
     
The patient is taking medication known to affect visual function       
     
If YES for any box above, the patient needs to be excluded 
PART D: Eligibility Please tick the appropriate box 
Patient is eligible and 
wants to take part  
  Patient is ineligible/does not 
want to take part  
 
 
PART E: Patient’s name and investigator’s 
signature 
1) Re-state patient’s name:_________________   
2) Investigator’s signature:________________    
 
Date:______________ 
 
 321 
 
Part F: Data Collection 
 
Autorefractor Rx 
RE  
LE  
 
 
Quality of Fundus 
Photograph 
(Tick appropriate box) 
RE Acceptable  
Unacceptable 
(Repeat) 
 
 LE Acceptable  
Unacceptable 
(Repeat) 
 
Quality of OCT Image 
(Tick appropriate box) 
RE Acceptable  
Unacceptable 
(Repeat) 
 
 LE Acceptable  
Unacceptable 
(Repeat) 
 
 
Colour Vision 
Diagnosis  
Certification 
 
r-g threshold  
y-b threshold  
 
14Hz Flicker Thresholds 
 
Contrast Threshold 
 
Standard deviation 
 
 
Dark Adaptometry  
 
Pupil Size 
(mm) 
  Cone Tau  
 Time to 
RCB 
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Appendix VII. Patient information sheet 
 
     
   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Information Booklet for participants 
 
 
Information Booklet for participants 
 
 
Information Booklet for participants 
 
 
Information Booklet for participants 
 
 
Information Booklet for participants 
 
Retinal Treatment and Research Unit  
Clinical Research Unit 
Bristol Eye Hospital 
Lower Maudlin Street 
Bristol 
BS1 2LX 
 
Tel: 0117 342 4770 
Fax: 0117 342 4891 
 
Dear Sir/Madam, 
Cardiff University in collaboration with Bristol Eye Hospital 
would like to invite you to take part in our study 
investigating the effect of low-level night-time light therapy 
on age-related macular degeneration. 
 
Before you decide, we would like you to understand why 
the research is being done and what it would involve for 
you. Please take the time to read this information sheet, 
feel free to talk to family and friends about the study if you 
wish. Before commencing the study we will go through the 
information sheet with you and answer any questions you 
may have. Please ask us if there is anything that is not 
clear. 
 
 
 
Retinal Treatment and Research Unit  
Clinical Research Unit 
Bristol Eye Hospital 
Lower Maudlin Street 
Bristol 
BS1 2LX 
 
Tel: 0117 342 4770 
Fax: 0117 342 4891 
 
Dear Sir/Madam, 
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What is this study about? 
Age-related macular degeneration (AMD) is a 
common eye condition among people aged 50 or 
older. It damages the macula, the part of the retina 
that gives us clear, central vision. This makes 
activities such as reading, driving and recognising 
familiar faces more difficult. New evidence 
suggests that a lack of oxygen in the retina may be 
involved in the development of AMD, especially at night-time. By exposing the 
eye to very dim light during the night, more oxygen is available for the eye to 
function better. Practically, this would involve wearing a comfortable sleep 
mask at night that emits a very dim green light. The sleep mask is currently 
being evaluated in a similar study as a treatment for another eye condition, 
diabetic retinopathy.  
 
The main aim of this study is to determine if wearing this sleep 
mask can stop the progression of early AMD. 
 
This trial forms part of a postgraduate doctoral research project.  
You have been asked to take part in this research because we are looking for 
60 volunteers with early AMD in one eye and wet AMD in the other eye to help 
us find out how effective the sleep mask is at reducing the progression of both 
wet and early AMD. You would be randomly allocated either to receive a sleep 
mask to wear overnight for 12 months or to receive your usual hospital care 
only (your regular Lucentis ® clinic appointments).  
 
What will happen to me if I take part? 
1. Those who wish to take part in the study will have an initial 
appointment of up to 60 minutes with one of our team for you to ask 
any questions you may have and provide your consent to participating 
in the study. We will ask you some questions regarding your general 
health, vision, sleeping habits, vitamin supplementation, smoking 
history and memory, and let you know if you are eligible to take part in 
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the study. If you are eligible and wish to take part, we will ask for your 
GP details so that we can inform them that you are taking part in the 
study. If you are eligible to take part, we will also take several 
measurements at this point to measure the sensitivity of the eyes after 
a period of time in the dark. This appointment will take place just before 
your Lucentis ® clinic, so that no extra visits to the hospital are needed. 
 
2. If you are eligible and willing to take part, a second appointment will 
take place just before your third Lucentis ® clinic. This will take around 
75 minutes. We will put a drop in each eye to make your pupils larger, 
if not already inserted by the staff in the Lucentis ® clinic. We will then 
take several measurements to monitor the sensitivity of the eyes after 
a period of time in the dark and in response to a flickering target, and 
we will assess your colour vision. This will involve looking at a computer 
screen and reporting the presence of different targets by pressing a 
button. A computer will then decide if you are in the treatment group 
(given a light mask) or the control group (not given a light mask) on 
the basis of chance. If assigned to the treatment group, you will be 
shown how to use and fit the mask and you will receive written 
instructions to take home with you. 
 
3. Each month, when you attend for your regular Lucentis ® clinic 
appointment, we will meet up with you at the clinic to see how you are 
getting on. We will also ask some questions about your sleep quality. 
This will take about 10 minutes. The light mask needs to be replaced 
every 12 weeks. At your monthly Lucentis® Clinic visits, if you are in the 
treatment group, we will ask you to bring along your used mask, so that 
we can check that it is working properly, provide you with a new fabric 
cover to the mask, and give you a new one to take home every 3 
months. We will also access some electronic data on the mask, which 
tells us how many hours it has been worn each night for the past month. 
In addition, with your permission, the study investigators will access 
your medical records each month as you attend your regular clinic 
 325 
 
appointments. This will allow us to monitor your vision, and the health 
of your eyes throughout the year. 
 
4. At the end of the 12 month period, there will be a final appointment 
before your Lucentis ® clinic. This will take about 75 minutes and 
include the same tests as the second appointment, with the addition of 
some questions about how you found the treatment and a questionnaire 
about your sleeping habits. The sleep masks will then be returned to 
the study investigator.  
 
What are the possible benefits of taking part?    
If it is found to be effective, this therapy could slow or stop the progression of 
AMD.  As this is the first trial of its kind, a larger study with more participants 
would then be carried out to confirm the results. All people who are found to 
be suitable and are enrolled in the trial will receive a complimentary £10 gift 
voucher. 
 
What does the treatment involve? 
1. If you are in the control group, you will receive treatment as usual for 
your eye with wet AMD, but will receive no additional treatment.  
 
2. If you are in the treatment group, you will receive treatment as usual 
for your eye with wet AMD, and will be given a light mask to wear each 
night for a year.  
 
3. The light mask consists of a fabric eye mask, containing a small plastic 
pod which houses light emitting diodes (LEDs). It is held in place by an 
adjustable fabric strap, which passes around the back of the head. The 
light mask provides a low level of illumination to the eyes at night, which 
shines through the eyelids to illuminate the back of the eyes when you 
are asleep. The light provided is approximately half as bright as the 
average brightness of a television set.   
 
326 
 
4. It is designed to be worn when you are in bed at night. The mask should 
be removed if you need to get up at any time during the night, for 
example to go to the bathroom.  
 
Are there any risks involved? 
1. Low-level night-time light therapy has been shown to be safe. 
However, because this is the first study in people with AMD, safety will 
be a priority in this study. We will be checking that sleep quality is not 
affected by a monthly check-up and checking the health of your eyes 
by looking at the photographs taken at your regular Lucentis® clinic. 
 
2. It is not anticipated that you will experience any discomfort associated 
with the mask, however should you feel at all uncomfortable wearing 
the mask after your Lucentis injection, we advise you to discontinue 
wear for a few nights, until your eye feels less tender. We will ask you 
to report any such problems when we see you each month at the clinic.  
 
3. The drops used to enlarge your pupil are the same as those used at 
every Lucentis ® clinic you attend. They may make your vision 
temporarily a little blurred and make you sensitive to bright lights for 
about 6 hours. During this time we advise you not to drive or to operate 
any dangerous machinery. Very rarely some people can develop an 
adverse reaction to these drops. In less than 1 in 20,000 people they 
may cause a rise in eye pressure, known as closed angle glaucoma. 
The symptoms of this can include, pain, a red eye and halos around 
lights. In the extremely unlikely event that this should occur, you should 
contact us urgently on the numbers shown below. If we are unavailable 
then you should go straight to eye casualty for assessment and 
treatment with other eye drops to bring the pressure back down. 
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Do I have to take part?                          
No – it is up to you whether you decide to take part or not. Participation in this 
study is purely voluntary. If you do decide to take part, you will be given this 
information sheet to keep and will be asked to sign a consent form. You can 
withdraw at any time without giving a reason. Please note that if you do not 
wish to take part in the study it will not affect your current or future care. 
 
What if there is a problem?          
If you do have a concern about any aspect of this study, you should ask to 
speak to the researchers (contact details below) who will do their best to 
answer your questions. If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure – details can be 
obtained from the researchers.  
 
What if I have any questions?         
Please ask. We are very happy to discuss any aspect of the study. Please do 
not send personal information regarding your medical status by e-mail, as this 
is not a secure means of communication. 
 
 Grant Robinson (Robinsondg2@cf.ac.uk)  
 
 Dr Alison Binns (BinnsAM@cf.ac.uk) 
 
 Dr Tom Margrain (MargrainTH@cf.ac.uk) 
 
 Tel: 02070408495 
 
 School of Optometry and Vision Sciences, Cardiff University.  
 
Where can I seek independent advice? 
For any concerns about your rights as a participant or any complaints, please 
contact the Patient Advice and Liaison Service (PALS), or call into our drop in 
service, located on Level 2, Queens Building, Bristol Royal Infirmary. 
 
Contact the ‘Patient Support and Complaints Team, Trust Headquarters, 
University Hospitals Bristol, Malborough Street, Bristol. BS1 3NU. (tel: 
01173423604 or e-Mail pals@uhbristol.nhs.uk).  
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What will happen if I don’t want to carry on with the study? 
You are free to withdraw at any time without giving a reason; however we will 
retain non identifiable data collected up to your withdrawal. Please note that if 
you do not wish to take part in the study it will not affect your current or future 
care. 
 
What if there is a problem?        
 In the unlikely event that harm should occur as a result of negligence 
associated with this study, cover is provided by the Cardiff University insurance 
policy. 
 
Will my taking part in this study be kept confidential?            
All information collected during the study will be processed and stored securely 
by the researchers using password-protected systems. Your personal 
information will be coded and only the researchers will be able to identify you 
during the study. All procedures are compliant with the Data Protection Act 
1998. With your permission, if you decide to take part, we will inform your GP 
of your participation in the study. 
 
What will happen to the results of the research study?        
The study results will be analysed and presented at national and international 
meetings and in scientific journals. Identities of participating volunteers will not 
be revealed in any resulting published material. If you wish to be provided with 
a summary of the research findings at the end of the study please tick the 
appropriate box on the consent form.   
 
Who is funding and reviewing the research?           
This study is being organised by Cardiff University in collaboration with Bristol 
Eye Hospital, and funded by the College of Optometrists. The light mask 
manufacturer, Polyphotonix Medical Ltd, is providing the light masks free of 
charge. This study was reviewed and approved by the College of Optometrists, 
the Greater Manchester South Research Ethics Committee and UH Bristol 
NHS Foundation Trust. 
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Appendix VIII. ALight trial consent form and CRFs 
Study Title:  Low-Level Night-Time Light Therapy for Age-Related 
Macular Degeneration 
Protocol:  22/09/14; Version: 15 
Names of Researchers: Dr Alison Binns 
          Dr Tom Margrain 
          Mr Grant Robinson      
6. I confirm that I have read and understand the ALight participant 
information sheet dated 22/09/2014. I have had the opportunity to 
consider the information, ask questions and have had these 
answered satisfactorily. 
7. I understand that my participation is voluntary and I am free to 
withdraw at any time without giving reason, without my medical 
care or legal rights being affected. 
8. I agree that my details can be used by the research team and 
understand that my personal details will be treated as STRICTLY 
CONFIDENTIAL. 
9. I understand that I will be selected for either the treatment or 
control group on the basis of chance and agree to comply with 
that treatment for the 12 month duration of the study. 
10. I agree to take part in the study in accordance with the terms set 
out in the consent form and ALight information sheet. 
11. I agree that the investigators may inform my GP that I am 
participating in this trial 
12. I agree that the investigators may access my medical records on 
a monthly basis. 
13. I would like to receive a summary of the research findings at the 
end of the study. 
Name of Patient Date Signature 
   
Name of person taking consent Date Signature 
   
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
 
Please 
initial 
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SCREENING VISIT  
PART A: Patient Details 
 
Today’s date    /   /     
 d d  m m  y y y y 
 
Patient’s surname                   
 
Patient’s first name                   
 
Patient’s date of birth    /   /     
 d d  m m  y y y y 
 
 
 
 
 
 
 
Patient’s Address             
            
            
            
 
 
 
Patient’s Telephone 
number 
Daytime :           
 Mobile/other :           
PART B: Explain study; ask if patient wants to take part 
 
 Yes  No 
     
Has the patient read the study information sheet?       
     
Has a full explanation of the study been provided?     
     
 
 
PART C: Audit Information 
 
 
 
 
 
 
Gender   Male   Female 
 
Ethnicity  White  Black / Black British   
     
  Asian / 
Asian British 
 Other Ethnic Group (please specify) 
_____________________________ 
 
Patient ID  (initials + 4 digit code)   0 1     
 
 
 
Does the patient want 
to take part?  
 Yes, sign 
consent form 
 Need more time, review at next 
Lucentis clinic 
   
 No, skip to 
part F 
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PART A: General Health 
 
 
 
Medical Illnesses   
(tick all that apply) 
 Diabetes  Alzheimer’s    None  
       
 Parkinson’s  Motor neurone 
disease 
   
        
     
  Other: 
specify 
  
 
Current medication  
 
 
PART B: Ocular Status 
 Right Eye Left Eye 
BCVA (ETDRS 
number of letters) 
  
Ocular Diagnosis 
(Tick all that apply) 
Early 
AMD 
 nAMD  Early 
AMD 
 nAMD  
Normal  Geographic 
Atrophy 
 Normal  Geographic 
Atrophy 
 
Other   Please Specify…  
 
Other  Please  
Specify…  
 
 
PART C: Assessment of the Ocular Media and Fundus 
 
 Right Eye Left Eye 
 
LOCS III Grade 
NC  NC  
NO  NO  
C  C  
P  P  
Fundus Appearance   
AMD Status (early, nAMD, 
GA) 
  
Van Herick Grade  
Exclude if Grade ≤1 
G1 G2 G3 G4 G1 G2 G3 G4 
     
   
AREDS Simplified Grade 
(Please tick appropriate box) 
G0 G1 G2 G3 G4 
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PART D: Cognitive Screening and Visual Function Questionnaire 
 
 
Cognitive Screening Test   
 
I would like you to repeat the following three words:  APPLE, PENNY, TABLE 
(Repeat until the patient registers all three words) 
 
A1 What is the day?  Correct Yes   No  
A2 What is the month?  Correct  Yes   No  
A3 What is the year?  Correct Yes   No  
A4 Spell WORLD 
backwards 
DLROW Number correct     
(Final cognitive screening question A5 follows the questions on visual function) 
Cognitive Screening Test 
 What were the 3 words that I asked 
you at the beginning? 
 
(apple, penny, table) 
 
Number correct  
1) ___________________ 
2) ___________________ 
3) ___________________ 
 
 
      _______________________ 
Did the patient pass the cognitive screen? 
Yes  (1)     (day, year, month correct; 3/5 WORLD; remember at least 2 words) 
No  (0)  Patient is ineligible (Skip to Part E) 
 
PART E: a) Check inclusion criteria 
 Yes  No 
     
The patient is between 55-88 years old      
     
The patient has visual acuity better than 40 letters in study eye      
     
The patient is receiving treatment for neovascular AMD in one eye 
only 
    
     
The patient has early AMD in the study eye     
     
It is within 1 month of 3rd anti-VEGF injection      
     
The patient is willing to adhere to treatment for the duration of 
the trial 
    
     
The patient has sufficient hearing to permit use of the telephone     
The patient can speak and understand English     
 
If NO for any box above, the patient needs to be excluded: Skip to Part F 
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b) Check exclusion 
criteria 
Yes  No 
     
The patient has advanced AMD in both eyes      
     
The patient has ocular pathology other than macular disease      
     
The patient has systemic disease that would affect visual function 
or compromise participation in a one year study 
    
     
The patient has cognitive impairment (MMSE)     
     
The patient is taking medication known to affect visual function       
The patient wears an oxygen mask at night     
The patient has a history of falls or high risk of falling     
 
If YES for any box above, the patient needs to be excluded: Skip to Part F 
 
 
PART F: Eligibility Please tick the appropriate box 
Patient is eligible and 
wants to take part (go to 
Part F) 
  Patient is ineligible/ does not 
want to take part (skip to part 
G) 
 
 
 
    
PART G: Patient is eligible and wants to take part, record patient and GP 
contact details  
Patient’s telephone number             
 
Best days / times to contact 
patient?  
 
 
 
 
GP name 
  
  
 
GP address  
 
 
 
 
 
GP telephone number              
 
 
 
 
PART H: Patient’s name and investigator’s signature 
 
1) Re-state patient’s name:   
_______________________                                                    _                                
2) Investigator’s signature:    
 
______    _______ ______                                                    __ 
 
Date 
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PART I: Health Questionnaires (Eligible participants only) 
Vitamin Supplementation    
Are you currently taking vitamin supplements regularly?  yes  no 
If so, for how many years have you been taking them?    years 
If known, what is the name of the vitamins you are taking? 
Smoking History 
1) Are you currently a smoker? 
 yes  no (skip 
to Q4) 
2) How many cigarettes do you smoke per 
day? 
 per day 
3) For how many years have you been 
smoking? 
 years 
4) Have you ever smoked in the past? 
 
 yes  no (skip 
Q5-7) 
5) How long ago did you give up? 
 
 months  years 
6) On average how many cigarettes did you 
smoke each day? 
 per day  
7) For how many years did you smoke 
 years 
 
Part J: Dark Adaptometry  
 
Study Eye (please tick appropriate 
box) 
Right                 Left  
 
Time of dilation    Drop used 
      
        
    
Full Dilation?      Time additional drop instilled? 
 
 
 
Time bleach started    Pupil size (mm) 
 
 
                           
                      
Cone tau 
 
 
RCB 
 
 
Quality of data 
 
 
 
 
 
 
 
   
Yes  No   
 
   
 
 
    
Acceptable  Unacceptable  
(repeat at baseline) 
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BASELINE VISIT 
PART A: Patient ID 
 
  0 1     
 
Study Eye (please tick appropriate box) Right  Left  
 
PART B: Assessment of the Ocular Media and Fundus 
Quality of Fundus 
Photograph 
(Tick appropriate box) 
RE Acceptable  Unacceptable 
(Repeat) 
 
 LE Acceptable  Unacceptable 
(Repeat) 
 
Quality of OCT Image 
(Tick appropriate box) 
RE Acceptable  Unacceptable 
(Repeat) 
 
 LE Acceptable  Unacceptable 
(Repeat) 
 
 
 
 
 Right Eye Left Eye 
Fundus appearance 
 
  
Drusen Volume (study eye) 
3mm2 
  
 
Drusen Volume (study eye) 
5mm2 
  
AMD Status (early, nAMD, dry 
AMD) 
 
 
 
AREDS Simplified Grade (Please 
tick appropriate box) 
G0 G1 G2 G3 G4 
     
 
 
PART C: Reassessment of Participants Eligibility (Part 1)   
 
Participant still meets eligibility criteria Yes  No     
Participant still willing to participate in the study Yes  No  Initial  
 
 
 
 
336 
 
PART D: Tests of Visual Function 
Study Eye (please tick appropriate 
box) 
Right                 Left  
 
 Right Eye Left Eye 
Auto-refraction   
Spectacle Prescription   
 
Visual Acuity Right Eye Left Eye 
BCVA (ETDRS number of 
letters) 
  
 
Colour Vision 
Diagnosis  
Certification  
r-g threshold  
y-b threshold  
 
 
14Hz Flicker Thresholds 
 
Contrast Threshold  
Standard deviation  
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Dark Adaptometry  
 
Quality of data obtained at 
screening visit  
 
 
If ‘Unacceptable’ then perform dark adaptometry and document results 
below.  
 
   
Time of  
dilation   
 
Drop used 
    
       
Full  
Dilation? 
 
 
Time of      
drop instillation 
        
                       
Time bleach started  
     
 
 
Pupil Size (mm)  
       
             
Cone tau 
 
 
RCB 
 
 
 
 
PART E: Reassessment of Participants Eligibility (Part 2)  
 
Participant still meets eligibility criteria Yes  No     
 
Participant still willing to participate in the 
study 
Yes  No  Initial  
 
 
 
 
 
 
 
 
 
 
Acceptable   Unacceptable  
    
 
Yes  No  
    
    
 
338 
 
 
PART F: Randomisation Record 
 
Envelope Number   
Group Allocation Intervention  Control   
Sleep masks 
provided 
Date       Time     
 d d m m y y          24 hour clock 
Sleep mask hours 
programmed for use (8 
hour window) 
Start 
Time 
     
 End 
Time 
     
  24 hour clock  
Sleep mask dates for use Start 
Date 
      
  d d m m y y 
 End 
Date 
      
  d d m m y y 
Training provided Date       Time     
  
 
d d m m y y     24 hour clock 
Reprise follow-up 
appointments information 
Yes  No   
Copy of PSQI given Yes  No  
 
 
£10 gift voucher given? Yes  No  Declined   
GP information letter 
sent? 
Yes  No  
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MONTHLY VISIT 
PART A: Patient ID 
 
  0 1     
 
Study Eye (please tick appropriate box) Right    Left  
Month of Study (1-11)  
PART B: Questionnaires 
Semi-Structured Questionnaire 
Have you experienced any new medical 
problems over the past month? 
If yes, please describe. 
 
How have you been getting on with your light 
mask? 
 
Have you been wearing the light mask every 
night?  
 
For approximately how many hours do you 
wear the mask at night?  
 
Has the light mask been comfortable to wear? 
Could you grade this on a scale of 1-10, where 
1 is so comfortable that you aren’t aware that 
the mask is there, and 10 is so uncomfortable 
that you can’t bear to wear it.  
 
If the mask is not completely comfortable, 
please could you describe the sources of 
discomfort e.g. the strap, the pressure of the 
mask on the face,  
 
Have you experienced any problems with 
sleeping when using the light mask? If yes, do 
you feel that this due to the brightness of the 
light, or to the physical sensation of wearing the 
mask?  
 
 
Have you had any problems in operating the 
mask? If so, please describe.  
 
Do you have any concerns or questions about 
the mask and its use? 
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Is there anything else you would like us to know 
about your experience of wearing the light 
mask? 
 
PART C: Current Mask Information 
Current light mask start date       
 D D M M Y Y 
Current light mask end date       
 D D M M Y Y 
1) Compliance data exported? 
(Please tick appropriate box) 
Yes  No  
2) Retraining provided? 
(Please tick appropriate box) 
Yes  No  
3) New mask issued? 
          (Please tick appropriate box) 
Yes 
(go to 
part D) 
 No 
(go to 
part E) 
 
 
Part D: New Mask Information 
 
4) New light mask start 
date 
      
 D D M M Y Y 
5) New light mask end date       
 D D M M Y Y 
 
 
Part E: Mask maintenance 
 
1) New fabric strap fitted? 
(Please tick appropriate 
box) 
Yes  No  
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Part F: Monthly Medical Record Assessment 
Quality of Fundus 
Photograph 
(Tick appropriate box) 
RE Acceptable  Unacceptable   
 LE     
Quality of OCT Image 
(Tick appropriate box) 
RE Acceptable  Unacceptable   
 LE     
 
 Right Eye Left Eye 
Fundus appearance 
 
  
Drusen Volume (study eye) 
3mm2 
  
Drusen Volume (study eye) 
5mm2 
  
AMD Status 
(early, nAMD, dry AMD) 
 
 
 
AREDS Simplified Grade 
(Please tick appropriate box) 
G0 G1 G2 G3 G4 
     
 
Conversion to wet AMD in study eye? 
(Please tick appropriate box) 
Yes – Withdraw 
from study and 
inform CI 
 No  
     
Any other change in medical status 
(systemic / ocular)?  
Yes  No  
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 FINAL VISIT 
PART A: Patient ID 
 
  0 1     
 
Study Eye (please tick appropriate box) Right    Left            
     
PART B: Assessment of the Ocular Media and Fundus 
Quality of Fundus 
Photograph 
(Tick appropriate box) 
RE Acceptable  Unacceptable 
(Repeat) 
 
 LE Acceptable  Unacceptable 
(Repeat) 
 
Quality of OCT Image 
(Tick appropriate box) 
RE Acceptable  Unacceptable 
(Repeat) 
 
 LE Acceptable  Unacceptable 
(Repeat) 
 
 
 Right Eye Left Eye 
 
LOCS III Grade 
NC  NC  
NO  NO  
C  C  
P  P  
Fundus Appearance   
AMD Status (early, nAMD, GA)   
Drusen Volume (study eye) 
3mm2 
  
Drusen volume (study eye) 
5mm2 
  
AREDS Simplified Grade (Please 
tick appropriate box) 
G0 G1 G2 G3 G4 
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 PART C: Tests of Visual Function 
Study Eye (please tick appropriate 
box) 
Right                 Left  
 
Visual Acuity Right Eye Left Eye 
BCVA (ETDRS number of 
letters) 
  
 
Colour Vision 
Diagnosis  
Certification  
r-g threshold  
y-b threshold  
 
 
14Hz Flicker Thresholds 
 
Contrast Threshold  
Standard deviation  
 
 
Dark Adaptometry  
 
Pupil Size 
(mm) 
  Cone Tau  
 Time to RCB  
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Appendix IX. Table of ALight trial baseline characteristics 
    LOCS III grade 
Smoking 
history 
Supplement 
history 
Study ID 
Study 
group 
AREDS  
grade 
BCVA  
(ETDRS 
score) 
NC NO C P 
Pack  
years 
Years  
taken 
 
MJ010001 
 
Intervention 
 
2 
 
-0.04 
 
2 
 
2 
 
1 
 
1 
 
15.00 
 
0.0 
MA010002 Intervention 4 0.22 2 2 1 1 0.00 3.0 
MN010003 Intervention 2 -0.10 2 2 1 1 40.00 0.0 
JC010004 Control 3 -0.12 0 0 0 0 50.00 0.0 
JN010005 Control 4 -0.04 0 0 0 0 0.00 2.0 
AS010006 Control 4 -0.06 1 1 1 1 5.60 0.5 
EA010007 Control 4 0.30 2 2 2 1 20.00 0.0 
JW010008 Control 3 0.16 2 2 2 1 0.00 0.0 
FC010009 Intervention 3 0.24 0 0 0 0 5.75 0.0 
JE010010 Intervention 3 0.08 0 0 0 0 19.60 0.0 
JC010011 Control 3 0.22 2 2 2 0 5.25 2.0 
CS010012 Intervention 4 0.24 2 2 0 0 5.25 2.0 
LA010013 Control 3 0.26 2 2 2 0 0.00 0.0 
JG010014 Intervention 3 0.18 2 2 1 1 0.00 0.0 
GP010015 Control 4 0.10 2 2 1 0 0.00 0.0 
CA010016 Intervention 4 0.02 0 0 0 0 3.00 2.0 
JW010017 Control 2 0.28 0 0 0 0 0.00 0.0 
GW010018 Intervention 3 -0.10 0 0 0 0 21.00 4.0 
JB010019 Intervention 3 0.02 0 0 0 0 15.00 0.0 
AN010020 Control 2 0.16 2 1 2 1 0.00 0.0 
RJ010021 Intervention 3 -0.12 1 0 0 0 7.50 1.0 
AB010022 Control 4 0.06 2 2 0 0 0.00 0.0 
MB010023 Control 4 -0.04 2 2 0 0 5.00 2.0 
RH010024 Intervention 2 0.28 2 2 2 1 30.00 0.0 
CG010025 Control 2 0.00 2 2 1 1 42.00 0.0 
MA010026 Control 4 0.20 2 1 1 1 0.00 1.0 
DJ010027 Control 2 -0.16 2 1 1 0 15.00 0.0 
KW010028 Intervention 2 0.20 2 2 0 0 0.00 0.0 
MH010029 Control 3 0.10 0 0 0 0 45.00 1.0 
JF010030 Control 4 -0.04 2 2 0 0 0.00 1.0 
DB010031 Intervention 2 -0.16 2 2 1 1 52.50 0.0 
AB010032 Intervention 3 0.08 2 2 2 1 0.00 5.0 
SG010033 Intervention 3 0.02 0 0 0 0 0.00 2.0 
GF010034 Intervention 3 0.30 2 2 1 0 0.00 0.0 
RG010035 Intervention 2 0.02 0 0 1 0 70.00 0.0 
ML010036 Control 3 0.20 2 2 2 1 0.00 0.0 
WB010037 Intervention 4 0.20 2 2 2 0 0.00 0.0 
HB010038 Control 4 0.18 1 1 0 0 2.25 0.0 
JH010039 Control 4 0.08 2 2 1 1 0.00 0.0 
BP010040 Intervention 4 0.26 0 0 0 0 30.00 0.0 
BJ010041 Intervention 3 0.00 0 0 0 0 50.00 0.0 
VB010042 Intervention 3 -0.04 0 0 0 0 0.00 1.0 
JW010043 Control 3 0.06 2 2 2 0 5.00 0.0 
NE010044 Control 2 -0.04 1 1 0 0 0.00 0.0 
RH010045 Intervention 4 0.00 2 2 0 0 2.00 0.0 
GL010046 Intervention 3 0.04 0 0 1 0 0.00 0.0 
PS010047 Intervention 2 0.08 1 1 1 0 0.00 0.0 
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AW010048 Control 4 0.02 1 1 2 0 0.00 0.0 
MM010049 Control 2 0.04 2 2 1 1 18.75 0.0 
PC010050 Intervention 2 0.02 1 1 2 0 0.00 0.0 
PR010051 Control 2 -0.04 2 2 2 1 62.50 0.0 
DR010052 Control 3 0.00 2 2 2 2 0.00 0.0 
IJ010053 Control 2 0.30 2 2 0 0 16.00 0.0 
AH010054 Control 3 0.08 1 2 2 0 24.00 0.0 
GC010055 Intervention 4 0.14 0 0 0 2 0.00 4.0 
JL010056 Intervention 3 0.14 2 2 1 1 0.00 0.0 
MP010057 Intervention 2 0.22 2 2 1 1 50.00 2.0 
PB010058 Control 4 0.04 2 2 1 1 0.00 0.0 
CE010059 Control 2 0.04 1 1 0 0 0.00 0.0 
AW010060 Intervention 4 0.18 0 0 0 0 0.00 2.0 
 
Study ID = study identification; AREDS Grade = Age Related Eye Disease Study Simplified Severity 
Grade (Ferris et al., 2005); BCVA = Best corrected visual acuity; ETDRS = Early Treatment Diabetic 
Retinopathy Study; LOCS III = Lens Opacities Classification System III (Chylack et al., 1993); NC = 
nuclear colour; NO = nuclear opalescence; C = cortical cataract; P = posterior subcapsular cataract 
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Appendix X. ALight trial 18-month post-hoc analysis 
 
When the AMD status of participants who showed no disease progression during the 
trial was reviewed 6 months following their end-of-study visit, hospital records 
reported that following final data collection 3 control participants and no intervention 
participants had developed nAMD in the study eye. This equated to 5% (n=1) of the 
intervention group and 17% (n=5) of the control group converting to nAMD over 18 
months. The mask wearer who converted to nAMD wore the mask for 70 nights prior 
to nAMD onset. When combined with 12-month disease progression data (n=8 
intervention and n=14 controls) 38% (n=8) of the intervention group and 59% (n=17) 
of the control group showed disease progression over 18 months. This difference 
between study groups failed to reach statistical significance (Mantel-Haenszel test, 
Common Odds Ratio = 0.794, P=0.559).  
For the purposes of this trial, drusen shrinkage was not included as an outcome 
measure as it was not possible to distinguish between regression preceding late stage 
AMD and regression which may indicate a reduction in disease severity. Post-hoc 
review of change in drusen volume for those who developed nAMD after their final 
study visit showed that 50% had shown significant drusen shrinkage throughout the 
trial. However, there was no significant difference (chi-squared test, P=0.57) in the 
proportion of those (intervention, 24%; control, 17%) showing drusen shrinkage 
between groups. The post-hoc review of AMD status 6 months after the final visit also 
showed that none of the intervention participants who displayed significant drusen 
shrinkage throughout the trial progressed to nAMD up to 18-months post 
randomisation.  
Post-hoc sample size calculations suggest that a sample size of 381 per group would 
be required to detect an effect of the magnitude seen in the ALight trial (80% power, 
P=0.05) at 12 months. It was interesting to note that a greater number of participants 
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progressed to nAMD in the control group (n=3, 10%) in the 6 months following the 
trial than in the treatment group (where no further participants converted). In other 
words, by the time 18 months had elapsed since mask wear commenced, 38% of 
mask wearers and 59% of the control group had exhibited signs of disease 
progression in the eye with early AMD (with 5% of the intervention group and 17% of 
the control group converting to nAMD in this timeframe). Based on post hoc analysis 
of these data, if conversion to nAMD only was specified as a measure of disease 
progression and change in drusen volume was not considered, an approximate 
sample size of 103 per group would be required to detect an effect of the magnitude 
seen in the present study (80% power, P=0.05) if the follow-up was extended to 18 
months. This suggests that further study of the longer term effectiveness of the 
intervention is of value; the 12 month follow up time may not have been long enough. 
